<!DOCTYPE html>
<html xmlns="http://www.w3.org/1999/xhtml">
<head>
<meta name="generator" content=
"HTML Tidy for HTML5 for Mac OS X version 5.4.0" />
<title></title>
</head>
<body link="blue" lang="EN-US" xml:lang="EN-US">
<div style="font-family:Times New Roman;">
<p style="margin:0in 0in .0001pt;"><a href="#TableOfContents"
title="Click to go to Table of Contents"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">Table of
Contents</font></a></p>
<p style="margin:0in 0in .0001pt;"><font size="1" face=
"Times New Roman" style="font-size:9.0pt;">&nbsp;</font></p>
<div style=
"border-bottom:solid windowtext 1.0pt;border-left:none;border-right:none;border-top:solid windowtext 3.0pt;padding:1.0pt 0in 1.0pt 0in;">
<p style="border:none;margin:0in 0in .0001pt;padding:0in;">
<font size="1" face="Times New Roman" style=
"font-size:1.0pt;">&nbsp;</font></p>
</div>
<p align="center" style=
"margin:0in 0in .0001pt;text-align:center;"><font size="1" face=
"Times New Roman" style="font-size:9.0pt;">&nbsp;</font></p>
<p align="center" style=
"margin:0in 0in .0001pt;text-align:center;"><b><font size="5" face=
"Times New Roman" style="font-size:18.0pt;font-weight:bold;">UNITED
STATES</font></b></p>
<p align="center" style=
"margin:0in 0in .0001pt;text-align:center;"><b><font size="5" face=
"Times New Roman" style=
"font-size:18.0pt;font-weight:bold;">SECURITIES AND EXCHANGE
COMMISSION</font></b></p>
<p align="center" style=
"margin:0in 0in .0001pt;text-align:center;"><b><font size="2" face=
"Times New Roman" style=
"font-size:10.0pt;font-weight:bold;">WASHINGTON, D.C.
20549</font></b></p>
<p align="center" style=
"margin:0in 0in .0001pt;text-align:center;"><font size="1" face=
"Times New Roman" style="font-size:9.0pt;">&nbsp;</font></p>
<div align="center" style=
"margin:0in 0in .0001pt;text-align:center;">
<hr size="1" width="25%" noshade="noshade" align="center" style=
"color:black;" /></div>
<p align="center" style=
"margin:0in 0in .0001pt;text-align:center;"><font size="1" face=
"Times New Roman" style="font-size:9.0pt;">&nbsp;</font></p>
<p align="center" style=
"margin:0in 0in .0001pt;text-align:center;"><b><font size="5" face=
"Times New Roman" style=
"font-size:18.0pt;font-weight:bold;">FORM&nbsp;10-Q</font></b></p>
<p align="center" style=
"margin:0in 0in .0001pt;text-align:center;"><font size="1" face=
"Times New Roman" style="font-size:9.0pt;">&nbsp;</font></p>
<div align="center" style=
"margin:0in 0in .0001pt;text-align:center;">
<hr size="1" width="25%" noshade="noshade" align="center" style=
"color:black;" /></div>
<p align="center" style=
"margin:0in 0in .0001pt;text-align:center;"><font size="1" face=
"Times New Roman" style="font-size:9.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><b><font size="2" face=
"Times New Roman" style="font-size:10.0pt;font-weight:bold;">(Mark
One)</font></b></p>
<p style="margin:0in 0in .0001pt .5in;text-indent:-.25in;">
<font size="3" face="Wingdings" style=
"font-size:12.0pt;">x</font><font size="1" style=
"font-size:3.0pt;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</font>
<b><font size="3" style=
"font-size:12.0pt;font-weight:bold;">QUARTERLY REPORT PURSUANT TO
SECTION&nbsp;13 OR 15(d)&nbsp;OF THE SECURITIES EXCHANGE ACT
OF&nbsp;1934</font></b></p>
<p align="center" style=
"margin:0in 0in .0001pt;text-align:center;"><font size="1" face=
"Times New Roman" style="font-size:9.0pt;">&nbsp;</font></p>
<p align="center" style=
"margin:0in 0in .0001pt;text-align:center;"><b><font size="2" face=
"Times New Roman" style="font-size:10.0pt;font-weight:bold;">For
the quarterly period ended March&nbsp;31, 2018</font></b></p>
<p align="center" style=
"margin:0in 0in .0001pt;text-align:center;"><font size="1" face=
"Times New Roman" style="font-size:9.0pt;">&nbsp;</font></p>
<p align="center" style=
"margin:0in 0in .0001pt;text-align:center;"><b><font size="2" face=
"Times New Roman" style=
"font-size:10.0pt;font-weight:bold;">or</font></b></p>
<p align="center" style=
"margin:0in 0in .0001pt;text-align:center;"><font size="1" face=
"Times New Roman" style="font-size:9.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt .5in;text-indent:-.25in;">
<font size="3" face="Wingdings" style=
"font-size:12.0pt;">o</font><font size="1" style=
"font-size:3.0pt;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</font>
<b><font size="3" style=
"font-size:12.0pt;font-weight:bold;">TRANSITION REPORT PURSUANT TO
SECTION&nbsp;13 OR 15(d)&nbsp;OF THE SECURITIES EXCHANGE ACT
OF&nbsp;1934</font></b></p>
<p align="center" style=
"margin:0in 0in .0001pt;text-align:center;"><font size="1" face=
"Times New Roman" style="font-size:9.0pt;">&nbsp;</font></p>
<p align="center" style=
"margin:0in 0in .0001pt;text-align:center;"><b><font size="2" face=
"Times New Roman" style="font-size:10.0pt;font-weight:bold;">For
the transition period from
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
to&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</font></b></p>
<p align="center" style=
"margin:0in 0in .0001pt;text-align:center;"><font size="1" face=
"Times New Roman" style="font-size:9.0pt;">&nbsp;</font></p>
<p align="center" style=
"margin:0in 0in .0001pt;text-align:center;"><b><font size="2" face=
"Times New Roman" style=
"font-size:10.0pt;font-weight:bold;">Commission File Number:
001-36817</font></b></p>
<p align="center" style=
"margin:0in 0in .0001pt;text-align:center;"><font size="1" face=
"Times New Roman" style="font-size:9.0pt;">&nbsp;</font></p>
<div align="center" style=
"margin:0in 0in .0001pt;text-align:center;">
<hr size="1" width="25%" noshade="noshade" align="center" style=
"color:black;" /></div>
<p align="center" style=
"margin:0in 0in .0001pt;text-align:center;"><font size="1" face=
"Times New Roman" style="font-size:9.0pt;">&nbsp;</font></p>
<p align="center" style=
"margin:0in 0in .0001pt;text-align:center;"><b><font size="5" face=
"Times New Roman" style=
"font-size:18.0pt;font-weight:bold;">AVINGER,&nbsp;INC.</font></b></p>
<p align="center" style=
"margin:0in 0in .0001pt;text-align:center;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">(Exact name of
registrant as specified in its charter)</font></p>
<p style="margin:0in 0in .0001pt;"><font size="1" face=
"Times New Roman" style="font-size:9.0pt;">&nbsp;</font></p>
<div align="center" style=
"margin:0in 0in .0001pt;text-align:center;">
<hr size="1" width="25%" noshade="noshade" align="center" style=
"color:black;" /></div>
<p style="margin:0in 0in .0001pt;"><font size="1" face=
"Times New Roman" style="font-size:9.0pt;">&nbsp;</font></p>
<div align="center">
<table border="0" cellspacing="0" cellpadding="0" width="100%"
style="border-collapse:collapse;">
<tr>
<td width="49%" valign="top" style=
"padding:0in 0in 0in 0in;width:49.0%;">
<p align="center" style=
"margin:0in 0in .0001pt;text-align:center;"><b><font size="2" face=
"Times New Roman" style=
"font-size:10.0pt;font-weight:bold;">Delaware</font></b></p>
</td>
<td width="2%" valign="bottom" style=
"padding:0in 0in 0in 0in;width:2.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>
</td>
<td width="49%" valign="top" style=
"padding:0in 0in 0in 0in;width:49.0%;">
<p align="center" style=
"margin:0in 0in .0001pt;text-align:center;"><b><font size="2" face=
"Times New Roman" style=
"font-size:10.0pt;font-weight:bold;">20-8873453</font></b></p>
</td>
</tr>
<tr>
<td width="49%" valign="top" style=
"padding:0in 0in 0in 0in;width:49.0%;">
<p align="center" style=
"margin:0in 0in .0001pt;text-align:center;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">(State or other
jurisdiction of</font></p>
</td>
<td width="2%" valign="bottom" style=
"padding:0in 0in 0in 0in;width:2.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>
</td>
<td width="49%" valign="top" style=
"padding:0in 0in 0in 0in;width:49.0%;">
<p align="center" style=
"margin:0in 0in .0001pt;text-align:center;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">(I.R.S.
Employer</font></p>
</td>
</tr>
<tr>
<td width="49%" valign="top" style=
"padding:0in 0in 0in 0in;width:49.0%;">
<p align="center" style=
"margin:0in 0in .0001pt;text-align:center;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">incorporation or
organization)</font></p>
</td>
<td width="2%" valign="bottom" style=
"padding:0in 0in 0in 0in;width:2.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>
</td>
<td width="49%" valign="top" style=
"padding:0in 0in 0in 0in;width:49.0%;">
<p align="center" style=
"margin:0in 0in .0001pt;text-align:center;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">Identification
Number)</font></p>
</td>
</tr>
</table>
</div>
<p style="margin:0in 0in .0001pt;"><font size="1" face=
"Times New Roman" style="font-size:9.0pt;">&nbsp;</font></p>
<p align="center" style=
"margin:0in 0in .0001pt;text-align:center;"><b><font size="2" face=
"Times New Roman" style="font-size:10.0pt;font-weight:bold;">400
Chesapeake Drive</font></b></p>
<p align="center" style=
"margin:0in 0in .0001pt;text-align:center;"><b><font size="2" face=
"Times New Roman" style=
"font-size:10.0pt;font-weight:bold;">Redwood City, California
94063</font></b></p>
<p align="center" style=
"margin:0in 0in .0001pt;text-align:center;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">(Address of principal
executive offices and zip code)</font></p>
<p style="margin:0in 0in .0001pt;"><font size="1" face=
"Times New Roman" style="font-size:9.0pt;">&nbsp;</font></p>
<p align="center" style=
"margin:0in 0in .0001pt;text-align:center;"><b><font size="2" face=
"Times New Roman" style=
"font-size:10.0pt;font-weight:bold;">(650)&nbsp;241-7900</font></b></p>
<p align="center" style=
"margin:0in 0in .0001pt;text-align:center;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">(Telephone number,
including area code)</font></p>
<p align="center" style=
"margin:0in 0in .0001pt;text-align:center;"><font size="1" face=
"Times New Roman" style="font-size:9.0pt;">&nbsp;</font></p>
<div align="center" style=
"margin:0in 0in .0001pt;text-align:center;">
<hr size="1" width="25%" noshade="noshade" align="center" style=
"color:black;" /></div>
<p align="center" style=
"margin:0in 0in .0001pt;text-align:center;"><font size="1" face=
"Times New Roman" style="font-size:9.0pt;">&nbsp;</font></p>
<p style=
"font-size:10.0pt;margin:0in 0in .0001pt;text-indent:.25in;">
<font size="2" face="Times New Roman" style=
"font-size:10.0pt;">Indicate by check mark whether the registrant
(1)&nbsp;has filed all reports required to be filed by
Section&nbsp;13 or 15(d)&nbsp;of the Securities Exchange Act of
1934 during the preceding 12&nbsp;months (or for such shorter
period that the registrant was required to file such reports), and
(2)&nbsp;has been subject to such filing requirements for the past
90&nbsp;days.&nbsp;&nbsp; Yes&nbsp;</font><font face=
"Wingdings">x</font> No&nbsp;<font face="Wingdings">o</font></p>
<p style="margin:0in 0in .0001pt;"><font size="1" face=
"Times New Roman" style="font-size:9.0pt;">&nbsp;</font></p>
<p style=
"font-size:10.0pt;margin:0in 0in .0001pt;text-indent:.25in;">
<font size="2" face="Times New Roman" style=
"font-size:10.0pt;">Indicate by check mark whether the registrant
has submitted electronically and posted on its corporate Web site,
if any, every Interactive Data File required to be submitted and
posted pursuant to Rule&nbsp;405 of Regulation&nbsp;S-T during the
preceding 12&nbsp;months (or for such shorter period that the
registrant was required to submit and post such files).&nbsp;&nbsp;
Yes</font> <font face="Wingdings">x</font> No <font face=
"Wingdings">o</font></p>
<p style="margin:0in 0in .0001pt;"><font size="1" face=
"Times New Roman" style="font-size:9.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.25in;"><font size="2"
face="Times New Roman" style="font-size:10.0pt;">Indicate by check
mark whether the registrant is a large accelerated filer, an
accelerated filer, a non-accelerated filer, a smaller reporting
company, or an emerging growth company. See definitions of “large
accelerated filer,” “accelerated filer,” “smaller reporting
company,” and “emerging growth company” in Rule&nbsp;12b-2 of the
Exchange Act.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="1" face=
"Times New Roman" style="font-size:9.0pt;">&nbsp;</font></p>
<div align="center">
<table border="0" cellspacing="0" cellpadding="0" width="100%"
style="border-collapse:collapse;">
<tr>
<td width="49%" valign="top" style=
"padding:0in 0in 0in 0in;width:49.0%;">
<p align="center" style=
"font-size:10.0pt;margin:0in 0in .0001pt;text-align:center;">
<font size="2" face="Times New Roman" style=
"font-size:10.0pt;">Large accelerated filer</font> <font face=
"Wingdings">o</font></p>
</td>
<td width="2%" valign="bottom" style=
"padding:0in 0in 0in 0in;width:2.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>
</td>
<td width="49%" valign="top" style=
"padding:0in 0in 0in 0in;width:49.0%;">
<p align="center" style=
"font-size:10.0pt;margin:0in 0in .0001pt;text-align:center;">
<font size="2" face="Times New Roman" style=
"font-size:10.0pt;">Accelerated filer</font> <font face=
"Wingdings">o</font></p>
</td>
</tr>
<tr>
<td width="49%" valign="top" style=
"padding:0in 0in 0in 0in;width:49.0%;">
<p align="center" style=
"margin:0in 0in .0001pt;text-align:center;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
</td>
<td width="2%" valign="bottom" style=
"padding:0in 0in 0in 0in;width:2.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
</td>
<td width="49%" valign="top" style=
"padding:0in 0in 0in 0in;width:49.0%;">
<p align="center" style=
"margin:0in 0in .0001pt;text-align:center;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
</td>
</tr>
<tr>
<td width="49%" valign="top" style=
"padding:0in 0in 0in 0in;width:49.0%;">
<p align="center" style=
"font-size:10.0pt;margin:0in 0in .0001pt;text-align:center;">
<font size="2" face="Times New Roman" style=
"font-size:10.0pt;">Non-accelerated filer</font> <font face=
"Wingdings">o</font></p>
</td>
<td width="2%" valign="bottom" style=
"padding:0in 0in 0in 0in;width:2.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>
</td>
<td width="49%" valign="top" style=
"padding:0in 0in 0in 0in;width:49.0%;">
<p align="center" style=
"font-size:10.0pt;margin:0in 0in .0001pt;text-align:center;">
<font size="2" face="Times New Roman" style=
"font-size:10.0pt;">Smaller reporting company</font> <font face=
"Wingdings">x</font></p>
</td>
</tr>
<tr>
<td width="49%" valign="top" style=
"padding:0in 0in 0in 0in;width:49.0%;">
<p align="center" style=
"margin:0in 0in .0001pt;text-align:center;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">(Do not check if a
smaller reporting company)</font></p>
</td>
<td width="2%" valign="bottom" style=
"padding:0in 0in 0in 0in;width:2.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>
</td>
<td width="49%" valign="top" style=
"padding:0in 0in 0in 0in;width:49.0%;">
<p align="center" style=
"margin:0in 0in .0001pt;text-align:center;"><font size="2" face=
"Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>
</td>
</tr>
<tr>
<td width="49%" valign="top" style=
"padding:0in 0in 0in 0in;width:49.0%;">
<p align="center" style=
"margin:0in 0in .0001pt;text-align:center;"><font size="2" face=
"Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>
</td>
<td width="2%" valign="bottom" style=
"padding:0in 0in 0in 0in;width:2.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>
</td>
<td width="49%" valign="top" style=
"padding:0in 0in 0in 0in;width:49.0%;">
<p align="center" style=
"font-size:10.0pt;margin:0in 0in .0001pt;text-align:center;">
<font size="2" face="Times New Roman" style=
"font-size:10.0pt;">Emerging growth company</font> <font face=
"Wingdings">x</font></p>
</td>
</tr>
</table>
</div>
<p style="margin:0in 0in .0001pt;"><font size="1" face=
"Times New Roman" style="font-size:9.0pt;">&nbsp;</font></p>
<p style=
"font-size:10.0pt;margin:0in 0in .0001pt;text-indent:.25in;">
<font size="2" face="Times New Roman" style="font-size:10.0pt;">If
an emerging growth company, indicate by check mark if the
registrant has elected not to use the extended transition period
for complying with any new or revised financial accounting
standards provided pursuant to Section&nbsp;13(a)&nbsp;of the
Exchange Act.</font> <font face="Wingdings">x</font></p>
<p style="margin:0in 0in .0001pt;"><font size="1" face=
"Times New Roman" style="font-size:9.0pt;">&nbsp;</font></p>
<p style=
"font-size:10.0pt;margin:0in 0in .0001pt;text-indent:.25in;">
<font size="2" face="Times New Roman" style=
"font-size:10.0pt;">Indicate by check mark whether the registrant
is a shell company (as defined in Rule&nbsp;12b-2 of the
Act).&nbsp;&nbsp; Yes</font> <font face="Wingdings">o</font> No
<font face="Wingdings">x</font></p>
<p style="margin:0in 0in .0001pt;"><font size="1" face=
"Times New Roman" style="font-size:9.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.25in;"><font size="2"
face="Times New Roman" style="font-size:10.0pt;">As of May&nbsp;10,
2018, the number of outstanding shares of the registrant’s common
stock, par value $0.001 per share, was 5,562,872.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="1" face=
"Times New Roman" style="font-size:9.0pt;">&nbsp;</font></p>
<div style=
"border-bottom:solid windowtext 3.0pt;border-left:none;border-right:none;border-top:solid windowtext 1.0pt;padding:1.0pt 0in 1.0pt 0in;">
<p style="border:none;margin:0in 0in .0001pt;padding:0in;">
<font size="1" face="Times New Roman" style=
"font-size:1.0pt;">&nbsp;</font></p>
</div>
<p style="margin:0in 0in .0001pt;"><font size="1" face=
"Times New Roman" style="font-size:9.0pt;">&nbsp;</font></p>
<div style="margin:0in 0in .0001pt;">
<hr size="3" width="100%" noshade="noshade" align="left" style=
"color:#010101;" /></div>
</div>
<!-- SEQ.=1,FOLIO='',FILE='C:\JMS\105435\18-8644-1\task8901253\8644-1-ba.htm',USER='105435',CD='May 15 17:57 2018' --><br clear="all"
style="page-break-before:always;" />
<div style="font-family:Times New Roman;">
<p style="margin:0in 0in .0001pt;"><a href="#TableOfContents"
title="Click to go to Table of Contents"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">Table of
Contents</font></a></p>
<p align="center" style=
"margin:0in 0in .0001pt;text-align:center;"><b><font size="2" face=
"Times New Roman" style=
"font-size:10.0pt;font-weight:bold;">&nbsp;</font></b></p>
<p align="center" style=
"margin:0in 0in .0001pt;text-align:center;"><b><font size="2" face=
"Times New Roman" style=
"font-size:10.0pt;font-weight:bold;">SPECIAL NOTE REGARDING
FORWARD-LOOKING STATEMENTS</font></b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2"
face="Times New Roman" style="font-size:10.0pt;">This Quarterly
Report on Form&nbsp;10-Q contains forward-looking statements
concerning our business, operations and financial performance and
condition, as well as our plans, objectives and expectations for
our business, operations and financial performance and condition.
Any statements contained herein that are not statements of
historical facts may be deemed to be forward-looking statements. In
some cases, you can identify forward-looking statements by
terminology such as “anticipate,” “assume,” “believe,” 
“contemplate,” “continue,” “could,” “due,” “estimate,” “expect,” 
“goal,” “intend,” “may,” “objective,” “plan,” “predict,” 
“potential,” “positioned,” “seek,” “should,” “target,” “will,” 
“would” and other similar expressions that are predictions of or
indicate future events and future trends, or the negative of these
terms or other comparable terminology. These forward-looking
statements include, but are not limited to, statements
about:</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style=
"font-size:10.0pt;margin:0in 0in .0001pt .75in;text-indent:-.25in;">
<font size="2" face="Symbol" style=
"font-size:10.0pt;">·</font><font size="1" style=
"font-size:3.0pt;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</font>
the outcome of and expectations regarding our clinical studies,
including our INSIGHT trial and plans to conduct further clinical
studies;</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style=
"font-size:10.0pt;margin:0in 0in .0001pt .75in;text-indent:-.25in;">
<font size="2" face="Symbol" style=
"font-size:10.0pt;">·</font><font size="1" style=
"font-size:3.0pt;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</font>
our plans to modify our current products, or develop new products,
to address additional indications;</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style=
"font-size:10.0pt;margin:0in 0in .0001pt .75in;text-indent:-.25in;">
<font size="2" face="Symbol" style=
"font-size:10.0pt;">·</font><font size="1" style=
"font-size:3.0pt;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</font>
our ability to obtain additional financing through future equity or
debt financings;</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style=
"font-size:10.0pt;margin:0in 0in .0001pt .75in;text-indent:-.25in;">
<font size="2" face="Symbol" style=
"font-size:10.0pt;">·</font><font size="1" style=
"font-size:3.0pt;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</font>
the expected timing of 510(k)&nbsp;clearances by FDA for enhanced
versions of Pantheris;</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style=
"font-size:10.0pt;margin:0in 0in .0001pt .75in;text-indent:-.25in;">
<font size="2" face="Symbol" style=
"font-size:10.0pt;">·</font><font size="1" style=
"font-size:3.0pt;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</font>
the expected timing of 510(k)&nbsp;submission to FDA, and
associated marketing clearances by FDA, for additional versions of
Pantheris designed for use in smaller vessels;</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style=
"font-size:10.0pt;margin:0in 0in .0001pt .75in;text-indent:-.25in;">
<font size="2" face="Symbol" style=
"font-size:10.0pt;">·</font><font size="1" style=
"font-size:3.0pt;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</font>
the expected growth in our business and our organization;</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style=
"font-size:10.0pt;margin:0in 0in .0001pt .75in;text-indent:-.25in;">
<font size="2" face="Symbol" style=
"font-size:10.0pt;">·</font><font size="1" style=
"font-size:3.0pt;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</font>
our expectations regarding government and third-party payor
coverage and reimbursement, including the ability of Pantheris to
qualify for reimbursement codes used by other atherectomy
products;</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style=
"font-size:10.0pt;margin:0in 0in .0001pt .75in;text-indent:-.25in;">
<font size="2" face="Symbol" style=
"font-size:10.0pt;">·</font><font size="1" style=
"font-size:3.0pt;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</font>
our ability to continue as a going concern;</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style=
"font-size:10.0pt;margin:0in 0in .0001pt .75in;text-indent:-.25in;">
<font size="2" face="Symbol" style=
"font-size:10.0pt;">·</font><font size="1" style=
"font-size:3.0pt;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</font>
our ability to retain and recruit key personnel, including the
continued development of our sales and marketing
infrastructure;</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style=
"font-size:10.0pt;margin:0in 0in .0001pt .75in;text-indent:-.25in;">
<font size="2" face="Symbol" style=
"font-size:10.0pt;">·</font><font size="1" style=
"font-size:3.0pt;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</font>
our ability to obtain and maintain intellectual property protection
for our products;</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style=
"font-size:10.0pt;margin:0in 0in .0001pt .75in;text-indent:-.25in;">
<font size="2" face="Symbol" style=
"font-size:10.0pt;">·</font><font size="1" style=
"font-size:3.0pt;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</font>
our estimates of our expenses, ongoing losses, future revenue,
capital requirements and our needs for, or ability to obtain,
additional financing;</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style=
"font-size:10.0pt;margin:0in 0in .0001pt .75in;text-indent:-.25in;">
<font size="2" face="Symbol" style=
"font-size:10.0pt;">·</font><font size="1" style=
"font-size:3.0pt;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</font>
our expectations regarding revenue, cost of revenue, gross margins,
and expenses, including research and development and selling,
general and administrative expenses;</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style=
"font-size:10.0pt;margin:0in 0in .0001pt .75in;text-indent:-.25in;">
<font size="2" face="Symbol" style=
"font-size:10.0pt;">·</font><font size="1" style=
"font-size:3.0pt;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</font>
our expectations regarding the time during which we will be an
emerging growth company under the Jumpstart Our Business Startups
Act;</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style=
"font-size:10.0pt;margin:0in 0in .0001pt .75in;text-indent:-.25in;">
<font size="2" face="Symbol" style=
"font-size:10.0pt;">·</font><font size="1" style=
"font-size:3.0pt;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</font>
our ability to identify and develop new and planned products and
acquire new products;</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style=
"font-size:10.0pt;margin:0in 0in .0001pt .75in;text-indent:-.25in;">
<font size="2" face="Symbol" style=
"font-size:10.0pt;">·</font><font size="1" style=
"font-size:3.0pt;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</font>
our financial performance;</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style=
"font-size:10.0pt;margin:0in 0in .0001pt .75in;text-indent:-.25in;">
<font size="2" face="Symbol" style=
"font-size:10.0pt;">·</font><font size="1" style=
"font-size:3.0pt;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</font>
our ability to remain in compliance with laws and regulations that
currently apply or become applicable to our business, both in the
United States and internationally; and</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style=
"font-size:10.0pt;margin:0in 0in .0001pt .75in;text-indent:-.25in;">
<font size="2" face="Symbol" style=
"font-size:10.0pt;">·</font><font size="1" style=
"font-size:3.0pt;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</font>
developments and projections relating to our competitors or our
industry.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<div style="margin:0in 0in .0001pt;">
<hr size="3" width="100%" noshade="noshade" align="left" style=
"color:#010101;" /></div>
</div>
<!-- SEQ.=1,FOLIO='',FILE='C:\JMS\C902520\18-8644-1\task8901027\8644-1-bc.htm',USER='C902520',CD='May 15 13:41 2018' --><br clear="all"
style="page-break-before:always;" />
<div>
<p style="margin:0in 0in .0001pt;"><a href="#TableOfContents"
title="Click to go to Table of Contents"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">Table of
Contents</font></a></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2"
face="Times New Roman" style="font-size:10.0pt;">We believe that it
is important to communicate our future expectations to our
investors. However, there may be events in the future that we are
not able to accurately predict or control and that may cause our
actual results to differ materially from the expectations we
describe in our forward-looking statements. These forward-looking
statements are based on management’s current expectations,
estimates, forecasts and projections about our business and the
industry in which we operate and management’s beliefs and
assumptions and are not guarantees of future performance or
development and involve known and unknown risks, uncertainties and
other factors that are in some cases beyond our control. As a
result, any or all of our forward-looking statements in this
Quarterly Report on Form&nbsp;10-Q may turn out to be inaccurate.
Factors that may cause actual results to differ materially from
current expectations include, among other things, those listed
under “Risk Factors” and elsewhere in this Quarterly Report on
Form&nbsp;10-Q. We urge you to consider these factors carefully in
evaluating the forward-looking statements. These forward-looking
statements speak only as of the date of this Quarterly Report on
Form&nbsp;10-Q. We assume no obligation to update or revise these
forward-looking statements for any reason, even if new information
becomes available in the future.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2"
face="Times New Roman" style="font-size:10.0pt;">You should not
rely upon forward-looking statements as predictions of future
events. Although we believe that the expectations reflected in the
forward-looking statements are reasonable, we cannot guarantee that
the future results, levels of activity, performance or events and
circumstances reflected in the forward-looking statements will be
achieved or occur. Except as required by law, we undertake no
obligation to update publicly any forward-looking statements for
any reason after the date of this Quarterly Report on
Form&nbsp;10-Q to conform these statements to actual results or to
changes in our expectations.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2"
face="Times New Roman" style="font-size:10.0pt;">You should read
this Quarterly Report on Form&nbsp;10-Q and the documents that we
reference in this Quarterly Report on Form&nbsp;10-Q and have filed
with the United States Securities and Exchange Commission (“SEC”)
as exhibits to the Quarterly Report on Form&nbsp;10-Q with the
understanding that our actual future results, levels of activity,
performance and events and circumstances may be materially
different from what we expect.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<div style="margin:0in 0in .0001pt;">
<hr size="3" width="100%" noshade="noshade" align="left" style=
"color:#010101;" /></div>
</div>
<!-- SEQ.=1,FOLIO='',FILE='C:\JMS\C902520\18-8644-1\task8901027\8644-1-bc.htm',USER='C902520',CD='May 15 13:41 2018' --><br clear="all"
style="page-break-before:always;" />
<div>
<p style="margin:0in 0in .0001pt;"><a href="#TableOfContents"
title="Click to go to Table of Contents"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">Table of
Contents</font></a></p>
<p align="center" style=
"margin:0in 0in .0001pt;text-align:center;"><b><font size="2" face=
"Times New Roman" style=
"font-size:10.0pt;font-weight:bold;">&nbsp;</font></b></p>
<p align="center" style=
"margin:0in 0in .0001pt;text-align:center;"><b><font size="2" face=
"Times New Roman" style=
"font-size:10.0pt;font-weight:bold;">AVINGER,&nbsp;INC.</font></b></p>
<p align="center" style=
"margin:0in 0in .0001pt;text-align:center;"><b><font size="2" face=
"Times New Roman" style="font-size:10.0pt;font-weight:bold;">AS OF
AND FOR THE QUARTERLY PERIOD ENDED SEPTEMBER 30,
2017</font></b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style=
"margin:0in 0in .0001pt;text-align:center;"><b><font size="2" face=
"Times New Roman" style="font-size:10.0pt;font-weight:bold;">TABLE
OF CONT<a name="TableOfContents" id=
"TableOfContents"></a>ENTS</font></b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<table border="0" cellspacing="0" cellpadding="0" width="100%"
style="border-collapse:collapse;">
<tr>
<td width="10%" valign="bottom" style=
"padding:0in 0in 0in 0in;width:10.84%;">
<p style="margin:0in 0in .0001pt;"><b><font size="1" face=
"Times New Roman" style=
"font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>
</td>
<td width="79%" valign="bottom" style=
"padding:0in 0in 0in 0in;width:79.16%;">
<p align="center" style=
"margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face=
"Times New Roman" style=
"font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>
</td>
<td width="10%" valign="bottom" style=
"border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:10.0%;">
<p align="center" style=
"margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face=
"Times New Roman" style=
"font-size:8.0pt;font-weight:bold;">Page</font></b></p>
</td>
</tr>
<tr>
<td width="10%" valign="top" style=
"padding:0in 0in 0in 0in;width:10.84%;">
<p style="margin:0in 0in .0001pt;"><a href=
"#PARTI_FINANCIALINFORMATION_115827"><font size="2" face=
"Times New Roman" style=
"font-size:10.0pt;"><b>Part&nbsp;I</b></font></a></p>
</td>
<td width="79%" valign="top" style=
"padding:0in 0in 0in 0in;width:79.16%;">
<p style="margin:0in 0in .0001pt;"><a href=
"#PARTI_FINANCIALINFORMATION_115827"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;"><b>Financial
Information</b></font></a></p>
</td>
<td width="10%" valign="bottom" style=
"padding:0in 0in 0in 0in;width:10.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;">
<font size="2" face="Times New Roman" style=
"font-size:1.0pt;">&nbsp;</font></p>
</td>
</tr>
<tr>
<td width="10%" valign="top" style=
"padding:0in 0in 0in 0in;width:10.84%;">
<p style="margin:0in 0in .0001pt;"><a href=
"#ITEM1_UNAUDITEDFINANCIALSTATEMEN_123519"><font size="2" face=
"Times New Roman" style=
"font-size:10.0pt;">Item&nbsp;1.</font></a></p>
</td>
<td width="79%" valign="top" style=
"padding:0in 0in 0in 0in;width:79.16%;">
<p style="margin:0in 0in .0001pt;"><a href=
"#ITEM1_UNAUDITEDFINANCIALSTATEMEN_123519"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">Unaudited Financial
Statements</font></a></p>
</td>
<td width="10%" valign="bottom" style=
"padding:0in 0in 0in 0in;width:10.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;">
<font size="2" face="Times New Roman" style=
"font-size:10.0pt;">1</font></p>
</td>
</tr>
<tr>
<td width="10%" valign="top" style=
"padding:0in 0in 0in 0in;width:10.84%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>
</td>
<td width="79%" valign="top" style=
"padding:0in 0in 0in 0in;width:79.16%;">
<p style="margin:0in 0in .0001pt;"><a href=
"#CONDENSEDBALANCESHEETS_123543" title="Click to goto "><font size=
"2" face="Times New Roman" style="font-size:10.0pt;">Condensed
Balance Sheets</font></a></p>
</td>
<td width="10%" valign="top" style=
"padding:0in 0in 0in 0in;width:10.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;">
<font size="2" face="Times New Roman" style=
"font-size:10.0pt;">1</font></p>
</td>
</tr>
<tr>
<td width="10%" valign="top" style=
"padding:0in 0in 0in 0in;width:10.84%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>
</td>
<td width="79%" valign="top" style=
"padding:0in 0in 0in 0in;width:79.16%;">
<p style="margin:0in 0in .0001pt;"><a href=
"#CONDENSEDSTATEMENTSOFOPERATIONSA_123604" title=
"Click to goto "><font size="2" face="Times New Roman" style=
"font-size:10.0pt;">Condensed Statements of Operations and
Comprehensive Loss</font></a></p>
</td>
<td width="10%" valign="top" style=
"padding:0in 0in 0in 0in;width:10.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;">
<font size="2" face="Times New Roman" style=
"font-size:10.0pt;">2</font></p>
</td>
</tr>
<tr>
<td width="10%" valign="top" style=
"padding:0in 0in 0in 0in;width:10.84%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>
</td>
<td width="79%" valign="top" style=
"padding:0in 0in 0in 0in;width:79.16%;">
<p style="margin:0in 0in .0001pt;"><a href=
"#CONDENSEDSTATEMENTSOFCASHFLOWS_123612" title=
"Click to goto "><font size="2" face="Times New Roman" style=
"font-size:10.0pt;">Condensed Statements of Cash
Flows</font></a></p>
</td>
<td width="10%" valign="top" style=
"padding:0in 0in 0in 0in;width:10.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;">
<font size="2" face="Times New Roman" style=
"font-size:10.0pt;">3</font></p>
</td>
</tr>
<tr>
<td width="10%" valign="top" style=
"padding:0in 0in 0in 0in;width:10.84%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>
</td>
<td width="79%" valign="top" style=
"padding:0in 0in 0in 0in;width:79.16%;">
<p style="margin:0in 0in .0001pt;"><a href=
"#NotestoCondensedFinancialStateme_114412" title=
"Click to goto "><font size="2" face="Times New Roman" style=
"font-size:10.0pt;">Notes to Condensed Financial
Statements</font></a></p>
</td>
<td width="10%" valign="top" style=
"padding:0in 0in 0in 0in;width:10.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;">
<font size="2" face="Times New Roman" style=
"font-size:10.0pt;">4</font></p>
</td>
</tr>
<tr>
<td width="10%" valign="top" style=
"padding:0in 0in 0in 0in;width:10.84%;">
<p style="margin:0in 0in .0001pt;"><a href=
"#ITEM2_MANAGEMENTSDISCUSSIONANDAN_113703"><font size="2" face=
"Times New Roman" style=
"font-size:10.0pt;">Item&nbsp;2.</font></a></p>
</td>
<td width="79%" valign="top" style=
"padding:0in 0in 0in 0in;width:79.16%;">
<p style="margin:0in 0in .0001pt;"><a href=
"#ITEM2_MANAGEMENTSDISCUSSIONANDAN_113703"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">Management’s Discussion
and Analysis of Financial Condition and Results of
Operations</font></a></p>
</td>
<td width="10%" valign="bottom" style=
"padding:0in 0in 0in 0in;width:10.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;">
<font size="2" face="Times New Roman" style=
"font-size:10.0pt;">22</font></p>
</td>
</tr>
<tr>
<td width="10%" valign="top" style=
"padding:0in 0in 0in 0in;width:10.84%;">
<p style="margin:0in 0in .0001pt;"><a href=
"#ITEM3_QUANTITATIVEANDQUALITATIVE_114241"><font size="2" face=
"Times New Roman" style=
"font-size:10.0pt;">Item&nbsp;3.</font></a></p>
</td>
<td width="79%" valign="top" style=
"padding:0in 0in 0in 0in;width:79.16%;">
<p style="margin:0in 0in .0001pt;"><a href=
"#ITEM3_QUANTITATIVEANDQUALITATIVE_114241"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">Quantitative and
Qualitative Disclosures About Market Risk</font></a></p>
</td>
<td width="10%" valign="bottom" style=
"padding:0in 0in 0in 0in;width:10.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;">
<font size="2" face="Times New Roman" style=
"font-size:10.0pt;">31</font></p>
</td>
</tr>
<tr>
<td width="10%" valign="top" style=
"padding:0in 0in 0in 0in;width:10.84%;">
<p style="margin:0in 0in .0001pt;"><a href=
"#ITEM4_CONTROLSANDPROCEDURES_114248"><font size="2" face=
"Times New Roman" style=
"font-size:10.0pt;">Item&nbsp;4.</font></a></p>
</td>
<td width="79%" valign="top" style=
"padding:0in 0in 0in 0in;width:79.16%;">
<p style="margin:0in 0in .0001pt;"><a href=
"#ITEM4_CONTROLSANDPROCEDURES_114248"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">Controls and
Procedures</font></a></p>
</td>
<td width="10%" valign="bottom" style=
"padding:0in 0in 0in 0in;width:10.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;">
<font size="2" face="Times New Roman" style=
"font-size:10.0pt;">31</font></p>
</td>
</tr>
<tr>
<td width="10%" valign="top" style=
"padding:0in 0in 0in 0in;width:10.84%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
</td>
<td width="79%" valign="top" style=
"padding:0in 0in 0in 0in;width:79.16%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
</td>
<td width="10%" valign="bottom" style=
"padding:0in 0in 0in 0in;width:10.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;">
<font size="2" face="Times New Roman" style=
"font-size:10.0pt;">&nbsp;</font></p>
</td>
</tr>
<tr>
<td width="10%" valign="top" style=
"padding:0in 0in 0in 0in;width:10.84%;">
<p style="margin:0in 0in .0001pt;"><a href=
"#PARTII_OTHERINFORMATION_114446"><font size="2" face=
"Times New Roman" style=
"font-size:10.0pt;"><b>Part&nbsp;II</b></font></a></p>
</td>
<td width="79%" valign="top" style=
"padding:0in 0in 0in 0in;width:79.16%;">
<p style="margin:0in 0in .0001pt;"><a href=
"#PARTII_OTHERINFORMATION_114446"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;"><b>Other
Information</b></font></a></p>
</td>
<td width="10%" valign="bottom" style=
"padding:0in 0in 0in 0in;width:10.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;">
<font size="2" face="Times New Roman" style=
"font-size:1.0pt;">&nbsp;</font></p>
</td>
</tr>
<tr>
<td width="10%" valign="top" style=
"padding:0in 0in 0in 0in;width:10.84%;">
<p style="margin:0in 0in .0001pt;"><a href=
"#ITEM1_LEGALPROCEEDINGS_114448"><font size="2" face=
"Times New Roman" style=
"font-size:10.0pt;">Item&nbsp;1.</font></a></p>
</td>
<td width="79%" valign="top" style=
"padding:0in 0in 0in 0in;width:79.16%;">
<p style="margin:0in 0in .0001pt;"><a href=
"#ITEM1_LEGALPROCEEDINGS_114448"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">Legal
Proceedings</font></a></p>
</td>
<td width="10%" valign="bottom" style=
"padding:0in 0in 0in 0in;width:10.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;">
<font size="2" face="Times New Roman" style=
"font-size:10.0pt;">33</font></p>
</td>
</tr>
<tr>
<td width="10%" valign="top" style=
"padding:0in 0in 0in 0in;width:10.84%;">
<p style="margin:0in 0in .0001pt;"><a href=
"#ITEM1A_RISKFACTORS_114449"><font size="2" face="Times New Roman"
style="font-size:10.0pt;">Item&nbsp;1A.</font></a></p>
</td>
<td width="79%" valign="top" style=
"padding:0in 0in 0in 0in;width:79.16%;">
<p style="margin:0in 0in .0001pt;"><a href=
"#ITEM1A_RISKFACTORS_114449"><font size="2" face="Times New Roman"
style="font-size:10.0pt;">Risk Factors</font></a></p>
</td>
<td width="10%" valign="bottom" style=
"padding:0in 0in 0in 0in;width:10.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;">
<font size="2" face="Times New Roman" style=
"font-size:10.0pt;">33</font></p>
</td>
</tr>
<tr>
<td width="10%" valign="top" style=
"padding:0in 0in 0in 0in;width:10.84%;">
<p style="margin:0in 0in .0001pt;"><a href=
"#ITEM2_UNREGISTEREDSALESOFEQUITYS_121058"><font size="2" face=
"Times New Roman" style=
"font-size:10.0pt;">Item&nbsp;2.</font></a></p>
</td>
<td width="79%" valign="top" style=
"padding:0in 0in 0in 0in;width:79.16%;">
<p style="margin:0in 0in .0001pt;"><a href=
"#ITEM2_UNREGISTEREDSALESOFEQUITYS_121058"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">Unregistered Sales of
Equity Securities and Use of Proceeds</font></a></p>
</td>
<td width="10%" valign="bottom" style=
"padding:0in 0in 0in 0in;width:10.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;">
<font size="2" face="Times New Roman" style=
"font-size:10.0pt;">60</font></p>
</td>
</tr>
<tr>
<td width="10%" valign="top" style=
"padding:0in 0in 0in 0in;width:10.84%;">
<p style="margin:0in 0in .0001pt;"><a href=
"#ITEM3_DEFAULTSUPONSENIORSECURITI_121104"><font size="2" face=
"Times New Roman" style=
"font-size:10.0pt;">Item&nbsp;3.</font></a></p>
</td>
<td width="79%" valign="top" style=
"padding:0in 0in 0in 0in;width:79.16%;">
<p style="margin:0in 0in .0001pt;"><a href=
"#ITEM3_DEFAULTSUPONSENIORSECURITI_121104"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">Defaults Upon Senior
Securities</font></a></p>
</td>
<td width="10%" valign="bottom" style=
"padding:0in 0in 0in 0in;width:10.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;">
<font size="2" face="Times New Roman" style=
"font-size:10.0pt;">60</font></p>
</td>
</tr>
<tr>
<td width="10%" valign="top" style=
"padding:0in 0in 0in 0in;width:10.84%;">
<p style="margin:0in 0in .0001pt;"><a href=
"#ITEM4_MINESAFETYDISCLOSURES_121108"><font size="2" face=
"Times New Roman" style=
"font-size:10.0pt;">Item&nbsp;4.</font></a></p>
</td>
<td width="79%" valign="top" style=
"padding:0in 0in 0in 0in;width:79.16%;">
<p style="margin:0in 0in .0001pt;"><a href=
"#ITEM4_MINESAFETYDISCLOSURES_121108"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">Mine Safety
Disclosures</font></a></p>
</td>
<td width="10%" valign="bottom" style=
"padding:0in 0in 0in 0in;width:10.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;">
<font size="2" face="Times New Roman" style=
"font-size:10.0pt;">60</font></p>
</td>
</tr>
<tr>
<td width="10%" valign="top" style=
"padding:0in 0in 0in 0in;width:10.84%;">
<p style="margin:0in 0in .0001pt;"><a href=
"#ITEM5_OTHERINFORMATION_121112"><font size="2" face=
"Times New Roman" style=
"font-size:10.0pt;">Item&nbsp;5.</font></a></p>
</td>
<td width="79%" valign="top" style=
"padding:0in 0in 0in 0in;width:79.16%;">
<p style="margin:0in 0in .0001pt;"><a href=
"#ITEM5_OTHERINFORMATION_121112"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">Other
Information</font></a></p>
</td>
<td width="10%" valign="bottom" style=
"padding:0in 0in 0in 0in;width:10.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;">
<font size="2" face="Times New Roman" style=
"font-size:10.0pt;">60</font></p>
</td>
</tr>
<tr>
<td width="10%" valign="top" style=
"padding:0in 0in 0in 0in;width:10.84%;">
<p style="margin:0in 0in .0001pt;"><a href=
"#ITEM6_EXHIBITS_121119"><font size="2" face="Times New Roman"
style="font-size:10.0pt;">Item&nbsp;6.</font></a></p>
</td>
<td width="79%" valign="top" style=
"padding:0in 0in 0in 0in;width:79.16%;">
<p style="margin:0in 0in .0001pt;"><a href=
"#ITEM6_EXHIBITS_121119"><font size="2" face="Times New Roman"
style="font-size:10.0pt;">Exhibits</font></a></p>
</td>
<td width="10%" valign="bottom" style=
"padding:0in 0in 0in 0in;width:10.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;">
<font size="2" face="Times New Roman" style=
"font-size:10.0pt;">61</font></p>
</td>
</tr>
<tr>
<td width="10%" valign="top" style=
"padding:0in 0in 0in 0in;width:10.84%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
</td>
<td width="79%" valign="top" style=
"padding:0in 0in 0in 0in;width:79.16%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
</td>
<td width="10%" valign="bottom" style=
"padding:0in 0in 0in 0in;width:10.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;">
<font size="2" face="Times New Roman" style=
"font-size:10.0pt;">&nbsp;</font></p>
</td>
</tr>
<tr>
<td width="90%" colspan="2" valign="top" style=
"padding:0in 0in 0in 0in;width:90.0%;">
<p style="margin:0in 0in .0001pt 10.0pt;text-indent:-10.0pt;">
<a href="#SIGNATURES_114037" title="Click to goto "><font size="2"
face="Times New Roman" style=
"font-size:10.0pt;">Signatures</font></a></p>
</td>
<td width="10%" valign="bottom" style=
"padding:0in 0in 0in 0in;width:10.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;">
<font size="2" face="Times New Roman" style=
"font-size:10.0pt;">62</font></p>
</td>
</tr>
</table>
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:39.0pt;"><font size=
"2" face="Times New Roman" style="font-size:10.0pt;">“Avinger,” 
“Pantheris,” and “Lumivascular” are trademarks of our company. Our
logo and our other trade names, trademarks and service marks
appearing in this Quarterly Report on Form&nbsp;10-Q are our
property. Other trade names, trademarks and service marks appearing
in this Quarterly Report on Form&nbsp;10-Q are the property of
their respective owners. Solely for convenience, our trademarks and
trade names referred to in this Quarterly Report on Form&nbsp;10-Q
appear without the ™ symbol, but those references are not intended
to indicate, in any way, that we will not assert, to the fullest
extent under applicable law, our rights, or the right of the
applicable licensor to these trademarks and trade names.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<div style="margin:0in 0in .0001pt;">
<hr size="3" width="100%" noshade="noshade" align="left" style=
"color:#010101;" /></div>
</div>
<!-- SEQ.=1,FOLIO='',FILE='C:\JMS\109761\18-8644-1\task8901132\8644-1-bg.htm',USER='109761',CD='May 15 15:27 2018' --><br clear="all"
style="page-break-before:always;" />
<div style="font-family:Times New Roman;">
<p style="margin:0in 0in .0001pt;"><a href="#TableOfContents"
title="Click to go to Table of Contents"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">Table of
Contents</font></a></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style=
"margin:0in 0in .0001pt;text-align:center;"><b><font size="2" face=
"Times New Roman" style=
"font-size:10.0pt;font-weight:bold;">PART&nbsp;I. FINANCIAL
INFORMATION</font></b><a name="PARTI_FINANCIALINFORMATION_115827"
id="PARTI_FINANCIALINFORMATION_115827"></a></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><b><font size="2" face=
"Times New Roman" style="font-size:10.0pt;font-weight:bold;">ITEM
1.&nbsp;&nbsp;&nbsp;&nbsp;UNAUDITED FINANCIAL
STATEMENTS</font></b><a name=
"ITEM1_UNAUDITEDFINANCIALSTATEMEN_123519" id=
"ITEM1_UNAUDITEDFINANCIALSTATEMEN_123519"></a></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style=
"margin:0in 0in .0001pt;text-align:center;"><b><font size="2" face=
"Times New Roman" style=
"font-size:10.0pt;font-weight:bold;">AVINGER,&nbsp;INC.</font></b></p>
<p align="center" style=
"margin:0in 0in .0001pt;text-align:center;"><b><font size="2" face=
"Times New Roman" style=
"font-size:10.0pt;font-weight:bold;">CONDENSED BALANCE
SHEETS</font></b><a name="CONDENSEDBALANCESHEETS_123543" id=
"CONDENSEDBALANCESHEETS_123543"></a></p>
<p align="center" style=
"margin:0in 0in .0001pt;text-align:center;"><b><font size="2" face=
"Times New Roman" style=
"font-size:10.0pt;font-weight:bold;">(unaudited)</font></b></p>
<p align="center" style=
"margin:0in 0in .0001pt;text-align:center;"><b><i><font size="2"
face="Times New Roman" style=
"font-size:10.0pt;font-style:italic;font-weight:bold;">(In
thousands, except share and per share data)</font></i></b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<table border="0" cellspacing="0" cellpadding="0" width="100%"
style="border-collapse:collapse;">
<tr>
<td width="70%" valign="bottom" style=
"padding:0in 0in 0in 0in;width:70.0%;">
<p style="margin:0in 0in .0001pt;"><b><font size="1" face=
"Times New Roman" style=
"font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>
</td>
<td width="2%" valign="bottom" style=
"padding:0in 0in 0in 0in;width:2.5%;">
<p align="center" style=
"margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face=
"Times New Roman" style=
"font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>
</td>
<td width="12%" colspan="2" valign="bottom" style=
"padding:0in 0in 0in 0in;width:12.0%;">
<p align="center" style=
"margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face=
"Times New Roman" style=
"font-size:8.0pt;font-weight:bold;">March&nbsp;31,</font></b></p>
</td>
<td width="2%" valign="bottom" style=
"padding:0in 0in 0in 0in;width:2.5%;">
<p align="center" style=
"margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face=
"Times New Roman" style=
"font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>
</td>
<td width="12%" colspan="2" valign="bottom" style=
"padding:0in 0in 0in 0in;width:12.0%;">
<p align="center" style=
"margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face=
"Times New Roman" style=
"font-size:8.0pt;font-weight:bold;">December&nbsp;31,</font></b></p>
</td>
<td width="1%" valign="bottom" style=
"padding:0in 0in 0in 0in;width:1.0%;">
<p align="center" style=
"margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face=
"Times New Roman" style=
"font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>
</td>
</tr>
<tr>
<td width="70%" valign="bottom" style=
"padding:0in 0in 0in 0in;width:70.0%;">
<p style="margin:0in 0in .0001pt;"><b><font size="1" face=
"Times New Roman" style=
"font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>
</td>
<td width="2%" valign="bottom" style=
"padding:0in 0in 0in 0in;width:2.5%;">
<p align="center" style=
"margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face=
"Times New Roman" style=
"font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>
</td>
<td width="12%" colspan="2" valign="bottom" style=
"border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:12.0%;">
<p align="center" style=
"margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face=
"Times New Roman" style=
"font-size:8.0pt;font-weight:bold;">2018</font></b></p>
</td>
<td width="2%" valign="bottom" style=
"padding:0in 0in 0in 0in;width:2.5%;">
<p align="center" style=
"margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face=
"Times New Roman" style=
"font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>
</td>
<td width="12%" colspan="2" valign="bottom" style=
"border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:12.0%;">
<p align="center" style=
"margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face=
"Times New Roman" style=
"font-size:8.0pt;font-weight:bold;">2017</font></b></p>
</td>
<td width="1%" valign="bottom" style=
"padding:0in 0in 0in 0in;width:1.0%;">
<p align="center" style=
"margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face=
"Times New Roman" style=
"font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>
</td>
</tr>
<tr>
<td width="70%" valign="top" bgcolor="#CCEEFF" style=
"background:#CCEEFF;padding:0in 0in 0in 0in;width:70.0%;">
<p style="margin:0in 0in .0001pt 10.1pt;text-indent:-10.1pt;">
<b><font size="2" face="Times New Roman" style=
"font-size:10.0pt;font-weight:bold;">Assets</font></b></p>
</td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style=
"background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>
</td>
<td width="12%" colspan="2" valign="bottom" bgcolor="#CCEEFF"
style="background:#CCEEFF;padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;">
<font size="2" face="Times New Roman" style=
"font-size:1.0pt;">&nbsp;</font></p>
</td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style=
"background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>
</td>
<td width="12%" colspan="2" valign="bottom" bgcolor="#CCEEFF"
style="background:#CCEEFF;padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;">
<font size="2" face="Times New Roman" style=
"font-size:1.0pt;">&nbsp;</font></p>
</td>
<td width="1%" valign="bottom" bgcolor="#CCEEFF" style=
"background:#CCEEFF;padding:0in 0in 0in 0in;width:1.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>
</td>
</tr>
<tr>
<td width="70%" valign="top" style=
"padding:0in 0in 0in 0in;width:70.0%;">
<p style="margin:0in 0in .0001pt 10.1pt;text-indent:-10.1pt;">
<font size="2" face="Times New Roman" style=
"font-size:10.0pt;">Current assets:</font></p>
</td>
<td width="2%" valign="bottom" style=
"padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>
</td>
<td width="12%" colspan="2" valign="bottom" style=
"padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;">
<font size="2" face="Times New Roman" style=
"font-size:1.0pt;">&nbsp;</font></p>
</td>
<td width="2%" valign="bottom" style=
"padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>
</td>
<td width="12%" colspan="2" valign="bottom" style=
"padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;">
<font size="2" face="Times New Roman" style=
"font-size:1.0pt;">&nbsp;</font></p>
</td>
<td width="1%" valign="bottom" style=
"padding:0in 0in 0in 0in;width:1.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>
</td>
</tr>
<tr>
<td width="70%" valign="top" bgcolor="#CCEEFF" style=
"background:#CCEEFF;padding:0in 0in 0in 0in;width:70.0%;">
<p style="margin:0in 0in .0001pt 40.0pt;text-indent:-10.0pt;">
<font size="2" face="Times New Roman" style=
"font-size:10.0pt;">Cash and cash equivalents</font></p>
</td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style=
"background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>
</td>
<td width="1%" valign="bottom" bgcolor="#CCEEFF" style=
"background:#CCEEFF;padding:0in 0in 0in 0in;width:1.12%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">$</font></p>
</td>
<td width="10%" valign="bottom" bgcolor="#CCEEFF" style=
"background:#CCEEFF;padding:0in 0in 0in 0in;width:10.88%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;">
<font size="2" face="Times New Roman" style=
"font-size:10.0pt;">14,418</font></p>
</td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style=
"background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>
</td>
<td width="1%" valign="bottom" bgcolor="#CCEEFF" style=
"background:#CCEEFF;padding:0in 0in 0in 0in;width:1.12%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">$</font></p>
</td>
<td width="10%" valign="bottom" bgcolor="#CCEEFF" style=
"background:#CCEEFF;padding:0in 0in 0in 0in;width:10.88%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;">
<font size="2" face="Times New Roman" style=
"font-size:10.0pt;">5,389</font></p>
</td>
<td width="1%" valign="bottom" bgcolor="#CCEEFF" style=
"background:#CCEEFF;padding:0in 0in 0in 0in;width:1.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>
</td>
</tr>
<tr>
<td width="70%" valign="top" style=
"padding:0in 0in 0in 0in;width:70.0%;">
<p style="margin:0in 0in .0001pt 40.0pt;text-indent:-10.0pt;">
<font size="2" face="Times New Roman" style=
"font-size:10.0pt;">Accounts receivable, net of allowance for
doubtful accounts of $140 and $146 at March&nbsp;31, 2018 and
December&nbsp;31, 2017, respectively</font></p>
</td>
<td width="2%" valign="bottom" style=
"padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>
</td>
<td width="12%" colspan="2" valign="bottom" style=
"padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;">
<font size="2" face="Times New Roman" style=
"font-size:10.0pt;">1,354</font></p>
</td>
<td width="2%" valign="bottom" style=
"padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>
</td>
<td width="12%" colspan="2" valign="bottom" style=
"padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;">
<font size="2" face="Times New Roman" style=
"font-size:10.0pt;">1,127</font></p>
</td>
<td width="1%" valign="bottom" style=
"padding:0in 0in 0in 0in;width:1.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>
</td>
</tr>
<tr>
<td width="70%" valign="top" bgcolor="#CCEEFF" style=
"background:#CCEEFF;padding:0in 0in 0in 0in;width:70.0%;">
<p style="margin:0in 0in .0001pt 40.0pt;text-indent:-10.0pt;">
<font size="2" face="Times New Roman" style=
"font-size:10.0pt;">Inventories</font></p>
</td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style=
"background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>
</td>
<td width="12%" colspan="2" valign="bottom" bgcolor="#CCEEFF"
style="background:#CCEEFF;padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;">
<font size="2" face="Times New Roman" style=
"font-size:10.0pt;">4,007</font></p>
</td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style=
"background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>
</td>
<td width="12%" colspan="2" valign="bottom" bgcolor="#CCEEFF"
style="background:#CCEEFF;padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;">
<font size="2" face="Times New Roman" style=
"font-size:10.0pt;">4,295</font></p>
</td>
<td width="1%" valign="bottom" bgcolor="#CCEEFF" style=
"background:#CCEEFF;padding:0in 0in 0in 0in;width:1.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>
</td>
</tr>
<tr>
<td width="70%" valign="top" style=
"padding:0in 0in 0in 0in;width:70.0%;">
<p style="margin:0in 0in .0001pt 40.0pt;text-indent:-10.0pt;">
<font size="2" face="Times New Roman" style=
"font-size:10.0pt;">Prepaid expenses and other current
assets</font></p>
</td>
<td width="2%" valign="bottom" style=
"padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>
</td>
<td width="12%" colspan="2" valign="bottom" style=
"border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;">
<font size="2" face="Times New Roman" style=
"font-size:10.0pt;">1,163</font></p>
</td>
<td width="2%" valign="bottom" style=
"padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>
</td>
<td width="12%" colspan="2" valign="bottom" style=
"border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;">
<font size="2" face="Times New Roman" style=
"font-size:10.0pt;">640</font></p>
</td>
<td width="1%" valign="bottom" style=
"padding:0in 0in 0in 0in;width:1.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>
</td>
</tr>
<tr>
<td width="70%" valign="top" bgcolor="#CCEEFF" style=
"background:#CCEEFF;padding:0in 0in 0in 0in;width:70.0%;">
<p style="margin:0in 0in .0001pt 30.3pt;text-indent:-10.1pt;">
<font size="2" face="Times New Roman" style=
"font-size:10.0pt;">Total current assets</font></p>
</td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style=
"background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>
</td>
<td width="12%" colspan="2" valign="bottom" bgcolor="#CCEEFF"
style="background:#CCEEFF;padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;">
<font size="2" face="Times New Roman" style=
"font-size:10.0pt;">20,942</font></p>
</td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style=
"background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>
</td>
<td width="12%" colspan="2" valign="bottom" bgcolor="#CCEEFF"
style="background:#CCEEFF;padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;">
<font size="2" face="Times New Roman" style=
"font-size:10.0pt;">11,451</font></p>
</td>
<td width="1%" valign="bottom" bgcolor="#CCEEFF" style=
"background:#CCEEFF;padding:0in 0in 0in 0in;width:1.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>
</td>
</tr>
<tr>
<td width="70%" valign="top" style=
"padding:0in 0in 0in 0in;width:70.0%;">
<p style="margin:0in 0in .0001pt 10.1pt;text-indent:-10.1pt;">
<font size="2" face="Times New Roman" style=
"font-size:10.0pt;">&nbsp;</font></p>
</td>
<td width="2%" valign="bottom" style=
"padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
</td>
<td width="12%" colspan="2" valign="bottom" style=
"padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;">
<font size="2" face="Times New Roman" style=
"font-size:10.0pt;">&nbsp;</font></p>
</td>
<td width="2%" valign="bottom" style=
"padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
</td>
<td width="12%" colspan="2" valign="bottom" style=
"padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;">
<font size="2" face="Times New Roman" style=
"font-size:10.0pt;">&nbsp;</font></p>
</td>
<td width="1%" valign="bottom" style=
"padding:0in 0in 0in 0in;width:1.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
</td>
</tr>
<tr>
<td width="70%" valign="top" bgcolor="#CCEEFF" style=
"background:#CCEEFF;padding:0in 0in 0in 0in;width:70.0%;">
<p style="margin:0in 0in .0001pt 10.1pt;text-indent:-10.1pt;">
<font size="2" face="Times New Roman" style=
"font-size:10.0pt;">Property and equipment, net</font></p>
</td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style=
"background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>
</td>
<td width="12%" colspan="2" valign="bottom" bgcolor="#CCEEFF"
style="background:#CCEEFF;padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;">
<font size="2" face="Times New Roman" style=
"font-size:10.0pt;">2,431</font></p>
</td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style=
"background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>
</td>
<td width="12%" colspan="2" valign="bottom" bgcolor="#CCEEFF"
style="background:#CCEEFF;padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;">
<font size="2" face="Times New Roman" style=
"font-size:10.0pt;">2,950</font></p>
</td>
<td width="1%" valign="bottom" bgcolor="#CCEEFF" style=
"background:#CCEEFF;padding:0in 0in 0in 0in;width:1.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>
</td>
</tr>
<tr>
<td width="70%" valign="top" style=
"padding:0in 0in 0in 0in;width:70.0%;">
<p style="margin:0in 0in .0001pt 10.1pt;text-indent:-10.1pt;">
<font size="2" face="Times New Roman" style=
"font-size:10.0pt;">Other assets</font></p>
</td>
<td width="2%" valign="bottom" style=
"padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>
</td>
<td width="12%" colspan="2" valign="bottom" style=
"border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;">
<font size="2" face="Times New Roman" style=
"font-size:10.0pt;">590</font></p>
</td>
<td width="2%" valign="bottom" style=
"padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>
</td>
<td width="12%" colspan="2" valign="bottom" style=
"border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;">
<font size="2" face="Times New Roman" style=
"font-size:10.0pt;">687</font></p>
</td>
<td width="1%" valign="bottom" style=
"padding:0in 0in 0in 0in;width:1.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>
</td>
</tr>
<tr>
<td width="70%" valign="top" bgcolor="#CCEEFF" style=
"background:#CCEEFF;padding:0in 0in 0in 0in;width:70.0%;">
<p style="margin:0in 0in .0001pt 30.3pt;text-indent:-10.1pt;">
<font size="2" face="Times New Roman" style=
"font-size:10.0pt;">Total assets</font></p>
</td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style=
"background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>
</td>
<td width="1%" valign="bottom" bgcolor="#CCEEFF" style=
"background:#CCEEFF;border:none;border-bottom:double windowtext 2.25pt;padding:0in 0in 0in 0in;width:1.12%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">$</font></p>
</td>
<td width="10%" valign="bottom" bgcolor="#CCEEFF" style=
"background:#CCEEFF;border:none;border-bottom:double windowtext 2.25pt;padding:0in 0in 0in 0in;width:10.88%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;">
<font size="2" face="Times New Roman" style=
"font-size:10.0pt;">23,963</font></p>
</td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style=
"background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>
</td>
<td width="1%" valign="bottom" bgcolor="#CCEEFF" style=
"background:#CCEEFF;border:none;border-bottom:double windowtext 2.25pt;padding:0in 0in 0in 0in;width:1.12%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">$</font></p>
</td>
<td width="10%" valign="bottom" bgcolor="#CCEEFF" style=
"background:#CCEEFF;border:none;border-bottom:double windowtext 2.25pt;padding:0in 0in 0in 0in;width:10.88%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;">
<font size="2" face="Times New Roman" style=
"font-size:10.0pt;">15,088</font></p>
</td>
<td width="1%" valign="bottom" bgcolor="#CCEEFF" style=
"background:#CCEEFF;padding:0in 0in 0in 0in;width:1.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>
</td>
</tr>
<tr>
<td width="70%" valign="top" style=
"padding:0in 0in 0in 0in;width:70.0%;">
<p style="margin:0in 0in .0001pt 10.1pt;text-indent:-10.1pt;">
<font size="2" face="Times New Roman" style=
"font-size:10.0pt;">&nbsp;</font></p>
</td>
<td width="2%" valign="bottom" style=
"padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
</td>
<td width="12%" colspan="2" valign="bottom" style=
"padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;">
<font size="2" face="Times New Roman" style=
"font-size:10.0pt;">&nbsp;</font></p>
</td>
<td width="2%" valign="bottom" style=
"padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
</td>
<td width="12%" colspan="2" valign="bottom" style=
"padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;">
<font size="2" face="Times New Roman" style=
"font-size:10.0pt;">&nbsp;</font></p>
</td>
<td width="1%" valign="bottom" style=
"padding:0in 0in 0in 0in;width:1.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
</td>
</tr>
<tr>
<td width="70%" valign="top" bgcolor="#CCEEFF" style=
"background:#CCEEFF;padding:0in 0in 0in 0in;width:70.0%;">
<p style="margin:0in 0in .0001pt 10.1pt;text-indent:-10.1pt;">
<b><font size="2" face="Times New Roman" style=
"font-size:10.0pt;font-weight:bold;">Liabilities and stockholders’
equity (deficit)</font></b></p>
</td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style=
"background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>
</td>
<td width="12%" colspan="2" valign="bottom" bgcolor="#CCEEFF"
style="background:#CCEEFF;padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;">
<font size="2" face="Times New Roman" style=
"font-size:1.0pt;">&nbsp;</font></p>
</td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style=
"background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>
</td>
<td width="12%" colspan="2" valign="bottom" bgcolor="#CCEEFF"
style="background:#CCEEFF;padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;">
<font size="2" face="Times New Roman" style=
"font-size:1.0pt;">&nbsp;</font></p>
</td>
<td width="1%" valign="bottom" bgcolor="#CCEEFF" style=
"background:#CCEEFF;padding:0in 0in 0in 0in;width:1.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>
</td>
</tr>
<tr>
<td width="70%" valign="top" style=
"padding:0in 0in 0in 0in;width:70.0%;">
<p style="margin:0in 0in .0001pt 10.1pt;text-indent:-10.1pt;">
<font size="2" face="Times New Roman" style=
"font-size:10.0pt;">Current liabilities:</font></p>
</td>
<td width="2%" valign="bottom" style=
"padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>
</td>
<td width="12%" colspan="2" valign="bottom" style=
"padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;">
<font size="2" face="Times New Roman" style=
"font-size:1.0pt;">&nbsp;</font></p>
</td>
<td width="2%" valign="bottom" style=
"padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>
</td>
<td width="12%" colspan="2" valign="bottom" style=
"padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;">
<font size="2" face="Times New Roman" style=
"font-size:1.0pt;">&nbsp;</font></p>
</td>
<td width="1%" valign="bottom" style=
"padding:0in 0in 0in 0in;width:1.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>
</td>
</tr>
<tr>
<td width="70%" valign="top" bgcolor="#CCEEFF" style=
"background:#CCEEFF;padding:0in 0in 0in 0in;width:70.0%;">
<p style="margin:0in 0in .0001pt 40.0pt;text-indent:-10.0pt;">
<font size="2" face="Times New Roman" style=
"font-size:10.0pt;">Accounts payable</font></p>
</td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style=
"background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>
</td>
<td width="1%" valign="bottom" bgcolor="#CCEEFF" style=
"background:#CCEEFF;padding:0in 0in 0in 0in;width:1.12%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">$</font></p>
</td>
<td width="10%" valign="bottom" bgcolor="#CCEEFF" style=
"background:#CCEEFF;padding:0in 0in 0in 0in;width:10.88%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;">
<font size="2" face="Times New Roman" style=
"font-size:10.0pt;">2,160</font></p>
</td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style=
"background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>
</td>
<td width="1%" valign="bottom" bgcolor="#CCEEFF" style=
"background:#CCEEFF;padding:0in 0in 0in 0in;width:1.12%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">$</font></p>
</td>
<td width="10%" valign="bottom" bgcolor="#CCEEFF" style=
"background:#CCEEFF;padding:0in 0in 0in 0in;width:10.88%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;">
<font size="2" face="Times New Roman" style=
"font-size:10.0pt;">1,273</font></p>
</td>
<td width="1%" valign="bottom" bgcolor="#CCEEFF" style=
"background:#CCEEFF;padding:0in 0in 0in 0in;width:1.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>
</td>
</tr>
<tr>
<td width="70%" valign="top" style=
"padding:0in 0in 0in 0in;width:70.0%;">
<p style="margin:0in 0in .0001pt 40.0pt;text-indent:-10.0pt;">
<font size="2" face="Times New Roman" style=
"font-size:10.0pt;">Accrued compensation</font></p>
</td>
<td width="2%" valign="bottom" style=
"padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>
</td>
<td width="12%" colspan="2" valign="bottom" style=
"padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;">
<font size="2" face="Times New Roman" style=
"font-size:10.0pt;">955</font></p>
</td>
<td width="2%" valign="bottom" style=
"padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>
</td>
<td width="12%" colspan="2" valign="bottom" style=
"padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;">
<font size="2" face="Times New Roman" style=
"font-size:10.0pt;">863</font></p>
</td>
<td width="1%" valign="bottom" style=
"padding:0in 0in 0in 0in;width:1.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>
</td>
</tr>
<tr>
<td width="70%" valign="top" bgcolor="#CCEEFF" style=
"background:#CCEEFF;padding:0in 0in 0in 0in;width:70.0%;">
<p style="margin:0in 0in .0001pt 40.0pt;text-indent:-10.0pt;">
<font size="2" face="Times New Roman" style=
"font-size:10.0pt;">Accrued expenses and other current
liabilities</font></p>
</td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style=
"background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>
</td>
<td width="12%" colspan="2" valign="bottom" bgcolor="#CCEEFF"
style="background:#CCEEFF;padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;">
<font size="2" face="Times New Roman" style=
"font-size:10.0pt;">907</font></p>
</td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style=
"background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>
</td>
<td width="12%" colspan="2" valign="bottom" bgcolor="#CCEEFF"
style="background:#CCEEFF;padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;">
<font size="2" face="Times New Roman" style=
"font-size:10.0pt;">3,597</font></p>
</td>
<td width="1%" valign="bottom" bgcolor="#CCEEFF" style=
"background:#CCEEFF;padding:0in 0in 0in 0in;width:1.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>
</td>
</tr>
<tr>
<td width="70%" valign="top" style=
"padding:0in 0in 0in 0in;width:70.0%;">
<p style="margin:0in 0in .0001pt 40.0pt;text-indent:-10.0pt;">
<font size="2" face="Times New Roman" style=
"font-size:10.0pt;">Borrowings</font></p>
</td>
<td width="2%" valign="bottom" style=
"padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>
</td>
<td width="12%" colspan="2" valign="bottom" style=
"padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;">
<font size="2" face="Times New Roman" style=
"font-size:10.0pt;">7,521</font></p>
</td>
<td width="2%" valign="bottom" style=
"padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>
</td>
<td width="12%" colspan="2" valign="bottom" style=
"padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;">
<font size="2" face="Times New Roman" style=
"font-size:10.0pt;">44,744</font></p>
</td>
<td width="1%" valign="bottom" style=
"padding:0in 0in 0in 0in;width:1.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>
</td>
</tr>
<tr>
<td width="70%" valign="top" bgcolor="#CCEEFF" style=
"background:#CCEEFF;padding:0in 0in 0in 0in;width:70.0%;">
<p style="margin:0in 0in .0001pt 40.0pt;text-indent:-10.0pt;">
<font size="2" face="Times New Roman" style=
"font-size:10.0pt;">Preferred stock dividends payable</font></p>
</td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style=
"background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>
</td>
<td width="12%" colspan="2" valign="bottom" bgcolor="#CCEEFF"
style="background:#CCEEFF;border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;">
<font size="2" face="Times New Roman" style=
"font-size:10.0pt;">410</font></p>
</td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style=
"background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>
</td>
<td width="12%" colspan="2" valign="bottom" bgcolor="#CCEEFF"
style="background:#CCEEFF;border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;">
<font size="2" face="Times New Roman" style="font-size:10.0pt;">—
</font></p>
</td>
<td width="1%" valign="bottom" bgcolor="#CCEEFF" style=
"background:#CCEEFF;padding:0in 0in 0in 0in;width:1.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>
</td>
</tr>
<tr>
<td width="70%" valign="top" style=
"padding:0in 0in 0in 0in;width:70.0%;">
<p style="margin:0in 0in .0001pt 30.0pt;text-indent:-10.0pt;">
<font size="2" face="Times New Roman" style=
"font-size:10.0pt;">Total current liabilities</font></p>
</td>
<td width="2%" valign="bottom" style=
"padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>
</td>
<td width="12%" colspan="2" valign="bottom" style=
"padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;">
<font size="2" face="Times New Roman" style=
"font-size:10.0pt;">11,953</font></p>
</td>
<td width="2%" valign="bottom" style=
"padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>
</td>
<td width="12%" colspan="2" valign="bottom" style=
"padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;">
<font size="2" face="Times New Roman" style=
"font-size:10.0pt;">50,477</font></p>
</td>
<td width="1%" valign="bottom" style=
"padding:0in 0in 0in 0in;width:1.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>
</td>
</tr>
<tr>
<td width="70%" valign="top" bgcolor="#CCEEFF" style=
"background:#CCEEFF;padding:0in 0in 0in 0in;width:70.0%;">
<p style="margin:0in 0in .0001pt 10.1pt;text-indent:-10.1pt;">
<font size="2" face="Times New Roman" style=
"font-size:10.0pt;">Other long-term liabilities</font></p>
</td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style=
"background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>
</td>
<td width="12%" colspan="2" valign="bottom" bgcolor="#CCEEFF"
style="background:#CCEEFF;border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;">
<font size="2" face="Times New Roman" style=
"font-size:10.0pt;">111</font></p>
</td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style=
"background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>
</td>
<td width="12%" colspan="2" valign="bottom" bgcolor="#CCEEFF"
style="background:#CCEEFF;border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;">
<font size="2" face="Times New Roman" style=
"font-size:10.0pt;">301</font></p>
</td>
<td width="1%" valign="bottom" bgcolor="#CCEEFF" style=
"background:#CCEEFF;padding:0in 0in 0in 0in;width:1.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>
</td>
</tr>
<tr>
<td width="70%" valign="top" style=
"padding:0in 0in 0in 0in;width:70.0%;">
<p style="margin:0in 0in .0001pt 30.3pt;text-indent:-10.1pt;">
<font size="2" face="Times New Roman" style=
"font-size:10.0pt;">Total liabilities</font></p>
</td>
<td width="2%" valign="bottom" style=
"padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>
</td>
<td width="12%" colspan="2" valign="bottom" style=
"padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;">
<font size="2" face="Times New Roman" style=
"font-size:10.0pt;">12,064</font></p>
</td>
<td width="2%" valign="bottom" style=
"padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>
</td>
<td width="12%" colspan="2" valign="bottom" style=
"padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;">
<font size="2" face="Times New Roman" style=
"font-size:10.0pt;">50,778</font></p>
</td>
<td width="1%" valign="bottom" style=
"padding:0in 0in 0in 0in;width:1.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>
</td>
</tr>
<tr>
<td width="70%" valign="top" bgcolor="#CCEEFF" style=
"background:#CCEEFF;padding:0in 0in 0in 0in;width:70.0%;">
<p style="margin:0in 0in .0001pt 10.1pt;text-indent:-10.1pt;">
<font size="2" face="Times New Roman" style=
"font-size:10.0pt;">&nbsp;</font></p>
</td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style=
"background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
</td>
<td width="12%" colspan="2" valign="bottom" bgcolor="#CCEEFF"
style="background:#CCEEFF;padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;">
<font size="2" face="Times New Roman" style=
"font-size:10.0pt;">&nbsp;</font></p>
</td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style=
"background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
</td>
<td width="12%" colspan="2" valign="bottom" bgcolor="#CCEEFF"
style="background:#CCEEFF;padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;">
<font size="2" face="Times New Roman" style=
"font-size:10.0pt;">&nbsp;</font></p>
</td>
<td width="1%" valign="bottom" bgcolor="#CCEEFF" style=
"background:#CCEEFF;padding:0in 0in 0in 0in;width:1.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
</td>
</tr>
<tr>
<td width="70%" valign="top" style=
"padding:0in 0in 0in 0in;width:70.0%;">
<p style="margin:0in 0in .0001pt 10.1pt;text-indent:-10.1pt;">
<font size="2" face="Times New Roman" style=
"font-size:10.0pt;">Commitments and contingencies (Note
7)</font></p>
</td>
<td width="2%" valign="bottom" style=
"padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>
</td>
<td width="12%" colspan="2" valign="bottom" style=
"padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;">
<font size="2" face="Times New Roman" style=
"font-size:1.0pt;">&nbsp;</font></p>
</td>
<td width="2%" valign="bottom" style=
"padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>
</td>
<td width="12%" colspan="2" valign="bottom" style=
"padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;">
<font size="2" face="Times New Roman" style=
"font-size:1.0pt;">&nbsp;</font></p>
</td>
<td width="1%" valign="bottom" style=
"padding:0in 0in 0in 0in;width:1.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>
</td>
</tr>
<tr>
<td width="70%" valign="top" bgcolor="#CCEEFF" style=
"background:#CCEEFF;padding:0in 0in 0in 0in;width:70.0%;">
<p style="margin:0in 0in .0001pt 10.1pt;text-indent:-10.1pt;">
<font size="2" face="Times New Roman" style=
"font-size:10.0pt;">Stockholders’ equity (deficit):</font></p>
</td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style=
"background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>
</td>
<td width="12%" colspan="2" valign="bottom" bgcolor="#CCEEFF"
style="background:#CCEEFF;padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;">
<font size="2" face="Times New Roman" style=
"font-size:1.0pt;">&nbsp;</font></p>
</td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style=
"background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>
</td>
<td width="12%" colspan="2" valign="bottom" bgcolor="#CCEEFF"
style="background:#CCEEFF;padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;">
<font size="2" face="Times New Roman" style=
"font-size:1.0pt;">&nbsp;</font></p>
</td>
<td width="1%" valign="bottom" bgcolor="#CCEEFF" style=
"background:#CCEEFF;padding:0in 0in 0in 0in;width:1.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>
</td>
</tr>
<tr>
<td width="70%" valign="top" style=
"padding:0in 0in 0in 0in;width:70.0%;">
<p style="margin:0in 0in .0001pt 10.1pt;text-indent:-10.1pt;">
<font size="2" face="Times New Roman" style=
"font-size:10.0pt;">&nbsp;</font></p>
</td>
<td width="2%" valign="bottom" style=
"padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
</td>
<td width="12%" colspan="2" valign="bottom" style=
"padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;">
<font size="2" face="Times New Roman" style=
"font-size:10.0pt;">&nbsp;</font></p>
</td>
<td width="2%" valign="bottom" style=
"padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
</td>
<td width="12%" colspan="2" valign="bottom" style=
"padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;">
<font size="2" face="Times New Roman" style=
"font-size:10.0pt;">&nbsp;</font></p>
</td>
<td width="1%" valign="bottom" style=
"padding:0in 0in 0in 0in;width:1.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
</td>
</tr>
<tr>
<td width="70%" valign="top" bgcolor="#CCEEFF" style=
"background:#CCEEFF;padding:0in 0in 0in 0in;width:70.0%;">
<p style="margin:0in 0in .0001pt 20.2pt;text-indent:-10.1pt;">
<font size="2" face="Times New Roman" style=
"font-size:10.0pt;">Preferred stock issuable in series, par value
of $0.001</font></p>
</td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style=
"background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>
</td>
<td width="12%" colspan="2" valign="bottom" bgcolor="#CCEEFF"
style="background:#CCEEFF;padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;">
<font size="2" face="Times New Roman" style=
"font-size:1.0pt;">&nbsp;</font></p>
</td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style=
"background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>
</td>
<td width="12%" colspan="2" valign="bottom" bgcolor="#CCEEFF"
style="background:#CCEEFF;padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;">
<font size="2" face="Times New Roman" style=
"font-size:1.0pt;">&nbsp;</font></p>
</td>
<td width="1%" valign="bottom" bgcolor="#CCEEFF" style=
"background:#CCEEFF;padding:0in 0in 0in 0in;width:1.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>
</td>
</tr>
<tr>
<td width="70%" valign="top" style=
"padding:0in 0in 0in 0in;width:70.0%;">
<p style="margin:0in 0in .0001pt 30.3pt;text-indent:-10.1pt;">
<font size="2" face="Times New Roman" style=
"font-size:10.0pt;">Shares authorized: 5,000,000 at March&nbsp;31,
2018 and December&nbsp;31, 2017</font></p>
<p style="margin:0in 0in .0001pt 30.3pt;text-indent:-10.1pt;">
<font size="2" face="Times New Roman" style=
"font-size:10.0pt;">Shares issued and outstanding: 52,762 and none
at March&nbsp;31, 2018 and December&nbsp;31, 2017,
respectively</font></p>
</td>
<td width="2%" valign="bottom" style=
"padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>
</td>
<td width="12%" colspan="2" valign="bottom" style=
"padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;">
<font size="2" face="Times New Roman" style="font-size:10.0pt;">—
</font></p>
</td>
<td width="2%" valign="bottom" style=
"padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>
</td>
<td width="12%" colspan="2" valign="bottom" style=
"padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;">
<font size="2" face="Times New Roman" style="font-size:10.0pt;">—
</font></p>
</td>
<td width="1%" valign="bottom" style=
"padding:0in 0in 0in 0in;width:1.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>
</td>
</tr>
<tr>
<td width="70%" valign="top" bgcolor="#CCEEFF" style=
"background:#CCEEFF;padding:0in 0in 0in 0in;width:70.0%;">
<p style="margin:0in 0in .0001pt 20.2pt;text-indent:-10.1pt;">
<font size="2" face="Times New Roman" style=
"font-size:10.0pt;">Common stock, par value of $0.001</font></p>
</td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style=
"background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>
</td>
<td width="12%" colspan="2" valign="bottom" bgcolor="#CCEEFF"
style="background:#CCEEFF;padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;">
<font size="2" face="Times New Roman" style=
"font-size:1.0pt;">&nbsp;</font></p>
</td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style=
"background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>
</td>
<td width="12%" colspan="2" valign="bottom" bgcolor="#CCEEFF"
style="background:#CCEEFF;padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;">
<font size="2" face="Times New Roman" style=
"font-size:1.0pt;">&nbsp;</font></p>
</td>
<td width="1%" valign="bottom" bgcolor="#CCEEFF" style=
"background:#CCEEFF;padding:0in 0in 0in 0in;width:1.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>
</td>
</tr>
<tr>
<td width="70%" valign="top" style=
"padding:0in 0in 0in 0in;width:70.0%;">
<p style="margin:0in 0in .0001pt 30.3pt;text-indent:-10.1pt;">
<font size="2" face="Times New Roman" style=
"font-size:10.0pt;">Shares authorized: 100,000,000 at
March&nbsp;31, 2018 and December&nbsp;31, 2017</font></p>
<p style="margin:0in 0in .0001pt 30.3pt;text-indent:-10.1pt;">
<font size="2" face="Times New Roman" style=
"font-size:10.0pt;">Shares issued and outstanding: 4,384,224 and
833,597 at March&nbsp;31, 2018 and December&nbsp;31, 2017,
respectively</font></p>
</td>
<td width="2%" valign="bottom" style=
"padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>
</td>
<td width="12%" colspan="2" valign="bottom" style=
"padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;">
<font size="2" face="Times New Roman" style=
"font-size:10.0pt;">3</font></p>
</td>
<td width="2%" valign="bottom" style=
"padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>
</td>
<td width="12%" colspan="2" valign="bottom" style=
"padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;">
<font size="2" face="Times New Roman" style=
"font-size:10.0pt;">1</font></p>
</td>
<td width="1%" valign="bottom" style=
"padding:0in 0in 0in 0in;width:1.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>
</td>
</tr>
<tr>
<td width="70%" valign="top" bgcolor="#CCEEFF" style=
"background:#CCEEFF;padding:0in 0in 0in 0in;width:70.0%;">
<p style="margin:0in 0in .0001pt 20.2pt;text-indent:-10.1pt;">
<font size="2" face="Times New Roman" style=
"font-size:10.0pt;">Additional paid-in capital</font></p>
</td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style=
"background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>
</td>
<td width="12%" colspan="2" valign="bottom" bgcolor="#CCEEFF"
style="background:#CCEEFF;padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;">
<font size="2" face="Times New Roman" style=
"font-size:10.0pt;">323,504</font></p>
</td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style=
"background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>
</td>
<td width="12%" colspan="2" valign="bottom" bgcolor="#CCEEFF"
style="background:#CCEEFF;padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;">
<font size="2" face="Times New Roman" style=
"font-size:10.0pt;">265,636</font></p>
</td>
<td width="1%" valign="bottom" bgcolor="#CCEEFF" style=
"background:#CCEEFF;padding:0in 0in 0in 0in;width:1.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>
</td>
</tr>
<tr>
<td width="70%" valign="top" style=
"padding:0in 0in 0in 0in;width:70.0%;">
<p style="margin:0in 0in .0001pt 20.2pt;text-indent:-10.1pt;">
<font size="2" face="Times New Roman" style=
"font-size:10.0pt;">Accumulated deficit</font></p>
</td>
<td width="2%" valign="bottom" style=
"padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>
</td>
<td width="12%" colspan="2" valign="bottom" style=
"border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;">
<font size="2" face="Times New Roman" style=
"font-size:10.0pt;">(311,608</font></p>
</td>
<td width="2%" valign="bottom" style=
"padding:0in 0in 0.375pt 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">)</font></p>
</td>
<td width="12%" colspan="2" valign="bottom" style=
"border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;">
<font size="2" face="Times New Roman" style=
"font-size:10.0pt;">(301,327</font></p>
</td>
<td width="1%" valign="bottom" style=
"padding:0in 0in 0.375pt 0in;width:1.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">)</font></p>
</td>
</tr>
<tr>
<td width="70%" valign="top" bgcolor="#CCEEFF" style=
"background:#CCEEFF;padding:0in 0in 0in 0in;width:70.0%;">
<p style="margin:0in 0in .0001pt 30.0pt;text-indent:-10.0pt;">
<font size="2" face="Times New Roman" style=
"font-size:10.0pt;">Total stockholders’ equity (deficit)</font></p>
</td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style=
"background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>
</td>
<td width="12%" colspan="2" valign="bottom" bgcolor="#CCEEFF"
style="background:#CCEEFF;border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;">
<font size="2" face="Times New Roman" style=
"font-size:10.0pt;">11,899</font></p>
</td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style=
"background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>
</td>
<td width="12%" colspan="2" valign="bottom" bgcolor="#CCEEFF"
style="background:#CCEEFF;border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;">
<font size="2" face="Times New Roman" style=
"font-size:10.0pt;">(35,690</font></p>
</td>
<td width="1%" valign="bottom" bgcolor="#CCEEFF" style=
"background:#CCEEFF;padding:0in 0in 0.375pt 0in;width:1.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">)</font></p>
</td>
</tr>
<tr>
<td width="70%" valign="top" style=
"padding:0in 0in 0in 0in;width:70.0%;">
<p style="margin:0in 0in .0001pt 30.0pt;text-indent:-10.0pt;">
<font size="2" face="Times New Roman" style=
"font-size:10.0pt;">Total liabilities and stockholders’ equity
(deficit)</font></p>
</td>
<td width="2%" valign="bottom" style=
"padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>
</td>
<td width="1%" valign="bottom" style=
"border:none;border-bottom:double windowtext 2.25pt;padding:0in 0in 0in 0in;width:1.12%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">$</font></p>
</td>
<td width="10%" valign="bottom" style=
"border:none;border-bottom:double windowtext 2.25pt;padding:0in 0in 0in 0in;width:10.88%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;">
<font size="2" face="Times New Roman" style=
"font-size:10.0pt;">23,963</font></p>
</td>
<td width="2%" valign="bottom" style=
"padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>
</td>
<td width="1%" valign="bottom" style=
"border:none;border-bottom:double windowtext 2.25pt;padding:0in 0in 0in 0in;width:1.12%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">$</font></p>
</td>
<td width="10%" valign="bottom" style=
"border:none;border-bottom:double windowtext 2.25pt;padding:0in 0in 0in 0in;width:10.88%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;">
<font size="2" face="Times New Roman" style=
"font-size:10.0pt;">15,088</font></p>
</td>
<td width="1%" valign="bottom" style=
"padding:0in 0in 0in 0in;width:1.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>
</td>
</tr>
</table>
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style=
"margin:0in 0in .0001pt;text-align:center;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">See accompanying
notes.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style=
"font-size:10.0pt;margin:0in 0in .0001pt;text-align:center;">
1<a name="PB_1_120524_7056" id="PB_1_120524_7056"></a></p>
<div style="margin:0in 0in .0001pt;">
<hr size="3" width="100%" noshade="noshade" align="left" style=
"color:#010101;" /></div>
</div>
<!-- SEQ.=1,FOLIO='1',FILE='C:\JMS\109927\18-8644-1\task8901854\8644-1-fa.htm',USER='109927',CD='May 16 01:15 2018' --><br clear="all"
style="page-break-before:always;" />
<div style="font-family:Times New Roman;">
<p style="margin:0in 0in .0001pt;"><a href="#TableOfContents"
title="Click to go to Table of Contents"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">Table of
Contents</font></a></p>
<p align="center" style=
"margin:0in 0in .0001pt;text-align:center;"><a name=
"CONDENSEDSTATEMENTSOFOPERATIONSA_123604" id=
"CONDENSEDSTATEMENTSOFOPERATIONSA_123604"></a><b><font size="2"
face="Times New Roman" style=
"font-size:10.0pt;font-weight:bold;">&nbsp;</font></b></p>
<p align="center" style=
"margin:0in 0in .0001pt;text-align:center;"><b><font size="2" face=
"Times New Roman" style=
"font-size:10.0pt;font-weight:bold;">AVINGER,&nbsp;INC.</font></b></p>
<p align="center" style=
"margin:0in 0in .0001pt;text-align:center;"><b><font size="2" face=
"Times New Roman" style=
"font-size:10.0pt;font-weight:bold;">CONDENSED STATEMENTS OF
OPERATIONS AND COMPREHENSIVE LOSS</font></b></p>
<p align="center" style=
"margin:0in 0in .0001pt;text-align:center;"><b><font size="2" face=
"Times New Roman" style=
"font-size:10.0pt;font-weight:bold;">(unaudited)</font></b></p>
<p align="center" style=
"margin:0in 0in .0001pt;text-align:center;"><b><i><font size="2"
face="Times New Roman" style=
"font-size:10.0pt;font-style:italic;font-weight:bold;">(In
thousands, except per share data)</font></i></b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<table border="0" cellspacing="0" cellpadding="0" width="100%"
style="border-collapse:collapse;">
<tr>
<td width="70%" valign="bottom" style=
"padding:0in 0in 0in 0in;width:70.0%;">
<p style="margin:0in 0in .0001pt;"><b><font size="1" face=
"Times New Roman" style=
"font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>
</td>
<td width="2%" valign="bottom" style=
"padding:0in 0in 0in 0in;width:2.5%;">
<p align="center" style=
"margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face=
"Times New Roman" style=
"font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>
</td>
<td width="26%" colspan="5" valign="bottom" style=
"border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:26.5%;">
<p align="center" style=
"margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face=
"Times New Roman" style=
"font-size:8.0pt;font-weight:bold;">Three&nbsp;Months&nbsp;Ended&nbsp;March&nbsp;31,</font></b></p>
</td>
<td width="1%" valign="bottom" style=
"padding:0in 0in 0in 0in;width:1.0%;">
<p align="center" style=
"margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face=
"Times New Roman" style=
"font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>
</td>
</tr>
<tr>
<td width="70%" valign="bottom" style=
"padding:0in 0in 0in 0in;width:70.0%;">
<p style="margin:0in 0in .0001pt;"><b><font size="1" face=
"Times New Roman" style=
"font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>
</td>
<td width="2%" valign="bottom" style=
"padding:0in 0in 0in 0in;width:2.5%;">
<p align="center" style=
"margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face=
"Times New Roman" style=
"font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>
</td>
<td width="12%" colspan="2" valign="bottom" style=
"border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:12.0%;">
<p align="center" style=
"margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face=
"Times New Roman" style=
"font-size:8.0pt;font-weight:bold;">2018</font></b></p>
</td>
<td width="2%" valign="bottom" style=
"padding:0in 0in 0in 0in;width:2.5%;">
<p align="center" style=
"margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face=
"Times New Roman" style=
"font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>
</td>
<td width="12%" colspan="2" valign="bottom" style=
"border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:12.0%;">
<p align="center" style=
"margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face=
"Times New Roman" style=
"font-size:8.0pt;font-weight:bold;position:relative;top:.5pt;">2017</font></b></p>
</td>
<td width="1%" valign="bottom" style=
"padding:0in 0in 0in 0in;width:1.0%;">
<p align="center" style=
"margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face=
"Times New Roman" style=
"font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>
</td>
</tr>
<tr>
<td width="70%" valign="top" bgcolor="#CCEEFF" style=
"background:#CCEEFF;padding:0in 0in 0in 0in;width:70.0%;">
<p style="margin:0in 0in .0001pt 10.1pt;text-indent:-10.1pt;">
<font size="2" face="Times New Roman" style=
"font-size:10.0pt;">Revenues</font></p>
</td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style=
"background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>
</td>
<td width="1%" valign="bottom" bgcolor="#CCEEFF" style=
"background:#CCEEFF;padding:0in 0in 0in 0in;width:1.12%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">$</font></p>
</td>
<td width="10%" valign="bottom" bgcolor="#CCEEFF" style=
"background:#CCEEFF;padding:0in 0in 0in 0in;width:10.88%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;">
<font size="2" face="Times New Roman" style=
"font-size:10.0pt;">1,809</font></p>
</td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style=
"background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>
</td>
<td width="1%" valign="bottom" bgcolor="#CCEEFF" style=
"background:#CCEEFF;padding:0in 0in 0in 0in;width:1.12%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">$</font></p>
</td>
<td width="10%" valign="bottom" bgcolor="#CCEEFF" style=
"background:#CCEEFF;padding:0in 0in 0in 0in;width:10.88%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;">
<font size="2" face="Times New Roman" style=
"font-size:10.0pt;">3,491</font></p>
</td>
<td width="1%" valign="bottom" bgcolor="#CCEEFF" style=
"background:#CCEEFF;padding:0in 0in 0in 0in;width:1.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>
</td>
</tr>
<tr>
<td width="70%" valign="top" style=
"padding:0in 0in 0in 0in;width:70.0%;">
<p style="margin:0in 0in .0001pt 10.1pt;text-indent:-10.1pt;">
<font size="2" face="Times New Roman" style=
"font-size:10.0pt;">Cost of revenues</font></p>
</td>
<td width="2%" valign="bottom" style=
"padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>
</td>
<td width="12%" colspan="2" valign="bottom" style=
"border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;">
<font size="2" face="Times New Roman" style=
"font-size:10.0pt;position:relative;top:.5pt;">1,415</font></p>
</td>
<td width="2%" valign="bottom" style=
"padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>
</td>
<td width="12%" colspan="2" valign="bottom" style=
"border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;">
<font size="2" face="Times New Roman" style=
"font-size:10.0pt;position:relative;top:.5pt;">4,075</font></p>
</td>
<td width="1%" valign="bottom" style=
"padding:0in 0in 0in 0in;width:1.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>
</td>
</tr>
<tr>
<td width="70%" valign="top" bgcolor="#CCEEFF" style=
"background:#CCEEFF;padding:0in 0in 0in 0in;width:70.0%;">
<p style="margin:0in 0in .0001pt 20.0pt;text-indent:-10.0pt;">
<font size="2" face="Times New Roman" style=
"font-size:10.0pt;">Gross profit (loss)</font></p>
</td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style=
"background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>
</td>
<td width="12%" colspan="2" valign="bottom" bgcolor="#CCEEFF"
style="background:#CCEEFF;padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;">
<font size="2" face="Times New Roman" style=
"font-size:10.0pt;">394</font></p>
</td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style=
"background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>
</td>
<td width="12%" colspan="2" valign="bottom" bgcolor="#CCEEFF"
style="background:#CCEEFF;padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;">
<font size="2" face="Times New Roman" style=
"font-size:10.0pt;">(584</font></p>
</td>
<td width="1%" valign="bottom" bgcolor="#CCEEFF" style=
"background:#CCEEFF;padding:0in 0in 0in 0in;width:1.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">)</font></p>
</td>
</tr>
<tr>
<td width="70%" valign="top" style=
"padding:0in 0in 0in 0in;width:70.0%;">
<p style="margin:0in 0in .0001pt 10.1pt;text-indent:-10.1pt;">
<font size="2" face="Times New Roman" style=
"font-size:10.0pt;">Operating expenses:</font></p>
</td>
<td width="2%" valign="bottom" style=
"padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>
</td>
<td width="12%" colspan="2" valign="bottom" style=
"padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;">
<font size="2" face="Times New Roman" style=
"font-size:1.0pt;">&nbsp;</font></p>
</td>
<td width="2%" valign="bottom" style=
"padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>
</td>
<td width="12%" colspan="2" valign="bottom" style=
"padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;">
<font size="2" face="Times New Roman" style=
"font-size:1.0pt;">&nbsp;</font></p>
</td>
<td width="1%" valign="bottom" style=
"padding:0in 0in 0in 0in;width:1.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>
</td>
</tr>
<tr>
<td width="70%" valign="top" bgcolor="#CCEEFF" style=
"background:#CCEEFF;padding:0in 0in 0in 0in;width:70.0%;">
<p style="margin:0in 0in .0001pt 30.0pt;text-indent:-10.0pt;">
<font size="2" face="Times New Roman" style=
"font-size:10.0pt;">Research and development</font></p>
</td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style=
"background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>
</td>
<td width="12%" colspan="2" valign="bottom" bgcolor="#CCEEFF"
style="background:#CCEEFF;padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;">
<font size="2" face="Times New Roman" style=
"font-size:10.0pt;">1,777</font></p>
</td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style=
"background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>
</td>
<td width="12%" colspan="2" valign="bottom" bgcolor="#CCEEFF"
style="background:#CCEEFF;padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;">
<font size="2" face="Times New Roman" style=
"font-size:10.0pt;">3,923</font></p>
</td>
<td width="1%" valign="bottom" bgcolor="#CCEEFF" style=
"background:#CCEEFF;padding:0in 0in 0in 0in;width:1.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>
</td>
</tr>
<tr>
<td width="70%" valign="top" style=
"padding:0in 0in 0in 0in;width:70.0%;">
<p style="margin:0in 0in .0001pt 30.0pt;text-indent:-10.0pt;">
<font size="2" face="Times New Roman" style=
"font-size:10.0pt;">Selling, general and administrative</font></p>
</td>
<td width="2%" valign="bottom" style=
"padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>
</td>
<td width="12%" colspan="2" valign="bottom" style=
"border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;">
<font size="2" face="Times New Roman" style=
"font-size:10.0pt;position:relative;top:.5pt;">4,260</font></p>
</td>
<td width="2%" valign="bottom" style=
"padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>
</td>
<td width="12%" colspan="2" valign="bottom" style=
"border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;">
<font size="2" face="Times New Roman" style=
"font-size:10.0pt;position:relative;top:.5pt;">9,318</font></p>
</td>
<td width="1%" valign="bottom" style=
"padding:0in 0in 0in 0in;width:1.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>
</td>
</tr>
<tr>
<td width="70%" valign="top" bgcolor="#CCEEFF" style=
"background:#CCEEFF;padding:0in 0in 0in 0in;width:70.0%;">
<p style="margin:0in 0in .0001pt 40.0pt;text-indent:-10.0pt;">
<font size="2" face="Times New Roman" style=
"font-size:10.0pt;">Total operating expenses</font></p>
</td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style=
"background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>
</td>
<td width="12%" colspan="2" valign="bottom" bgcolor="#CCEEFF"
style="background:#CCEEFF;border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;">
<font size="2" face="Times New Roman" style=
"font-size:10.0pt;">6,037</font></p>
</td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style=
"background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>
</td>
<td width="12%" colspan="2" valign="bottom" bgcolor="#CCEEFF"
style="background:#CCEEFF;border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;">
<font size="2" face="Times New Roman" style=
"font-size:10.0pt;">13,241</font></p>
</td>
<td width="1%" valign="bottom" bgcolor="#CCEEFF" style=
"background:#CCEEFF;padding:0in 0in 0in 0in;width:1.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>
</td>
</tr>
<tr>
<td width="70%" valign="top" style=
"padding:0in 0in 0in 0in;width:70.0%;">
<p style="margin:0in 0in .0001pt 10.0pt;text-indent:-10.0pt;">
<font size="2" face="Times New Roman" style=
"font-size:10.0pt;">Loss from operations</font></p>
</td>
<td width="2%" valign="bottom" style=
"padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>
</td>
<td width="12%" colspan="2" valign="bottom" style=
"padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;">
<font size="2" face="Times New Roman" style=
"font-size:10.0pt;">(5,643</font></p>
</td>
<td width="2%" valign="bottom" style=
"padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">)</font></p>
</td>
<td width="12%" colspan="2" valign="bottom" style=
"padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;">
<font size="2" face="Times New Roman" style=
"font-size:10.0pt;">(13,825</font></p>
</td>
<td width="1%" valign="bottom" style=
"padding:0in 0in 0in 0in;width:1.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">)</font></p>
</td>
</tr>
<tr>
<td width="70%" valign="top" bgcolor="#CCEEFF" style=
"background:#CCEEFF;padding:0in 0in 0in 0in;width:70.0%;">
<p style="margin:0in 0in .0001pt 10.0pt;text-indent:-10.0pt;">
<font size="2" face="Times New Roman" style=
"font-size:10.0pt;">Interest income</font></p>
</td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style=
"background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>
</td>
<td width="12%" colspan="2" valign="bottom" bgcolor="#CCEEFF"
style="background:#CCEEFF;padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;">
<font size="2" face="Times New Roman" style=
"font-size:10.0pt;">33</font></p>
</td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style=
"background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>
</td>
<td width="12%" colspan="2" valign="bottom" bgcolor="#CCEEFF"
style="background:#CCEEFF;padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;">
<font size="2" face="Times New Roman" style=
"font-size:10.0pt;">32</font></p>
</td>
<td width="1%" valign="bottom" bgcolor="#CCEEFF" style=
"background:#CCEEFF;padding:0in 0in 0in 0in;width:1.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>
</td>
</tr>
<tr>
<td width="70%" valign="top" style=
"padding:0in 0in 0in 0in;width:70.0%;">
<p style="margin:0in 0in .0001pt 10.0pt;text-indent:-10.0pt;">
<font size="2" face="Times New Roman" style=
"font-size:10.0pt;">Interest expense</font></p>
</td>
<td width="2%" valign="bottom" style=
"padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>
</td>
<td width="12%" colspan="2" valign="bottom" style=
"padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;">
<font size="2" face="Times New Roman" style=
"font-size:10.0pt;">(4,672</font></p>
</td>
<td width="2%" valign="bottom" style=
"padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">)</font></p>
</td>
<td width="12%" colspan="2" valign="bottom" style=
"padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;">
<font size="2" face="Times New Roman" style=
"font-size:10.0pt;">(1,550</font></p>
</td>
<td width="1%" valign="bottom" style=
"padding:0in 0in 0in 0in;width:1.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">)</font></p>
</td>
</tr>
<tr>
<td width="70%" valign="top" bgcolor="#CCEEFF" style=
"background:#CCEEFF;padding:0in 0in 0in 0in;width:70.0%;">
<p style="margin:0in 0in .0001pt 10.0pt;text-indent:-10.0pt;">
<font size="2" face="Times New Roman" style=
"font-size:10.0pt;">Other income (expense), net</font></p>
</td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style=
"background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>
</td>
<td width="12%" colspan="2" valign="bottom" bgcolor="#CCEEFF"
style="background:#CCEEFF;border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;">
<font size="2" face="Times New Roman" style=
"font-size:10.0pt;">1</font></p>
</td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style=
"background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>
</td>
<td width="12%" colspan="2" valign="bottom" bgcolor="#CCEEFF"
style="background:#CCEEFF;border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;">
<font size="2" face="Times New Roman" style=
"font-size:10.0pt;">3</font></p>
</td>
<td width="1%" valign="bottom" bgcolor="#CCEEFF" style=
"background:#CCEEFF;padding:0in 0in 0in 0in;width:1.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>
</td>
</tr>
<tr>
<td width="70%" valign="top" style=
"padding:0in 0in 0in 0in;width:70.0%;">
<p style="margin:0in 0in .0001pt 10.0pt;text-indent:-10.0pt;">
<font size="2" face="Times New Roman" style="font-size:10.0pt;">Net
loss and comprehensive loss</font></p>
</td>
<td width="2%" valign="bottom" style=
"padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>
</td>
<td width="12%" colspan="2" valign="bottom" style=
"padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;">
<font size="2" face="Times New Roman" style=
"font-size:10.0pt;">(10,281</font></p>
</td>
<td width="2%" valign="bottom" style=
"padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">)</font></p>
</td>
<td width="12%" colspan="2" valign="bottom" style=
"padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;">
<font size="2" face="Times New Roman" style=
"font-size:10.0pt;">(15,340</font></p>
</td>
<td width="1%" valign="bottom" style=
"padding:0in 0in 0in 0in;width:1.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">)</font></p>
</td>
</tr>
<tr>
<td width="70%" valign="top" bgcolor="#CCEEFF" style=
"background:#CCEEFF;padding:0in 0in 0in 0in;width:70.0%;">
<p style="margin:0in 0in .0001pt 10.0pt;text-indent:-10.0pt;">
<font size="2" face="Times New Roman" style=
"font-size:10.0pt;">Accretion of preferred stock
dividends</font></p>
</td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style=
"background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>
</td>
<td width="12%" colspan="2" valign="bottom" bgcolor="#CCEEFF"
style="background:#CCEEFF;padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;">
<font size="2" face="Times New Roman" style=
"font-size:10.0pt;">(410</font></p>
</td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style=
"background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">)</font></p>
</td>
<td width="12%" colspan="2" valign="bottom" bgcolor="#CCEEFF"
style="background:#CCEEFF;padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;">
<font size="2" face="Times New Roman" style="font-size:10.0pt;">—
</font></p>
</td>
<td width="1%" valign="bottom" bgcolor="#CCEEFF" style=
"background:#CCEEFF;padding:0in 0in 0in 0in;width:1.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>
</td>
</tr>
<tr>
<td width="70%" valign="top" style=
"padding:0in 0in 0in 0in;width:70.0%;">
<p style="margin:0in 0in .0001pt 10.0pt;text-indent:-10.0pt;">
<font size="2" face="Times New Roman" style=
"font-size:10.0pt;">Deemed dividend arising from beneficial
conversion feature of convertible preferred stock</font></p>
</td>
<td width="2%" valign="bottom" style=
"padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>
</td>
<td width="12%" colspan="2" valign="bottom" style=
"border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;">
<font size="2" face="Times New Roman" style=
"font-size:10.0pt;">(5,216</font></p>
</td>
<td width="2%" valign="bottom" style=
"padding:0in 0in 0.375pt 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">)</font></p>
</td>
<td width="12%" colspan="2" valign="bottom" style=
"border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;">
<font size="2" face="Times New Roman" style="font-size:10.0pt;">—
</font></p>
</td>
<td width="1%" valign="bottom" style=
"padding:0in 0in 0in 0in;width:1.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>
</td>
</tr>
<tr>
<td width="70%" valign="top" bgcolor="#CCEEFF" style=
"background:#CCEEFF;padding:0in 0in 0in 0in;width:70.0%;">
<p style="margin:0in 0in .0001pt 10.0pt;text-indent:-10.0pt;">
<font size="2" face="Times New Roman" style="font-size:10.0pt;">Net
loss applicable to common stockholders</font></p>
</td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style=
"background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>
</td>
<td width="1%" valign="bottom" bgcolor="#CCEEFF" style=
"background:#CCEEFF;border:none;border-bottom:double windowtext 2.25pt;padding:0in 0in 0in 0in;width:1.12%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">$</font></p>
</td>
<td width="10%" valign="bottom" bgcolor="#CCEEFF" style=
"background:#CCEEFF;border:none;border-bottom:double windowtext 2.25pt;padding:0in 0in 0in 0in;width:10.88%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;">
<font size="2" face="Times New Roman" style=
"font-size:10.0pt;">(15,907</font></p>
</td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style=
"background:#CCEEFF;padding:0in 0in 1.125pt 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">)</font></p>
</td>
<td width="1%" valign="bottom" bgcolor="#CCEEFF" style=
"background:#CCEEFF;border:none;border-bottom:double windowtext 2.25pt;padding:0in 0in 0in 0in;width:1.12%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">$</font></p>
</td>
<td width="10%" valign="bottom" bgcolor="#CCEEFF" style=
"background:#CCEEFF;border:none;border-bottom:double windowtext 2.25pt;padding:0in 0in 0in 0in;width:10.88%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;">
<font size="2" face="Times New Roman" style=
"font-size:10.0pt;">(15,340</font></p>
</td>
<td width="1%" valign="bottom" bgcolor="#CCEEFF" style=
"background:#CCEEFF;padding:0in 0in 1.125pt 0in;width:1.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">)</font></p>
</td>
</tr>
<tr>
<td width="70%" valign="top" style=
"padding:0in 0in 0in 0in;width:70.0%;">
<p style="margin:0in 0in .0001pt 10.0pt;text-indent:-10.0pt;">
<font size="2" face="Times New Roman" style="font-size:10.0pt;">Net
loss per share attributable to common stockholders, basic and
diluted</font></p>
</td>
<td width="2%" valign="bottom" style=
"padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>
</td>
<td width="1%" valign="bottom" style=
"border:none;border-bottom:double windowtext 2.25pt;padding:0in 0in 0in 0in;width:1.12%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">$</font></p>
</td>
<td width="10%" valign="bottom" style=
"border:none;border-bottom:double windowtext 2.25pt;padding:0in 0in 0in 0in;width:10.88%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;">
<font size="2" face="Times New Roman" style=
"font-size:10.0pt;">(7.99</font></p>
</td>
<td width="2%" valign="bottom" style=
"padding:0in 0in 1.125pt 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">)</font></p>
</td>
<td width="1%" valign="bottom" style=
"border:none;border-bottom:double windowtext 2.25pt;padding:0in 0in 0in 0in;width:1.12%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">$</font></p>
</td>
<td width="10%" valign="bottom" style=
"border:none;border-bottom:double windowtext 2.25pt;padding:0in 0in 0in 0in;width:10.86%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;">
<font size="2" face="Times New Roman" style=
"font-size:10.0pt;">(25.74</font></p>
</td>
<td width="1%" valign="bottom" style=
"padding:0in 0in 1.125pt 0in;width:1.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">)</font></p>
</td>
</tr>
<tr>
<td width="70%" valign="top" bgcolor="#CCEEFF" style=
"background:#CCEEFF;padding:0in 0in 0in 0in;width:70.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style=
"font-size:10.0pt;">Weighted&nbsp;average&nbsp;common&nbsp;shares&nbsp;used&nbsp;to&nbsp;<font style="position:relative;top:-.5pt;">compute&nbsp;net&nbsp;loss&nbsp;per&nbsp;share,&nbsp;basic&nbsp;and&nbsp;diluted</font></font></p>
</td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style=
"background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>
</td>
<td width="12%" colspan="2" valign="bottom" bgcolor="#CCEEFF"
style="background:#CCEEFF;border:none;border-bottom:double windowtext 2.25pt;padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;">
<font size="2" face="Times New Roman" style=
"font-size:10.0pt;">1,992</font></p>
</td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style=
"background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;">
<font size="2" face="Times New Roman" style=
"font-size:1.0pt;">&nbsp;</font></p>
</td>
<td width="12%" colspan="2" valign="bottom" bgcolor="#CCEEFF"
style="background:#CCEEFF;border:none;border-bottom:double windowtext 2.25pt;padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;">
<font size="2" face="Times New Roman" style=
"font-size:10.0pt;">596</font></p>
</td>
<td width="1%" valign="bottom" bgcolor="#CCEEFF" style=
"background:#CCEEFF;padding:0in 0in 0in 0in;width:1.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>
</td>
</tr>
</table>
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style=
"margin:0in 0in .0001pt;text-align:center;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">See accompanying
notes.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style=
"font-size:10.0pt;margin:0in 0in .0001pt;text-align:center;">
2<a name="PB_2_120852_5335" id="PB_2_120852_5335"></a></p>
<div style="margin:0in 0in .0001pt;">
<hr size="3" width="100%" noshade="noshade" align="left" style=
"color:#010101;" /></div>
</div>
<!-- SEQ.=1,FOLIO='2',FILE='C:\JMS\109927\18-8644-1\task8901854\8644-1-fa.htm',USER='109927',CD='May 16 01:15 2018' --><br clear="all"
style="page-break-before:always;" />
<div style="font-family:Times New Roman;">
<p style="margin:0in 0in .0001pt;"><a href="#TableOfContents"
title="Click to go to Table of Contents"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">Table of
Contents</font></a></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style=
"margin:0in 0in .0001pt;text-align:center;"><b><font size="2" face=
"Times New Roman" style=
"font-size:10.0pt;font-weight:bold;">AVINGER,&nbsp;INC.</font></b></p>
<p align="center" style=
"margin:0in 0in .0001pt;text-align:center;"><b><font size="2" face=
"Times New Roman" style=
"font-size:10.0pt;font-weight:bold;">CONDENSED STATEMENTS OF CASH
FLOWS</font></b><a name="CONDENSEDSTATEMENTSOFCASHFLOWS_123612" id=
"CONDENSEDSTATEMENTSOFCASHFLOWS_123612"></a></p>
<p align="center" style=
"margin:0in 0in .0001pt;text-align:center;"><b><font size="2" face=
"Times New Roman" style=
"font-size:10.0pt;font-weight:bold;">(unaudited)</font></b></p>
<p align="center" style=
"margin:0in 0in .0001pt;text-align:center;"><b><i><font size="2"
face="Times New Roman" style=
"font-size:10.0pt;font-style:italic;font-weight:bold;">(In
thousands)</font></i></b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<table border="0" cellspacing="0" cellpadding="0" width="100%"
style="border-collapse:collapse;">
<tr>
<td width="68%" valign="bottom" style=
"padding:0in 0in 0in 0in;width:68.5%;">
<p style="margin:0in 0in .0001pt;"><b><font size="1" face=
"Times New Roman" style=
"font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>
</td>
<td width="2%" valign="bottom" style=
"padding:0in 0in 0in 0in;width:2.5%;">
<p align="center" style=
"margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face=
"Times New Roman" style=
"font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>
</td>
<td width="27%" colspan="5" valign="bottom" style=
"border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:27.34%;">
<p align="center" style=
"margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face=
"Times New Roman" style=
"font-size:8.0pt;font-weight:bold;">Three&nbsp;Months&nbsp;Ended&nbsp;March&nbsp;31,</font></b></p>
</td>
<td width="1%" valign="bottom" style=
"padding:0in 0in 0in 0in;width:1.66%;">
<p align="center" style=
"margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face=
"Times New Roman" style=
"font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>
</td>
</tr>
<tr>
<td width="68%" valign="bottom" style=
"padding:0in 0in 0in 0in;width:68.5%;">
<p style="margin:0in 0in .0001pt;"><b><font size="1" face=
"Times New Roman" style=
"font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>
</td>
<td width="2%" valign="bottom" style=
"padding:0in 0in 0in 0in;width:2.5%;">
<p align="center" style=
"margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face=
"Times New Roman" style=
"font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>
</td>
<td width="12%" colspan="2" valign="bottom" style=
"border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:12.0%;">
<p align="center" style=
"margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face=
"Times New Roman" style=
"font-size:8.0pt;font-weight:bold;">2018</font></b></p>
</td>
<td width="2%" valign="bottom" style=
"padding:0in 0in 0in 0in;width:2.5%;">
<p align="center" style=
"margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face=
"Times New Roman" style=
"font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>
</td>
<td width="12%" colspan="2" valign="bottom" style=
"border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:12.84%;">
<p align="center" style=
"margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face=
"Times New Roman" style=
"font-size:8.0pt;font-weight:bold;">2017</font></b></p>
</td>
<td width="1%" valign="bottom" style=
"padding:0in 0in 0in 0in;width:1.66%;">
<p align="center" style=
"margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face=
"Times New Roman" style=
"font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>
</td>
</tr>
<tr>
<td width="68%" valign="top" bgcolor="#CCEEFF" style=
"background:#CCEEFF;padding:0in 0in 0in 0in;width:68.5%;">
<p style="margin:0in 0in .0001pt 10.1pt;text-indent:-10.1pt;">
<b><font size="2" face="Times New Roman" style=
"font-size:10.0pt;font-weight:bold;">Cash flows from operating
activities</font></b></p>
</td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style=
"background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>
</td>
<td width="12%" colspan="2" valign="bottom" bgcolor="#CCEEFF"
style="background:#CCEEFF;padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;">
<font size="2" face="Times New Roman" style=
"font-size:1.0pt;">&nbsp;</font></p>
</td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style=
"background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>
</td>
<td width="12%" colspan="2" valign="bottom" bgcolor="#CCEEFF"
style="background:#CCEEFF;padding:0in 0in 0in 0in;width:12.84%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;">
<font size="2" face="Times New Roman" style=
"font-size:1.0pt;">&nbsp;</font></p>
</td>
<td width="1%" valign="bottom" bgcolor="#CCEEFF" style=
"background:#CCEEFF;padding:0in 0in 0in 0in;width:1.66%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>
</td>
</tr>
<tr>
<td width="68%" valign="bottom" style=
"padding:0in 0in 0in 0in;width:68.5%;">
<p style="margin:0in 0in .0001pt 20.0pt;text-indent:-10.0pt;">
<font size="2" face="Times New Roman" style="font-size:10.0pt;">Net
loss</font></p>
</td>
<td width="2%" valign="bottom" style=
"padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>
</td>
<td width="1%" valign="bottom" style=
"padding:0in 0in 0in 0in;width:1.12%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">$</font></p>
</td>
<td width="10%" valign="bottom" style=
"padding:0in 0in 0in 0in;width:10.88%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;">
<font size="2" face="Times New Roman" style=
"font-size:10.0pt;">(10,281</font></p>
</td>
<td width="2%" valign="bottom" style=
"padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">)</font></p>
</td>
<td width="12%" colspan="2" valign="bottom" style=
"padding:0in 0in 0in 0in;width:12.84%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;">
<font size="2" face="Times New Roman" style=
"font-size:10.0pt;">(15,340</font></p>
</td>
<td width="1%" valign="bottom" style=
"padding:0in 0in 0in 0in;width:1.66%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">)</font></p>
</td>
</tr>
<tr>
<td width="68%" valign="bottom" bgcolor="#CCEEFF" style=
"background:#CCEEFF;padding:0in 0in 0in 0in;width:68.5%;">
<p style="margin:0in 0in .0001pt 20.0pt;text-indent:-10.0pt;">
<font size="2" face="Times New Roman" style=
"font-size:10.0pt;">Adjustments to reconcile net loss to net cash
used in operating activities:</font></p>
</td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style=
"background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>
</td>
<td width="12%" colspan="2" valign="bottom" bgcolor="#CCEEFF"
style="background:#CCEEFF;padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;">
<font size="2" face="Times New Roman" style=
"font-size:1.0pt;">&nbsp;</font></p>
</td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style=
"background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>
</td>
<td width="12%" colspan="2" valign="bottom" bgcolor="#CCEEFF"
style="background:#CCEEFF;padding:0in 0in 0in 0in;width:12.84%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;">
<font size="2" face="Times New Roman" style=
"font-size:1.0pt;">&nbsp;</font></p>
</td>
<td width="1%" valign="bottom" bgcolor="#CCEEFF" style=
"background:#CCEEFF;padding:0in 0in 0in 0in;width:1.66%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>
</td>
</tr>
<tr>
<td width="68%" valign="bottom" style=
"padding:0in 0in 0in 0in;width:68.5%;">
<p style="margin:0in 0in .0001pt 30.0pt;text-indent:-10.0pt;">
<font size="2" face="Times New Roman" style=
"font-size:10.0pt;">Depreciation and amortization</font></p>
</td>
<td width="2%" valign="bottom" style=
"padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>
</td>
<td width="12%" colspan="2" valign="bottom" style=
"padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;">
<font size="2" face="Times New Roman" style=
"font-size:10.0pt;">277</font></p>
</td>
<td width="2%" valign="bottom" style=
"padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>
</td>
<td width="12%" colspan="2" valign="bottom" style=
"padding:0in 0in 0in 0in;width:12.84%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;">
<font size="2" face="Times New Roman" style=
"font-size:10.0pt;">428</font></p>
</td>
<td width="1%" valign="bottom" style=
"padding:0in 0in 0in 0in;width:1.66%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>
</td>
</tr>
<tr>
<td width="68%" valign="bottom" bgcolor="#CCEEFF" style=
"background:#CCEEFF;padding:0in 0in 0in 0in;width:68.5%;">
<p style="margin:0in 0in .0001pt 30.0pt;text-indent:-10.0pt;">
<font size="2" face="Times New Roman" style=
"font-size:10.0pt;">Amortization of debt issuance costs and debt
discount</font></p>
</td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style=
"background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>
</td>
<td width="12%" colspan="2" valign="bottom" bgcolor="#CCEEFF"
style="background:#CCEEFF;padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;">
<font size="2" face="Times New Roman" style=
"font-size:10.0pt;">(128</font></p>
</td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style=
"background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">)</font></p>
</td>
<td width="12%" colspan="2" valign="bottom" bgcolor="#CCEEFF"
style="background:#CCEEFF;padding:0in 0in 0in 0in;width:12.84%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;">
<font size="2" face="Times New Roman" style=
"font-size:10.0pt;">62</font></p>
</td>
<td width="1%" valign="bottom" bgcolor="#CCEEFF" style=
"background:#CCEEFF;padding:0in 0in 0in 0in;width:1.66%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>
</td>
</tr>
<tr>
<td width="68%" valign="bottom" style=
"padding:0in 0in 0in 0in;width:68.5%;">
<p style="margin:0in 0in .0001pt 30.0pt;text-indent:-10.0pt;">
<font size="2" face="Times New Roman" style=
"font-size:10.0pt;">Stock-based compensation</font></p>
</td>
<td width="2%" valign="bottom" style=
"padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>
</td>
<td width="12%" colspan="2" valign="bottom" style=
"padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;">
<font size="2" face="Times New Roman" style=
"font-size:10.0pt;">619</font></p>
</td>
<td width="2%" valign="bottom" style=
"padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>
</td>
<td width="12%" colspan="2" valign="bottom" style=
"padding:0in 0in 0in 0in;width:12.84%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;">
<font size="2" face="Times New Roman" style=
"font-size:10.0pt;">1,542</font></p>
</td>
<td width="1%" valign="bottom" style=
"padding:0in 0in 0in 0in;width:1.66%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>
</td>
</tr>
<tr>
<td width="68%" valign="bottom" bgcolor="#CCEEFF" style=
"background:#CCEEFF;padding:0in 0in 0in 0in;width:68.5%;">
<p style="margin:0in 0in .0001pt 30.0pt;text-indent:-10.0pt;">
<font size="2" face="Times New Roman" style=
"font-size:10.0pt;">Noncash interest expense and other
charges</font></p>
</td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style=
"background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>
</td>
<td width="12%" colspan="2" valign="bottom" bgcolor="#CCEEFF"
style="background:#CCEEFF;padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;">
<font size="2" face="Times New Roman" style=
"font-size:10.0pt;">4,705</font></p>
</td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style=
"background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>
</td>
<td width="12%" colspan="2" valign="bottom" bgcolor="#CCEEFF"
style="background:#CCEEFF;padding:0in 0in 0in 0in;width:12.84%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;">
<font size="2" face="Times New Roman" style=
"font-size:10.0pt;">536</font></p>
</td>
<td width="1%" valign="bottom" bgcolor="#CCEEFF" style=
"background:#CCEEFF;padding:0in 0in 0in 0in;width:1.66%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>
</td>
</tr>
<tr>
<td width="68%" valign="bottom" style=
"padding:0in 0in 0in 0in;width:68.5%;">
<p style="margin:0in 0in .0001pt 30.0pt;text-indent:-10.0pt;">
<font size="2" face="Times New Roman" style=
"font-size:10.0pt;">Provision for doubtful accounts
receivable</font></p>
</td>
<td width="2%" valign="bottom" style=
"padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>
</td>
<td width="12%" colspan="2" valign="bottom" style=
"padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;">
<font size="2" face="Times New Roman" style=
"font-size:10.0pt;">(6</font></p>
</td>
<td width="2%" valign="bottom" style=
"padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">)</font></p>
</td>
<td width="12%" colspan="2" valign="bottom" style=
"padding:0in 0in 0in 0in;width:12.84%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;">
<font size="2" face="Times New Roman" style=
"font-size:10.0pt;">94</font></p>
</td>
<td width="1%" valign="bottom" style=
"padding:0in 0in 0in 0in;width:1.66%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>
</td>
</tr>
<tr>
<td width="68%" valign="bottom" bgcolor="#CCEEFF" style=
"background:#CCEEFF;padding:0in 0in 0in 0in;width:68.5%;">
<p style="margin:0in 0in .0001pt 30.0pt;text-indent:-10.0pt;">
<font size="2" face="Times New Roman" style=
"font-size:10.0pt;">Provision for excess and obsolete
inventories</font></p>
</td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style=
"background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>
</td>
<td width="12%" colspan="2" valign="bottom" bgcolor="#CCEEFF"
style="background:#CCEEFF;padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;">
<font size="2" face="Times New Roman" style=
"font-size:10.0pt;">(79</font></p>
</td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style=
"background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">)</font></p>
</td>
<td width="12%" colspan="2" valign="bottom" bgcolor="#CCEEFF"
style="background:#CCEEFF;padding:0in 0in 0in 0in;width:12.84%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;">
<font size="2" face="Times New Roman" style=
"font-size:10.0pt;">1,257</font></p>
</td>
<td width="1%" valign="bottom" bgcolor="#CCEEFF" style=
"background:#CCEEFF;padding:0in 0in 0in 0in;width:1.66%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>
</td>
</tr>
<tr>
<td width="68%" valign="bottom" style=
"padding:0in 0in 0in 0in;width:68.5%;">
<p style="margin:0in 0in .0001pt 30.0pt;text-indent:-10.0pt;">
<font size="2" face="Times New Roman" style=
"font-size:10.0pt;">Changes in operating assets and
liabilities:</font></p>
</td>
<td width="2%" valign="bottom" style=
"padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>
</td>
<td width="12%" colspan="2" valign="bottom" style=
"padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;">
<font size="2" face="Times New Roman" style=
"font-size:1.0pt;">&nbsp;</font></p>
</td>
<td width="2%" valign="bottom" style=
"padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>
</td>
<td width="12%" colspan="2" valign="bottom" style=
"padding:0in 0in 0in 0in;width:12.84%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;">
<font size="2" face="Times New Roman" style=
"font-size:1.0pt;">&nbsp;</font></p>
</td>
<td width="1%" valign="bottom" style=
"padding:0in 0in 0in 0in;width:1.66%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>
</td>
</tr>
<tr>
<td width="68%" valign="bottom" bgcolor="#CCEEFF" style=
"background:#CCEEFF;padding:0in 0in 0in 0in;width:68.5%;">
<p style="margin:0in 0in .0001pt 40.0pt;text-indent:-10.0pt;">
<font size="2" face="Times New Roman" style=
"font-size:10.0pt;">Accounts receivable</font></p>
</td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style=
"background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>
</td>
<td width="12%" colspan="2" valign="bottom" bgcolor="#CCEEFF"
style="background:#CCEEFF;padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;">
<font size="2" face="Times New Roman" style=
"font-size:10.0pt;">(221</font></p>
</td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style=
"background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">)</font></p>
</td>
<td width="12%" colspan="2" valign="bottom" bgcolor="#CCEEFF"
style="background:#CCEEFF;padding:0in 0in 0in 0in;width:12.84%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;">
<font size="2" face="Times New Roman" style=
"font-size:10.0pt;">1,387</font></p>
</td>
<td width="1%" valign="bottom" bgcolor="#CCEEFF" style=
"background:#CCEEFF;padding:0in 0in 0in 0in;width:1.66%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>
</td>
</tr>
<tr>
<td width="68%" valign="bottom" style=
"padding:0in 0in 0in 0in;width:68.5%;">
<p style="margin:0in 0in .0001pt 40.0pt;text-indent:-10.0pt;">
<font size="2" face="Times New Roman" style=
"font-size:10.0pt;">Inventories</font></p>
</td>
<td width="2%" valign="bottom" style=
"padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>
</td>
<td width="12%" colspan="2" valign="bottom" style=
"padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;">
<font size="2" face="Times New Roman" style=
"font-size:10.0pt;">563</font></p>
</td>
<td width="2%" valign="bottom" style=
"padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>
</td>
<td width="12%" colspan="2" valign="bottom" style=
"padding:0in 0in 0in 0in;width:12.84%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;">
<font size="2" face="Times New Roman" style=
"font-size:10.0pt;">(1,165</font></p>
</td>
<td width="1%" valign="bottom" style=
"padding:0in 0in 0in 0in;width:1.66%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">)</font></p>
</td>
</tr>
<tr>
<td width="68%" valign="bottom" bgcolor="#CCEEFF" style=
"background:#CCEEFF;padding:0in 0in 0in 0in;width:68.5%;">
<p style="margin:0in 0in .0001pt 40.0pt;text-indent:-10.0pt;">
<font size="2" face="Times New Roman" style=
"font-size:10.0pt;">Prepaid expenses and other current
assets</font></p>
</td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style=
"background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>
</td>
<td width="12%" colspan="2" valign="bottom" bgcolor="#CCEEFF"
style="background:#CCEEFF;padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;">
<font size="2" face="Times New Roman" style=
"font-size:10.0pt;">(523</font></p>
</td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style=
"background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">)</font></p>
</td>
<td width="12%" colspan="2" valign="bottom" bgcolor="#CCEEFF"
style="background:#CCEEFF;padding:0in 0in 0in 0in;width:12.84%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;">
<font size="2" face="Times New Roman" style=
"font-size:10.0pt;">(697</font></p>
</td>
<td width="1%" valign="bottom" bgcolor="#CCEEFF" style=
"background:#CCEEFF;padding:0in 0in 0in 0in;width:1.66%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">)</font></p>
</td>
</tr>
<tr>
<td width="68%" valign="bottom" style=
"padding:0in 0in 0in 0in;width:68.5%;">
<p style="margin:0in 0in .0001pt 40.0pt;text-indent:-10.0pt;">
<font size="2" face="Times New Roman" style=
"font-size:10.0pt;">Other assets</font></p>
</td>
<td width="2%" valign="bottom" style=
"padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>
</td>
<td width="12%" colspan="2" valign="bottom" style=
"padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;">
<font size="2" face="Times New Roman" style=
"font-size:10.0pt;">98</font></p>
</td>
<td width="2%" valign="bottom" style=
"padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>
</td>
<td width="12%" colspan="2" valign="bottom" style=
"padding:0in 0in 0in 0in;width:12.84%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;">
<font size="2" face="Times New Roman" style="font-size:10.0pt;">—
</font></p>
</td>
<td width="1%" valign="bottom" style=
"padding:0in 0in 0in 0in;width:1.66%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>
</td>
</tr>
<tr>
<td width="68%" valign="bottom" bgcolor="#CCEEFF" style=
"background:#CCEEFF;padding:0in 0in 0in 0in;width:68.5%;">
<p style="margin:0in 0in .0001pt 40.0pt;text-indent:-10.0pt;">
<font size="2" face="Times New Roman" style=
"font-size:10.0pt;">Accounts payable</font></p>
</td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style=
"background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>
</td>
<td width="12%" colspan="2" valign="bottom" bgcolor="#CCEEFF"
style="background:#CCEEFF;padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;">
<font size="2" face="Times New Roman" style=
"font-size:10.0pt;">486</font></p>
</td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style=
"background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>
</td>
<td width="12%" colspan="2" valign="bottom" bgcolor="#CCEEFF"
style="background:#CCEEFF;padding:0in 0in 0in 0in;width:12.84%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;">
<font size="2" face="Times New Roman" style=
"font-size:10.0pt;">(446</font></p>
</td>
<td width="1%" valign="bottom" bgcolor="#CCEEFF" style=
"background:#CCEEFF;padding:0in 0in 0in 0in;width:1.66%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">)</font></p>
</td>
</tr>
<tr>
<td width="68%" valign="bottom" style=
"padding:0in 0in 0in 0in;width:68.5%;">
<p style="margin:0in 0in .0001pt 40.0pt;text-indent:-10.0pt;">
<font size="2" face="Times New Roman" style=
"font-size:10.0pt;">Accrued compensation</font></p>
</td>
<td width="2%" valign="bottom" style=
"padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>
</td>
<td width="12%" colspan="2" valign="bottom" style=
"padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;">
<font size="2" face="Times New Roman" style=
"font-size:10.0pt;">92</font></p>
</td>
<td width="2%" valign="bottom" style=
"padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>
</td>
<td width="12%" colspan="2" valign="bottom" style=
"padding:0in 0in 0in 0in;width:12.84%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;">
<font size="2" face="Times New Roman" style=
"font-size:10.0pt;">(619</font></p>
</td>
<td width="1%" valign="bottom" style=
"padding:0in 0in 0in 0in;width:1.66%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">)</font></p>
</td>
</tr>
<tr>
<td width="68%" valign="bottom" bgcolor="#CCEEFF" style=
"background:#CCEEFF;padding:0in 0in 0in 0in;width:68.5%;">
<p style="margin:0in 0in .0001pt 40.0pt;text-indent:-10.0pt;">
<font size="2" face="Times New Roman" style=
"font-size:10.0pt;">Accrued expenses and other current
liabilities</font></p>
</td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style=
"background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>
</td>
<td width="12%" colspan="2" valign="bottom" bgcolor="#CCEEFF"
style="background:#CCEEFF;padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;">
<font size="2" face="Times New Roman" style=
"font-size:10.0pt;">(2,288</font></p>
</td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style=
"background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">)</font></p>
</td>
<td width="12%" colspan="2" valign="bottom" bgcolor="#CCEEFF"
style="background:#CCEEFF;padding:0in 0in 0in 0in;width:12.84%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;">
<font size="2" face="Times New Roman" style=
"font-size:10.0pt;">(8</font></p>
</td>
<td width="1%" valign="bottom" bgcolor="#CCEEFF" style=
"background:#CCEEFF;padding:0in 0in 0in 0in;width:1.66%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">)</font></p>
</td>
</tr>
<tr>
<td width="68%" valign="bottom" style=
"padding:0in 0in 0in 0in;width:68.5%;">
<p style="margin:0in 0in .0001pt 40.0pt;text-indent:-10.0pt;">
<font size="2" face="Times New Roman" style=
"font-size:10.0pt;">Other long-term liabilities and accrued
interest</font></p>
</td>
<td width="2%" valign="bottom" style=
"padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>
</td>
<td width="12%" colspan="2" valign="bottom" style=
"border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;">
<font size="2" face="Times New Roman" style=
"font-size:10.0pt;">(191</font></p>
</td>
<td width="2%" valign="bottom" style=
"padding:0in 0in 0.375pt 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">)</font></p>
</td>
<td width="12%" colspan="2" valign="bottom" style=
"border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:12.84%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;">
<font size="2" face="Times New Roman" style=
"font-size:10.0pt;">(294</font></p>
</td>
<td width="1%" valign="bottom" style=
"padding:0in 0in 0.375pt 0in;width:1.66%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">)</font></p>
</td>
</tr>
<tr>
<td width="68%" valign="bottom" bgcolor="#CCEEFF" style=
"background:#CCEEFF;padding:0in 0in 0in 0in;width:68.5%;">
<p style="margin:0in 0in .0001pt 50.0pt;text-indent:-10.0pt;">
<font size="2" face="Times New Roman" style="font-size:10.0pt;">Net
cash used in operating activities</font></p>
</td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style=
"background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>
</td>
<td width="12%" colspan="2" valign="bottom" bgcolor="#CCEEFF"
style="background:#CCEEFF;padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;">
<font size="2" face="Times New Roman" style=
"font-size:10.0pt;">(6,877</font></p>
</td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style=
"background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">)</font></p>
</td>
<td width="12%" colspan="2" valign="bottom" bgcolor="#CCEEFF"
style="background:#CCEEFF;padding:0in 0in 0in 0in;width:12.84%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;">
<font size="2" face="Times New Roman" style=
"font-size:10.0pt;">(13,263</font></p>
</td>
<td width="1%" valign="bottom" bgcolor="#CCEEFF" style=
"background:#CCEEFF;padding:0in 0in 0in 0in;width:1.66%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">)</font></p>
</td>
</tr>
<tr>
<td width="68%" valign="top" style=
"padding:0in 0in 0in 0in;width:68.5%;">
<p style="margin:0in 0in .0001pt 10.1pt;text-indent:-10.1pt;">
<font size="2" face="Times New Roman" style=
"font-size:10.0pt;">&nbsp;</font></p>
</td>
<td width="2%" valign="bottom" style=
"padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
</td>
<td width="12%" colspan="2" valign="bottom" style=
"padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;">
<font size="2" face="Times New Roman" style=
"font-size:10.0pt;">&nbsp;</font></p>
</td>
<td width="2%" valign="bottom" style=
"padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
</td>
<td width="12%" colspan="2" valign="bottom" style=
"padding:0in 0in 0in 0in;width:12.84%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;">
<font size="2" face="Times New Roman" style=
"font-size:10.0pt;">&nbsp;</font></p>
</td>
<td width="1%" valign="bottom" style=
"padding:0in 0in 0in 0in;width:1.66%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
</td>
</tr>
<tr>
<td width="68%" valign="top" bgcolor="#CCEEFF" style=
"background:#CCEEFF;padding:0in 0in 0in 0in;width:68.5%;">
<p style="margin:0in 0in .0001pt 10.1pt;text-indent:-10.1pt;">
<b><font size="2" face="Times New Roman" style=
"font-size:10.0pt;font-weight:bold;">Cash flows from investing
activities</font></b></p>
</td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style=
"background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>
</td>
<td width="12%" colspan="2" valign="bottom" bgcolor="#CCEEFF"
style="background:#CCEEFF;padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;">
<font size="2" face="Times New Roman" style=
"font-size:1.0pt;">&nbsp;</font></p>
</td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style=
"background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>
</td>
<td width="12%" colspan="2" valign="bottom" bgcolor="#CCEEFF"
style="background:#CCEEFF;padding:0in 0in 0in 0in;width:12.84%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;">
<font size="2" face="Times New Roman" style=
"font-size:1.0pt;">&nbsp;</font></p>
</td>
<td width="1%" valign="bottom" bgcolor="#CCEEFF" style=
"background:#CCEEFF;padding:0in 0in 0in 0in;width:1.66%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>
</td>
</tr>
<tr>
<td width="68%" valign="bottom" style=
"padding:0in 0in 0in 0in;width:68.5%;">
<p style="margin:0in 0in .0001pt 20.0pt;text-indent:-10.0pt;">
<font size="2" face="Times New Roman" style=
"font-size:10.0pt;">Purchase of property and equipment</font></p>
</td>
<td width="2%" valign="bottom" style=
"padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>
</td>
<td width="12%" colspan="2" valign="bottom" style=
"border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;">
<font size="2" face="Times New Roman" style=
"font-size:10.0pt;">46</font></p>
</td>
<td width="2%" valign="bottom" style=
"padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>
</td>
<td width="12%" colspan="2" valign="bottom" style=
"border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:12.84%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;">
<font size="2" face="Times New Roman" style=
"font-size:10.0pt;">(29</font></p>
</td>
<td width="1%" valign="bottom" style=
"padding:0in 0in 0.375pt 0in;width:1.66%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">)</font></p>
</td>
</tr>
<tr>
<td width="68%" valign="bottom" bgcolor="#CCEEFF" style=
"background:#CCEEFF;padding:0in 0in 0in 0in;width:68.5%;">
<p style="margin:0in 0in .0001pt 50.0pt;text-indent:-10.0pt;">
<font size="2" face="Times New Roman" style="font-size:10.0pt;">Net
cash provided by (used in) investing activities</font></p>
</td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style=
"background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>
</td>
<td width="12%" colspan="2" valign="bottom" bgcolor="#CCEEFF"
style="background:#CCEEFF;padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;">
<font size="2" face="Times New Roman" style=
"font-size:10.0pt;">46</font></p>
</td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style=
"background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>
</td>
<td width="12%" colspan="2" valign="bottom" bgcolor="#CCEEFF"
style="background:#CCEEFF;padding:0in 0in 0in 0in;width:12.84%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;">
<font size="2" face="Times New Roman" style=
"font-size:10.0pt;">(29</font></p>
</td>
<td width="1%" valign="bottom" bgcolor="#CCEEFF" style=
"background:#CCEEFF;padding:0in 0in 0in 0in;width:1.66%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">)</font></p>
</td>
</tr>
<tr>
<td width="68%" valign="top" style=
"padding:0in 0in 0in 0in;width:68.5%;">
<p style="margin:0in 0in .0001pt 10.1pt;text-indent:-10.1pt;">
<font size="2" face="Times New Roman" style=
"font-size:10.0pt;">&nbsp;</font></p>
</td>
<td width="2%" valign="bottom" style=
"padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
</td>
<td width="12%" colspan="2" valign="bottom" style=
"padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;">
<font size="2" face="Times New Roman" style=
"font-size:10.0pt;">&nbsp;</font></p>
</td>
<td width="2%" valign="bottom" style=
"padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
</td>
<td width="12%" colspan="2" valign="bottom" style=
"padding:0in 0in 0in 0in;width:12.84%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;">
<font size="2" face="Times New Roman" style=
"font-size:10.0pt;">&nbsp;</font></p>
</td>
<td width="1%" valign="bottom" style=
"padding:0in 0in 0in 0in;width:1.66%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
</td>
</tr>
<tr>
<td width="68%" valign="top" bgcolor="#CCEEFF" style=
"background:#CCEEFF;padding:0in 0in 0in 0in;width:68.5%;">
<p style="margin:0in 0in .0001pt 10.1pt;text-indent:-10.1pt;">
<b><font size="2" face="Times New Roman" style=
"font-size:10.0pt;font-weight:bold;">Cash flows from financing
activities</font></b></p>
</td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style=
"background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>
</td>
<td width="12%" colspan="2" valign="bottom" bgcolor="#CCEEFF"
style="background:#CCEEFF;padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;">
<font size="2" face="Times New Roman" style=
"font-size:1.0pt;">&nbsp;</font></p>
</td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style=
"background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>
</td>
<td width="12%" colspan="2" valign="bottom" bgcolor="#CCEEFF"
style="background:#CCEEFF;padding:0in 0in 0in 0in;width:12.84%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;">
<font size="2" face="Times New Roman" style=
"font-size:1.0pt;">&nbsp;</font></p>
</td>
<td width="1%" valign="bottom" bgcolor="#CCEEFF" style=
"background:#CCEEFF;padding:0in 0in 0in 0in;width:1.66%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>
</td>
</tr>
<tr>
<td width="68%" valign="bottom" style=
"padding:0in 0in 0in 0in;width:68.5%;">
<p style="margin:0in 0in .0001pt 20.0pt;text-indent:-10.0pt;">
<font size="2" face="Times New Roman" style=
"font-size:10.0pt;">Principal paydown of capital lease
obligations</font></p>
</td>
<td width="2%" valign="bottom" style=
"padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>
</td>
<td width="12%" colspan="2" valign="bottom" style=
"padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;">
<font size="2" face="Times New Roman" style="font-size:10.0pt;">—
</font></p>
</td>
<td width="2%" valign="bottom" style=
"padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>
</td>
<td width="12%" colspan="2" valign="bottom" style=
"padding:0in 0in 0in 0in;width:12.84%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;">
<font size="2" face="Times New Roman" style=
"font-size:10.0pt;">(6</font></p>
</td>
<td width="1%" valign="bottom" style=
"padding:0in 0in 0in 0in;width:1.66%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">)</font></p>
</td>
</tr>
<tr>
<td width="68%" valign="bottom" bgcolor="#CCEEFF" style=
"background:#CCEEFF;padding:0in 0in 0in 0in;width:68.5%;">
<p style="margin:0in 0in .0001pt 20.0pt;text-indent:-10.0pt;">
<font size="2" face="Times New Roman" style=
"font-size:10.0pt;">Proceeds from the issuance of convertible
preferred stock, net of issuance costs</font></p>
</td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style=
"background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>
</td>
<td width="12%" colspan="2" valign="bottom" bgcolor="#CCEEFF"
style="background:#CCEEFF;padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;">
<font size="2" face="Times New Roman" style=
"font-size:10.0pt;">15,534</font></p>
</td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style=
"background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>
</td>
<td width="12%" colspan="2" valign="bottom" bgcolor="#CCEEFF"
style="background:#CCEEFF;padding:0in 0in 0in 0in;width:12.84%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;">
<font size="2" face="Times New Roman" style="font-size:10.0pt;">—
</font></p>
</td>
<td width="1%" valign="bottom" bgcolor="#CCEEFF" style=
"background:#CCEEFF;padding:0in 0in 0in 0in;width:1.66%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>
</td>
</tr>
<tr>
<td width="68%" valign="bottom" style=
"padding:0in 0in 0in 0in;width:68.5%;">
<p style="margin:0in 0in .0001pt 20.0pt;text-indent:-10.0pt;">
<font size="2" face="Times New Roman" style=
"font-size:10.0pt;">Proceeds from the issuance of common stock
related to CRG loan, net of issuance costs</font></p>
</td>
<td width="2%" valign="bottom" style=
"padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>
</td>
<td width="12%" colspan="2" valign="bottom" style=
"padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;">
<font size="2" face="Times New Roman" style="font-size:10.0pt;">—
</font></p>
</td>
<td width="2%" valign="bottom" style=
"padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>
</td>
<td width="12%" colspan="2" valign="bottom" style=
"padding:0in 0in 0in 0in;width:12.84%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;">
<font size="2" face="Times New Roman" style=
"font-size:10.0pt;">236</font></p>
</td>
<td width="1%" valign="bottom" style=
"padding:0in 0in 0in 0in;width:1.66%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>
</td>
</tr>
<tr>
<td width="68%" valign="bottom" bgcolor="#CCEEFF" style=
"background:#CCEEFF;padding:0in 0in 0in 0in;width:68.5%;">
<p style="margin:0in 0in .0001pt 20.0pt;text-indent:-10.0pt;">
<font size="2" face="Times New Roman" style=
"font-size:10.0pt;">Proceeds from public offerings, net of issuance
costs</font></p>
</td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style=
"background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>
</td>
<td width="12%" colspan="2" valign="bottom" bgcolor="#CCEEFF"
style="background:#CCEEFF;border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;">
<font size="2" face="Times New Roman" style=
"font-size:10.0pt;">326</font></p>
</td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style=
"background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>
</td>
<td width="12%" colspan="2" valign="bottom" bgcolor="#CCEEFF"
style="background:#CCEEFF;border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:12.84%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;">
<font size="2" face="Times New Roman" style="font-size:10.0pt;">—
</font></p>
</td>
<td width="1%" valign="bottom" bgcolor="#CCEEFF" style=
"background:#CCEEFF;padding:0in 0in 0in 0in;width:1.66%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>
</td>
</tr>
<tr>
<td width="68%" valign="bottom" style=
"padding:0in 0in 0in 0in;width:68.5%;">
<p style="margin:0in 0in .0001pt 50.0pt;text-indent:-10.0pt;">
<font size="2" face="Times New Roman" style="font-size:10.0pt;">Net
cash provided by financing activities</font></p>
</td>
<td width="2%" valign="bottom" style=
"padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>
</td>
<td width="12%" colspan="2" valign="bottom" style=
"padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;">
<font size="2" face="Times New Roman" style=
"font-size:10.0pt;">15,860</font></p>
</td>
<td width="2%" valign="bottom" style=
"padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>
</td>
<td width="12%" colspan="2" valign="bottom" style=
"padding:0in 0in 0in 0in;width:12.84%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;">
<font size="2" face="Times New Roman" style=
"font-size:10.0pt;">230</font></p>
</td>
<td width="1%" valign="bottom" style=
"padding:0in 0in 0in 0in;width:1.66%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>
</td>
</tr>
<tr>
<td width="68%" valign="top" bgcolor="#CCEEFF" style=
"background:#CCEEFF;padding:0in 0in 0in 0in;width:68.5%;">
<p style="margin:0in 0in .0001pt 10.1pt;text-indent:-10.1pt;">
<font size="2" face="Times New Roman" style=
"font-size:10.0pt;">&nbsp;</font></p>
</td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style=
"background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
</td>
<td width="12%" colspan="2" valign="bottom" bgcolor="#CCEEFF"
style="background:#CCEEFF;padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;">
<font size="2" face="Times New Roman" style=
"font-size:10.0pt;">&nbsp;</font></p>
</td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style=
"background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
</td>
<td width="12%" colspan="2" valign="bottom" bgcolor="#CCEEFF"
style="background:#CCEEFF;padding:0in 0in 0in 0in;width:12.84%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;">
<font size="2" face="Times New Roman" style=
"font-size:10.0pt;">&nbsp;</font></p>
</td>
<td width="1%" valign="bottom" bgcolor="#CCEEFF" style=
"background:#CCEEFF;padding:0in 0in 0in 0in;width:1.66%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
</td>
</tr>
<tr>
<td width="68%" valign="top" style=
"padding:0in 0in 0in 0in;width:68.5%;">
<p style="margin:0in 0in .0001pt 10.1pt;text-indent:-10.1pt;">
<font size="2" face="Times New Roman" style="font-size:10.0pt;">Net
change in cash and cash equivalents</font></p>
</td>
<td width="2%" valign="bottom" style=
"padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>
</td>
<td width="12%" colspan="2" valign="bottom" style=
"padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;">
<font size="2" face="Times New Roman" style=
"font-size:10.0pt;">9,029</font></p>
</td>
<td width="2%" valign="bottom" style=
"padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>
</td>
<td width="12%" colspan="2" valign="bottom" style=
"padding:0in 0in 0in 0in;width:12.84%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;">
<font size="2" face="Times New Roman" style=
"font-size:10.0pt;">(13,062</font></p>
</td>
<td width="1%" valign="bottom" style=
"padding:0in 0in 0in 0in;width:1.66%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">)</font></p>
</td>
</tr>
<tr>
<td width="68%" valign="top" bgcolor="#CCEEFF" style=
"background:#CCEEFF;padding:0in 0in 0in 0in;width:68.5%;">
<p style="margin:0in 0in .0001pt 10.1pt;text-indent:-10.1pt;">
<font size="2" face="Times New Roman" style=
"font-size:10.0pt;">Cash and cash equivalents, beginning of
period</font></p>
</td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style=
"background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>
</td>
<td width="12%" colspan="2" valign="bottom" bgcolor="#CCEEFF"
style="background:#CCEEFF;border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;">
<font size="2" face="Times New Roman" style=
"font-size:10.0pt;">5,389</font></p>
</td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style=
"background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>
</td>
<td width="12%" colspan="2" valign="bottom" bgcolor="#CCEEFF"
style="background:#CCEEFF;border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:12.84%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;">
<font size="2" face="Times New Roman" style=
"font-size:10.0pt;">36,096</font></p>
</td>
<td width="1%" valign="bottom" bgcolor="#CCEEFF" style=
"background:#CCEEFF;padding:0in 0in 0in 0in;width:1.66%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>
</td>
</tr>
<tr>
<td width="68%" valign="top" style=
"padding:0in 0in 0in 0in;width:68.5%;">
<p style="margin:0in 0in .0001pt 10.1pt;text-indent:-10.1pt;">
<font size="2" face="Times New Roman" style=
"font-size:10.0pt;">Cash and cash equivalents, end of
period</font></p>
</td>
<td width="2%" valign="bottom" style=
"padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>
</td>
<td width="12%" colspan="2" valign="bottom" style=
"border:none;border-bottom:double windowtext 2.25pt;padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;">
<font size="2" face="Times New Roman" style=
"font-size:10.0pt;">14,418</font></p>
</td>
<td width="2%" valign="bottom" style=
"padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>
</td>
<td width="1%" valign="bottom" style=
"border:none;border-bottom:double windowtext 2.25pt;padding:0in 0in 0in 0in;width:1.12%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">$</font></p>
</td>
<td width="11%" valign="bottom" style=
"border:none;border-bottom:double windowtext 2.25pt;padding:0in 0in 0in 0in;width:11.72%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;">
<font size="2" face="Times New Roman" style=
"font-size:10.0pt;">23,034</font></p>
</td>
<td width="1%" valign="bottom" style=
"padding:0in 0in 0in 0in;width:1.66%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>
</td>
</tr>
<tr>
<td width="68%" valign="top" bgcolor="#CCEEFF" style=
"background:#CCEEFF;padding:0in 0in 0in 0in;width:68.5%;">
<p style="margin:0in 0in .0001pt 10.1pt;text-indent:-10.1pt;">
<font size="2" face="Times New Roman" style=
"font-size:10.0pt;">&nbsp;</font></p>
</td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style=
"background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
</td>
<td width="12%" colspan="2" valign="bottom" bgcolor="#CCEEFF"
style="background:#CCEEFF;padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;">
<font size="2" face="Times New Roman" style=
"font-size:10.0pt;">&nbsp;</font></p>
</td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style=
"background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
</td>
<td width="12%" colspan="2" valign="bottom" bgcolor="#CCEEFF"
style="background:#CCEEFF;padding:0in 0in 0in 0in;width:12.84%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;">
<font size="2" face="Times New Roman" style=
"font-size:10.0pt;">&nbsp;</font></p>
</td>
<td width="1%" valign="bottom" bgcolor="#CCEEFF" style=
"background:#CCEEFF;padding:0in 0in 0in 0in;width:1.66%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
</td>
</tr>
<tr>
<td width="68%" valign="top" style=
"padding:0in 0in 0in 0in;width:68.5%;">
<p style="margin:0in 0in .0001pt 10.1pt;text-indent:-10.1pt;">
<b><font size="2" face="Times New Roman" style=
"font-size:10.0pt;font-weight:bold;">Supplemental disclosure of
cash flow information</font></b></p>
</td>
<td width="2%" valign="bottom" style=
"padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>
</td>
<td width="12%" colspan="2" valign="bottom" style=
"padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;">
<font size="2" face="Times New Roman" style=
"font-size:1.0pt;">&nbsp;</font></p>
</td>
<td width="2%" valign="bottom" style=
"padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>
</td>
<td width="12%" colspan="2" valign="bottom" style=
"padding:0in 0in 0in 0in;width:12.84%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;">
<font size="2" face="Times New Roman" style=
"font-size:1.0pt;">&nbsp;</font></p>
</td>
<td width="1%" valign="bottom" style=
"padding:0in 0in 0in 0in;width:1.66%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>
</td>
</tr>
<tr>
<td width="68%" valign="bottom" bgcolor="#CCEEFF" style=
"background:#CCEEFF;padding:0in 0in 0in 0in;width:68.5%;">
<p style="margin:0in 0in .0001pt 20.0pt;text-indent:-10.0pt;">
<font size="2" face="Times New Roman" style=
"font-size:10.0pt;">Cash paid for interest</font></p>
</td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style=
"background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>
</td>
<td width="1%" valign="bottom" bgcolor="#CCEEFF" style=
"background:#CCEEFF;border:none;border-bottom:double windowtext 2.25pt;padding:0in 0in 0in 0in;width:1.12%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">$</font></p>
</td>
<td width="10%" valign="bottom" bgcolor="#CCEEFF" style=
"background:#CCEEFF;border:none;border-bottom:double windowtext 2.25pt;padding:0in 0in 0in 0in;width:10.88%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;">
<font size="2" face="Times New Roman" style="font-size:10.0pt;">—
</font></p>
</td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style=
"background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>
</td>
<td width="1%" valign="bottom" bgcolor="#CCEEFF" style=
"background:#CCEEFF;border:none;border-bottom:double windowtext 2.25pt;padding:0in 0in 0in 0in;width:1.12%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">$</font></p>
</td>
<td width="11%" valign="bottom" bgcolor="#CCEEFF" style=
"background:#CCEEFF;border:none;border-bottom:double windowtext 2.25pt;padding:0in 0in 0in 0in;width:11.72%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;">
<font size="2" face="Times New Roman" style=
"font-size:10.0pt;">1,193</font></p>
</td>
<td width="1%" valign="bottom" bgcolor="#CCEEFF" style=
"background:#CCEEFF;padding:0in 0in 0in 0in;width:1.66%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>
</td>
</tr>
<tr>
<td width="68%" valign="bottom" style=
"padding:0in 0in 0in 0in;width:68.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
</td>
<td width="2%" valign="bottom" style=
"padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
</td>
<td width="12%" colspan="2" valign="bottom" style=
"padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;">
<font size="2" face="Times New Roman" style=
"font-size:10.0pt;">&nbsp;</font></p>
</td>
<td width="2%" valign="bottom" style=
"padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
</td>
<td width="12%" colspan="2" valign="bottom" style=
"padding:0in 0in 0in 0in;width:12.84%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;">
<font size="2" face="Times New Roman" style=
"font-size:10.0pt;">&nbsp;</font></p>
</td>
<td width="1%" valign="bottom" style=
"padding:0in 0in 0in 0in;width:1.66%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
</td>
</tr>
<tr>
<td width="68%" valign="bottom" bgcolor="#CCEEFF" style=
"background:#CCEEFF;padding:0in 0in 0in 0in;width:68.5%;">
<p style="margin:0in 0in .0001pt 20.0pt;text-indent:-10.0pt;">
<font size="2" face="Times New Roman" style=
"font-size:10.0pt;">Noncash operating and financing
activities:</font></p>
</td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style=
"background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>
</td>
<td width="12%" colspan="2" valign="bottom" bgcolor="#CCEEFF"
style="background:#CCEEFF;padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;">
<font size="2" face="Times New Roman" style=
"font-size:1.0pt;">&nbsp;</font></p>
</td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style=
"background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>
</td>
<td width="12%" colspan="2" valign="bottom" bgcolor="#CCEEFF"
style="background:#CCEEFF;padding:0in 0in 0in 0in;width:12.84%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;">
<font size="2" face="Times New Roman" style=
"font-size:1.0pt;">&nbsp;</font></p>
</td>
<td width="1%" valign="bottom" bgcolor="#CCEEFF" style=
"background:#CCEEFF;padding:0in 0in 0in 0in;width:1.66%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>
</td>
</tr>
<tr>
<td width="68%" valign="bottom" style=
"padding:0in 0in 0in 0in;width:68.5%;">
<p style="margin:0in 0in .0001pt 30.0pt;text-indent:-10.0pt;">
<font size="2" face="Times New Roman" style=
"font-size:10.0pt;">Conversion of CRG loan principal into
Series&nbsp;A preferred stock</font></p>
</td>
<td width="2%" valign="bottom" style=
"padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>
</td>
<td width="1%" valign="bottom" style=
"border:none;border-bottom:double windowtext 2.25pt;padding:0in 0in 0in 0in;width:1.12%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">$</font></p>
</td>
<td width="10%" valign="bottom" style=
"border:none;border-bottom:double windowtext 2.25pt;padding:0in 0in 0in 0in;width:10.88%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;">
<font size="2" face="Times New Roman" style=
"font-size:10.0pt;">38,000</font></p>
</td>
<td width="2%" valign="bottom" style=
"padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>
</td>
<td width="1%" valign="bottom" style=
"border:none;border-bottom:double windowtext 2.25pt;padding:0in 0in 0in 0in;width:1.12%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">$</font></p>
</td>
<td width="11%" valign="bottom" style=
"border:none;border-bottom:double windowtext 2.25pt;padding:0in 0in 0in 0in;width:11.72%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;">
<font size="2" face="Times New Roman" style="font-size:10.0pt;">—
</font></p>
</td>
<td width="1%" valign="bottom" style=
"padding:0in 0in 0in 0in;width:1.66%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>
</td>
</tr>
<tr>
<td width="68%" valign="bottom" bgcolor="#CCEEFF" style=
"background:#CCEEFF;padding:0in 0in 0in 0in;width:68.5%;">
<p style="margin:0in 0in .0001pt 30.0pt;text-indent:-10.0pt;">
<font size="2" face="Times New Roman" style=
"font-size:10.0pt;">Series&nbsp;A preferred stock accrued
dividends</font></p>
</td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style=
"background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>
</td>
<td width="1%" valign="bottom" bgcolor="#CCEEFF" style=
"background:#CCEEFF;border:none;border-bottom:double windowtext 2.25pt;padding:0in 0in 0in 0in;width:1.12%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">$</font></p>
</td>
<td width="10%" valign="bottom" bgcolor="#CCEEFF" style=
"background:#CCEEFF;border:none;border-bottom:double windowtext 2.25pt;padding:0in 0in 0in 0in;width:10.88%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;">
<font size="2" face="Times New Roman" style=
"font-size:10.0pt;">410</font></p>
</td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style=
"background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>
</td>
<td width="1%" valign="bottom" bgcolor="#CCEEFF" style=
"background:#CCEEFF;border:none;border-bottom:double windowtext 2.25pt;padding:0in 0in 0in 0in;width:1.12%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">$</font></p>
</td>
<td width="11%" valign="bottom" bgcolor="#CCEEFF" style=
"background:#CCEEFF;border:none;border-bottom:double windowtext 2.25pt;padding:0in 0in 0in 0in;width:11.72%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;">
<font size="2" face="Times New Roman" style=
"font-size:10.0pt;">93</font></p>
</td>
<td width="1%" valign="bottom" bgcolor="#CCEEFF" style=
"background:#CCEEFF;padding:0in 0in 0in 0in;width:1.66%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>
</td>
</tr>
<tr>
<td width="68%" valign="bottom" style=
"padding:0in 0in 0in 0in;width:68.5%;">
<p style="margin:0in 0in .0001pt 30.0pt;text-indent:-10.0pt;">
<font size="2" face="Times New Roman" style=
"font-size:10.0pt;">Deemed dividend arising from beneficial
conversion feature of convertible preferred stock</font></p>
</td>
<td width="2%" valign="bottom" style=
"padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>
</td>
<td width="1%" valign="bottom" style=
"padding:0in 0in 0in 0in;width:1.12%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">$</font></p>
</td>
<td width="10%" valign="bottom" style=
"padding:0in 0in 0in 0in;width:10.88%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;">
<font size="2" face="Times New Roman" style=
"font-size:10.0pt;">5,216</font></p>
</td>
<td width="2%" valign="bottom" style=
"padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>
</td>
<td width="1%" valign="bottom" style=
"padding:0in 0in 0in 0in;width:1.12%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">$</font></p>
</td>
<td width="11%" valign="bottom" style=
"padding:0in 0in 0in 0in;width:11.7%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;">
<font size="2" face="Times New Roman" style=
"font-size:10.0pt;">0</font></p>
</td>
<td width="1%" valign="bottom" style=
"padding:0in 0in 0in 0in;width:1.66%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>
</td>
</tr>
</table>
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style=
"margin:0in 0in .0001pt;text-align:center;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">See accompanying
notes.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style=
"font-size:10.0pt;margin:0in 0in .0001pt;text-align:center;">
3<a name="PB_3_121737_5796" id="PB_3_121737_5796"></a></p>
<div style="margin:0in 0in .0001pt;">
<hr size="3" width="100%" noshade="noshade" align="left" style=
"color:#010101;" /></div>
</div>
<!-- SEQ.=1,FOLIO='3',FILE='C:\JMS\109927\18-8644-1\task8901854\8644-1-fa.htm',USER='109927',CD='May 16 01:15 2018' --><br clear="all"
style="page-break-before:always;" />
<div style="font-family:Times New Roman;">
<p style="margin:0in 0in .0001pt;"><a href="#TableOfContents"
title="Click to go to Table of Contents"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">Table of
Contents</font></a></p>
<p align="center" style=
"margin:0in 0in .0001pt;text-align:center;"><b><font size="2" face=
"Times New Roman" style=
"font-size:10.0pt;font-weight:bold;">&nbsp;</font></b></p>
<p align="center" style=
"margin:0in 0in .0001pt;text-align:center;"><b><font size="2" face=
"Times New Roman" style=
"font-size:10.0pt;font-weight:bold;">AVINGER,&nbsp;INC.</font></b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style=
"margin:0in 0in .0001pt;text-align:center;"><b><font size="2" face=
"Times New Roman" style="font-size:10.0pt;font-weight:bold;">Notes
to Condensed Financial Statements</font></b><a name=
"NotestoCondensedFinancialStateme_114412" id=
"NotestoCondensedFinancialStateme_114412"></a></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><b><font size="2" face=
"Times New Roman" style="font-size:10.0pt;font-weight:bold;">1.
Organization</font></b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><b><font size="2" face=
"Times New Roman" style=
"font-size:10.0pt;font-weight:bold;">Organization, Nature of
Business</font></b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style=
"font-size:10.0pt;margin:0in 0in .0001pt;text-indent:.5in;">
<font size="2" face="Times New Roman" style=
"font-size:10.0pt;">Avinger,&nbsp;Inc. (the “Company”), a Delaware
corporation, was founded in March&nbsp;2007 by cardiologist and
medical device entrepreneur Dr.&nbsp;John B. Simpson. The Company
designs, manufactures and sells image-guided, catheter-based
systems that are used by physicians to treat patients with
peripheral artery disease (“PAD”). Patients with PAD have a
build-up of plaque in the arteries that supply blood to areas away
from the heart, particularly the pelvis and legs. The Company
manufactures and sells a suite of products in the United States (
“U.S.”) and in select international markets. The Company has
developed its Lumivascular platform, which integrates optical
coherence tomography (“OCT”) visualization with interventional
catheters and is the industry’s only system that provides real-time
intravascular imaging during the treatment portion of PAD
procedures. The Company’s Lumivascular platform consists of a
capital component, Lightbox, as well as a variety of disposable
catheter products. The Company’s current products include its
non-imaging catheters, Wildcat and Kittycat, as well as its
Lumivascular platform products, Ocelot, Ocelot PIXL and Ocelot
MVRX, all of which are designed to allow physicians to penetrate a
total blockage in an artery, known as a chronic total occlusion (
“CTO”). In March&nbsp;2016, the Company also received
510(k)&nbsp;clearance from the U.S. Food and Drug Administration (
“FDA”) for commercialization of Pantheris, the Company’s
image-guided atherectomy system, designed to allow physicians to
precisely remove arterial plaque in PAD patients. The
Company</font> commenced sales of Pantheris in the U.S. and select
international markets promptly thereafter. The Company is located
in Redwood City, California.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><b><font size="2" face=
"Times New Roman" style=
"font-size:10.0pt;font-weight:bold;">Liquidity
Matters</font></b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style=
"font-size:10.0pt;margin:0in 0in .0001pt;text-indent:.5in;">
<font size="2" face="Times New Roman" style="font-size:10.0pt;">The
accompanying financial statements have been prepared assuming that
the Company will continue as a going concern, which contemplates
the realization of assets and the satisfaction of liabilities in
the normal course of business.&nbsp; The Company adopted Financial
Accounting Standards Board (“FASB”) issued Accounting Standards
Update (“ASU”)&nbsp; No.&nbsp;2014-15,&nbsp;Presentation of
Financial Statements - Going Concern (Subtopic 205-40) effective
December&nbsp;31, 2016, which requires the Company to make certain
disclosures if it concludes that there is substantial doubt about
the entity’s ability to continue as a going concern within one year
from the date of the issuance of these financial statements. The
accompanying financial statements have been prepared assuming that
the Company will continue as a going concern, which contemplates
the realization of assets and the satisfaction of liabilities in
the normal course of business.&nbsp; In the course of its
activities, the Company has incurred losses and negative cash flows
from operations since its inception. As of March&nbsp;31, 2018, the
Company had an accumulated deficit of $311,608. The Company expects
to incur losses for the foreseeable future. The Company believes
that its cash and cash equivalents of $14,418,000 at March&nbsp;31,
2018 and expected revenues will be sufficient to allow the Company
to fund its current operations until approximately October&nbsp;31,
2018. The Company will seek additional sources of funding in the
form of debt financing or equity issuances, however, there can be
no assurance that the Company will be successful in acquiring
additional funding at levels sufficient to fund its operations.
These conditions raise substantial doubt about the Company’s
ability to continue as a going concern.&nbsp;If the Company is
unable to raise additional capital in sufficient amounts or on
terms acceptable to it, the Company may have to significantly
reduce its operations or delay, scale back or discontinue the
development of one or more of its products. The financial
statements do not include any adjustments that might result from
the outcome of this uncertainty. The Company’s ultimate success
will largely depend on its continued development of innovative
medical technologies, its ability to successfully commercialize its
products and its ability to raise significant additional funding.
Additionally, due to the substantial doubt about the Company’s
ability to continue operating as a going concern and the material
adverse change clause in the Loan Agreement with</font> CRG
Partners III L.P. and certain of its affiliated funds (collectively
“CRG”), the entire amount of borrowings at March&nbsp;31, 2018 and
December&nbsp;31, 2017 has been classified as current in these
financial statements. CRG has not invoked the material adverse
change clause. On November&nbsp;3, 2017, the Company entered into a
purchase agreement with Lincoln Park Capital Fund, LLC (“Lincoln
Park”), pursuant to which Lincoln Park is obligated to purchase, at
the Company’s request, up to $15,000,000 of the Company’s common
stock over a 30-month period, subject to certain limitations set
forth in the agreement (the “Lincoln Park Purchase Agreement”
).&nbsp; As a fee for Lincoln Park’s commitment to purchase such
shares, the Company issued 23,584 shares of common stock to Lincoln
Park on November&nbsp;3, 2017. As obligated under a registration
rights agreement entered into with Lincoln Park in connection with
the Purchase Agreement, the Company filed a registration statement
on Form&nbsp;S-1 on November&nbsp;6, 2017 for up to 248,750 of such
shares, which registration statement was declared effective by the
SEC on November&nbsp;17, 2017.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style=
"font-size:10.0pt;margin:0in 0in .0001pt;text-align:center;">
4<a name="PB_4_112730_7472" id="PB_4_112730_7472"></a></p>
<div style="margin:0in 0in .0001pt;">
<hr size="3" width="100%" noshade="noshade" align="left" style=
"color:#010101;" /></div>
</div>
<!-- SEQ.=1,FOLIO='4',FILE='C:\JMS\109754\18-8644-1\task8901843\8644-1-fn.htm',USER='109754',CD='May 16 01:11 2018' --><br clear="all"
style="page-break-before:always;" />
<div style="font-family:Times New Roman;">
<p style="margin:0in 0in .0001pt;"><a href="#TableOfContents"
title="Click to go to Table of Contents"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">Table of
Contents</font></a></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><b><font size="2" face=
"Times New Roman" style="font-size:10.0pt;font-weight:bold;">Public
Offerings</font></b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style=
"font-size:10.0pt;margin:0in 0in .0001pt;text-indent:.5in;">
<font size="2" face="Times New Roman"><font style=
"font-size:10.0pt;">In January&nbsp;2015, the Company issued and
sold 125,000 shares of its common stock in its initial public
offering (“IPO”) at a public offering price of $520.00 per share,
for net proceeds of approximately $56,897,000 after deducting
underwriting discounts and</font></font> commissions of
approximately $4,550,000 and expenses of approximately $3,553,000.
Upon the closing of the IPO, all shares of convertible preferred
stock then outstanding converted into an aggregate of 174,028
shares of common stock resulting in the reclassification of
$137,626,000 from outside of stockholders’ equity to additional
paid-in capital.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style=
"font-size:10.0pt;margin:0in 0in .0001pt;text-indent:.5in;">
<font size="2" face="Times New Roman" style="font-size:10.0pt;">On
February&nbsp;3, 2016, the Company filed a universal shelf
registration statement to offer up to $150,000,000 of its
securities and entered into an “at-the-market” program pursuant to
a Sales Agreement with Cowen and Company (“Cowen”), through which
it may, from time to time, issue and sell shares of common stock
having an aggregate offering value of up to $50,000,000.&nbsp;The
shelf registration statement also covers the resale of the shares
sold to</font> CRG in September&nbsp;2015.&nbsp;The registration
statement was declared effective by the SEC on March&nbsp;8, 2016.
During the three months ended March&nbsp;31, 2018 and 2017, the
Company sold no shares of common stock through the “at-the-market”
program. Due to the SEC’s “baby shelf rules,” which prohibit
companies with a public float of less than $75 million from issuing
securities under a shelf registration statement in excess of
one-third of such company’s public float in a twelve-month period,
the Company is unable to issue more shares in its “at-the-market”
program at this time. In August&nbsp;2016, the Company issued and
sold 246,445 shares of its common stock in its follow-on public
offering, which includes the exercise in full by the underwriters
of their option to purchase 32,145 shares of common stock, at a
public offering price of $140.00 per share. Net proceeds from the
follow-on public offering were approximately $31,549,000 after
deducting underwriting discounts and commissions of approximately
$2,415,000 and expenses of approximately $538,000.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><b><font size="2" face=
"Times New Roman" style="font-size:10.0pt;font-weight:bold;">2.
Summary of Significant Accounting Policies</font></b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><b><font size="2" face=
"Times New Roman" style="font-size:10.0pt;font-weight:bold;">Basis
of Presentation</font></b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style=
"font-size:10.0pt;margin:0in 0in .0001pt;text-indent:.5in;">
<font size="2" face="Times New Roman" style="font-size:10.0pt;">The
accompanying unaudited condensed financial statements have been
prepared in accordance with United States generally accepted
accounting principles (“U.S.&nbsp;GAAP”) and pursuant to the
rules&nbsp;and regulations of the SEC.</font> The accompanying
unaudited condensed interim financial statements have been prepared
on the same basis as the annual financial statements and, in the
opinion of management, reflect all adjustments, which include only
normal recurring adjustments, necessary for a fair statement of the
Company’s financial information. The results for the three months
ended March&nbsp;31, 2018, are not necessarily indicative of
results to be expected for the year ending December&nbsp;31, 2018,
or for any other interim period or for any future year. The
December&nbsp;31, 2017 condensed balance sheet data has been
derived from audited financial statements. Certain information and
footnote disclosures normally included in annual financial
statements prepared in accordance with U.S. GAAP have been
condensed or omitted pursuant to SEC rules&nbsp;and regulations
relating to interim financial statements. These unaudited condensed
financial statements and notes should be read in conjunction with
the financial statements included in the Company’s Form&nbsp;10-K
for the fiscal year ended December&nbsp;31, 2017, which was filed
with the SEC on March&nbsp;30, 2018. The Company’s significant
accounting policies are more fully described in Note 2 of the Notes
to Financial Statements included in the Company’s Annual Report on
Form&nbsp;10-K for the year ended December&nbsp;31, 2018.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2"
face="Times New Roman" style="font-size:10.0pt;">On
January&nbsp;30, 2018, the Company’s Board of Directors approved an
amendment to the Company’s amended and restated certificate of
incorporation to effect a 1-for-40 reverse stock split of the
Company’s common stock. The par value of the common stock and
convertible preferred stock was not adjusted as a result of the
reverse stock split. All common stock, stock options and warrants,
and per share amounts in the financial statements have been
retroactively adjusted for all periods presented to give effect to
the reverse stock split. The reverse stock split was effected on
January&nbsp;30, 2018.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><b><font size="2" face=
"Times New Roman" style="font-size:10.0pt;font-weight:bold;">Use of
Estimates</font></b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style=
"font-size:10.0pt;margin:0in 0in .0001pt;text-indent:.5in;">
<font size="2" face="Times New Roman" style="font-size:10.0pt;">The
preparation of financial statements in conformity with
U.S.&nbsp;GAAP requires management to make estimates and
assumptions that affect the amounts and disclosures reported in the
financial statements. Management uses significant judgment when
making estimates related to its common stock valuation and related
stock-based compensation,</font> the valuation of the common stock
warrants, the valuation of compound embedded derivatives,
provisions for doubtful accounts receivable and excess and obsolete
inventories, clinical trial accruals, and its reserves for sales
returns and warranty costs. Management bases its estimates on
historical experience and on various other assumptions that are
believed to be reasonable under the circumstances, the results of
which form the basis for making judgments about the carrying values
of assets and liabilities that are not readily apparent from other
sources. Although these estimates are based on the Company’s
knowledge of current events and actions it may undertake in the
future, actual results may ultimately materially differ from these
estimates and assumptions.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style=
"font-size:10.0pt;margin:0in 0in .0001pt;text-align:center;">
5<a name="PB_5_112825_7056" id="PB_5_112825_7056"></a></p>
<div style="margin:0in 0in .0001pt;">
<hr size="3" width="100%" noshade="noshade" align="left" style=
"color:#010101;" /></div>
</div>
<!-- SEQ.=1,FOLIO='5',FILE='C:\JMS\109754\18-8644-1\task8901843\8644-1-fn.htm',USER='109754',CD='May 16 01:11 2018' --><br clear="all"
style="page-break-before:always;" />
<div style="font-family:Times New Roman;">
<p style="margin:0in 0in .0001pt;"><a href="#TableOfContents"
title="Click to go to Table of Contents"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">Table of
Contents</font></a></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><b><font size="2" face=
"Times New Roman" style="font-size:10.0pt;font-weight:bold;">Fair
Value of Financial Instruments</font></b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">The Company has
evaluated the estimated fair value of its financial instruments as
of March&nbsp;31, 2018 and December&nbsp;31, 2017. Financial
instruments consist of cash and cash equivalents, accounts
receivable and payable, and other current liabilities and
borrowings. The carrying amounts of cash and cash equivalents,
accounts receivable and payable, and other current liabilities
approximate their respective fair values because of the short-term
nature of those instruments. Based upon the borrowing terms and
conditions currently available to the Company, the carrying values
of the borrowings approximate their fair value.</font></p>
<p style="margin:0in 0in .0001pt;"><b><font size="2" face=
"Times New Roman" style=
"font-size:10.0pt;font-weight:bold;">&nbsp;</font></b></p>
<p style="margin:0in 0in .0001pt;"><b><font size="2" face=
"Times New Roman" style="font-size:10.0pt;font-weight:bold;">Cash
and Cash Equivalents</font></b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2"
face="Times New Roman" style="font-size:10.0pt;">The Company
considers all highly liquid investments with an original maturity
of three months or less at the time of purchase to be cash
equivalents. Cash equivalents are considered available-for-sale
marketable securities and are recorded at fair value, using level 1
inputs, based on quoted market prices. As of March&nbsp;31, 2018
and December&nbsp;31, 2017, the Company’s cash equivalents are
entirely comprised of investments in money market funds. Any
related unrealized gains and losses are recorded in other
comprehensive income (loss) and included as a separate component of
stockholders’ equity (deficit). There were no unrealized gains and
losses as of March&nbsp;31, 2018 and December&nbsp;31, 2017. Any
realized gains and losses and interest and dividends on
available-for-sale securities are included in interest income or
expense and computed using the specific identification cost
method.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><b><font size="2" face=
"Times New Roman" style=
"font-size:10.0pt;font-weight:bold;">Concentration of Credit Risk,
and Other Risks and Uncertainties</font></b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2"
face="Times New Roman" style="font-size:10.0pt;">Financial
instruments that potentially subject the Company to credit risk
consist of cash and cash equivalents and accounts receivable to the
extent of the amounts recorded on the balance sheets.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2"
face="Times New Roman" style="font-size:10.0pt;">The Company’s
policy is to invest in cash and cash equivalents, consisting of
money market funds. These financial instruments are held in Company
accounts at one financial institution. The counterparties to the
agreements relating to the Company’s investments consist of
financial institutions of high credit standing.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2"
face="Times New Roman" style="font-size:10.0pt;">The Company
provides for uncollectible amounts when specific credit problems
arise. Management’s estimates for uncollectible amounts have been
adequate, and management believes that all significant credit risks
have been identified at March&nbsp;31, 2018 and December&nbsp;31,
2017.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style=
"font-size:10.0pt;margin:0in 0in .0001pt;text-indent:.5in;">
<font size="2" face="Times New Roman" style="font-size:10.0pt;">The
Company’s accounts receivable are due from a variety of health-care
organizations in the United States and select international
markets. At March&nbsp;31, 2018 and December&nbsp;31, 2017, there
were no customers that represented 10% or more of the Company’s
accounts receivable. For the three</font> months ended
March&nbsp;31, 2018 and 2017, there were no customers that
represented 10% or more of revenues. Disruption of sales orders or
a deterioration of financial condition of its customers would have
a negative impact on the Company’s financial position and results
of operations.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2"
face="Times New Roman" style="font-size:10.0pt;">The Company
manufactures its commercial products in-house, including Pantheris
and the Ocelot family of catheters. Certain of the Company’s
product components and sub-assemblies continue to be manufactured
by sole suppliers. Disruption in component or sub-assembly supply
from these manufacturers or from in-house production would have a
negative impact on the Company’s financial position and results of
operations.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2"
face="Times New Roman" style="font-size:10.0pt;">The Company is
subject to certain risks, including that its devices may not be
approved or cleared for marketing by governmental authorities or be
successfully marketed. There can be no assurance that the Company’s
products will achieve widespread adoption in the marketplace, nor
can there be any assurance that existing devices or any future
devices can be developed or manufactured at an acceptable cost and
with appropriate performance characteristics. The Company is also
subject to risks common to companies in the medical device
industry, including, but not limited to, new technological
innovations, dependence upon third-party payors to provide adequate
coverage and reimbursement, dependence on key personnel and
suppliers, protection of proprietary technology, product liability
claims, and compliance with government regulations.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2"
face="Times New Roman" style="font-size:10.0pt;">Existing or future
devices developed by the Company may require approvals or
clearances from the FDA or international regulatory agencies. In
addition, in order to continue the Company’s operations, compliance
with various federal and state laws is required. If the Company
were denied or delayed in receiving such approvals or clearances,
it may be necessary to adjust operations to align with the Company’
s currently approved portfolio. If clearance for the products in
the current portfolio were withdrawn by the FDA, this may have a
material adverse impact on the Company.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><b><font size="2" face=
"Times New Roman" style=
"font-size:10.0pt;font-weight:bold;">Revenue
Recognition</font></b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;"><font size="2"
face="Times New Roman" style="font-size:10.0pt;">The Company’s
revenues are derived from (1)&nbsp;sale of its
Lightbox&nbsp;(2)&nbsp;sale of disposables, which consist of
catheters and accessories, and (3)&nbsp;sale of customer service
contracts.</font> The Company sells its products directly to
hospitals and medical centers as well as through distributors. The
Company accounts for a contract with a customer when there is a
legally enforceable contract between the Company</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style=
"font-size:10.0pt;margin:0in 0in .0001pt;text-align:center;">
6<a name="PB_6_112923_5335" id="PB_6_112923_5335"></a></p>
<div style="margin:0in 0in .0001pt;">
<hr size="3" width="100%" noshade="noshade" align="left" style=
"color:#010101;" /></div>
</div>
<!-- SEQ.=1,FOLIO='6',FILE='C:\JMS\109754\18-8644-1\task8901843\8644-1-fn.htm',USER='109754',CD='May 16 01:11 2018' --><br clear="all"
style="page-break-before:always;" />
<div style="font-family:Times New Roman;">
<p style="margin:0in 0in .0001pt;"><a href="#TableOfContents"
title="Click to go to Table of Contents"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">Table of
Contents</font></a></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;"><font size="2"
face="Times New Roman" style="font-size:10.0pt;">and the customer,
the rights of the parties are identified, the contract has
commercial substance, and collectability of the contract
consideration is probable. The Company’s revenues are measured
based on consideration specified in the contract with each
customer, net of any sales incentives and taxes collected from
customers that are remitted to government authorities.</font> For
all sales, the Company uses either a signed agreement or a binding
purchase order as evidence of an arrangement. The Company’s revenue
recognition policies generally result in revenue recognition at the
following points:</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style=
"font-size:10.0pt;margin:0in 0in .0001pt 1.0in;text-indent:-.5in;">
<font size="2" face="Times New Roman" style=
"font-size:10.0pt;">1.</font><font size="1" style=
"font-size:3.0pt;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</font>
Lightbox sales: The Company sells its products directly to
hospitals and medical centers. Provided all other criteria for
revenue recognition have been met, the Company recognizes revenue
for Lightbox sales directly to end customers when delivery and
acceptance occurs, which is defined as receipt by the Company of an
executed form by the customer acknowledging that the training and
installation process is complete.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style=
"font-size:10.0pt;margin:0in 0in .0001pt 1.0in;text-indent:-.5in;">
<font size="2" face="Times New Roman" style=
"font-size:10.0pt;">2.</font><font size="1" style=
"font-size:3.0pt;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</font>
Sales of disposables: Disposable revenues consist of sales of the
Company’s catheters and accessories and are recognized when the
product has shipped, risk of loss and title has passed to the
customer and collectability is reasonably assured.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style=
"font-size:10.0pt;margin:0in 0in .0001pt 1.0in;text-indent:-.5in;">
<font size="2" face="Times New Roman" style=
"font-size:10.0pt;">3.</font><font size="1" style=
"font-size:3.0pt;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</font>
Service revenue: Service revenue is recognized ratably over the
term of the service period. To date, service revenue has been
insignificant.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style=
"font-size:10.0pt;margin:0in 0in .0001pt;text-indent:.5in;">
<font size="2" face="Times New Roman" style="font-size:10.0pt;">The
Company offers its customers the ability to purchase or lease its
Lightbox.</font> In addition, the Company provides a Lightbox under
a limited commercial evaluation program to allow certain strategic
accounts to install and utilize the Lightbox for a limited trial
period of three to six months. When a Lightbox is placed under a
lease agreement or under a commercial evaluation program, the
Company retains title to the equipment and it remains capitalized
on its balance sheet under property and equipment. Depreciation
expense on these placed Lightboxes is recorded to cost of revenues
on a straight-line basis. The costs to maintain these placed
Lightboxes are charged to cost of revenues as incurred.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2"
face="Times New Roman" style="font-size:10.0pt;">The Company
evaluates its lease and commercial evaluation program agreements
and accounts for these contracts under the guidance in ASC 840,
<i>Leases</i> and Accounting Standards Update No.&nbsp;2014 09,
<i>Revenue from Contracts with Customers (Topic 606)</i>. The
guidance requires arrangement consideration to be allocated between
a lease deliverable and a non-lease deliverable based upon the
relative selling-price of the deliverables, using a specific
hierarchy. The hierarchy is as follows: vendor-specific objective
evidence of fair value of the respective elements, third-party
evidence of selling price, or best estimate of selling price (“BESP”
). The Company allocates arrangement consideration using
BESP.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2"
face="Times New Roman" style="font-size:10.0pt;">The Company
assessed whether the embedded lease is an operating lease or
sales-type lease. Based on the Company’s assessment of the guidance
and given that any payments under the lease agreements are
dependent upon contingent future sales, it was determined that
collectability of the minimum lease payments is not reasonably
predictable. Accordingly, the Company concluded the embedded lease
did not meet the criteria of a sales-type lease and accounts for it
as an operating lease. The Company recognizes revenue allocated to
the lease as the contingent disposable product purchases are
delivered and are included in revenues within the statement of
operations and comprehensive loss.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2"
face="Times New Roman" style="font-size:10.0pt;">For sales through
distributors, the Company recognizes revenue when title to the
product and the risk of loss transfers from the Company to the
distributor. The distributors are responsible for all marketing,
sales, training and warranty in their respective territories. The
standard terms and conditions contained in the Company’s
distribution agreements do not provide price protection or stock
rotation rights to any of its distributors. In addition, its
distributor agreements do not allow the distributor to return or
exchange products, and the distributor is obligated to pay the
Company upon invoice regardless of its ability to resell the
product.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2"
face="Times New Roman" style="font-size:10.0pt;">The Company
estimates reductions in revenue for potential returns of products
by customers. In making such estimates, management analyzes
historical returns, current economic trends and changes in customer
demand and acceptance of its products. The Company expenses
shipping and handling costs as incurred and includes them in the
cost of revenues. In those cases where the Company bills shipping
and handling costs to customers, it will classify the amounts
billed as a component of revenue.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><b><font size="2" face=
"Times New Roman" style="font-size:10.0pt;font-weight:bold;">Cost
of Revenues</font></b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2"
face="Times New Roman" style="font-size:10.0pt;">Cost of revenues
consists primarily of manufacturing overhead costs, material costs
and direct labor. A significant portion of the Company’s cost of
revenues currently consists of manufacturing overhead costs. These
overhead costs include the cost of quality assurance, material
procurement, inventory control, facilities, equipment and
operations supervision and management. Cost of revenues also
includes depreciation expense for the Lightboxes under lease
agreements and certain direct costs such as shipping
costs.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style=
"font-size:10.0pt;margin:0in 0in .0001pt;text-align:center;">
7<a name="PB_7_112951_5796" id="PB_7_112951_5796"></a></p>
<div style="margin:0in 0in .0001pt;">
<hr size="3" width="100%" noshade="noshade" align="left" style=
"color:#010101;" /></div>
</div>
<!-- SEQ.=1,FOLIO='7',FILE='C:\JMS\109754\18-8644-1\task8901843\8644-1-fn.htm',USER='109754',CD='May 16 01:11 2018' --><br clear="all"
style="page-break-before:always;" />
<div style="font-family:Times New Roman;">
<p style="margin:0in 0in .0001pt;"><a href="#TableOfContents"
title="Click to go to Table of Contents"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">Table of
Contents</font></a></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><b><font size="2" face=
"Times New Roman" style=
"font-size:10.0pt;font-weight:bold;">Product Warranty
Costs</font></b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2"
face="Times New Roman" style="font-size:10.0pt;">The Company
typically offers a one-year warranty for parts and labor on its
products commencing upon the transfer of title and risk of loss to
the customer. The Company accrues for the estimated cost of product
warranties upon invoicing its customers, based on historical
results. Warranty costs are reflected in the statement of
operations and comprehensive loss as a cost of revenues. The
warranty obligation is affected by product failure rates, material
usage and service delivery costs incurred in correcting a product
failure. Should actual product failure rates, material usage or
service delivery costs differ from these estimates, revisions to
the estimated warranty liability would be required. Periodically
the Company assesses the adequacy of its recorded warranty
liabilities and adjusts the amounts as necessary. Warranty
provisions and claims are summarized as follows (in
thousands):</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<table border="0" cellspacing="0" cellpadding="0" width="53%"
style="border-collapse:collapse;margin-left:1.75in;">
<tr>
<td width="70%" valign="bottom" style=
"padding:0in 0in 0in 0in;width:70.94%;">
<p style="margin:0in 0in .0001pt;"><b><font size="1" face=
"Times New Roman" style=
"font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>
</td>
<td width="4%" valign="bottom" style=
"padding:0in 0in 0in 0in;width:4.68%;">
<p align="center" style=
"margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face=
"Times New Roman" style=
"font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>
</td>
<td width="22%" colspan="2" valign="bottom" style=
"border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:22.5%;">
<p align="center" style=
"margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face=
"Times New Roman" style=
"font-size:8.0pt;font-weight:bold;">Amount</font></b></p>
</td>
<td width="1%" valign="bottom" style=
"padding:0in 0in 0in 0in;width:1.88%;">
<p align="center" style=
"margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face=
"Times New Roman" style=
"font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>
</td>
</tr>
<tr>
<td width="70%" valign="top" bgcolor="#CCEEFF" style=
"background:#CCEEFF;padding:0in 0in 0in 0in;width:70.94%;">
<p style="margin:0in 0in .0001pt 10.1pt;text-indent:-10.1pt;">
<font size="2" face="Times New Roman" style=
"font-size:10.0pt;">Balance at December&nbsp;31, 2017</font></p>
</td>
<td width="4%" valign="bottom" bgcolor="#CCEEFF" style=
"background:#CCEEFF;padding:0in 0in 0in 0in;width:4.68%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>
</td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style=
"background:#CCEEFF;padding:0in 0in 0in 0in;width:2.12%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">$</font></p>
</td>
<td width="20%" valign="bottom" bgcolor="#CCEEFF" style=
"background:#CCEEFF;padding:0in 0in 0in 0in;width:20.38%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;">
<font size="2" face="Times New Roman" style=
"font-size:10.0pt;">(390</font></p>
</td>
<td width="1%" valign="bottom" bgcolor="#CCEEFF" style=
"background:#CCEEFF;padding:0in 0in 0in 0in;width:1.88%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">)</font></p>
</td>
</tr>
<tr>
<td width="70%" valign="top" style=
"padding:0in 0in 0in 0in;width:70.94%;">
<p style="margin:0in 0in .0001pt 20.2pt;text-indent:-10.1pt;">
<font size="2" face="Times New Roman" style=
"font-size:10.0pt;">Warranty provision</font></p>
</td>
<td width="4%" valign="bottom" style=
"padding:0in 0in 0in 0in;width:4.68%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>
</td>
<td width="22%" colspan="2" valign="bottom" style=
"padding:0in 0in 0in 0in;width:22.5%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;">
<font size="2" face="Times New Roman" style="font-size:10.0pt;">—
</font></p>
</td>
<td width="1%" valign="bottom" style=
"padding:0in 0in 0in 0in;width:1.88%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>
</td>
</tr>
<tr>
<td width="70%" valign="top" bgcolor="#CCEEFF" style=
"background:#CCEEFF;padding:0in 0in 0in 0in;width:70.94%;">
<p style="margin:0in 0in .0001pt 20.2pt;text-indent:-10.1pt;">
<font size="2" face="Times New Roman" style=
"font-size:10.0pt;">Usage/Release</font></p>
</td>
<td width="4%" valign="bottom" bgcolor="#CCEEFF" style=
"background:#CCEEFF;padding:0in 0in 0in 0in;width:4.68%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>
</td>
<td width="22%" colspan="2" valign="bottom" bgcolor="#CCEEFF"
style="background:#CCEEFF;border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:22.5%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;">
<font size="2" face="Times New Roman" style=
"font-size:10.0pt;">5</font></p>
</td>
<td width="1%" valign="bottom" bgcolor="#CCEEFF" style=
"background:#CCEEFF;padding:0in 0in 0in 0in;width:1.88%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>
</td>
</tr>
<tr>
<td width="70%" valign="top" style=
"padding:0in 0in 0in 0in;width:70.94%;">
<p style="margin:0in 0in .0001pt 10.1pt;text-indent:-10.1pt;">
<font size="2" face="Times New Roman" style=
"font-size:10.0pt;">Balance at March&nbsp;31, 2018</font></p>
</td>
<td width="4%" valign="bottom" style=
"padding:0in 0in 0in 0in;width:4.68%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>
</td>
<td width="2%" valign="bottom" style=
"border:none;border-bottom:double windowtext 2.25pt;padding:0in 0in 0in 0in;width:2.12%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">$</font></p>
</td>
<td width="20%" valign="bottom" style=
"border:none;border-bottom:double windowtext 2.25pt;padding:0in 0in 0in 0in;width:20.36%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;">
<font size="2" face="Times New Roman" style=
"font-size:10.0pt;">(385</font></p>
</td>
<td width="1%" valign="bottom" style=
"padding:0in 0in 2.25pt 0in;width:1.88%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">)</font></p>
</td>
</tr>
</table>
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><b><font size="2" face=
"Times New Roman" style="font-size:10.0pt;font-weight:bold;">Net
Loss per Share Attributable to Common Stockholders</font></b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2"
face="Times New Roman" style="font-size:10.0pt;">Basic net loss per
share attributable to common stockholders is computed by dividing
the net loss attributable to common stockholders by the weighted
average number of shares of common stock outstanding during the
period, without consideration for potential dilutive common shares.
Diluted net loss per share attributable to common stockholders is
computed by dividing the net loss attributable to common
stockholders by the weighted average number of shares of common
stock and dilutive potential shares of common stock outstanding
during the period. Any common stock shares subject to repurchase
are excluded from the calculations as the continued vesting of such
shares is contingent upon the holders’ continued service to the
Company. As of March&nbsp;31, 2018 and 2017, there were no shares
subject to repurchase. Since the Company was in a loss position for
all periods presented, basic net loss per share attributable to
common stockholders is the same as diluted net loss per share
attributable to common stockholders as the inclusion of all
potentially dilutive common shares would have been
anti-dilutive.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2"
face="Times New Roman" style="font-size:10.0pt;">Net loss per share
attributable to common stockholders was determined as follows (in
thousands, except per share data):</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<table border="0" cellspacing="0" cellpadding="0" width="73%"
style="border-collapse:collapse;margin-left:1.0in;">
<tr>
<td width="59%" valign="bottom" style=
"padding:0in 0in 0in 0in;width:59.1%;">
<p style="margin:0in 0in .0001pt;"><b><font size="1" face=
"Times New Roman" style=
"font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>
</td>
<td width="3%" valign="bottom" style=
"padding:0in 0in 0in 0in;width:3.4%;">
<p align="center" style=
"margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face=
"Times New Roman" style=
"font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>
</td>
<td width="36%" colspan="5" valign="bottom" style=
"border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:36.14%;">
<p align="center" style=
"margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face=
"Times New Roman" style=
"font-size:8.0pt;font-weight:bold;">Three&nbsp;Months&nbsp;Ended&nbsp;March&nbsp;31,</font></b></p>
</td>
<td width="1%" valign="bottom" style=
"padding:0in 0in 0in 0in;width:1.36%;">
<p align="center" style=
"margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face=
"Times New Roman" style=
"font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>
</td>
</tr>
<tr>
<td width="59%" valign="bottom" style=
"padding:0in 0in 0in 0in;width:59.1%;">
<p style="margin:0in 0in .0001pt;"><b><font size="1" face=
"Times New Roman" style=
"font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>
</td>
<td width="3%" valign="bottom" style=
"padding:0in 0in 0in 0in;width:3.4%;">
<p align="center" style=
"margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face=
"Times New Roman" style=
"font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>
</td>
<td width="16%" colspan="2" valign="bottom" style=
"border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:16.36%;">
<p align="center" style=
"margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face=
"Times New Roman" style=
"font-size:8.0pt;font-weight:bold;">2018</font></b></p>
</td>
<td width="3%" valign="bottom" style=
"padding:0in 0in 0in 0in;width:3.4%;">
<p align="center" style=
"margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face=
"Times New Roman" style=
"font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>
</td>
<td width="16%" colspan="2" valign="bottom" style=
"border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:16.38%;">
<p align="center" style=
"margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face=
"Times New Roman" style=
"font-size:8.0pt;font-weight:bold;">2017</font></b></p>
</td>
<td width="1%" valign="bottom" style=
"padding:0in 0in 0in 0in;width:1.36%;">
<p align="center" style=
"margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face=
"Times New Roman" style=
"font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>
</td>
</tr>
<tr>
<td width="59%" valign="top" bgcolor="#CCEEFF" style=
"background:#CCEEFF;padding:0in 0in 0in 0in;width:59.1%;">
<p style=
"font-size:10.0pt;margin:0in 0in .0001pt 10.1pt;text-indent:-10.1pt;">
<font size="2" face="Times New Roman" style="font-size:10.0pt;">Net
loss</font> attributable to common stockholders</p>
</td>
<td width="3%" valign="bottom" bgcolor="#CCEEFF" style=
"background:#CCEEFF;padding:0in 0in 0in 0in;width:3.4%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>
</td>
<td width="1%" valign="bottom" bgcolor="#CCEEFF" style=
"background:#CCEEFF;border:none;border-bottom:double windowtext 2.25pt;padding:0in 0in 0in 0in;width:1.54%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">$</font></p>
</td>
<td width="14%" valign="bottom" bgcolor="#CCEEFF" style=
"background:#CCEEFF;border:none;border-bottom:double windowtext 2.25pt;padding:0in 0in 0in 0in;width:14.82%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;">
<font size="2" face="Times New Roman" style=
"font-size:10.0pt;">(15,907</font></p>
</td>
<td width="3%" valign="bottom" bgcolor="#CCEEFF" style=
"background:#CCEEFF;padding:0in 0in 1.125pt 0in;width:3.4%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">)</font></p>
</td>
<td width="1%" valign="bottom" bgcolor="#CCEEFF" style=
"background:#CCEEFF;border:none;border-bottom:double windowtext 2.25pt;padding:0in 0in 0in 0in;width:1.54%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">$</font></p>
</td>
<td width="14%" valign="bottom" bgcolor="#CCEEFF" style=
"background:#CCEEFF;border:none;border-bottom:double windowtext 2.25pt;padding:0in 0in 0in 0in;width:14.84%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;">
<font size="2" face="Times New Roman" style=
"font-size:10.0pt;">(15,340</font></p>
</td>
<td width="1%" valign="bottom" bgcolor="#CCEEFF" style=
"background:#CCEEFF;padding:0in 0in 1.125pt 0in;width:1.36%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">)</font></p>
</td>
</tr>
<tr>
<td width="59%" valign="top" style=
"padding:0in 0in 0in 0in;width:59.1%;">
<p style="margin:0in 0in .0001pt 10.1pt;text-indent:-10.1pt;">
<font size="2" face="Times New Roman" style=
"font-size:10.0pt;">Weighted average common stock
outstanding</font></p>
</td>
<td width="3%" valign="bottom" style=
"padding:0in 0in 0in 0in;width:3.4%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>
</td>
<td width="16%" colspan="2" valign="bottom" style=
"border:none;border-bottom:double windowtext 2.25pt;padding:0in 0in 0in 0in;width:16.36%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;">
<font size="2" face="Times New Roman" style=
"font-size:10.0pt;">1,992</font></p>
</td>
<td width="3%" valign="bottom" style=
"padding:0in 0in 0in 0in;width:3.4%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>
</td>
<td width="16%" colspan="2" valign="bottom" style=
"border:none;border-bottom:double windowtext 2.25pt;padding:0in 0in 0in 0in;width:16.38%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;">
<font size="2" face="Times New Roman" style=
"font-size:10.0pt;">596</font></p>
</td>
<td width="1%" valign="bottom" style=
"padding:0in 0in 0in 0in;width:1.36%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>
</td>
</tr>
<tr>
<td width="59%" valign="top" bgcolor="#CCEEFF" style=
"background:#CCEEFF;padding:0in 0in 0in 0in;width:59.1%;">
<p style="margin:0in 0in .0001pt 10.1pt;text-indent:-10.1pt;">
<font size="2" face="Times New Roman" style="font-size:10.0pt;">Net
loss per share attributable to common stockholders, basic and
diluted</font></p>
</td>
<td width="3%" valign="bottom" bgcolor="#CCEEFF" style=
"background:#CCEEFF;padding:0in 0in 0in 0in;width:3.4%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>
</td>
<td width="1%" valign="bottom" bgcolor="#CCEEFF" style=
"background:#CCEEFF;border:none;border-bottom:double windowtext 2.25pt;padding:0in 0in 0in 0in;width:1.54%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">$</font></p>
</td>
<td width="14%" valign="bottom" bgcolor="#CCEEFF" style=
"background:#CCEEFF;border:none;border-bottom:double windowtext 2.25pt;padding:0in 0in 0in 0in;width:14.82%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;">
<font size="2" face="Times New Roman" style=
"font-size:10.0pt;">(7.99</font></p>
</td>
<td width="3%" valign="bottom" bgcolor="#CCEEFF" style=
"background:#CCEEFF;padding:0in 0in 2.25pt 0in;width:3.4%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">)</font></p>
</td>
<td width="1%" valign="bottom" bgcolor="#CCEEFF" style=
"background:#CCEEFF;border:none;border-bottom:double windowtext 2.25pt;padding:0in 0in 0in 0in;width:1.54%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">$</font></p>
</td>
<td width="14%" valign="bottom" bgcolor="#CCEEFF" style=
"background:#CCEEFF;border:none;border-bottom:double windowtext 2.25pt;padding:0in 0in 0in 0in;width:14.82%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;">
<font size="2" face="Times New Roman" style=
"font-size:10.0pt;">(25.74</font></p>
</td>
<td width="1%" valign="bottom" bgcolor="#CCEEFF" style=
"background:#CCEEFF;padding:0in 0in 2.25pt 0in;width:1.36%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">)</font></p>
</td>
</tr>
</table>
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2"
face="Times New Roman" style="font-size:10.0pt;">The following
potentially dilutive securities outstanding have been excluded from
the computations of diluted weighted average shares outstanding
because such securities have an anti-dilutive impact due to losses
reported:</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<table border="0" cellspacing="0" cellpadding="0" width="73%"
style="border-collapse:collapse;margin-left:1.0in;">
<tr>
<td width="59%" valign="bottom" style=
"padding:0in 0in 0in 0in;width:59.1%;">
<p style="margin:0in 0in .0001pt;"><b><font size="1" face=
"Times New Roman" style=
"font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>
</td>
<td width="3%" valign="bottom" style=
"padding:0in 0in 0in 0in;width:3.4%;">
<p align="center" style=
"margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face=
"Times New Roman" style=
"font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>
</td>
<td width="36%" colspan="3" valign="bottom" style=
"border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:36.14%;">
<p align="center" style=
"margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face=
"Times New Roman" style=
"font-size:8.0pt;font-weight:bold;">Three&nbsp;Months&nbsp;Ended&nbsp;March&nbsp;31,</font></b></p>
</td>
<td width="1%" valign="bottom" style=
"padding:0in 0in 0in 0in;width:1.36%;">
<p align="center" style=
"margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face=
"Times New Roman" style=
"font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>
</td>
</tr>
<tr>
<td width="59%" valign="bottom" style=
"padding:0in 0in 0in 0in;width:59.1%;">
<p style="margin:0in 0in .0001pt;"><b><font size="1" face=
"Times New Roman" style=
"font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>
</td>
<td width="3%" valign="bottom" style=
"padding:0in 0in 0in 0in;width:3.4%;">
<p align="center" style=
"margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face=
"Times New Roman" style=
"font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>
</td>
<td width="16%" valign="bottom" style=
"border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:16.36%;">
<p align="center" style=
"margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face=
"Times New Roman" style=
"font-size:8.0pt;font-weight:bold;">2018</font></b></p>
</td>
<td width="3%" valign="bottom" style=
"padding:0in 0in 0in 0in;width:3.4%;">
<p align="center" style=
"margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face=
"Times New Roman" style=
"font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>
</td>
<td width="16%" valign="bottom" style=
"border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:16.36%;">
<p align="center" style=
"margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face=
"Times New Roman" style=
"font-size:8.0pt;font-weight:bold;">2017</font></b></p>
</td>
<td width="1%" valign="bottom" style=
"padding:0in 0in 0in 0in;width:1.36%;">
<p align="center" style=
"margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face=
"Times New Roman" style=
"font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>
</td>
</tr>
<tr>
<td width="59%" valign="top" bgcolor="#CCEEFF" style=
"background:#CCEEFF;padding:0in 0in 0in 0in;width:59.1%;">
<p style="margin:0in 0in .0001pt 10.1pt;text-indent:-10.1pt;">
<font size="2" face="Times New Roman" style=
"font-size:10.0pt;">Common stock warrants</font></p>
</td>
<td width="3%" valign="bottom" bgcolor="#CCEEFF" style=
"background:#CCEEFF;padding:0in 0in 0in 0in;width:3.4%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>
</td>
<td width="16%" valign="bottom" bgcolor="#CCEEFF" style=
"background:#CCEEFF;padding:0in 0in 0in 0in;width:16.36%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;">
<font size="2" face="Times New Roman" style=
"font-size:10.0pt;">18,032,715</font></p>
</td>
<td width="3%" valign="bottom" bgcolor="#CCEEFF" style=
"background:#CCEEFF;padding:0in 0in 0in 0in;width:3.4%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>
</td>
<td width="16%" valign="bottom" bgcolor="#CCEEFF" style=
"background:#CCEEFF;padding:0in 0in 0in 0in;width:16.36%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;">
<font size="2" face="Times New Roman" style=
"font-size:10.0pt;">53,803</font></p>
</td>
<td width="1%" valign="bottom" bgcolor="#CCEEFF" style=
"background:#CCEEFF;padding:0in 0in 0in 0in;width:1.36%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>
</td>
</tr>
<tr>
<td width="59%" valign="top" style=
"padding:0in 0in 0in 0in;width:59.1%;">
<p style="margin:0in 0in .0001pt 10.1pt;text-indent:-10.1pt;">
<font size="2" face="Times New Roman" style=
"font-size:10.0pt;">Common stock options</font></p>
</td>
<td width="3%" valign="bottom" style=
"padding:0in 0in 0in 0in;width:3.4%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>
</td>
<td width="16%" valign="bottom" style=
"padding:0in 0in 0in 0in;width:16.36%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;">
<font size="2" face="Times New Roman" style=
"font-size:10.0pt;">55,862</font></p>
</td>
<td width="3%" valign="bottom" style=
"padding:0in 0in 0in 0in;width:3.4%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>
</td>
<td width="16%" valign="bottom" style=
"padding:0in 0in 0in 0in;width:16.36%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;">
<font size="2" face="Times New Roman" style=
"font-size:10.0pt;">112,259</font></p>
</td>
<td width="1%" valign="bottom" style=
"padding:0in 0in 0in 0in;width:1.36%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>
</td>
</tr>
<tr>
<td width="59%" valign="top" bgcolor="#CCEEFF" style=
"background:#CCEEFF;padding:0in 0in 0in 0in;width:59.1%;">
<p style="margin:0in 0in .0001pt 10.1pt;text-indent:-10.1pt;">
<font size="2" face="Times New Roman" style=
"font-size:10.0pt;">Preferred stock</font></p>
</td>
<td width="3%" valign="bottom" bgcolor="#CCEEFF" style=
"background:#CCEEFF;padding:0in 0in 0in 0in;width:3.4%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>
</td>
<td width="16%" valign="bottom" bgcolor="#CCEEFF" style=
"background:#CCEEFF;padding:0in 0in 0in 0in;width:16.36%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;">
<font size="2" face="Times New Roman" style=
"font-size:10.0pt;">52,762</font></p>
</td>
<td width="3%" valign="bottom" bgcolor="#CCEEFF" style=
"background:#CCEEFF;padding:0in 0in 0in 0in;width:3.4%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>
</td>
<td width="16%" valign="bottom" bgcolor="#CCEEFF" style=
"background:#CCEEFF;padding:0in 0in 0in 0in;width:16.36%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;">
<font size="2" face="Times New Roman" style="font-size:10.0pt;">—
</font></p>
</td>
<td width="1%" valign="bottom" bgcolor="#CCEEFF" style=
"background:#CCEEFF;padding:0in 0in 0in 0in;width:1.36%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>
</td>
</tr>
<tr>
<td width="59%" valign="top" style=
"padding:0in 0in 0in 0in;width:59.1%;">
<p style="margin:0in 0in .0001pt 10.1pt;text-indent:-10.1pt;">
<font size="2" face="Times New Roman" style=
"font-size:10.0pt;">Unvested restricted stock units</font></p>
</td>
<td width="3%" valign="bottom" style=
"padding:0in 0in 0in 0in;width:3.4%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>
</td>
<td width="16%" valign="bottom" style=
"border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:16.36%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;">
<font size="2" face="Times New Roman" style=
"font-size:10.0pt;">3,457</font></p>
</td>
<td width="3%" valign="bottom" style=
"padding:0in 0in 0in 0in;width:3.4%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>
</td>
<td width="16%" valign="bottom" style=
"border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:16.36%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;">
<font size="2" face="Times New Roman" style=
"font-size:10.0pt;">11,115</font></p>
</td>
<td width="1%" valign="bottom" style=
"padding:0in 0in 0in 0in;width:1.36%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>
</td>
</tr>
<tr>
<td width="59%" valign="top" bgcolor="#CCEEFF" style=
"background:#CCEEFF;padding:0in 0in 0in 0in;width:59.1%;">
<p style="margin:0in 0in .0001pt 10.1pt;text-indent:-10.1pt;">
<font size="2" face="Times New Roman" style=
"font-size:1.0pt;">&nbsp;</font></p>
</td>
<td width="3%" valign="bottom" bgcolor="#CCEEFF" style=
"background:#CCEEFF;padding:0in 0in 0in 0in;width:3.4%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>
</td>
<td width="16%" valign="bottom" bgcolor="#CCEEFF" style=
"background:#CCEEFF;border:none;border-bottom:double windowtext 2.25pt;padding:0in 0in 0in 0in;width:16.36%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;">
<font size="2" face="Times New Roman" style=
"font-size:10.0pt;">18,144,796</font></p>
</td>
<td width="3%" valign="bottom" bgcolor="#CCEEFF" style=
"background:#CCEEFF;padding:0in 0in 0in 0in;width:3.4%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>
</td>
<td width="16%" valign="bottom" bgcolor="#CCEEFF" style=
"background:#CCEEFF;border:none;border-bottom:double windowtext 2.25pt;padding:0in 0in 0in 0in;width:16.36%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;">
<font size="2" face="Times New Roman" style=
"font-size:10.0pt;">177,177</font></p>
</td>
<td width="1%" valign="bottom" bgcolor="#CCEEFF" style=
"background:#CCEEFF;padding:0in 0in 0in 0in;width:1.36%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>
</td>
</tr>
</table>
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><b><font size="2" face=
"Times New Roman" style=
"font-size:10.0pt;font-weight:bold;">Comprehensive
Loss</font></b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2"
face="Times New Roman" style="font-size:10.0pt;">For the three
months ended March&nbsp;31, 2018 and 2017, there was no difference
between comprehensive loss and the Company’s net loss.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style=
"font-size:10.0pt;margin:0in 0in .0001pt;text-align:center;">
8<a name="PB_8_113236_2897" id="PB_8_113236_2897"></a></p>
<div style="margin:0in 0in .0001pt;">
<hr size="3" width="100%" noshade="noshade" align="left" style=
"color:#010101;" /></div>
</div>
<!-- SEQ.=1,FOLIO='8',FILE='C:\JMS\109754\18-8644-1\task8901843\8644-1-fn.htm',USER='109754',CD='May 16 01:11 2018' --><br clear="all"
style="page-break-before:always;" />
<div style="font-family:Times New Roman;">
<p style="margin:0in 0in .0001pt;"><a href="#TableOfContents"
title="Click to go to Table of Contents"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">Table of
Contents</font></a></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><b><font size="2" face=
"Times New Roman" style=
"font-size:10.0pt;font-weight:bold;">Segment and Geographical
Information</font></b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style=
"font-size:10.0pt;margin:0in 0in .0001pt;text-indent:.5in;">
<font size="2" face="Times New Roman" style="font-size:10.0pt;">The
Company operates and manages its business as one reportable and
operating segment. The Company’s chief executive officer, who is
the chief operating decision maker, reviews financial information
on an aggregate basis for purposes of allocating resources and
evaluating financial performance.</font> Primarily all of the
Company’s long-lived assets are based in the United States.
Long-lived assets are comprised of property and equipment. For the
three months ended March&nbsp;31, 2018 and 2017, 92% and 96%,
respectively, of the Company’s revenues were in the United States
based on the shipping location of the external customer.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><b><font size="2" face=
"Times New Roman" style="font-size:10.0pt;font-weight:bold;">Recent
Accounting Pronouncements</font></b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2"
face="Times New Roman" style="font-size:10.0pt;">In May&nbsp;2014,
the “FASB” issued Accounting Standards Update
No.&nbsp;2014-09,<i>&nbsp;Revenue from Contracts with Customers
(Topic&nbsp;606)</i>, which supersedes the revenue recognition
requirements in ASC&nbsp;605,<i>&nbsp;Revenue Recognition</i>. This
ASU is based on the principle that revenue is recognized to depict
the transfer of goods or services to customers in an amount that
reflects the consideration to which the entity expects to be
entitled in exchange for those goods or services. The ASU also
requires additional disclosure about the nature, amount, timing and
uncertainty of revenue and cash flows arising from customer
contracts, including significant judgments and changes in judgments
and assets recognized from costs incurred to obtain or fulfill a
contract. In August&nbsp;2015, FASB issued ASU
No.&nbsp;2015-14,<i>&nbsp;Revenue from Contracts with Customers
(Topic&nbsp;606): Deferral of the Effective Date</i>, which
effectively delayed the adoption date by one year, to an effective
date for public entities for annual and interim periods beginning
after December&nbsp;15, 2017.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2"
face="Times New Roman" style="font-size:10.0pt;">In
March&nbsp;2016, the FASB issued ASU No.&nbsp;2016-08, “Revenue
from Contracts with Customers (Topic 606)”: Principal Versus Agent
Considerations (Reporting Revenue Gross Versus Net), to clarify
certain aspects of the principal-versus-agent guidance in its new
revenue recognition standard.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:38.25pt;"><font size=
"2" face="Times New Roman" style="font-size:10.0pt;">In
April&nbsp;2016, the FASB issued ASU No.&nbsp;2016-10, “Revenue
from Contracts with Customers (Topic 606)”: Identifying Performance
Obligations and Licensing to clarify how to identify the
performance obligations and the licensing implementation guidance
in its new revenue recognition standard.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:38.25pt;"><font size=
"2" face="Times New Roman" style="font-size:10.0pt;">In
May&nbsp;2016, the FASB issued ASU No.&nbsp;2016-12, “Revenue from
Contracts with Customers (Topic 606)”: Narrow-Scope Improvements
and Practical Expedients, to address certain issues identified by
the Transition Resource Group, (the “TRG”) in the guidance on
assessing collectability, presentation of sales tax, noncash
consideration, and completed contracts and contracts modifications
at transition.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:38.25pt;"><font size=
"2" face="Times New Roman" style="font-size:10.0pt;">The adoption
of ASC 606, using the modified retrospective approach in the first
quarter of 2018 did not have a material impact on the Company’s
financial statements</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:38.25pt;"><font size=
"2" face="Times New Roman" style="font-size:10.0pt;">In
February&nbsp;2016, the FASB issued ASU No.&nbsp;2016-02,&nbsp;
“<i>Leases (Topic 842)”</i>. This update requires an entity to
recognize assets and liabilities for leases with lease terms of
more than 12 months on the balance sheet. ASU 2016-02 is effective
for public entities for fiscal years beginning after
December&nbsp;15, 2018.&nbsp;&nbsp;The Company is in the process of
developing a project plan and establishing teams to implement the
guidance.&nbsp;&nbsp;Although the Company is currently evaluating
the impact of this guidance on its consolidated financial
statements and related disclosures, the Company expects that all of
its operating lease commitments with a term will be subject to the
new standard and recognized as operating lease liabilities and
right-of-use assets upon adoption.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:27.8pt;"><font size=
"2" face="Times New Roman" style="font-size:10.0pt;">In
March&nbsp;2017, “the FASB issued ASU No.&nbsp;2017-08,&nbsp;
“<i>Receivables — Nonrefundable Fees and Other Costs (Subtopic
310-20)”: Premium Amortization on Purchased Callable Debt
Securities.</i>&nbsp;&nbsp;This update shortens the premium
amortization period for certain purchased callable debt securities
held at a premium.&nbsp;&nbsp;ASU 2017-08 is effective for public
entities for annual periods beginning after December&nbsp;15,
2018.&nbsp;&nbsp;The Company has not determined the potential
effects of the guidance on its consolidated financial
statements.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:27.8pt;"><font size=
"2" face="Times New Roman" style="font-size:10.0pt;">In
February&nbsp;2018, the FASB issued ASU No.&nbsp;2018-02,&nbsp;
“<i>Income Statement — Reporting Comprehensive Income (Topic 220)”
.</i>&nbsp;&nbsp;This update provides companies with the option to
reclassify stranded tax effects caused by the 2017 Tax Cuts and
Jobs Act (the 2017 Tax Act) from accumulated other comprehensive
income to retained earnings.&nbsp;&nbsp;ASU 2018-02 is effective
for public entities for annual periods beginning after
December&nbsp;15, 2018, with early adoption
permitted.&nbsp;&nbsp;The Company has not determined the potential
effects of the guidance on its consolidated financial
statements.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2"
face="Times New Roman" style="font-size:10.0pt;">In
March&nbsp;2018, the FASB issued ASU No.&nbsp;2018-05,&nbsp;
“<i>Income Taxes (Topic 740)”</i>.&nbsp;&nbsp;This update amends
the certain paragraphs in ASC 740 to reflect the provisions of SEC
Staff Accounting Bulletin (SAB) 118, which provides guidance for
companies that are not able to complete their accounting for income
tax effects of the 2017 Tax Act in the period of
enactment.&nbsp;&nbsp;ASU 2018-05 is effective
immediately.&nbsp;&nbsp;The adoption of this ASU did not have a
material impact on the Company’s consolidated financial
statements.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style=
"font-size:10.0pt;margin:0in 0in .0001pt;text-align:center;">
9<a name="PB_9_113338_3020" id="PB_9_113338_3020"></a></p>
<div style="margin:0in 0in .0001pt;">
<hr size="3" width="100%" noshade="noshade" align="left" style=
"color:#010101;" /></div>
</div>
<!-- SEQ.=1,FOLIO='9',FILE='C:\JMS\109754\18-8644-1\task8901843\8644-1-fn.htm',USER='109754',CD='May 16 01:11 2018' --><br clear="all"
style="page-break-before:always;" />
<div style="font-family:Times New Roman;">
<p style="margin:0in 0in .0001pt;"><a href="#TableOfContents"
title="Click to go to Table of Contents"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">Table of
Contents</font></a></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><b><font size="2" face=
"Times New Roman" style="font-size:10.0pt;font-weight:bold;">3.
Fair Value Measurements</font></b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2"
face="Times New Roman" style="font-size:10.0pt;">The Company
measures certain financial assets and liabilities at fair value on
a recurring basis. Fair value is an exit price, representing the
amount that would be received to sell an asset or paid to transfer
a liability in an orderly transaction between market participants.
As such, fair value is a market-based measurement that should be
determined based on assumptions that market participants would use
in pricing an asset or a liability. A three-tier fair value
hierarchy is established as a basis for considering such
assumptions and for inputs used in the valuation methodologies in
measuring fair value:</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2"
face="Times New Roman" style="font-size:10.0pt;">Level&nbsp;1—
Quoted prices in active markets for identical assets or
liabilities.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2"
face="Times New Roman" style="font-size:10.0pt;">Level&nbsp;2—
Inputs other than quoted prices included within Level&nbsp;1 that
are observable, either directly or indirectly, such as quoted
prices for similar assets or liabilities; quoted prices in markets
that are not active; or other inputs that are observable or can be
corroborated by observable market data for substantially the full
term of the assets or liabilities.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2"
face="Times New Roman" style="font-size:10.0pt;">Level&nbsp;3—
Unobservable inputs that are supported by little or no market
activity and that are significant to the fair value of the assets
or liabilities.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style=
"font-size:10.0pt;margin:0in 0in .0001pt;text-indent:.5in;">
<font size="2" face="Times New Roman" style="font-size:10.0pt;">As
of March&nbsp;31, 2018 and December&nbsp;31, 2017, cash equivalents
were all categorized as Level&nbsp;1 and consisted of money market
funds. As of March&nbsp;31, 2018 and December&nbsp;31, 2017, there
were no financial assets and liabilities categorized as Level 2 or
3. There were no transfers</font> between fair value hierarchy
levels during the three months ended March&nbsp;31, 2018 and
2017.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><b><font size="2" face=
"Times New Roman" style="font-size:10.0pt;font-weight:bold;">4.
Inventories</font></b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2"
face="Times New Roman" style="font-size:10.0pt;">Inventories
consisted of the following (in thousands):</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<table border="0" cellspacing="0" cellpadding="0" width="60%"
style="border-collapse:collapse;margin-left:1.5in;">
<tr>
<td width="50%" valign="bottom" style=
"padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><b><font size="1" face=
"Times New Roman" style=
"font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>
</td>
<td width="4%" valign="bottom" style=
"padding:0in 0in 0in 0in;width:4.16%;">
<p align="center" style=
"margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face=
"Times New Roman" style=
"font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>
</td>
<td width="20%" colspan="2" valign="bottom" style=
"padding:0in 0in 0in 0in;width:20.0%;">
<p align="center" style=
"margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face=
"Times New Roman" style=
"font-size:8.0pt;font-weight:bold;">March&nbsp;31,</font></b></p>
</td>
<td width="4%" valign="bottom" style=
"padding:0in 0in 0in 0in;width:4.16%;">
<p align="center" style=
"margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face=
"Times New Roman" style=
"font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>
</td>
<td width="20%" colspan="2" valign="bottom" style=
"padding:0in 0in 0in 0in;width:20.0%;">
<p align="center" style=
"margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face=
"Times New Roman" style=
"font-size:8.0pt;font-weight:bold;">December&nbsp;31,</font></b></p>
</td>
<td width="1%" valign="bottom" style=
"padding:0in 0in 0in 0in;width:1.66%;">
<p align="center" style=
"margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face=
"Times New Roman" style=
"font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>
</td>
</tr>
<tr>
<td width="50%" valign="bottom" style=
"padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><b><font size="1" face=
"Times New Roman" style=
"font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>
</td>
<td width="4%" valign="bottom" style=
"padding:0in 0in 0in 0in;width:4.16%;">
<p align="center" style=
"margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face=
"Times New Roman" style=
"font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>
</td>
<td width="20%" colspan="2" valign="bottom" style=
"border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:20.0%;">
<p align="center" style=
"margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face=
"Times New Roman" style=
"font-size:8.0pt;font-weight:bold;">2018</font></b></p>
</td>
<td width="4%" valign="bottom" style=
"padding:0in 0in 0in 0in;width:4.16%;">
<p align="center" style=
"margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face=
"Times New Roman" style=
"font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>
</td>
<td width="20%" colspan="2" valign="bottom" style=
"border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:20.0%;">
<p align="center" style=
"margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face=
"Times New Roman" style=
"font-size:8.0pt;font-weight:bold;">2017</font></b></p>
</td>
<td width="1%" valign="bottom" style=
"padding:0in 0in 0in 0in;width:1.66%;">
<p align="center" style=
"margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face=
"Times New Roman" style=
"font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>
</td>
</tr>
<tr>
<td width="50%" valign="top" bgcolor="#CCEEFF" style=
"background:#CCEEFF;padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt 10.1pt;text-indent:-10.1pt;">
<font size="2" face="Times New Roman" style="font-size:10.0pt;">Raw
materials</font></p>
</td>
<td width="4%" valign="bottom" bgcolor="#CCEEFF" style=
"background:#CCEEFF;padding:0in 0in 0in 0in;width:4.16%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>
</td>
<td width="1%" valign="bottom" bgcolor="#CCEEFF" style=
"background:#CCEEFF;padding:0in 0in 0in 0in;width:1.88%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">$</font></p>
</td>
<td width="18%" valign="bottom" bgcolor="#CCEEFF" style=
"background:#CCEEFF;padding:0in 0in 0in 0in;width:18.12%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;">
<font size="2" face="Times New Roman" style=
"font-size:10.0pt;">759</font></p>
</td>
<td width="4%" valign="bottom" bgcolor="#CCEEFF" style=
"background:#CCEEFF;padding:0in 0in 0in 0in;width:4.16%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>
</td>
<td width="1%" valign="bottom" bgcolor="#CCEEFF" style=
"background:#CCEEFF;padding:0in 0in 0in 0in;width:1.88%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">$</font></p>
</td>
<td width="18%" valign="bottom" bgcolor="#CCEEFF" style=
"background:#CCEEFF;padding:0in 0in 0in 0in;width:18.12%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;">
<font size="2" face="Times New Roman" style=
"font-size:10.0pt;">1,286</font></p>
</td>
<td width="1%" valign="bottom" bgcolor="#CCEEFF" style=
"background:#CCEEFF;padding:0in 0in 0in 0in;width:1.66%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>
</td>
</tr>
<tr>
<td width="50%" valign="top" style=
"padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt 10.1pt;text-indent:-10.1pt;">
<font size="2" face="Times New Roman" style=
"font-size:10.0pt;">Work-in-process</font></p>
</td>
<td width="4%" valign="bottom" style=
"padding:0in 0in 0in 0in;width:4.16%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>
</td>
<td width="20%" colspan="2" valign="bottom" style=
"padding:0in 0in 0in 0in;width:20.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;">
<font size="2" face="Times New Roman" style=
"font-size:10.0pt;">187</font></p>
</td>
<td width="4%" valign="bottom" style=
"padding:0in 0in 0in 0in;width:4.16%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>
</td>
<td width="20%" colspan="2" valign="bottom" style=
"padding:0in 0in 0in 0in;width:20.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;">
<font size="2" face="Times New Roman" style="font-size:10.0pt;">—
</font></p>
</td>
<td width="1%" valign="bottom" style=
"padding:0in 0in 0in 0in;width:1.66%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>
</td>
</tr>
<tr>
<td width="50%" valign="top" bgcolor="#CCEEFF" style=
"background:#CCEEFF;padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt 10.1pt;text-indent:-10.1pt;">
<font size="2" face="Times New Roman" style=
"font-size:10.0pt;">Finished products</font></p>
</td>
<td width="4%" valign="bottom" bgcolor="#CCEEFF" style=
"background:#CCEEFF;padding:0in 0in 0in 0in;width:4.16%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>
</td>
<td width="20%" colspan="2" valign="bottom" bgcolor="#CCEEFF"
style="background:#CCEEFF;border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:20.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;">
<font size="2" face="Times New Roman" style=
"font-size:10.0pt;">3,061</font></p>
</td>
<td width="4%" valign="bottom" bgcolor="#CCEEFF" style=
"background:#CCEEFF;padding:0in 0in 0in 0in;width:4.16%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>
</td>
<td width="20%" colspan="2" valign="bottom" bgcolor="#CCEEFF"
style="background:#CCEEFF;border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:20.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;">
<font size="2" face="Times New Roman" style=
"font-size:10.0pt;">3,009</font></p>
</td>
<td width="1%" valign="bottom" bgcolor="#CCEEFF" style=
"background:#CCEEFF;padding:0in 0in 0in 0in;width:1.66%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>
</td>
</tr>
<tr>
<td width="50%" valign="top" style=
"padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt 10.1pt;text-indent:-10.1pt;">
<font size="2" face="Times New Roman" style=
"font-size:10.0pt;">Total inventories</font></p>
</td>
<td width="4%" valign="bottom" style=
"padding:0in 0in 0in 0in;width:4.16%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>
</td>
<td width="1%" valign="bottom" style=
"border:none;border-bottom:double windowtext 2.25pt;padding:0in 0in 0in 0in;width:1.88%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">$</font></p>
</td>
<td width="18%" valign="bottom" style=
"border:none;border-bottom:double windowtext 2.25pt;padding:0in 0in 0in 0in;width:18.12%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;">
<font size="2" face="Times New Roman" style=
"font-size:10.0pt;">4,007</font></p>
</td>
<td width="4%" valign="bottom" style=
"padding:0in 0in 0in 0in;width:4.16%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>
</td>
<td width="1%" valign="bottom" style=
"border:none;border-bottom:double windowtext 2.25pt;padding:0in 0in 0in 0in;width:1.88%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">$</font></p>
</td>
<td width="18%" valign="bottom" style=
"border:none;border-bottom:double windowtext 2.25pt;padding:0in 0in 0in 0in;width:18.12%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;">
<font size="2" face="Times New Roman" style=
"font-size:10.0pt;">4,295</font></p>
</td>
<td width="1%" valign="bottom" style=
"padding:0in 0in 0in 0in;width:1.66%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>
</td>
</tr>
</table>
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style=
"font-size:10.0pt;margin:0in 0in .0001pt;text-align:center;">
10<a name="PB_10_113509_7748" id="PB_10_113509_7748"></a></p>
<div style="margin:0in 0in .0001pt;">
<hr size="3" width="100%" noshade="noshade" align="left" style=
"color:#010101;" /></div>
</div>
<!-- SEQ.=1,FOLIO='10',FILE='C:\JMS\109754\18-8644-1\task8901843\8644-1-fn.htm',USER='109754',CD='May 16 01:11 2018' --><br clear="all"
style="page-break-before:always;" />
<div style="font-family:Times New Roman;">
<p style="margin:0in 0in .0001pt;"><a href="#TableOfContents"
title="Click to go to Table of Contents"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">Table of
Contents</font></a></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><b><font size="2" face=
"Times New Roman" style="font-size:10.0pt;font-weight:bold;">5.
Borrowings</font></b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><i><font size="2" face=
"Times New Roman" style=
"font-size:10.0pt;font-style:italic;">CRG</font></i></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style=
"font-size:10.0pt;margin:0in 0in .0001pt;text-indent:.5in;">
<font size="2" face="Times New Roman" style="font-size:10.0pt;">On
September&nbsp;22, 2015, the Company entered into a</font> Term
Loan Agreement (the “Loan Agreement”) with CRG under which, subject
to certain conditions, the Company had the right to borrow up to
$50,000,000 in principal amount from CRG on or before
March&nbsp;29, 2017. The Company borrowed $30,000,000 on
September&nbsp;22, 2015. The Company borrowed an additional
$10,000,000 on June&nbsp;15, 2016 under the Loan Agreement. The
Company would have been eligible to borrow an additional
$10,000,000, on or prior to March&nbsp;29, 2017, upon achievement
of certain revenue milestones, among other conditions, but those
milestones were not achieved.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2"
face="Times New Roman" style="font-size:10.0pt;">On
October&nbsp;28, 2016, the Company and CRG amended the Loan
Agreement to reduce the minimum revenue that the Company was
required to achieve in 2016 to $18,000,000. On February&nbsp;14,
2018, the Company and CRG further amended the Loan Agreement
concurrent with the conversion of $38,000,000 of the principal
amount of the senior secured term loan (plus $3,800,000 in back-end
fees and prepayment premium applicable thereto) into a newly
authorized Series&nbsp;A convertible preferred stock (see Note 8,
below). For the three months ended March&nbsp;31, 2018, the
$3,800,000 was accounted for in the condensed statement of
operations and comprehensive loss as interest expense.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2"
face="Times New Roman" style="font-size:10.0pt;">Under the Loan
Agreement, as in effect prior to amendment, the first sixteen
quarterly payments were to be interest only payments, and the last
eight quarterly payments were to be equal installments in which
interest and principal amounts would be paid. Interest is
calculated at a fixed rate of 12.5%&nbsp;per annum. The Company
makes quarterly payments of interest only in arrears commencing on
September&nbsp;30, 2015. During the interest only period, the
Company had the right to elect to make the 12.5% interest payment
by making a cash payment for 8.5%&nbsp;per annum of interest and
making a payment-in-kind (“PIK”) for the remaining amount, for
which the 4.0%&nbsp;per annum of interest would be added to the
outstanding principal amount of the borrowings. To date, the
Company has elected the PIK interest option to the extent available
and has made a cash payment for the remaining amount. Principal is
repayable in eight equal quarterly installments during the final
two years of the term. Under the original Loan Agreement, all
unpaid principal, and accrued and unpaid interest, was to be due
and payable in full on September&nbsp;30, 2021.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style=
"font-size:10.0pt;margin:0in 0in .0001pt;text-indent:.5in;">
<font size="2" face="Times New Roman" style="font-size:10.0pt;">The
Company may voluntarily prepay the borrowings in full, with a
prepayment premium beginning at 5.0% and declining by 1.0% annually
thereafter, with no premium being payable if prepayment occurs
after the fifth year of the loan. Each tranche of borrowing
required the payment, on the borrowing date, of a financing fee
equal to 1.5% of the borrowed loan principal, which is recorded as
a discount to the debt. In addition, a facility fee equal to 7.0%
of the amounts borrowed plus any PIK was to be payable at the end
of the term or when the borrowings are repaid in full. A long-term
liability is being accreted using the effective interest method for
the facility fee over the term of the Loan Agreement with a
corresponding discount to the debt. The borrowings are
collateralized by a security interest in substantially all of the
Company’s assets. The Loan Agreement requires that the Company
adheres to certain affirmative and negative covenants, including
financial reporting requirements, certain minimum financial
covenants for pre-specified liquidity and revenue requirements and
a prohibition against the incurrence of indebtedness, or creation
of additional liens, other than as specifically permitted by the
terms of the Loan Agreement. In particular, the covenants of the
original Loan Agreement included a covenant that the Company
maintain a minimum of $5,000,000 of cash and certain cash
equivalents, and the Company had to achieve minimum revenue of
$7,000,000 in 2015,</font> $23,000,000 in 2016, $40,000,000 in
2017, $50,000,000 in 2018, $60,000,000 in 2019 and $70,000,000 in
2020 and in each year thereafter, as applicable. On
October&nbsp;28, 2016, the Company amended the terms of the Loan
Agreement, to reduce the minimum revenue that the Company must
achieve in 2016 to $18,000,000. If the Company fails to meet the
applicable minimum revenue target in any calendar year, the Loan
Agreement provides the Company with a cure right if it prepays a
portion of the outstanding principal equal to 2.0 times the revenue
shortfall. In addition, the Loan Agreement prohibits the payment of
cash dividends on the Company’s capital stock and also places
restrictions on mergers, sales of assets, investments, incurrence
of liens, incurrence of indebtedness and transactions with
affiliates. CRG may accelerate the payment terms of the Loan
Agreement upon the occurrence of certain events of default set
forth therein, which include the failure of the Company to make
timely payments of amounts due under the Loan Agreement, the
failure of the Company to adhere to the covenants set forth in the
Loan Agreement, the insolvency of the Company or upon the
occurrence of a material adverse change.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2"
face="Times New Roman" style="font-size:10.0pt;">On
December&nbsp;14, 2017, the Company entered into a waiver and
consent agreement (the “Waiver and Consent”) with CRG.&nbsp; The
Waiver and Consent provided for the waiver of the minimum required
revenue financial covenant for the twelve-month period beginning
January&nbsp;1, 2017, as required under the terms of the Loan
Agreement.&nbsp; Pursuant to the Waiver and Consent, CRG also
consented to the Company’s payment of the cash interest payment due
on December&nbsp;31, 2017 in the form of a PIK loan
instead.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2"
face="Times New Roman" style="font-size:10.0pt;">On
February&nbsp;14, 2018, the Company entered into Amendment
No.&nbsp;2 to the Loan Agreement to, among other things:</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style=
"font-size:10.0pt;margin:0in 0in .0001pt 1.0in;text-indent:-.25in;">
<font size="2" face="Symbol" style=
"font-size:10.0pt;">·</font><font size="1" style=
"font-size:3.0pt;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</font>
extend the interest only payment period and the period during which
the Company may elect to pay a portion of the interest in PIK
interest payments through June&nbsp;30, 2021;</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style=
"font-size:10.0pt;margin:0in 0in .0001pt;text-align:center;">
11<a name="PB_11_113642_141" id="PB_11_113642_141"></a></p>
<div style="margin:0in 0in .0001pt;">
<hr size="3" width="100%" noshade="noshade" align="left" style=
"color:#010101;" /></div>
</div>
<!-- SEQ.=1,FOLIO='11',FILE='C:\JMS\109754\18-8644-1\task8901843\8644-1-fn.htm',USER='109754',CD='May 16 01:11 2018' --><br clear="all"
style="page-break-before:always;" />
<div style="font-family:Times New Roman;">
<p style="margin:0in 0in .0001pt;"><a href="#TableOfContents"
title="Click to go to Table of Contents"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">Table of
Contents</font></a></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style=
"font-size:10.0pt;margin:0in 0in .0001pt 1.0in;text-indent:-.25in;">
<font size="2" face="Symbol" style=
"font-size:10.0pt;">·</font><font size="1" style=
"font-size:3.0pt;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</font>
permit the Company to make the entire interest payment for payment
dates in 2018 and 2019 in PIK interest payments, provided no
default has occurred and is continuing;</p>
<p style=
"font-size:10.0pt;margin:0in 0in .0001pt 1.0in;text-indent:-.25in;">
<font size="2" face="Symbol" style=
"font-size:10.0pt;">·</font><font size="1" style=
"font-size:3.0pt;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</font>
extend the maturity date to June&nbsp;30, 2023;</p>
<p style=
"font-size:10.0pt;margin:0in 0in .0001pt 1.0in;text-indent:-.25in;">
<font size="2" face="Symbol" style=
"font-size:10.0pt;">·</font><font size="1" style=
"font-size:3.0pt;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</font>
modify certain of the covenants, including the indebtedness
covenant, lien covenant and restricted payments covenant, to
eliminate or modify permitted exceptions to the restrictions in
those covenants;</p>
<p style=
"font-size:10.0pt;margin:0in 0in .0001pt 1.0in;text-indent:-.25in;">
<font size="2" face="Symbol" style=
"font-size:10.0pt;">·</font><font size="1" style=
"font-size:3.0pt;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</font>
modify the financial covenants to reduce the minimum liquidity
requirement to $3,500,000 at all times, to eliminate the minimum
revenue requirements for 2018 and 2019, and to reduce the minimum
revenue requirements to $15,000,000 million for 2020, $20,000,000
for 2021 and $25,000,000 for 2022; and</p>
<p style=
"font-size:10.0pt;margin:0in 0in .0001pt 1.0in;text-indent:-.25in;">
<font size="2" face="Symbol" style=
"font-size:10.0pt;">·</font><font size="1" style=
"font-size:3.0pt;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</font>
provide CRG with board observer rights.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2"
face="Times New Roman" style="font-size:10.0pt;">As of
March&nbsp;31, 2018, the Company was in compliance with all
applicable covenants under the Loan Agreement.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2"
face="Times New Roman" style="font-size:10.0pt;">As of
March&nbsp;31, 2018, principal and PIK payments under the Loan
Agreement were as follows (in thousands):</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<table border="0" cellspacing="0" cellpadding="0" width="80%"
style="border-collapse:collapse;margin-left:.5in;width:80.0%;">
<tr>
<td width="71%" valign="bottom" style=
"padding:0in 0in 0in 0in;width:71.08%;">
<p style="margin:0in 0in .0001pt;"><b><font size="1" face=
"Times New Roman" style=
"font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>
</td>
<td width="3%" valign="bottom" style=
"padding:0in 0in 0in 0in;width:3.9%;">
<p align="center" style=
"margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face=
"Times New Roman" style=
"font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>
</td>
<td width="23%" colspan="2" valign="bottom" style=
"padding:0in 0in 0in 0in;width:23.46%;">
<p align="center" style=
"margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face=
"Times New Roman" style=
"font-size:8.0pt;font-weight:bold;">Principal&nbsp;and&nbsp;PIK</font></b></p>
</td>
<td width="1%" valign="bottom" style=
"padding:0in 0in 0in 0in;width:1.56%;">
<p align="center" style=
"margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face=
"Times New Roman" style=
"font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>
</td>
</tr>
<tr>
<td width="71%" valign="bottom" style=
"border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:71.08%;">
<p style="margin:0in 0in .0001pt;"><b><font size="1" face=
"Times New Roman" style=
"font-size:8.0pt;font-weight:bold;">Period&nbsp;Ending&nbsp;March&nbsp;31,</font></b></p>
</td>
<td width="3%" valign="bottom" style=
"padding:0in 0in 0in 0in;width:3.9%;">
<p align="center" style=
"margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face=
"Times New Roman" style=
"font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>
</td>
<td width="23%" colspan="2" valign="bottom" style=
"border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:23.46%;">
<p align="center" style=
"margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face=
"Times New Roman" style=
"font-size:8.0pt;font-weight:bold;">Loan&nbsp;Repayments</font></b></p>
</td>
<td width="1%" valign="bottom" style=
"padding:0in 0in 0in 0in;width:1.56%;">
<p align="center" style=
"margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face=
"Times New Roman" style=
"font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>
</td>
</tr>
<tr>
<td width="71%" valign="top" bgcolor="#CCEEFF" style=
"background:#CCEEFF;padding:0in 0in 0in 0in;width:71.08%;">
<p style="margin:0in 0in .0001pt 10.0pt;text-indent:-10.0pt;">
<font size="2" face="Times New Roman" style=
"font-size:10.0pt;">2018</font></p>
</td>
<td width="3%" valign="bottom" bgcolor="#CCEEFF" style=
"background:#CCEEFF;padding:0in 0in 0in 0in;width:3.9%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>
</td>
<td width="1%" valign="bottom" bgcolor="#CCEEFF" style=
"background:#CCEEFF;padding:0in 0in 0in 0in;width:1.74%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">$</font></p>
</td>
<td width="21%" valign="bottom" bgcolor="#CCEEFF" style=
"background:#CCEEFF;padding:0in 0in 0in 0in;width:21.7%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;">
<font size="2" face="Times New Roman" style="font-size:10.0pt;">—
</font></p>
</td>
<td width="1%" valign="bottom" bgcolor="#CCEEFF" style=
"background:#CCEEFF;padding:0in 0in 0in 0in;width:1.56%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>
</td>
</tr>
<tr>
<td width="71%" valign="top" style=
"padding:0in 0in 0in 0in;width:71.08%;">
<p style="margin:0in 0in .0001pt 10.0pt;text-indent:-10.0pt;">
<font size="2" face="Times New Roman" style=
"font-size:10.0pt;">2019</font></p>
</td>
<td width="3%" valign="bottom" style=
"padding:0in 0in 0in 0in;width:3.9%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>
</td>
<td width="23%" colspan="2" valign="bottom" style=
"padding:0in 0in 0in 0in;width:23.46%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;">
<font size="2" face="Times New Roman" style="font-size:10.0pt;">—
</font></p>
</td>
<td width="1%" valign="bottom" style=
"padding:0in 0in 0in 0in;width:1.56%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>
</td>
</tr>
<tr>
<td width="71%" valign="top" bgcolor="#CCEEFF" style=
"background:#CCEEFF;padding:0in 0in 0in 0in;width:71.08%;">
<p style="margin:0in 0in .0001pt 10.0pt;text-indent:-10.0pt;">
<font size="2" face="Times New Roman" style=
"font-size:10.0pt;">2020</font></p>
</td>
<td width="3%" valign="bottom" bgcolor="#CCEEFF" style=
"background:#CCEEFF;padding:0in 0in 0in 0in;width:3.9%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>
</td>
<td width="23%" colspan="2" valign="bottom" bgcolor="#CCEEFF"
style="background:#CCEEFF;padding:0in 0in 0in 0in;width:23.46%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;">
<font size="2" face="Times New Roman" style="font-size:10.0pt;">—
</font></p>
</td>
<td width="1%" valign="bottom" bgcolor="#CCEEFF" style=
"background:#CCEEFF;padding:0in 0in 0in 0in;width:1.56%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>
</td>
</tr>
<tr>
<td width="71%" valign="top" style=
"padding:0in 0in 0in 0in;width:71.08%;">
<p style="margin:0in 0in .0001pt 10.0pt;text-indent:-10.0pt;">
<font size="2" face="Times New Roman" style=
"font-size:10.0pt;">2021</font></p>
</td>
<td width="3%" valign="bottom" style=
"padding:0in 0in 0in 0in;width:3.9%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>
</td>
<td width="23%" colspan="2" valign="bottom" style=
"padding:0in 0in 0in 0in;width:23.46%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;">
<font size="2" face="Times New Roman" style="font-size:10.0pt;">—
</font></p>
</td>
<td width="1%" valign="bottom" style=
"padding:0in 0in 0in 0in;width:1.56%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>
</td>
</tr>
<tr>
<td width="71%" valign="top" bgcolor="#CCEEFF" style=
"background:#CCEEFF;padding:0in 0in 0in 0in;width:71.08%;">
<p style="margin:0in 0in .0001pt 10.0pt;text-indent:-10.0pt;">
<font size="2" face="Times New Roman" style=
"font-size:10.0pt;">2022 and after</font></p>
</td>
<td width="3%" valign="bottom" bgcolor="#CCEEFF" style=
"background:#CCEEFF;padding:0in 0in 0in 0in;width:3.9%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>
</td>
<td width="23%" colspan="2" valign="bottom" bgcolor="#CCEEFF"
style="background:#CCEEFF;border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:23.46%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;">
<font size="2" face="Times New Roman" style=
"font-size:10.0pt;">2,000</font></p>
</td>
<td width="1%" valign="bottom" bgcolor="#CCEEFF" style=
"background:#CCEEFF;padding:0in 0in 0in 0in;width:1.56%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>
</td>
</tr>
<tr>
<td width="71%" valign="top" style=
"padding:0in 0in 0in 0in;width:71.08%;">
<p style="margin:0in 0in .0001pt 10.0pt;text-indent:-10.0pt;">
<font size="2" face="Times New Roman" style=
"font-size:1.0pt;">&nbsp;</font></p>
</td>
<td width="3%" valign="bottom" style=
"padding:0in 0in 0in 0in;width:3.9%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>
</td>
<td width="23%" colspan="2" valign="bottom" style=
"padding:0in 0in 0in 0in;width:23.46%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;">
<font size="2" face="Times New Roman" style=
"font-size:10.0pt;">2,000</font></p>
</td>
<td width="1%" valign="bottom" style=
"padding:0in 0in 0in 0in;width:1.56%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>
</td>
</tr>
<tr>
<td width="71%" valign="top" bgcolor="#CCEEFF" style=
"background:#CCEEFF;padding:0in 0in 0in 0in;width:71.08%;">
<p style="margin:0in 0in .0001pt 10.0pt;text-indent:-10.0pt;">
<font size="2" face="Times New Roman" style=
"font-size:10.0pt;">Add: Accretion of closing fees</font></p>
</td>
<td width="3%" valign="bottom" bgcolor="#CCEEFF" style=
"background:#CCEEFF;padding:0in 0in 0in 0in;width:3.9%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>
</td>
<td width="23%" colspan="2" valign="bottom" bgcolor="#CCEEFF"
style="background:#CCEEFF;padding:0in 0in 0in 0in;width:23.46%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;">
<font size="2" face="Times New Roman" style=
"font-size:10.0pt;">994</font></p>
</td>
<td width="1%" valign="bottom" bgcolor="#CCEEFF" style=
"background:#CCEEFF;padding:0in 0in 0in 0in;width:1.56%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>
</td>
</tr>
<tr>
<td width="71%" valign="top" style=
"padding:0in 0in 0in 0in;width:71.08%;">
<p style="margin:0in 0in .0001pt 10.0pt;text-indent:-10.0pt;">
<font size="2" face="Times New Roman" style=
"font-size:10.0pt;">Add: PIK</font></p>
</td>
<td width="3%" valign="bottom" style=
"padding:0in 0in 0in 0in;width:3.9%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>
</td>
<td width="23%" colspan="2" valign="bottom" style=
"border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:23.46%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;">
<font size="2" face="Times New Roman" style=
"font-size:10.0pt;">5,312</font></p>
</td>
<td width="1%" valign="bottom" style=
"padding:0in 0in 0in 0in;width:1.56%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>
</td>
</tr>
<tr>
<td width="71%" valign="top" bgcolor="#CCEEFF" style=
"background:#CCEEFF;padding:0in 0in 0in 0in;width:71.08%;">
<p style="margin:0in 0in .0001pt 10.0pt;text-indent:-10.0pt;">
<font size="2" face="Times New Roman" style=
"font-size:1.0pt;">&nbsp;</font></p>
</td>
<td width="3%" valign="bottom" bgcolor="#CCEEFF" style=
"background:#CCEEFF;padding:0in 0in 0in 0in;width:3.9%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>
</td>
<td width="23%" colspan="2" valign="bottom" bgcolor="#CCEEFF"
style="background:#CCEEFF;padding:0in 0in 0in 0in;width:23.46%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;">
<font size="2" face="Times New Roman" style=
"font-size:10.0pt;">8,306</font></p>
</td>
<td width="1%" valign="bottom" bgcolor="#CCEEFF" style=
"background:#CCEEFF;padding:0in 0in 0in 0in;width:1.56%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>
</td>
</tr>
<tr>
<td width="71%" valign="top" style=
"padding:0in 0in 0in 0in;width:71.08%;">
<p style="margin:0in 0in .0001pt 10.0pt;text-indent:-10.0pt;">
<font size="2" face="Times New Roman" style=
"font-size:10.0pt;">Less: Amount representing debt financing
costs</font></p>
</td>
<td width="3%" valign="bottom" style=
"padding:0in 0in 0in 0in;width:3.9%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>
</td>
<td width="23%" colspan="2" valign="bottom" style=
"border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:23.46%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;">
<font size="2" face="Times New Roman" style=
"font-size:10.0pt;">(846</font></p>
</td>
<td width="1%" valign="bottom" style=
"padding:0in 0in 0.375pt 0in;width:1.56%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">)</font></p>
</td>
</tr>
<tr>
<td width="71%" valign="top" bgcolor="#CCEEFF" style=
"background:#CCEEFF;padding:0in 0in 0in 0in;width:71.08%;">
<p style="margin:0in 0in .0001pt 10.0pt;text-indent:-10.0pt;">
<font size="2" face="Times New Roman" style=
"font-size:10.0pt;">Borrowings, net of current portion (principal
only)</font></p>
</td>
<td width="3%" valign="bottom" bgcolor="#CCEEFF" style=
"background:#CCEEFF;padding:0in 0in 0in 0in;width:3.9%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>
</td>
<td width="23%" colspan="2" valign="bottom" bgcolor="#CCEEFF"
style="background:#CCEEFF;padding:0in 0in 0in 0in;width:23.46%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;">
<font size="2" face="Times New Roman" style=
"font-size:10.0pt;">7,460</font></p>
</td>
<td width="1%" valign="bottom" bgcolor="#CCEEFF" style=
"background:#CCEEFF;padding:0in 0in 0in 0in;width:1.56%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>
</td>
</tr>
<tr>
<td width="71%" valign="top" style=
"padding:0in 0in 0in 0in;width:71.08%;">
<p style="margin:0in 0in .0001pt 10.0pt;text-indent:-10.0pt;">
<font size="2" face="Times New Roman" style=
"font-size:10.0pt;">Add: Acrued interest</font></p>
</td>
<td width="3%" valign="bottom" style=
"padding:0in 0in 0in 0in;width:3.9%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>
</td>
<td width="23%" colspan="2" valign="bottom" style=
"border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:23.46%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;">
<font size="2" face="Times New Roman" style=
"font-size:10.0pt;">61</font></p>
</td>
<td width="1%" valign="bottom" style=
"padding:0in 0in 0in 0in;width:1.56%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>
</td>
</tr>
<tr>
<td width="71%" valign="top" bgcolor="#CCEEFF" style=
"background:#CCEEFF;padding:0in 0in 0in 0in;width:71.08%;">
<p style="margin:0in 0in .0001pt 10.0pt;text-indent:-10.0pt;">
<font size="2" face="Times New Roman" style=
"font-size:10.0pt;">Borrowings, net of current portion as
shown</font></p>
</td>
<td width="3%" valign="bottom" bgcolor="#CCEEFF" style=
"background:#CCEEFF;padding:0in 0in 0in 0in;width:3.9%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>
</td>
<td width="1%" valign="bottom" bgcolor="#CCEEFF" style=
"background:#CCEEFF;border:none;border-bottom:double windowtext 2.25pt;padding:0in 0in 0in 0in;width:1.74%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">$</font></p>
</td>
<td width="21%" valign="bottom" bgcolor="#CCEEFF" style=
"background:#CCEEFF;border:none;border-bottom:double windowtext 2.25pt;padding:0in 0in 0in 0in;width:21.7%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;">
<font size="2" face="Times New Roman" style=
"font-size:10.0pt;">7,521</font></p>
</td>
<td width="1%" valign="bottom" bgcolor="#CCEEFF" style=
"background:#CCEEFF;padding:0in 0in 0in 0in;width:1.56%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>
</td>
</tr>
</table>
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style=
"font-size:10.0pt;margin:0in 0in .0001pt;text-align:center;">
12<a name="PB_12_113722_7608" id="PB_12_113722_7608"></a></p>
<div style="margin:0in 0in .0001pt;">
<hr size="3" width="100%" noshade="noshade" align="left" style=
"color:#010101;" /></div>
</div>
<!-- SEQ.=1,FOLIO='12',FILE='C:\JMS\109754\18-8644-1\task8901843\8644-1-fn.htm',USER='109754',CD='May 16 01:11 2018' --><br clear="all"
style="page-break-before:always;" />
<div style="font-family:Times New Roman;">
<p style="margin:0in 0in .0001pt;"><a href="#TableOfContents"
title="Click to go to Table of Contents"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">Table of
Contents</font></a></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2"
face="Times New Roman" style="font-size:10.0pt;">Contemporaneously
with the execution of the Loan Agreement in September&nbsp;2015,
the Company entered into a Securities Purchase Agreement (the “CRG
Purchase Agreement”) with CRG which allowed it to purchase up to
$5,000,000 of the Company’s common stock.&nbsp;CRG purchased 8,705
shares of common stock on September&nbsp;22, 2015 at a price of
$559.64 per share, which is the 10-day average of closing prices of
the Company’s common stock ending on September&nbsp;21, 2015. The
closing price on September&nbsp;22, 2015 was $558.80 yielding a
$0.84 per share premium. Both the premium and the issuance costs
were allocated to the borrowings under Loan Agreement and the
common stock purchase under the CRG Purchase Agreement based on the
relative fair values of each security. The portion of the premium
allocated to the borrowings is being amortized over the term of the
Loan Agreement. Pursuant to the CRG Purchase Agreement, the Company
filed a shelf registration statement covering, among other things,
the resale of the shares sold to CRG and must comply with certain
affirmative covenants during the time that such registration
statement remains in effect.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2"
face="Times New Roman" style="font-size:10.0pt;">In connection with
the initial drawdown under the Loan Agreement, the Company recorded
a debt discount of $876,000 as contra-debt. The debt discount
comprised financing fees of $450,000, paid directly to CRG, and an
allocation of the other costs directly attributable to the Loan
Agreement and CRG Securities Purchase Agreement of $541,000 net of
the common stock premium of $115,000 based on the relative fair
values of each security. In connection with the June&nbsp;2016
drawdown under the Loan Agreement, the Company recorded a debt
discount of $275,000 which comprised financing fees of $150,000,
paid directly to CRG, and other costs directly attributable to the
Loan Agreement with CRG of $125,000. Concurrent with the Amendment
No.2 to the Loan Agreement, the Company recorded an additional debt
discount of $154,000 of issuance costs. The debt discount is being
amortized as non-cash interest expense using the effective interest
method over the term of the Loan Agreement. As of March&nbsp;31,
2018 and December&nbsp;31, 2017, the balance of the aggregate debt
discount was $840,000 and $716,000, respectively.&nbsp; The Company’
s interest expense associated with the debt discount amounted to
$26,000 and $30,000 during the three months ended March&nbsp;31,
2018 and 2017, respectively.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2"
face="Times New Roman" style="font-size:10.0pt;">As noted in Note 1
to these financial statements, due to the substantial doubt about
the Company’s ability to continue operating as a going concern and
the material adverse change clause in the CRG Loan Agreement, the
entire amount of borrowings at March&nbsp;31, 2018 and
December&nbsp;31, 2017 has been classified as current in these
financial statements. CRG has not invoked the material adverse
change clause.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><i><font size="2" face=
"Times New Roman" style="font-size:10.0pt;font-style:italic;">PDL
BioPharma</font></i></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2"
face="Times New Roman" style="font-size:10.0pt;">On April&nbsp;18,
2013, the Company entered into a Credit Agreement ( “Agreement”)
with PDL BioPharma,&nbsp;Inc. (“PDL”) whereby PDL agreed to loan up
to $40,000,000. Contemporaneous with the execution of the Agreement
the Company borrowed an initial $20,000,000 (“Term Note”
).</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style=
"font-size:10.0pt;margin:0in 0in .0001pt;text-align:center;">
13<a name="PB_13_115346_8626" id="PB_13_115346_8626"></a></p>
<div style="margin:0in 0in .0001pt;">
<hr size="3" width="100%" noshade="noshade" align="left" style=
"color:#010101;" /></div>
</div>
<!-- SEQ.=1,FOLIO='13',FILE='C:\JMS\109754\18-8644-1\task8901843\8644-1-fp.htm',USER='109754',CD='May 16 01:09 2018' --><br clear="all"
style="page-break-before:always;" />
<div style="font-family:Times New Roman;">
<p style="margin:0in 0in .0001pt;"><a href="#TableOfContents"
title="Click to go to Table of Contents"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">Table of
Contents</font></a></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2"
face="Times New Roman" style="font-size:10.0pt;">The Term Note was
scheduled to mature April&nbsp;18, 2018, had a stated interest rate
of 12.0% per annum and could be prepaid by the Company at any time.
The Company paid interest-only through the first ten quarters and,
thereafter, repayment of principal in equal installments including
accrued and unpaid interest, payable each quarter. As provided
under the terms of the Agreement, for the first eight quarterly
interest payments, or through 2015, on the Term Note the Company
elected to convert an amount of interest, up to 1.5% per annum,
into additional loans, referred to as PIK loans. The PIK loans
accrued interest and were added to the aggregate principal balance
of the Term Note.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style=
"font-size:10.0pt;margin:0in 0in .0001pt;text-indent:.5in;">
<font size="2" face="Times New Roman" style="font-size:10.0pt;">In
September&nbsp;2015, in connection with the consummation of the
Loan Agreement with CRG, the Company repaid all amounts outstanding
under the Agreement. The payoff amount of $21,363,000 included
accrued interest through the repayment date of $563,000 and
$200,000 as an end-of-term final payment fee recorded in other
income (expense), net on the statement of loss and comprehensive
loss.</font> For the three months ended March&nbsp;31, 2018 and
2017, the Company incurred interest expense of $303,000 and
$241,000, respectively.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style=
"font-size:10.0pt;margin:0in 0in .0001pt;text-indent:.5in;">
<font size="2" face="Times New Roman" style="font-size:10.0pt;">In
addition to the interest and principal payments</font>, the Company
also paid a royalty, referred to as Assigned Interests, equal to
1.8% of the Company’s quarterly net revenues. Upon the prepayment
of the Term Note, the Company’s obligations relating to Assigned
Interests continue, and are payable through the maturity date at a
reduced rate of 0.9% of the quarterly net revenues, subject to
certain quarterly minimum mandatory amounts, which are payable
monthly. The ongoing obligation was determined to be an embedded
element of the Agreement and cannot be bifurcated from the Term
Note for accounting purposes. Accordingly, the Company continued to
account for the Assigned Interests obligation relating to future
royalties as a debt instrument by applying the retrospective
approach and reviews its estimate of forecasted Assigned Interests
payable annually. Under the retrospective method, the Company
computes a new effective interest rate based on the original
carrying amount, actual cash flows to date, and remaining estimated
cash flows over the maturity date. The new effective interest rate,
20.4% as of December&nbsp;31, 2016, was used to adjust the carrying
amount to the present value of the revised estimated cash flows,
discounted at the new effective interest rate. At the time of the
repayment the resulting increase in the carrying value of the
Assigned Interests, of $942,000, was recognized as a component of
other income (expense), net, on the statements of operations and
comprehensive loss. The Company has an aggregate accrual for its
Assigned Interests obligations of $61,000 and $364,000,
representing the net present value of the future minimum royalty
obligation as of March&nbsp;31, 2018 and December&nbsp;31, 2017,
respectively. The Assigned Interest liability was included within
accrued expenses and other current liabilities as of March&nbsp;31,
2018 and December&nbsp;31, 2017, on the balance sheet.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:38.15pt;"><font size=
"2" face="Times New Roman" style="font-size:10.0pt;">Additionally,
until April&nbsp;2018, the Company must periodically pay PDL a
percentage of its net revenue and comply with certain affirmative
covenants and negative covenants limiting its ability to, among
other things, undergo a change in control or dispose of assets, in
each case subject to certain exceptions. The Company was in
compliance with the covenants under the Agreement as of
March&nbsp;31, 2018.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style=
"font-size:10.0pt;margin:0in 0in .0001pt;text-align:center;">
14<a name="PB_14_115407_7056" id="PB_14_115407_7056"></a></p>
<div style="margin:0in 0in .0001pt;">
<hr size="3" width="100%" noshade="noshade" align="left" style=
"color:#010101;" /></div>
</div>
<!-- SEQ.=1,FOLIO='14',FILE='C:\JMS\109754\18-8644-1\task8901843\8644-1-fp.htm',USER='109754',CD='May 16 01:09 2018' --><br clear="all"
style="page-break-before:always;" />
<div style="font-family:Times New Roman;">
<p style="margin:0in 0in .0001pt;"><a href="#TableOfContents"
title="Click to go to Table of Contents"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">Table of
Contents</font></a></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><b><font size="2" face=
"Times New Roman" style="font-size:10.0pt;font-weight:bold;">6.
Capital Leases</font></b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2"
face="Times New Roman" style="font-size:10.0pt;">Capital lease
obligations consist of leased office equipment. As of
March&nbsp;31, 2018 and December&nbsp;31, 2017, the aggregate
amount of capital leases recorded within property and equipment,
net, on the accompanying balance sheet is $9,000 and $14,000,
respectively. The current portion of the capital lease obligations
is included in accrued liabilities and the balance included within
other long-term liabilities represents the long-term
portion.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2"
face="Times New Roman" style="font-size:10.0pt;">The future minimum
lease payments as of March&nbsp;31, 2018, are as follows (in
thousands):</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<table border="0" cellspacing="0" cellpadding="0" width="60%"
style="border-collapse:collapse;margin-left:1.5in;">
<tr>
<td width="71%" valign="bottom" style=
"padding:0in 0in 0in 0in;width:71.16%;">
<p style="margin:0in 0in .0001pt;"><b><font size="1" face=
"Times New Roman" style=
"font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>
</td>
<td width="4%" valign="bottom" style=
"padding:0in 0in 0in 0in;width:4.16%;">
<p align="center" style=
"margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face=
"Times New Roman" style=
"font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>
</td>
<td width="23%" colspan="2" valign="bottom" style=
"padding:0in 0in 0in 0in;width:23.0%;">
<p align="center" style=
"margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face=
"Times New Roman" style=
"font-size:8.0pt;font-weight:bold;">Future&nbsp;Minimum</font></b></p>
</td>
<td width="1%" valign="bottom" style=
"padding:0in 0in 0in 0in;width:1.66%;">
<p align="center" style=
"margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face=
"Times New Roman" style=
"font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>
</td>
</tr>
<tr>
<td width="71%" valign="bottom" style=
"border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:71.16%;">
<p style="margin:0in 0in .0001pt;"><b><font size="1" face=
"Times New Roman" style=
"font-size:8.0pt;font-weight:bold;">Period&nbsp;ending&nbsp;December&nbsp;31,</font></b></p>
</td>
<td width="4%" valign="bottom" style=
"padding:0in 0in 0in 0in;width:4.16%;">
<p align="center" style=
"margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face=
"Times New Roman" style=
"font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>
</td>
<td width="23%" colspan="2" valign="bottom" style=
"border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:23.0%;">
<p align="center" style=
"margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face=
"Times New Roman" style=
"font-size:8.0pt;font-weight:bold;">Lease&nbsp;Payments</font></b></p>
</td>
<td width="1%" valign="bottom" style=
"padding:0in 0in 0in 0in;width:1.66%;">
<p align="center" style=
"margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face=
"Times New Roman" style=
"font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>
</td>
</tr>
<tr>
<td width="71%" valign="top" bgcolor="#CCEEFF" style=
"background:#CCEEFF;padding:0in 0in 0in 0in;width:71.16%;">
<p style="margin:0in 0in .0001pt 10.1pt;text-indent:-10.1pt;">
<font size="2" face="Times New Roman" style=
"font-size:10.0pt;">2018</font></p>
</td>
<td width="4%" valign="bottom" bgcolor="#CCEEFF" style=
"background:#CCEEFF;padding:0in 0in 0in 0in;width:4.16%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>
</td>
<td width="1%" valign="bottom" bgcolor="#CCEEFF" style=
"background:#CCEEFF;padding:0in 0in 0in 0in;width:1.88%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">$</font></p>
</td>
<td width="21%" valign="bottom" bgcolor="#CCEEFF" style=
"background:#CCEEFF;padding:0in 0in 0in 0in;width:21.12%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;">
<font size="2" face="Times New Roman" style=
"font-size:10.0pt;">8</font></p>
</td>
<td width="1%" valign="bottom" bgcolor="#CCEEFF" style=
"background:#CCEEFF;padding:0in 0in 0in 0in;width:1.66%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>
</td>
</tr>
<tr>
<td width="71%" valign="top" style=
"padding:0in 0in 0in 0in;width:71.16%;">
<p style="margin:0in 0in .0001pt 10.1pt;text-indent:-10.1pt;">
<font size="2" face="Times New Roman" style=
"font-size:10.0pt;">2019</font></p>
</td>
<td width="4%" valign="bottom" style=
"padding:0in 0in 0in 0in;width:4.16%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>
</td>
<td width="23%" colspan="2" valign="bottom" style=
"border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:23.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;">
<font size="2" face="Times New Roman" style=
"font-size:10.0pt;">1</font></p>
</td>
<td width="1%" valign="bottom" style=
"padding:0in 0in 0in 0in;width:1.66%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>
</td>
</tr>
<tr>
<td width="71%" valign="top" bgcolor="#CCEEFF" style=
"background:#CCEEFF;padding:0in 0in 0in 0in;width:71.16%;">
<p style="margin:0in 0in .0001pt 10.1pt;text-indent:-10.1pt;">
<font size="2" face="Times New Roman" style=
"font-size:10.0pt;">Total minimum payments</font></p>
</td>
<td width="4%" valign="bottom" bgcolor="#CCEEFF" style=
"background:#CCEEFF;padding:0in 0in 0in 0in;width:4.16%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>
</td>
<td width="23%" colspan="2" valign="bottom" bgcolor="#CCEEFF"
style="background:#CCEEFF;padding:0in 0in 0in 0in;width:23.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;">
<font size="2" face="Times New Roman" style=
"font-size:10.0pt;">9</font></p>
</td>
<td width="1%" valign="bottom" bgcolor="#CCEEFF" style=
"background:#CCEEFF;padding:0in 0in 0in 0in;width:1.66%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>
</td>
</tr>
<tr>
<td width="71%" valign="top" style=
"padding:0in 0in 0in 0in;width:71.16%;">
<p style="margin:0in 0in .0001pt 10.1pt;text-indent:-10.1pt;">
<font size="2" face="Times New Roman" style=
"font-size:10.0pt;">Less: Amount representing future
interest</font></p>
</td>
<td width="4%" valign="bottom" style=
"padding:0in 0in 0in 0in;width:4.16%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>
</td>
<td width="23%" colspan="2" valign="bottom" style=
"border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:23.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;">
<font size="2" face="Times New Roman" style="font-size:10.0pt;">—
</font></p>
</td>
<td width="1%" valign="bottom" style=
"padding:0in 0in 0in 0in;width:1.66%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>
</td>
</tr>
<tr>
<td width="71%" valign="top" bgcolor="#CCEEFF" style=
"background:#CCEEFF;padding:0in 0in 0in 0in;width:71.16%;">
<p style="margin:0in 0in .0001pt 10.1pt;text-indent:-10.1pt;">
<font size="2" face="Times New Roman" style=
"font-size:10.0pt;">Present value of minimum lease
payments</font></p>
</td>
<td width="4%" valign="bottom" bgcolor="#CCEEFF" style=
"background:#CCEEFF;padding:0in 0in 0in 0in;width:4.16%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>
</td>
<td width="1%" valign="bottom" bgcolor="#CCEEFF" style=
"background:#CCEEFF;border:none;border-bottom:double windowtext 2.25pt;padding:0in 0in 0in 0in;width:1.88%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">$</font></p>
</td>
<td width="21%" valign="bottom" bgcolor="#CCEEFF" style=
"background:#CCEEFF;border:none;border-bottom:double windowtext 2.25pt;padding:0in 0in 0in 0in;width:21.12%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;">
<font size="2" face="Times New Roman" style=
"font-size:10.0pt;">9</font></p>
</td>
<td width="1%" valign="bottom" bgcolor="#CCEEFF" style=
"background:#CCEEFF;padding:0in 0in 0in 0in;width:1.66%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>
</td>
</tr>
</table>
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><b><font size="2" face=
"Times New Roman" style="font-size:10.0pt;font-weight:bold;">7.
Commitments and Contingencies</font></b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><b><font size="2" face=
"Times New Roman" style="font-size:10.0pt;font-weight:bold;">Lease
Commitments</font></b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style=
"font-size:10.0pt;margin:0in 0in .0001pt;text-indent:.5in;">
<font size="2" face="Times New Roman" style="font-size:10.0pt;">The
Company’s operating lease obligations primarily consist of leased
office, laboratory, and manufacturing space under a non-cancelable
operating lease that expires in November&nbsp;2019. The lease
agreement includes a renewal provision allowing the Company to
extend this lease for an additional period of three years. In
addition to the minimum future lease commitments presented below,
the lease requires the Company to pay property taxes, insurance,
maintenance, and repair costs. The lease includes a rent holiday
concession and escalation clauses for increased rent over the lease
term. Rent expense is recognized using the straight-line method
over the term of the lease. The Company records deferred rent
calculated as the difference between rent expense and the cash
rental payments.</font> In connection with the facility lease, the
landlord also provided incentives of $369,000 to the Company in the
form of leasehold improvements. These amounts were reflected as
deferred rent and were amortized as a reduction to rent expense
over the original term of the Company’s operating lease. In
February&nbsp;2016, the Company entered into an additional
non-cancelable operating lease for warehouse and storage space that
expires in November&nbsp;2019. Rent expense was $240,000 and
$506,000 for the three months ended March&nbsp;31, 2018 and
2017.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2"
face="Times New Roman" style="font-size:10.0pt;">On
October&nbsp;19, 2017, the Company entered into an agreement to
sublease one of its facilities (Note 10). The sublease agreement
commenced on approximately December&nbsp;1, 2017 and is scheduled
to expire on November&nbsp;15, 2019 (which is 15 days prior to the
expiration of the facility lease). The sublessee pays a base rent
of $3.25 per rentable square foot, for a total of $79,950 per
month, increasing to $3.35 per rentable square foot, for a total of
$82,410 per month as of December&nbsp;1, 2018. In addition to the
base rent, the sublessee pays the Landlord’s operating expenses and
property taxes due and payable with respect to the subleased
facility.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2"
face="Times New Roman" style="font-size:10.0pt;">The future
aggregate minimum lease payments, net of sublease income, as of
March&nbsp;31, 2018, are as follows (in thousands):</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<table border="0" cellspacing="0" cellpadding="0" width="60%"
style="border-collapse:collapse;margin-left:1.5in;">
<tr>
<td width="71%" valign="bottom" style=
"padding:0in 0in 0in 0in;width:71.16%;">
<p style="margin:0in 0in .0001pt;"><b><font size="1" face=
"Times New Roman" style=
"font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>
</td>
<td width="4%" valign="bottom" style=
"padding:0in 0in 0in 0in;width:4.16%;">
<p align="center" style=
"margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face=
"Times New Roman" style=
"font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>
</td>
<td width="23%" colspan="2" valign="bottom" style=
"padding:0in 0in 0in 0in;width:23.0%;">
<p align="center" style=
"margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face=
"Times New Roman" style=
"font-size:8.0pt;font-weight:bold;">Future&nbsp;Minimum</font></b></p>
</td>
<td width="1%" valign="bottom" style=
"padding:0in 0in 0in 0in;width:1.66%;">
<p align="center" style=
"margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face=
"Times New Roman" style=
"font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>
</td>
</tr>
<tr>
<td width="71%" valign="bottom" style=
"border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:71.16%;">
<p style="margin:0in 0in .0001pt;"><b><font size="1" face=
"Times New Roman" style=
"font-size:8.0pt;font-weight:bold;">Year&nbsp;ending&nbsp;December&nbsp;31,</font></b></p>
</td>
<td width="4%" valign="bottom" style=
"padding:0in 0in 0in 0in;width:4.16%;">
<p align="center" style=
"margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face=
"Times New Roman" style=
"font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>
</td>
<td width="23%" colspan="2" valign="bottom" style=
"border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:23.0%;">
<p align="center" style=
"margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face=
"Times New Roman" style=
"font-size:8.0pt;font-weight:bold;">Lease&nbsp;Payments</font></b></p>
</td>
<td width="1%" valign="bottom" style=
"padding:0in 0in 0in 0in;width:1.66%;">
<p align="center" style=
"margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face=
"Times New Roman" style=
"font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>
</td>
</tr>
<tr>
<td width="71%" valign="top" bgcolor="#CCEEFF" style=
"background:#CCEEFF;padding:0in 0in 0in 0in;width:71.16%;">
<p style="margin:0in 0in .0001pt 10.1pt;text-indent:-10.1pt;">
<font size="2" face="Times New Roman" style=
"font-size:10.0pt;">2018</font></p>
</td>
<td width="4%" valign="bottom" bgcolor="#CCEEFF" style=
"background:#CCEEFF;padding:0in 0in 0in 0in;width:4.16%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>
</td>
<td width="1%" valign="bottom" bgcolor="#CCEEFF" style=
"background:#CCEEFF;padding:0in 0in 0in 0in;width:1.88%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">$</font></p>
</td>
<td width="21%" valign="bottom" bgcolor="#CCEEFF" style=
"background:#CCEEFF;padding:0in 0in 0in 0in;width:21.12%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;">
<font size="2" face="Times New Roman" style=
"font-size:10.0pt;">805</font></p>
</td>
<td width="1%" valign="bottom" bgcolor="#CCEEFF" style=
"background:#CCEEFF;padding:0in 0in 0in 0in;width:1.66%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>
</td>
</tr>
<tr>
<td width="71%" valign="top" style=
"padding:0in 0in 0in 0in;width:71.16%;">
<p style="margin:0in 0in .0001pt 10.1pt;text-indent:-10.1pt;">
<font size="2" face="Times New Roman" style=
"font-size:10.0pt;">2019</font></p>
</td>
<td width="4%" valign="bottom" style=
"padding:0in 0in 0in 0in;width:4.16%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>
</td>
<td width="23%" colspan="2" valign="bottom" style=
"border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:23.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;">
<font size="2" face="Times New Roman" style=
"font-size:10.0pt;">1,009</font></p>
</td>
<td width="1%" valign="bottom" style=
"padding:0in 0in 0in 0in;width:1.66%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>
</td>
</tr>
<tr>
<td width="71%" valign="top" bgcolor="#CCEEFF" style=
"background:#CCEEFF;padding:0in 0in 0in 0in;width:71.16%;">
<p style="margin:0in 0in .0001pt 10.1pt;text-indent:-10.1pt;">
<font size="2" face="Times New Roman" style=
"font-size:10.0pt;">Total minimum lease payments</font></p>
</td>
<td width="4%" valign="bottom" bgcolor="#CCEEFF" style=
"background:#CCEEFF;padding:0in 0in 0in 0in;width:4.16%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>
</td>
<td width="1%" valign="bottom" bgcolor="#CCEEFF" style=
"background:#CCEEFF;border:none;border-bottom:double windowtext 2.25pt;padding:0in 0in 0in 0in;width:1.88%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">$</font></p>
</td>
<td width="21%" valign="bottom" bgcolor="#CCEEFF" style=
"background:#CCEEFF;border:none;border-bottom:double windowtext 2.25pt;padding:0in 0in 0in 0in;width:21.12%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;">
<font size="2" face="Times New Roman" style=
"font-size:10.0pt;">1,814</font></p>
</td>
<td width="1%" valign="bottom" bgcolor="#CCEEFF" style=
"background:#CCEEFF;padding:0in 0in 0in 0in;width:1.66%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>
</td>
</tr>
</table>
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><b><font size="2" face=
"Times New Roman" style=
"font-size:10.0pt;font-weight:bold;">Purchase
Obligations</font></b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2"
face="Times New Roman" style="font-size:10.0pt;">Purchase
obligations consist of agreements to purchase goods and services
entered into in the ordinary course of business. The Company had
non-cancellable commitments to suppliers for purchases totaling
$1,899,000 and $1,172,000 as of March&nbsp;31, 2018 and
December&nbsp;31, 2017, respectively.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><b><font size="2" face=
"Times New Roman" style=
"font-size:10.0pt;font-weight:bold;">Indemnification</font></b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2"
face="Times New Roman" style="font-size:10.0pt;">In the normal
course of business, the Company enters into contracts and
agreements that contain a variety of representations and warranties
and may provide for indemnification of the counterparty. The
Company’s exposure under these agreements is unknown because it
involves claims that may be made against it in the future, but have
not yet been made. To date, the Company has not been subject to any
claims or been required to defend any action related to its
indemnification obligations.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style=
"font-size:10.0pt;margin:0in 0in .0001pt;text-align:center;">
15<a name="PB_15_115645_5335" id="PB_15_115645_5335"></a></p>
<div style="margin:0in 0in .0001pt;">
<hr size="3" width="100%" noshade="noshade" align="left" style=
"color:#010101;" /></div>
</div>
<!-- SEQ.=1,FOLIO='15',FILE='C:\JMS\109754\18-8644-1\task8901843\8644-1-fp.htm',USER='109754',CD='May 16 01:09 2018' --><br clear="all"
style="page-break-before:always;" />
<div style="font-family:Times New Roman;">
<p style="margin:0in 0in .0001pt;"><a href="#TableOfContents"
title="Click to go to Table of Contents"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">Table of
Contents</font></a></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2"
face="Times New Roman" style="font-size:10.0pt;">The Company
indemnifies each of its directors and officers for certain events
or occurrences, subject to certain limits, while the director is or
was serving at the Company’s request in such capacity, as permitted
under Delaware law and in accordance with its certificate of
incorporation and bylaws. The term of the indemnification period
lasts as long as a director may be subject to any proceeding
arising out of acts or omissions of such director in such capacity.
The maximum amount of potential future indemnification is
unlimited; however, the Company currently holds director liability
insurance. This insurance allows the transfer of risk associated
with the Company’s exposure and may enable it to recover a portion
of any future amounts paid. The Company believes that the fair
value of these indemnification obligations is minimal. Accordingly,
it has not recognized any liabilities relating to these obligations
for any period presented.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><b><font size="2" face=
"Times New Roman" style="font-size:10.0pt;font-weight:bold;">Legal
Proceedings</font></b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2"
face="Times New Roman" style="font-size:10.0pt;">Except as set
forth below, the Company is not involved in any pending legal
proceedings that it believes could have a material adverse effect
on its financial condition, results of operations or cash flows.
From time to time, the Company may pursue litigation to assert its
legal right and such litigation may be costly and divert the
efforts and attention of its management and technical personnel
which could adversely affect its business.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2"
face="Times New Roman" style="font-size:10.0pt;">Between
May&nbsp;22, 2017 and May&nbsp;25, 2017, three purported class
action lawsuits were filed in the Superior Court of the State of
California, County of San Mateo (“State Court”), against the
Company, certain of its officers and directors and the underwriters
of the Company’s January&nbsp;2015 IPO. The actions were captioned
Grotewiel v. Avinger,&nbsp;Inc., et al., No.&nbsp;17-CIV-02240,
Gonzalez v. Avinger,&nbsp;Inc., et al., No.&nbsp;17-CIV-02284, and
Olberding v. Avinger,&nbsp;Inc., et al., No.&nbsp;17-CIV-02307.
These lawsuits allege that the registration statement for the
Company’s IPO made false and misleading statements and omissions in
violation of the Securities Act of 1933. Plaintiffs seek to
represent a class of purchasers of our common stock in and/or
traceable to our IPO. Plaintiffs seek, among other things,
unspecified compensatory damages, interest, costs, recission, and
attorneys’ fees. On June&nbsp;12, 2017, defendants removed these
actions to the United States District Court for the Northern
District of California (“Federal Court”), where they were captioned
Grotewiel v. Avinger,&nbsp;Inc., No.&nbsp;17-cv-03400, Gonzalez v.
Avinger,&nbsp;Inc., No.&nbsp;17-cv-03401, and Olberding v.
Avinger,&nbsp;Inc., No.&nbsp;17-cv-03398, and where the actions
were related and assigned to the same judge.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style=
"font-size:10.0pt;margin:0in 0in .0001pt;text-indent:.5in;">
<font size="2" face="Times New Roman" style="font-size:10.0pt;">On
October&nbsp;11, 2017, the Federal Court appointed a lead plaintiff
and approved the selection of a lead counsel in the Grotewiel
action (“Federal Action”). An amended complaint in the Federal
Action is due on November&nbsp;21, 2017. On June&nbsp;22, 2017, and
June&nbsp;23, 2017, plaintiffs Olberding and Gonzalez moved to
remand their cases to the State Court. Defendants opposed these
motions. On July&nbsp;21, 2017, the Federal Court granted the
motions to remand the Olberding and Gonzalez actions to the State
Court.&nbsp; On August&nbsp;9, 2017, the State Court consolidated
the Olberding and Grotewiel actions under the caption Gonzalez v.
Avinger,&nbsp;Inc., et al., No.&nbsp;17-CIV-02284 (“State Action”
).&nbsp;On September&nbsp;22, 2017, an amended complaint was filed
in the State Action. On October&nbsp;31, 2017, the parties in the
State Action stipulated to a stay of proceedings until judgment is
entered in the Federal Action.</font> On November&nbsp;2, 2017,
pursuant to stipulation of the parties, the State Court entered an
order staying proceedings in the State Action until judgment is
entered in the Federal Action.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2"
face="Times New Roman" style="font-size:10.0pt;">The Company and
its directors believe that the foregoing lawsuits were entirely
without merit; however, in the interest of avoiding the cost and
disruption of continuing to defend against these lawsuits, on
February&nbsp;8, 2018, the Company participated in a mediation to
explore whether a settlement could be reached. While a settlement
was not reached then, the parties continued discussions and they
ultimately reached agreement.&nbsp; On March&nbsp;19, 2018, the
Company entered into a binding memorandum of understanding to
settle the securities class actions pending against the Company and
several of its officers and directors. The settlement is for a
total of $5 million and, if approved by the court, will result in a
full release of claims against all defendants. The settlement is
subject to final documentation, notice to class members, and
approval of the court. The Company’s total contribution to the
settlement fund is $1.76 million.&nbsp; As such, the Company
included $1.76 million for litigation settlement within accrued
expenses and other current liabilities as of December&nbsp;31,
2017.&nbsp; In March&nbsp;2018, the Company paid out the $1.76
million.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><b><font size="2" face=
"Times New Roman" style="font-size:10.0pt;font-weight:bold;">8.
Stockholders’ Equity (Deficit)</font></b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><b><font size="2" face=
"Times New Roman" style=
"font-size:10.0pt;font-weight:bold;">Preferred Stock</font></b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2"
face="Times New Roman" style="font-size:10.0pt;">As of
March&nbsp;31, 2018, the Company’s certificate of incorporation, as
amended and restated, authorizes the Company to issue up to
5,000,000 shares of preferred stock with $0.001 par value per
share, of which 52,762 shares were issued and
outstanding.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><i><font size="2" face=
"Times New Roman" style=
"font-size:10.0pt;font-style:italic;">Series&nbsp;A Preferred
Stock</font></i></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2"
face="Times New Roman" style="font-size:10.0pt;">On
February&nbsp;14, 2018, the Company entered into a Series&nbsp;A
Purchase Agreement with CRG, pursuant to which it agreed to convert
$38,000,000 of the outstanding principal amount of its senior
secured term loan (plus $3,800,000 in back-end fees and</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style=
"font-size:10.0pt;margin:0in 0in .0001pt;text-align:center;">
16<a name="PB_16_115754_5796" id="PB_16_115754_5796"></a></p>
<div style="margin:0in 0in .0001pt;">
<hr size="3" width="100%" noshade="noshade" align="left" style=
"color:#010101;" /></div>
</div>
<!-- SEQ.=1,FOLIO='16',FILE='C:\JMS\109754\18-8644-1\task8901843\8644-1-fp.htm',USER='109754',CD='May 16 01:09 2018' --><br clear="all"
style="page-break-before:always;" />
<div style="font-family:Times New Roman;">
<p style="margin:0in 0in .0001pt;"><a href="#TableOfContents"
title="Click to go to Table of Contents"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">Table of
Contents</font></a></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;"><font size="2"
face="Times New Roman" style="font-size:10.0pt;">prepayment premium
applicable thereto)</font>, totaling $41,800,000, into a newly
authorized Series&nbsp;A preferred stock.&nbsp; The Series&nbsp;A
preferred stock is initially convertible into 20,900,000 shares of
common stock subject to certain limitations contained in the
Series&nbsp;A Purchase Agreement. &nbsp;Under the terms of the
Series&nbsp;A Purchase Agreement, the holders of Series&nbsp;A
preferred stock are entitled to receive annual accruing dividends
at a rate of 8%, payable in additional shares of Series&nbsp;A
preferred stock or cash, at the Company’s option. The shares of
Series&nbsp;A preferred stock have no voting rights and rank senior
to all other classes and series of the Company’s equity in terms of
repayment and certain other rights. The Series&nbsp;A preferred
stock and any of the Company’s common stock issued upon conversion
of the Series&nbsp;A preferred stock are subject to a lockup
agreement through February&nbsp;14, 2019.&nbsp; As of
March&nbsp;31, 2018, 41,800 shares of Series&nbsp;A preferred stock
were outstanding.&nbsp; The Series&nbsp;A preferred stock accrued
dividends of $410,000 was included within borrowings.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><i><font size="2" face=
"Times New Roman" style=
"font-size:10.0pt;font-style:italic;">Series&nbsp;B Preferred
Stock</font></i></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2"
face="Times New Roman" style="font-size:10.0pt;">On
February&nbsp;16, 2018, the Company completed a public offering of
17,979 shares of Series&nbsp;B convertible preferred stock (the 
“Series&nbsp;B preferred stock”). As a result, the Company received
net proceeds of approximately $16.0 million after underwriting
discounts, commissions, legal and accounting fees of approximately
$1.9 million. The Series&nbsp;B preferred stock has a liquidation
preference of $0.001 per share, full ratchet price based
anti-dilution protection, has no voting rights and is subject to
certain ownership limitations. The Series&nbsp;B preferred stock is
immediately convertible at the option of the holder, has no stated
maturity, and does not pay regularly stated dividends or
interest.&nbsp; As of March&nbsp;31, 2018, 10,962 shares of
Series&nbsp;B preferred stock were outstanding.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2"
face="Times New Roman" style="font-size:10.0pt;">The Company
evaluated the Series&nbsp;B convertible preferred stock issuance in
accordance with the provisions of ASC 815, <i>Derivatives and
Hedging</i>, including consideration of embedded derivatives
requiring bifurcation. The issuance of the convertible preferred
stock could generate a beneficial conversion feature (BCF), which
arises when a debt or equity security is issued with an embedded
conversion option that is beneficial to the investor or in the
money at inception because the conversion option has an effective
conversion price that is less than the market price of the
underlying stock at the commitment date. The Company recognized the
BCF by allocating the intrinsic value of the conversion option,
which is the number of shares of common stock available upon
conversion multiplied by the difference between the effective
conversion price per share and the fair value of common stock per
share on the commitment date, to additional paid-in capital,
resulting in a discount on the convertible preferred stock. As the
Series&nbsp;B convertible preferred stock may be converted
immediately, the Company recognized a BCF of $5.2 million as a
deemed dividend in the condensed consolidated statements of
operations as of February&nbsp;16, 2018.&nbsp;This one-time,
non-cash charge impacted net loss attributable to common
stockholders and net loss per share attributable to common
stockholders for the three months ended March&nbsp;31,
2018.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><b><font size="2" face=
"Times New Roman" style="font-size:10.0pt;font-weight:bold;">Common
Stock</font></b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style=
"font-size:10.0pt;margin:0in 0in .0001pt;text-indent:.5in;">
<font size="2" face="Times New Roman" style="font-size:10.0pt;">As
of March&nbsp;31, 2018, the Company’s certificate of incorporation,
as amended and restated, authorizes the Company to issue up to
100,000,000 shares of common stock with $0.001 par value per share,
of which</font> 4,384,224&nbsp;shares were issued and
outstanding.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><b><font size="2" face=
"Times New Roman" style="font-size:10.0pt;font-weight:bold;">Common
Stock Warrants</font></b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2"
face="Times New Roman" style="font-size:10.0pt;">In connection with
the issuance of the Company’s Series&nbsp;E Convertible preferred
stock in September&nbsp;2014 through January&nbsp;2015, the Company
issued, to each investor who purchased shares of Series&nbsp;E
Convertible preferred stock, warrants to purchase up to the number
of shares of common stock equal to 50% of the number of shares of
the Company’s Series&nbsp;E Convertible preferred stock purchased
by such investor.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style=
"font-size:10.0pt;margin:0in 0in .0001pt;text-indent:.5in;">
<font size="2" face="Times New Roman" style="font-size:10.0pt;">The
warrants are immediately exercisable, at an exercise price per
share of $504.00, and expire upon the earlier of September&nbsp;2,
2019 or upon the consummation of a change of control of the
Company. The Company determined that these common stock warrants
meet the requirements for equity classification.</font> In
connection with the issuance of its Series&nbsp;E Convertible
preferred stock in September&nbsp;through December&nbsp;2014, the
Company issued warrants to purchase an aggregate of 33,314 shares
of common stock. The common stock warrants were recorded at their
allocated fair value of $175,000 within stockholders’ equity
(deficit).</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2"
face="Times New Roman" style="font-size:10.0pt;">In connection with
the issuance of the Company’s Series&nbsp;E Convertible preferred
stock in January&nbsp;2015, the Company issued warrants to purchase
an aggregate of 6,129 shares of common stock. The common stock
warrants were recorded at their allocated fair value of $804,000
within stockholders’ equity (deficit).</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2"
face="Times New Roman" style="font-size:10.0pt;">On
January&nbsp;14, 2015, the Company amended its Series&nbsp;E
Convertible preferred stock Purchase Agreement to provide for the
issuance of common stock warrants to each investor who purchased
shares of Series&nbsp;E Convertible preferred stock equal to 70% of
the number of shares of the Company’s Series&nbsp;E Convertible
preferred stock purchased by such investor. As with the common
stock warrants previously issued, any new common stock warrants
were immediately exercisable, at an exercise price of $504.00 per
share, and expire upon the earlier of September&nbsp;2, 2019 or
upon consummation of a change in control of the Company. As a
result of this amendment to the Series&nbsp;E Convertible preferred
stock Purchase Agreement, the Company issued additional warrants to
purchase 15,801 shares of common stock to investors who previously
acquired shares of Series&nbsp;E Convertible preferred stock from
September&nbsp;2014 through January&nbsp;2015.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2"
face="Times New Roman" style="font-size:10.0pt;">On
February&nbsp;16, 2018, in connection with the Company’s completed
public offering of Series&nbsp;B preferred stock, the Company
issued warrants to purchase an aggregate of 17,979,000 shares of
common stock (the “Series&nbsp;B Warrants”).&nbsp; Each share of
Series&nbsp;B preferred stock is accompanied by one warrant that
expires on the seventh anniversary of the date of issuance to
purchase up to 500 shares of common stock and one warrant that
expires on the earlier of (i)&nbsp;the seventh anniversary of the
date of issuance or (ii)&nbsp;the 60th calendar day following the
receipt and announcement of FDA clearance of the Company’s
Pantheris below-the-knee device (or the same or similar product
with a different name) to purchase up to 500 shares of common
stock; provided, however, if at any time during such 60-day period
the volume weighted average price for any trading day is less than
the then effective exercise price, the termination date shall be
extended to the seven year anniversary of the initial exercise
date.&nbsp; The Company assessed the Series&nbsp;B Warrants under
FASB ASC 480 and determined that the Series&nbsp;B Warrants were
outside the scope of ASC 480. The Company next</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style=
"font-size:10.0pt;margin:0in 0in .0001pt;text-align:center;">
17<a name="PB_17_115809_2897" id="PB_17_115809_2897"></a></p>
<div style="margin:0in 0in .0001pt;">
<hr size="3" width="100%" noshade="noshade" align="left" style=
"color:#010101;" /></div>
</div>
<!-- SEQ.=1,FOLIO='17',FILE='C:\JMS\109754\18-8644-1\task8901843\8644-1-fp.htm',USER='109754',CD='May 16 01:09 2018' --><br clear="all"
style="page-break-before:always;" />
<div style="font-family:Times New Roman;">
<p style="margin:0in 0in .0001pt;"><a href="#TableOfContents"
title="Click to go to Table of Contents"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">Table of
Contents</font></a></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">assessed the
Series&nbsp;B Warrants under FASB ASC 815. Under the related
guidance, a reporting entity shall not consider a contract to be a
derivative instrument if the contract is both (1)&nbsp;indexed to
the entity’s own stock and (2)&nbsp;classified in stockholders’
equity. The Company determined that the Series&nbsp;B Warrants were
indexed to the Company’s stock, as the agreements do not contain
any exercise contingencies and the Series&nbsp;B Warrants’
settlement amount equals the difference between the fair value of
the Company’s common stock price and the Series&nbsp;B Warrant
strike price. The Company also assessed the classification as
stockholders’ equity and determined the Series&nbsp;B Warrants met
all of the criteria for classification as equity under ASC 815.
Based on this analysis, the Company determined that the
Series&nbsp;B Warrants should be classified as equity. As of
March&nbsp;31, 2018, Series&nbsp;B Warrants to purchase an
aggregate of 17,979,000 shares of common stock were
outstanding.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2"
face="Times New Roman" style="font-size:10.0pt;">As of
March&nbsp;31, 2018 and December&nbsp;31, 2017, warrants to
purchase an aggregate of 18,032,715 and 53,715 shares of common
stock were outstanding, respectively.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><b><font size="2" face=
"Times New Roman" style="font-size:10.0pt;font-weight:bold;">Stock
Plans</font></b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style=
"font-size:10.0pt;margin:0in 0in .0001pt;text-indent:.5in;">
<font size="2" face="Times New Roman" style="font-size:10.0pt;">In
January&nbsp;2015, the Board of Directors adopted and the Company’s
stockholders approved the 2015 Equity Incentive Plan (“2015 Plan”).
The 2015 Plan</font> replaced the 2009 Stock Plan (the “2009 Plan”)
which was terminated immediately prior to consummation of the
Company’s IPO, collectively the “Plans.” The 2015 Plan provides for
the grant of incentive stock options (“ISOs”) to employees and for
the grant of nonstatutory stock options (“NSOs”), restricted stock,
RSUs, stock appreciation rights, performance units and performance
shares to employees, directors and consultants. Initially a total
of 33,000 shares of common stock were reserved for issuance
pursuant to the 2015 Plan. The shares reserved for issuance under
the 2015 Plan included shares reserved but not issued under the
2009 Plan, plus any share awards granted under the 2009 Plan that
expire or terminate without having been exercised in full or that
are forfeited or repurchased. In addition, the number of shares
available for issuance under the 2015 Plan includes an automatic
annual increase on the first day of each fiscal year beginning in
fiscal 2016, equal to the lesser of 42,250 shares, 5.0% of the
outstanding shares of common stock as of the last day of the
immediately preceding fiscal year or an amount as determined by the
Board of Directors. For fiscal 2017, the common stock available for
issuance under the 2015 Plan was increased by 29,720 shares of
common stock. As of March&nbsp;31, 2018, 121,775 shares were
available for grant under the 2015 Plan.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2"
face="Times New Roman" style="font-size:10.0pt;">Pursuant to the
Plans,&nbsp;ISOs and NSOs may be granted with exercise prices at
not less than 100% of the fair value of the common stock on the
date of grant and the exercise price of ISOs granted to a
stockholder, who, at the time of grant, owns stock representing
more than 10% of the voting power of all classes of the stock of
the Company, shall be not less than 110% of the fair market value
per share of common stock on the date of grant. The Company’s Board
of Directors determines the vesting schedule of the options.
Options granted generally vest over four years and expire ten years
from the date of grant.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2"
face="Times New Roman" style="font-size:10.0pt;">Stock option
activity under the Plans is set forth below:</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<table border="0" cellspacing="0" cellpadding="0" width="66%"
style="border-collapse:collapse;margin-left:1.25in;">
<tr>
<td width="36%" valign="bottom" style=
"padding:0in 0in 0in 0in;width:36.32%;">
<p style="margin:0in 0in .0001pt;"><b><font size="1" face=
"Times New Roman" style=
"font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>
</td>
<td width="3%" valign="bottom" style=
"padding:0in 0in 0in 0in;width:3.74%;">
<p align="center" style=
"margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face=
"Times New Roman" style=
"font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>
</td>
<td width="58%" colspan="7" valign="bottom" style=
"border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:58.46%;">
<p align="center" style=
"margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face=
"Times New Roman" style=
"font-size:8.0pt;font-weight:bold;">Options&nbsp;Outstanding</font></b></p>
</td>
<td width="1%" valign="bottom" style=
"padding:0in 0in 0in 0in;width:1.46%;">
<p align="center" style=
"margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face=
"Times New Roman" style=
"font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>
</td>
</tr>
<tr>
<td width="36%" valign="bottom" style=
"padding:0in 0in 0in 0in;width:36.32%;">
<p style="margin:0in 0in .0001pt;"><b><font size="1" face=
"Times New Roman" style=
"font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>
</td>
<td width="3%" valign="bottom" style=
"padding:0in 0in 0in 0in;width:3.74%;">
<p align="center" style=
"margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face=
"Times New Roman" style=
"font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>
</td>
<td width="17%" valign="bottom" style=
"padding:0in 0in 0in 0in;width:17.0%;">
<p align="center" style=
"margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face=
"Times New Roman" style=
"font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>
</td>
<td width="3%" valign="bottom" style=
"padding:0in 0in 0in 0in;width:3.74%;">
<p align="center" style=
"margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face=
"Times New Roman" style=
"font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>
</td>
<td width="18%" colspan="2" valign="bottom" style=
"padding:0in 0in 0in 0in;width:18.0%;">
<p align="center" style=
"margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face=
"Times New Roman" style=
"font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>
</td>
<td width="3%" valign="bottom" style=
"padding:0in 0in 0in 0in;width:3.74%;">
<p align="center" style=
"margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face=
"Times New Roman" style=
"font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>
</td>
<td width="16%" colspan="2" valign="bottom" style=
"padding:0in 0in 0in 0in;width:16.0%;">
<p align="center" style=
"margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face=
"Times New Roman" style=
"font-size:8.0pt;font-weight:bold;">Aggregate</font></b></p>
</td>
<td width="1%" valign="bottom" style=
"padding:0in 0in 0in 0in;width:1.46%;">
<p align="center" style=
"margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face=
"Times New Roman" style=
"font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>
</td>
</tr>
<tr>
<td width="36%" valign="bottom" style=
"padding:0in 0in 0in 0in;width:36.32%;">
<p style="margin:0in 0in .0001pt;"><b><font size="1" face=
"Times New Roman" style=
"font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>
</td>
<td width="3%" valign="bottom" style=
"padding:0in 0in 0in 0in;width:3.74%;">
<p align="center" style=
"margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face=
"Times New Roman" style=
"font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>
</td>
<td width="17%" valign="bottom" style=
"border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:17.0%;">
<p align="center" style=
"margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face=
"Times New Roman" style=
"font-size:8.0pt;font-weight:bold;">Number&nbsp;of<br />
Shares</font></b></p>
</td>
<td width="3%" valign="bottom" style=
"padding:0in 0in 0in 0in;width:3.74%;">
<p align="center" style=
"margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face=
"Times New Roman" style=
"font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>
</td>
<td width="18%" colspan="2" valign="bottom" style=
"border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:18.0%;">
<p align="center" style=
"margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face=
"Times New Roman" style=
"font-size:8.0pt;font-weight:bold;">Weighted&nbsp;Average<br />
Exercise&nbsp;Price</font></b></p>
</td>
<td width="3%" valign="bottom" style=
"padding:0in 0in 0in 0in;width:3.74%;">
<p align="center" style=
"margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face=
"Times New Roman" style=
"font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>
</td>
<td width="16%" colspan="2" valign="bottom" style=
"border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:16.0%;">
<p align="center" style=
"margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face=
"Times New Roman" style=
"font-size:8.0pt;font-weight:bold;">Intrinsic&nbsp;Value<br />
(in&nbsp;thousands)</font></b></p>
</td>
<td width="1%" valign="bottom" style=
"padding:0in 0in 0in 0in;width:1.46%;">
<p align="center" style=
"margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face=
"Times New Roman" style=
"font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>
</td>
</tr>
<tr>
<td width="36%" valign="top" bgcolor="#CCEEFF" style=
"background:#CCEEFF;padding:0in 0in 0in 0in;width:36.32%;">
<p style="margin:0in 0in .0001pt 10.1pt;text-indent:-10.1pt;">
<font size="2" face="Times New Roman" style=
"font-size:10.0pt;">Balance at December&nbsp;31, 2017</font></p>
</td>
<td width="3%" valign="bottom" bgcolor="#CCEEFF" style=
"background:#CCEEFF;padding:0in 0in 0in 0in;width:3.74%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>
</td>
<td width="17%" valign="bottom" bgcolor="#CCEEFF" style=
"background:#CCEEFF;border:none;border-bottom:double windowtext 2.25pt;padding:0in 0in 0in 0in;width:17.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;">
<font size="2" face="Times New Roman" style=
"font-size:10.0pt;">76,644</font></p>
</td>
<td width="3%" valign="bottom" bgcolor="#CCEEFF" style=
"background:#CCEEFF;padding:0in 0in 0in 0in;width:3.74%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>
</td>
<td width="1%" valign="bottom" bgcolor="#CCEEFF" style=
"background:#CCEEFF;padding:0in 0in 0in 0in;width:1.68%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">$</font></p>
</td>
<td width="16%" valign="bottom" bgcolor="#CCEEFF" style=
"background:#CCEEFF;padding:0in 0in 0in 0in;width:16.32%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;">
<font size="2" face="Times New Roman" style=
"font-size:10.0pt;">291.72</font></p>
</td>
<td width="3%" valign="bottom" bgcolor="#CCEEFF" style=
"background:#CCEEFF;padding:0in 0in 0in 0in;width:3.74%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>
</td>
<td width="1%" valign="bottom" bgcolor="#CCEEFF" style=
"background:#CCEEFF;padding:0in 0in 0in 0in;width:1.68%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">$</font></p>
</td>
<td width="14%" valign="bottom" bgcolor="#CCEEFF" style=
"background:#CCEEFF;padding:0in 0in 0in 0in;width:14.32%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;">
<font size="2" face="Times New Roman" style="font-size:10.0pt;">—
</font></p>
</td>
<td width="1%" valign="bottom" bgcolor="#CCEEFF" style=
"background:#CCEEFF;padding:0in 0in 0in 0in;width:1.46%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>
</td>
</tr>
<tr>
<td width="36%" valign="top" style=
"padding:0in 0in 0in 0in;width:36.32%;">
<p style="margin:0in 0in .0001pt 20.0pt;text-indent:-10.0pt;">
<font size="2" face="Times New Roman" style=
"font-size:10.0pt;">Options granted</font></p>
</td>
<td width="3%" valign="bottom" style=
"padding:0in 0in 0in 0in;width:3.74%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>
</td>
<td width="17%" valign="bottom" style=
"padding:0in 0in 0in 0in;width:17.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;">
<font size="2" face="Times New Roman" style="font-size:10.0pt;">—
</font></p>
</td>
<td width="3%" valign="bottom" style=
"padding:0in 0in 0in 0in;width:3.74%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>
</td>
<td width="1%" valign="bottom" style=
"padding:0in 0in 0in 0in;width:1.68%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">$</font></p>
</td>
<td width="16%" valign="bottom" style=
"padding:0in 0in 0in 0in;width:16.32%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;">
<font size="2" face="Times New Roman" style="font-size:10.0pt;">—
</font></p>
</td>
<td width="3%" valign="bottom" style=
"padding:0in 0in 0in 0in;width:3.74%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>
</td>
<td width="16%" colspan="2" valign="bottom" style=
"padding:0in 0in 0in 0in;width:16.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;">
<font size="2" face="Times New Roman" style=
"font-size:1.0pt;">&nbsp;</font></p>
</td>
<td width="1%" valign="bottom" style=
"padding:0in 0in 0in 0in;width:1.46%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>
</td>
</tr>
<tr>
<td width="36%" valign="top" bgcolor="#CCEEFF" style=
"background:#CCEEFF;padding:0in 0in 0in 0in;width:36.32%;">
<p style="margin:0in 0in .0001pt 20.0pt;text-indent:-10.0pt;">
<font size="2" face="Times New Roman" style=
"font-size:10.0pt;">Options exercised</font></p>
</td>
<td width="3%" valign="bottom" bgcolor="#CCEEFF" style=
"background:#CCEEFF;padding:0in 0in 0in 0in;width:3.74%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>
</td>
<td width="17%" valign="bottom" bgcolor="#CCEEFF" style=
"background:#CCEEFF;padding:0in 0in 0in 0in;width:17.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;">
<font size="2" face="Times New Roman" style="font-size:10.0pt;">—
</font></p>
</td>
<td width="3%" valign="bottom" bgcolor="#CCEEFF" style=
"background:#CCEEFF;padding:0in 0in 0in 0in;width:3.74%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>
</td>
<td width="1%" valign="bottom" bgcolor="#CCEEFF" style=
"background:#CCEEFF;padding:0in 0in 0in 0in;width:1.68%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">$</font></p>
</td>
<td width="16%" valign="bottom" bgcolor="#CCEEFF" style=
"background:#CCEEFF;padding:0in 0in 0in 0in;width:16.32%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;">
<font size="2" face="Times New Roman" style="font-size:10.0pt;">—
</font></p>
</td>
<td width="3%" valign="bottom" bgcolor="#CCEEFF" style=
"background:#CCEEFF;padding:0in 0in 0in 0in;width:3.74%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>
</td>
<td width="16%" colspan="2" valign="bottom" bgcolor="#CCEEFF"
style="background:#CCEEFF;padding:0in 0in 0in 0in;width:16.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;">
<font size="2" face="Times New Roman" style=
"font-size:1.0pt;">&nbsp;</font></p>
</td>
<td width="1%" valign="bottom" bgcolor="#CCEEFF" style=
"background:#CCEEFF;padding:0in 0in 0in 0in;width:1.46%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>
</td>
</tr>
<tr>
<td width="36%" valign="top" style=
"padding:0in 0in 0in 0in;width:36.32%;">
<p style="margin:0in 0in .0001pt 20.0pt;text-indent:-10.0pt;">
<font size="2" face="Times New Roman" style=
"font-size:10.0pt;">Options cancelled</font></p>
</td>
<td width="3%" valign="bottom" style=
"padding:0in 0in 0in 0in;width:3.74%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>
</td>
<td width="17%" valign="bottom" style=
"border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:17.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;">
<font size="2" face="Times New Roman" style=
"font-size:10.0pt;">(20,782</font></p>
</td>
<td width="3%" valign="bottom" style=
"padding:0in 0in 0.375pt 0in;width:3.74%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">)</font></p>
</td>
<td width="1%" valign="bottom" style=
"padding:0in 0in 0in 0in;width:1.68%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">$</font></p>
</td>
<td width="16%" valign="bottom" style=
"padding:0in 0in 0in 0in;width:16.32%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;">
<font size="2" face="Times New Roman" style=
"font-size:10.0pt;">252.85</font></p>
</td>
<td width="3%" valign="bottom" style=
"padding:0in 0in 0in 0in;width:3.74%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>
</td>
<td width="16%" colspan="2" valign="bottom" style=
"padding:0in 0in 0in 0in;width:16.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;">
<font size="2" face="Times New Roman" style=
"font-size:1.0pt;">&nbsp;</font></p>
</td>
<td width="1%" valign="bottom" style=
"padding:0in 0in 0in 0in;width:1.46%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>
</td>
</tr>
<tr>
<td width="36%" valign="top" bgcolor="#CCEEFF" style=
"background:#CCEEFF;padding:0in 0in 0in 0in;width:36.32%;">
<p style="margin:0in 0in .0001pt 10.1pt;text-indent:-10.1pt;">
<font size="2" face="Times New Roman" style=
"font-size:10.0pt;">Balance at March&nbsp;31, 2018</font></p>
</td>
<td width="3%" valign="bottom" bgcolor="#CCEEFF" style=
"background:#CCEEFF;padding:0in 0in 0in 0in;width:3.74%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>
</td>
<td width="17%" valign="bottom" bgcolor="#CCEEFF" style=
"background:#CCEEFF;border:none;border-bottom:double windowtext 2.25pt;padding:0in 0in 0in 0in;width:17.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;">
<font size="2" face="Times New Roman" style=
"font-size:10.0pt;">55,862</font></p>
</td>
<td width="3%" valign="bottom" bgcolor="#CCEEFF" style=
"background:#CCEEFF;padding:0in 0in 0in 0in;width:3.74%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>
</td>
<td width="1%" valign="bottom" bgcolor="#CCEEFF" style=
"background:#CCEEFF;padding:0in 0in 0in 0in;width:1.68%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">$</font></p>
</td>
<td width="16%" valign="bottom" bgcolor="#CCEEFF" style=
"background:#CCEEFF;padding:0in 0in 0in 0in;width:16.32%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;">
<font size="2" face="Times New Roman" style=
"font-size:10.0pt;">306.18</font></p>
</td>
<td width="3%" valign="bottom" bgcolor="#CCEEFF" style=
"background:#CCEEFF;padding:0in 0in 0in 0in;width:3.74%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>
</td>
<td width="1%" valign="bottom" bgcolor="#CCEEFF" style=
"background:#CCEEFF;padding:0in 0in 0in 0in;width:1.68%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">$</font></p>
</td>
<td width="14%" valign="bottom" bgcolor="#CCEEFF" style=
"background:#CCEEFF;padding:0in 0in 0in 0in;width:14.3%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;">
<font size="2" face="Times New Roman" style="font-size:10.0pt;">—
</font></p>
</td>
<td width="1%" valign="bottom" bgcolor="#CCEEFF" style=
"background:#CCEEFF;padding:0in 0in 0in 0in;width:1.46%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>
</td>
</tr>
</table>
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style=
"font-size:10.0pt;margin:0in 0in .0001pt;text-indent:.5in;">
<font size="2" face="Times New Roman" style="font-size:10.0pt;">As
of March&nbsp;31, 2018, the aggregate intrinsic value of options
outstanding and vested was zero. There were no options granted or
exercised during the</font> three months ended March&nbsp;31, 2018.
The aggregate intrinsic value was calculated as the difference
between the exercise prices of the underlying options and the
closing market price of the common stock on the date of exercise.
Because of the Company’s net operating losses, the Company did not
realize any tax benefits from share-based payment arrangements for
the three months ended March&nbsp;31, 2018 and 2017.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style=
"font-size:10.0pt;margin:0in 0in .0001pt;text-align:center;">
18<a name="PB_18_120046_3020" id="PB_18_120046_3020"></a></p>
<div style="margin:0in 0in .0001pt;">
<hr size="3" width="100%" noshade="noshade" align="left" style=
"color:#010101;" /></div>
</div>
<!-- SEQ.=1,FOLIO='18',FILE='C:\JMS\109754\18-8644-1\task8901843\8644-1-fp.htm',USER='109754',CD='May 16 01:09 2018' --><br clear="all"
style="page-break-before:always;" />
<div style="font-family:Times New Roman;">
<p style="margin:0in 0in .0001pt;"><a href="#TableOfContents"
title="Click to go to Table of Contents"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">Table of
Contents</font></a></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2"
face="Times New Roman" style="font-size:10.0pt;">The Company’s RSUs
vest annually over four years in equal increments. A summary of all
RSU activity is presented below:</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<table border="0" cellspacing="0" cellpadding="0" width="80%"
style="border-collapse:collapse;margin-left:.75in;">
<tr>
<td width="31%" valign="bottom" style=
"padding:0in 0in 0in 0in;width:31.72%;">
<p style="margin:0in 0in .0001pt;"><b><font size="1" face=
"Times New Roman" style=
"font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>
</td>
<td width="1%" valign="bottom" style=
"padding:0in 0in 0in 0in;width:1.5%;">
<p align="center" style=
"margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face=
"Times New Roman" style=
"font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>
</td>
<td width="13%" valign="bottom" style=
"padding:0in 0in 0in 0in;width:13.0%;">
<p align="center" style=
"margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face=
"Times New Roman" style=
"font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>
</td>
<td width="2%" valign="bottom" style=
"padding:0in 0in 0in 0in;width:2.0%;">
<p align="center" style=
"margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face=
"Times New Roman" style=
"font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>
</td>
<td width="16%" colspan="2" valign="bottom" style=
"padding:0in 0in 0in 0in;width:16.26%;">
<p align="center" style=
"margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face=
"Times New Roman" style=
"font-size:8.0pt;font-weight:bold;">Weighted&nbsp;Average</font></b></p>
</td>
<td width="2%" valign="bottom" style=
"padding:0in 0in 0in 0in;width:2.0%;">
<p align="center" style=
"margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face=
"Times New Roman" style=
"font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>
</td>
<td width="16%" valign="bottom" style=
"padding:0in 0in 0in 0in;width:16.26%;">
<p align="center" style=
"margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face=
"Times New Roman" style=
"font-size:8.0pt;font-weight:bold;">Weighted&nbsp;Average</font></b></p>
</td>
<td width="2%" valign="bottom" style=
"padding:0in 0in 0in 0in;width:2.0%;">
<p align="center" style=
"margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face=
"Times New Roman" style=
"font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>
</td>
<td width="14%" colspan="2" valign="bottom" style=
"padding:0in 0in 0in 0in;width:14.0%;">
<p align="center" style=
"margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face=
"Times New Roman" style=
"font-size:8.0pt;font-weight:bold;">Aggregate</font></b></p>
</td>
<td width="1%" valign="bottom" style=
"padding:0in 0in 0in 0in;width:1.24%;">
<p align="center" style=
"margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face=
"Times New Roman" style=
"font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>
</td>
</tr>
<tr>
<td width="31%" valign="bottom" style=
"padding:0in 0in 0in 0in;width:31.72%;">
<p style="margin:0in 0in .0001pt;"><b><font size="1" face=
"Times New Roman" style=
"font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>
</td>
<td width="1%" valign="bottom" style=
"padding:0in 0in 0in 0in;width:1.5%;">
<p align="center" style=
"margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face=
"Times New Roman" style=
"font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>
</td>
<td width="13%" valign="bottom" style=
"padding:0in 0in 0in 0in;width:13.0%;">
<p align="center" style=
"margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face=
"Times New Roman" style=
"font-size:8.0pt;font-weight:bold;">Number&nbsp;of</font></b></p>
</td>
<td width="2%" valign="bottom" style=
"padding:0in 0in 0in 0in;width:2.0%;">
<p align="center" style=
"margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face=
"Times New Roman" style=
"font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>
</td>
<td width="16%" colspan="2" valign="bottom" style=
"padding:0in 0in 0in 0in;width:16.26%;">
<p align="center" style=
"margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face=
"Times New Roman" style=
"font-size:8.0pt;font-weight:bold;">Grant&nbsp;Date</font></b></p>
</td>
<td width="2%" valign="bottom" style=
"padding:0in 0in 0in 0in;width:2.0%;">
<p align="center" style=
"margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face=
"Times New Roman" style=
"font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>
</td>
<td width="16%" valign="bottom" style=
"padding:0in 0in 0in 0in;width:16.26%;">
<p align="center" style=
"margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face=
"Times New Roman" style=
"font-size:8.0pt;font-weight:bold;">Remaining</font></b></p>
</td>
<td width="2%" valign="bottom" style=
"padding:0in 0in 0in 0in;width:2.0%;">
<p align="center" style=
"margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face=
"Times New Roman" style=
"font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>
</td>
<td width="14%" colspan="2" valign="bottom" style=
"padding:0in 0in 0in 0in;width:14.0%;">
<p align="center" style=
"margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face=
"Times New Roman" style=
"font-size:8.0pt;font-weight:bold;">Intrinsic&nbsp;Value</font></b></p>
</td>
<td width="1%" valign="bottom" style=
"padding:0in 0in 0in 0in;width:1.24%;">
<p align="center" style=
"margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face=
"Times New Roman" style=
"font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>
</td>
</tr>
<tr>
<td width="31%" valign="bottom" style=
"padding:0in 0in 0in 0in;width:31.72%;">
<p style="margin:0in 0in .0001pt;"><b><font size="1" face=
"Times New Roman" style=
"font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>
</td>
<td width="1%" valign="bottom" style=
"padding:0in 0in 0in 0in;width:1.5%;">
<p align="center" style=
"margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face=
"Times New Roman" style=
"font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>
</td>
<td width="13%" valign="bottom" style=
"border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:13.0%;">
<p align="center" style=
"margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face=
"Times New Roman" style=
"font-size:8.0pt;font-weight:bold;">Shares</font></b></p>
</td>
<td width="2%" valign="bottom" style=
"padding:0in 0in 0in 0in;width:2.0%;">
<p align="center" style=
"margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face=
"Times New Roman" style=
"font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>
</td>
<td width="16%" colspan="2" valign="bottom" style=
"border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:16.26%;">
<p align="center" style=
"margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face=
"Times New Roman" style=
"font-size:8.0pt;font-weight:bold;">Fair&nbsp;Value</font></b></p>
</td>
<td width="2%" valign="bottom" style=
"padding:0in 0in 0in 0in;width:2.0%;">
<p align="center" style=
"margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face=
"Times New Roman" style=
"font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>
</td>
<td width="16%" valign="bottom" style=
"border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:16.26%;">
<p align="center" style=
"margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face=
"Times New Roman" style=
"font-size:8.0pt;font-weight:bold;">Contractual&nbsp;Term</font></b></p>
</td>
<td width="2%" valign="bottom" style=
"padding:0in 0in 0in 0in;width:2.0%;">
<p align="center" style=
"margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face=
"Times New Roman" style=
"font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>
</td>
<td width="14%" colspan="2" valign="bottom" style=
"border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:14.0%;">
<p align="center" style=
"margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face=
"Times New Roman" style=
"font-size:8.0pt;font-weight:bold;">(in&nbsp;thousands)</font></b></p>
</td>
<td width="1%" valign="bottom" style=
"padding:0in 0in 0in 0in;width:1.24%;">
<p align="center" style=
"margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face=
"Times New Roman" style=
"font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>
</td>
</tr>
<tr>
<td width="31%" valign="top" bgcolor="#CCEEFF" style=
"background:#CCEEFF;padding:0in 0in 0in 0in;width:31.72%;">
<p style="margin:0in 0in .0001pt 10.1pt;text-indent:-10.1pt;">
<font size="2" face="Times New Roman" style=
"font-size:10.0pt;">Awards outstanding at December&nbsp;31,
2017</font></p>
</td>
<td width="1%" valign="bottom" bgcolor="#CCEEFF" style=
"background:#CCEEFF;padding:0in 0in 0in 0in;width:1.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>
</td>
<td width="13%" valign="bottom" bgcolor="#CCEEFF" style=
"background:#CCEEFF;border:none;border-bottom:double windowtext 2.25pt;padding:0in 0in 0in 0in;width:13.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;">
<font size="2" face="Times New Roman" style=
"font-size:10.0pt;">5,089</font></p>
</td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style=
"background:#CCEEFF;padding:0in 0in 0in 0in;width:2.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>
</td>
<td width="1%" valign="bottom" bgcolor="#CCEEFF" style=
"background:#CCEEFF;padding:0in 0in 0in 0in;width:1.4%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">$</font></p>
</td>
<td width="14%" valign="bottom" bgcolor="#CCEEFF" style=
"background:#CCEEFF;padding:0in 0in 0in 0in;width:14.84%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;">
<font size="2" face="Times New Roman" style=
"font-size:10.0pt;">237.78</font></p>
</td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style=
"background:#CCEEFF;padding:0in 0in 0in 0in;width:2.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>
</td>
<td width="16%" valign="bottom" bgcolor="#CCEEFF" style=
"background:#CCEEFF;padding:0in 0in 0in 0in;width:16.26%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;">
<font size="2" face="Times New Roman" style=
"font-size:10.0pt;">2.87</font></p>
</td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style=
"background:#CCEEFF;padding:0in 0in 0in 0in;width:2.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>
</td>
<td width="1%" valign="bottom" bgcolor="#CCEEFF" style=
"background:#CCEEFF;padding:0in 0in 0in 0in;width:1.4%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">$</font></p>
</td>
<td width="12%" valign="bottom" bgcolor="#CCEEFF" style=
"background:#CCEEFF;padding:0in 0in 0in 0in;width:12.6%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;">
<font size="2" face="Times New Roman" style=
"font-size:10.0pt;">37</font></p>
</td>
<td width="1%" valign="bottom" bgcolor="#CCEEFF" style=
"background:#CCEEFF;padding:0in 0in 0in 0in;width:1.24%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>
</td>
</tr>
<tr>
<td width="31%" valign="top" style=
"padding:0in 0in 0in 0in;width:31.72%;">
<p style="margin:0in 0in .0001pt 20.0pt;text-indent:-10.0pt;">
<font size="2" face="Times New Roman" style=
"font-size:10.0pt;">Awarded</font></p>
</td>
<td width="1%" valign="bottom" style=
"padding:0in 0in 0in 0in;width:1.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>
</td>
<td width="13%" valign="bottom" style=
"padding:0in 0in 0in 0in;width:13.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;">
<font size="2" face="Times New Roman" style="font-size:10.0pt;">—
</font></p>
</td>
<td width="2%" valign="bottom" style=
"padding:0in 0in 0in 0in;width:2.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>
</td>
<td width="1%" valign="bottom" style=
"padding:0in 0in 0in 0in;width:1.4%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">$</font></p>
</td>
<td width="14%" valign="bottom" style=
"padding:0in 0in 0in 0in;width:14.86%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;">
<font size="2" face="Times New Roman" style="font-size:10.0pt;">—
</font></p>
</td>
<td width="2%" valign="bottom" style=
"padding:0in 0in 0in 0in;width:2.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>
</td>
<td width="16%" valign="bottom" style=
"padding:0in 0in 0in 0in;width:16.26%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;">
<font size="2" face="Times New Roman" style=
"font-size:1.0pt;">&nbsp;</font></p>
</td>
<td width="2%" valign="bottom" style=
"padding:0in 0in 0in 0in;width:2.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>
</td>
<td width="14%" colspan="2" valign="bottom" style=
"padding:0in 0in 0in 0in;width:14.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;">
<font size="2" face="Times New Roman" style=
"font-size:1.0pt;">&nbsp;</font></p>
</td>
<td width="1%" valign="bottom" style=
"padding:0in 0in 0in 0in;width:1.24%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>
</td>
</tr>
<tr>
<td width="31%" valign="top" bgcolor="#CCEEFF" style=
"background:#CCEEFF;padding:0in 0in 0in 0in;width:31.72%;">
<p style="margin:0in 0in .0001pt 20.0pt;text-indent:-10.0pt;">
<font size="2" face="Times New Roman" style=
"font-size:10.0pt;">Released</font></p>
</td>
<td width="1%" valign="bottom" bgcolor="#CCEEFF" style=
"background:#CCEEFF;padding:0in 0in 0in 0in;width:1.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>
</td>
<td width="13%" valign="bottom" bgcolor="#CCEEFF" style=
"background:#CCEEFF;padding:0in 0in 0in 0in;width:13.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;">
<font size="2" face="Times New Roman" style=
"font-size:10.0pt;">(1,166</font></p>
</td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style=
"background:#CCEEFF;padding:0in 0in 0in 0in;width:2.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">)</font></p>
</td>
<td width="1%" valign="bottom" bgcolor="#CCEEFF" style=
"background:#CCEEFF;padding:0in 0in 0in 0in;width:1.4%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">$</font></p>
</td>
<td width="14%" valign="bottom" bgcolor="#CCEEFF" style=
"background:#CCEEFF;padding:0in 0in 0in 0in;width:14.86%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;">
<font size="2" face="Times New Roman" style=
"font-size:10.0pt;">225.52</font></p>
</td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style=
"background:#CCEEFF;padding:0in 0in 0in 0in;width:2.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>
</td>
<td width="16%" valign="bottom" bgcolor="#CCEEFF" style=
"background:#CCEEFF;padding:0in 0in 0in 0in;width:16.26%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;">
<font size="2" face="Times New Roman" style=
"font-size:1.0pt;">&nbsp;</font></p>
</td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style=
"background:#CCEEFF;padding:0in 0in 0in 0in;width:2.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>
</td>
<td width="14%" colspan="2" valign="bottom" bgcolor="#CCEEFF"
style="background:#CCEEFF;padding:0in 0in 0in 0in;width:14.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;">
<font size="2" face="Times New Roman" style=
"font-size:1.0pt;">&nbsp;</font></p>
</td>
<td width="1%" valign="bottom" bgcolor="#CCEEFF" style=
"background:#CCEEFF;padding:0in 0in 0in 0in;width:1.24%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>
</td>
</tr>
<tr>
<td width="31%" valign="top" style=
"padding:0in 0in 0in 0in;width:31.72%;">
<p style="margin:0in 0in .0001pt 20.0pt;text-indent:-10.0pt;">
<font size="2" face="Times New Roman" style=
"font-size:10.0pt;">Forfeited</font></p>
</td>
<td width="1%" valign="bottom" style=
"padding:0in 0in 0in 0in;width:1.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>
</td>
<td width="13%" valign="bottom" style=
"border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:13.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;">
<font size="2" face="Times New Roman" style=
"font-size:10.0pt;">(466</font></p>
</td>
<td width="2%" valign="bottom" style=
"padding:0in 0in 0.375pt 0in;width:2.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">)</font></p>
</td>
<td width="1%" valign="bottom" style=
"padding:0in 0in 0in 0in;width:1.4%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">$</font></p>
</td>
<td width="14%" valign="bottom" style=
"padding:0in 0in 0in 0in;width:14.86%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;">
<font size="2" face="Times New Roman" style=
"font-size:10.0pt;">204.09</font></p>
</td>
<td width="2%" valign="bottom" style=
"padding:0in 0in 0in 0in;width:2.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>
</td>
<td width="16%" valign="bottom" style=
"padding:0in 0in 0in 0in;width:16.26%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;">
<font size="2" face="Times New Roman" style=
"font-size:1.0pt;">&nbsp;</font></p>
</td>
<td width="2%" valign="bottom" style=
"padding:0in 0in 0in 0in;width:2.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>
</td>
<td width="14%" colspan="2" valign="bottom" style=
"padding:0in 0in 0in 0in;width:14.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;">
<font size="2" face="Times New Roman" style=
"font-size:1.0pt;">&nbsp;</font></p>
</td>
<td width="1%" valign="bottom" style=
"padding:0in 0in 0in 0in;width:1.24%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>
</td>
</tr>
<tr>
<td width="31%" valign="top" bgcolor="#CCEEFF" style=
"background:#CCEEFF;padding:0in 0in 0in 0in;width:31.72%;">
<p style="margin:0in 0in .0001pt 10.1pt;text-indent:-10.1pt;">
<font size="2" face="Times New Roman" style=
"font-size:10.0pt;">Awards outstanding at March&nbsp;31,
2018</font></p>
</td>
<td width="1%" valign="bottom" bgcolor="#CCEEFF" style=
"background:#CCEEFF;padding:0in 0in 0in 0in;width:1.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>
</td>
<td width="13%" valign="bottom" bgcolor="#CCEEFF" style=
"background:#CCEEFF;border:none;border-bottom:double windowtext 2.25pt;padding:0in 0in 0in 0in;width:13.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;">
<font size="2" face="Times New Roman" style=
"font-size:10.0pt;">3,457</font></p>
</td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style=
"background:#CCEEFF;padding:0in 0in 0in 0in;width:2.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>
</td>
<td width="1%" valign="bottom" bgcolor="#CCEEFF" style=
"background:#CCEEFF;padding:0in 0in 0in 0in;width:1.4%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">$</font></p>
</td>
<td width="14%" valign="bottom" bgcolor="#CCEEFF" style=
"background:#CCEEFF;padding:0in 0in 0in 0in;width:14.86%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;">
<font size="2" face="Times New Roman" style=
"font-size:10.0pt;">246.45</font></p>
</td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style=
"background:#CCEEFF;padding:0in 0in 0in 0in;width:2.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>
</td>
<td width="16%" valign="bottom" bgcolor="#CCEEFF" style=
"background:#CCEEFF;padding:0in 0in 0in 0in;width:16.26%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;">
<font size="2" face="Times New Roman" style=
"font-size:10.0pt;">2.61</font></p>
</td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style=
"background:#CCEEFF;padding:0in 0in 0in 0in;width:2.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>
</td>
<td width="1%" valign="bottom" bgcolor="#CCEEFF" style=
"background:#CCEEFF;padding:0in 0in 0in 0in;width:1.4%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">$</font></p>
</td>
<td width="12%" valign="bottom" bgcolor="#CCEEFF" style=
"background:#CCEEFF;padding:0in 0in 0in 0in;width:12.6%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;">
<font size="2" face="Times New Roman" style=
"font-size:10.0pt;">5</font></p>
</td>
<td width="1%" valign="bottom" bgcolor="#CCEEFF" style=
"background:#CCEEFF;padding:0in 0in 0in 0in;width:1.24%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>
</td>
</tr>
</table>
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2"
face="Times New Roman" style="font-size:10.0pt;">As of
March&nbsp;31, 2018, $787,000 of total unrecognized compensation
expense related to employee RSUs was expected to be recognized over
a weighted-average period of 2.6 years. The Company used the
closing market price of $1.33 per share at March&nbsp;31, 2018, to
determine the aggregate intrinsic value.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><b><font size="2" face=
"Times New Roman" style="font-size:10.0pt;font-weight:bold;">2015
Employee Stock Purchase Plan</font></b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style=
"font-size:10.0pt;margin:0in 0in .0001pt;text-indent:.5in;">
<font size="2" face="Times New Roman" style="font-size:10.0pt;">In
January&nbsp;2015, the Board of Directors adopted and the Company’s
stockholders approved the 2015 Employee Stock Purchase Plan (“ESPP”
) under which eligible employees are permitted to purchase common
stock at a discount through payroll deductions. Initially 12,500
shares of common stock were reserved for issuance, which is subject
to an automatic increase on the first day of each fiscal year,
commencing in 2016, by an amount equal to the lesser of
(i)&nbsp;12,325 shares (ii)&nbsp;1.5% of the outstanding shares of
common stock as of the last day of the immediately preceding fiscal
year; or (iii)&nbsp;an amount as determined by the Board of
Directors. For fiscal 2017, the common stock available for issuance
under the ESPP was increased by 8,916 shares of common stock. The
price of the common stock purchased will be the lower of 85% of the
fair market value of the common stock at the beginning of an
offering period or at the end of a purchase period. The ESPP is
intended to qualify as an “employee stock purchase plan” within the
meaning of Section&nbsp;423 of the Internal Revenue Code of 1986,
as amended. The first offering under the ESPP began in
February&nbsp;2015. As of March&nbsp;31, 2018, approximately 27,515
shares of common stock remained reserved for issuance under the
ESPP. The Company incurred $1,000 and $64,000 in stock-based
compensation expense related to the ESPP for the three months ended
March&nbsp;31, 2018 and 2017</font>, respectively.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><b><font size="2" face=
"Times New Roman" style="font-size:10.0pt;font-weight:bold;">9.
Stock-Based Compensation</font></b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style=
"font-size:10.0pt;margin:0in 0in .0001pt;text-indent:.5in;">
<font size="2" face="Times New Roman" style=
"font-size:10.0pt;">Stock-based compensation for the Company
includes amortization related to all stock options, RSUs and shares
issued under the ESPP, based on the grant-date estimated fair
value.</font> The Company estimates the fair value of stock options
and shares issued under the ESPP on the date of grant using the
Black-Scholes option-pricing model. The Black-Scholes model
determines the fair value of stock-based payment awards based on
the fair market value of the Company’s common stock on the date of
grant and is affected by assumptions regarding a number of complex
and subjective variables. These variables include, but are not
limited to, the fair value of the Company’s common stock, and the
volatility over the expected term of the awards.&nbsp; The Company
has opted to use the “simplified method” for estimating the
expected term of options, whereby the expected term equals the
arithmetic average of the vesting term and the original contractual
term of the option. Prior to the Company’s IPO in
January&nbsp;2015, due to the Company’s limited operating history
and a lack of company specific historical and implied volatility
data, the Company based its estimate of expected volatility on the
historical volatility of a group of similar companies that are
publicly traded. When selecting these public companies on which it
has based its expected stock price volatility, the Company selected
companies with comparable characteristics to it, including
enterprise value, stage of development, risk profile, and position
within the industry as well as selecting companies with historical
share price information sufficient to meet the expected life of the
stock-based awards. The historical volatility data was computed
using the daily closing prices for the selected companies’ shares
during the equivalent period of the calculated expected term of the
share-based payments. Following the closing of the Company’s IPO,
the Company supplements its own available company specific
historical volatility with the volatility of the previously
selected peer group of publicly traded companies. The Company will
continue to analyze the historical stock price volatility and
expected term assumptions as more historical data for the Company’s
common stock becomes available. The risk-free rate assumption is
based on the U.S. Treasury instruments with maturities similar to
the expected term of the Company’s stock options. The expected
dividend assumption is based on the Company’s history of not paying
dividends and its expectation that it will not declare dividends
for the foreseeable future.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style=
"font-size:10.0pt;margin:0in 0in .0001pt;text-indent:.5in;">
<font size="2" face="Times New Roman" style="font-size:10.0pt;">As
noncash stock-based compensation expense recognized in the
financial statements is based on awards ultimately expected to
vest, it has been reduced for estimated forfeitures. During the
year ended December&nbsp;31, 2016,</font> the Company estimated a
forfeiture rate for its stock options and RSUs based on an analysis
of its actual forfeitures based on actual forfeiture experience and
other factors. Forfeitures are estimated at the time of grant and
revised, if necessary, over the service period to the extent that
actual forfeitures differ, or are expected to differ, from prior
estimates. Forfeitures are estimated based on estimated future
employee turnover and</p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2"
face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style=
"font-size:10.0pt;margin:0in 0in .0001pt;text-align:center;">
19<a name="PB_19_120628_7748" id="PB_19_120628_7748"></a></p>
<div style="margin:0in 0in .0001pt;">
<hr size="3" width="100%" noshade="noshade" align="left" style=
"color:#010101;" /></div>
</div>
<!-- SEQ.=1,FOLIO='19',FILE='C:\JMS\109754\18-8644-1\task8901843\8644-1-fp.htm',USER='109754',CD='May 16 01:09 2018' --><br clear="all"
style="page-break-before:always;" />
<div style="font-family:Times New Roman;">
<p style="margin:0in 0in .0001pt;"><a href="#TableOfContents"
title="Click to go to Table of Contents"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">Table of
Contents</font></a></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2"
face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">historical experience.
Effective January&nbsp;1, 2017, the Company adopted ASU 2016-09 and
elected to recognize forfeitures when they occur using a modified
retrospective approach.&nbsp; The fair value for the Company’s
employee stock options was estimated at the date of grant using the
Black-Scholes valuation model with the following average
assumptions:</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<table border="0" cellspacing="0" cellpadding="0" width="46%"
style="border-collapse:collapse;margin-left:2.0in;">
<tr>
<td width="67%" valign="bottom" style=
"padding:0in 0in 0in 0in;width:67.42%;">
<p style="margin:0in 0in .0001pt;"><b><font size="1" face=
"Times New Roman" style=
"font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>
</td>
<td width="2%" valign="bottom" style=
"padding:0in 0in 0in 0in;width:2.78%;">
<p align="center" style=
"margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face=
"Times New Roman" style=
"font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>
</td>
<td width="25%" valign="bottom" style=
"padding:0in 0in 0in 0in;width:25.72%;">
<p align="center" style=
"margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face=
"Times New Roman" style=
"font-size:8.0pt;font-weight:bold;">Three&nbsp;Months<br />
Ended&nbsp;March&nbsp;31,</font></b></p>
</td>
<td width="4%" valign="bottom" style=
"padding:0in 0in 0in 0in;width:4.08%;">
<p align="center" style=
"margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face=
"Times New Roman" style=
"font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>
</td>
</tr>
<tr>
<td width="67%" valign="bottom" style=
"padding:0in 0in 0in 0in;width:67.42%;">
<p style="margin:0in 0in .0001pt;"><b><font size="1" face=
"Times New Roman" style=
"font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>
</td>
<td width="2%" valign="bottom" style=
"padding:0in 0in 0in 0in;width:2.78%;">
<p align="center" style=
"margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face=
"Times New Roman" style=
"font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>
</td>
<td width="25%" valign="bottom" style=
"border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:25.72%;">
<p align="center" style=
"margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face=
"Times New Roman" style=
"font-size:8.0pt;font-weight:bold;">2017</font></b></p>
</td>
<td width="4%" valign="bottom" style=
"padding:0in 0in 0in 0in;width:4.08%;">
<p align="center" style=
"margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face=
"Times New Roman" style=
"font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>
</td>
</tr>
<tr>
<td width="67%" valign="top" bgcolor="#CCEEFF" style=
"background:#CCEEFF;padding:0in 0in 0in 0in;width:67.42%;">
<p style="margin:0in 0in .0001pt 10.1pt;text-indent:-10.1pt;">
<font size="2" face="Times New Roman" style=
"font-size:10.0pt;">Expected term (years)</font></p>
</td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style=
"background:#CCEEFF;padding:0in 0in 0in 0in;width:2.78%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>
</td>
<td width="25%" valign="bottom" bgcolor="#CCEEFF" style=
"background:#CCEEFF;padding:0in 0in 0in 0in;width:25.72%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;">
<font size="2" face="Times New Roman" style=
"font-size:10.0pt;">5.9</font></p>
</td>
<td width="4%" valign="bottom" bgcolor="#CCEEFF" style=
"background:#CCEEFF;padding:0in 0in 0in 0in;width:4.08%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>
</td>
</tr>
<tr>
<td width="67%" valign="top" style=
"padding:0in 0in 0in 0in;width:67.42%;">
<p style="margin:0in 0in .0001pt 10.1pt;text-indent:-10.1pt;">
<font size="2" face="Times New Roman" style=
"font-size:10.0pt;">Expected volatility</font></p>
</td>
<td width="2%" valign="bottom" style=
"padding:0in 0in 0in 0in;width:2.78%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>
</td>
<td width="25%" valign="bottom" style=
"padding:0in 0in 0in 0in;width:25.72%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;">
<font size="2" face="Times New Roman" style=
"font-size:10.0pt;">56.5</font></p>
</td>
<td width="4%" valign="bottom" style=
"padding:0in 0in 0in 0in;width:4.08%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">%</font></p>
</td>
</tr>
<tr>
<td width="67%" valign="top" bgcolor="#CCEEFF" style=
"background:#CCEEFF;padding:0in 0in 0in 0in;width:67.42%;">
<p style="margin:0in 0in .0001pt 10.1pt;text-indent:-10.1pt;">
<font size="2" face="Times New Roman" style=
"font-size:10.0pt;">Risk-free interest rate</font></p>
</td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style=
"background:#CCEEFF;padding:0in 0in 0in 0in;width:2.78%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>
</td>
<td width="25%" valign="bottom" bgcolor="#CCEEFF" style=
"background:#CCEEFF;padding:0in 0in 0in 0in;width:25.72%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;">
<font size="2" face="Times New Roman" style=
"font-size:10.0pt;">2.2</font></p>
</td>
<td width="4%" valign="bottom" bgcolor="#CCEEFF" style=
"background:#CCEEFF;padding:0in 0in 0in 0in;width:4.08%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">%</font></p>
</td>
</tr>
<tr>
<td width="67%" valign="top" style=
"padding:0in 0in 0in 0in;width:67.42%;">
<p style="margin:0in 0in .0001pt 10.1pt;text-indent:-10.1pt;">
<font size="2" face="Times New Roman" style=
"font-size:10.0pt;">Dividend rate</font></p>
</td>
<td width="2%" valign="bottom" style=
"padding:0in 0in 0in 0in;width:2.78%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>
</td>
<td width="25%" valign="bottom" style=
"padding:0in 0in 0in 0in;width:25.72%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;">
<font size="2" face="Times New Roman" style="font-size:10.0pt;">—
</font></p>
</td>
<td width="4%" valign="bottom" style=
"padding:0in 0in 0in 0in;width:4.08%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>
</td>
</tr>
</table>
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2"
face="Times New Roman" style="font-size:10.0pt;">As of
March&nbsp;31, 2018 and December&nbsp;31, 2017, the total
unamortized compensation expense related to stock option awards
granted to employees and directors was $2,138,000 and $2,979,000,
which is expected to be amortized over the next 1.24 and 1.45
years, respectively.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style=
"font-size:10.0pt;margin:0in 0in .0001pt;text-align:center;">
20<a name="PB_20_120844_141" id="PB_20_120844_141"></a></p>
<div style="margin:0in 0in .0001pt;">
<hr size="3" width="100%" noshade="noshade" align="left" style=
"color:#010101;" /></div>
</div>
<!-- SEQ.=1,FOLIO='20',FILE='C:\JMS\109754\18-8644-1\task8901843\8644-1-fp.htm',USER='109754',CD='May 16 01:09 2018' --><br clear="all"
style="page-break-before:always;" />
<div style="font-family:Times New Roman;">
<p style="margin:0in 0in .0001pt;"><a href="#TableOfContents"
title="Click to go to Table of Contents"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">Table of
Contents</font></a></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2"
face="Times New Roman" style="font-size:10.0pt;">The fair value of
the shares to be issued under the Company’s ESPP was estimated
using the Black-Scholes valuation model with the following
assumptions:</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<table border="0" cellspacing="0" cellpadding="0" width="46%"
style="border-collapse:collapse;margin-left:2.0in;">
<tr>
<td width="66%" valign="bottom" style=
"padding:0in 0in 0in 0in;width:66.78%;">
<p style="margin:0in 0in .0001pt;"><b><font size="1" face=
"Times New Roman" style=
"font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>
</td>
<td width="2%" valign="bottom" style=
"padding:0in 0in 0in 0in;width:2.5%;">
<p align="center" style=
"margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face=
"Times New Roman" style=
"font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>
</td>
<td width="26%" valign="bottom" style=
"padding:0in 0in 0in 0in;width:26.6%;">
<p align="center" style=
"margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face=
"Times New Roman" style=
"font-size:8.0pt;font-weight:bold;">Three&nbsp;Months<br />
Ended&nbsp;March&nbsp;31,</font></b></p>
</td>
<td width="4%" valign="bottom" style=
"padding:0in 0in 0in 0in;width:4.1%;">
<p align="center" style=
"margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face=
"Times New Roman" style=
"font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>
</td>
</tr>
<tr>
<td width="66%" valign="bottom" style=
"padding:0in 0in 0in 0in;width:66.78%;">
<p style="margin:0in 0in .0001pt;"><b><font size="1" face=
"Times New Roman" style=
"font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>
</td>
<td width="2%" valign="bottom" style=
"padding:0in 0in 0in 0in;width:2.5%;">
<p align="center" style=
"margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face=
"Times New Roman" style=
"font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>
</td>
<td width="26%" valign="bottom" style=
"border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:26.6%;">
<p align="center" style=
"margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face=
"Times New Roman" style=
"font-size:8.0pt;font-weight:bold;">2017</font></b></p>
</td>
<td width="4%" valign="bottom" style=
"padding:0in 0in 0in 0in;width:4.1%;">
<p align="center" style=
"margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face=
"Times New Roman" style=
"font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>
</td>
</tr>
<tr>
<td width="66%" valign="top" bgcolor="#CCEEFF" style=
"background:#CCEEFF;padding:0in 0in 0in 0in;width:66.78%;">
<p style="margin:0in 0in .0001pt 10.1pt;text-indent:-10.1pt;">
<font size="2" face="Times New Roman" style=
"font-size:10.0pt;">Expected term (years)</font></p>
</td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style=
"background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>
</td>
<td width="26%" valign="bottom" bgcolor="#CCEEFF" style=
"background:#CCEEFF;padding:0in 0in 0in 0in;width:26.6%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;">
<font size="2" face="Times New Roman" style=
"font-size:10.0pt;">0.5</font></p>
</td>
<td width="4%" valign="bottom" bgcolor="#CCEEFF" style=
"background:#CCEEFF;padding:0in 0in 0in 0in;width:4.1%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>
</td>
</tr>
<tr>
<td width="66%" valign="top" style=
"padding:0in 0in 0in 0in;width:66.78%;">
<p style="margin:0in 0in .0001pt 10.1pt;text-indent:-10.1pt;">
<font size="2" face="Times New Roman" style=
"font-size:10.0pt;">Expected volatility</font></p>
</td>
<td width="2%" valign="bottom" style=
"padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>
</td>
<td width="26%" valign="bottom" style=
"padding:0in 0in 0in 0in;width:26.6%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;">
<font size="2" face="Times New Roman" style=
"font-size:10.0pt;">89.2</font></p>
</td>
<td width="4%" valign="bottom" style=
"padding:0in 0in 0in 0in;width:4.1%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">%</font></p>
</td>
</tr>
<tr>
<td width="66%" valign="top" bgcolor="#CCEEFF" style=
"background:#CCEEFF;padding:0in 0in 0in 0in;width:66.78%;">
<p style="margin:0in 0in .0001pt 10.1pt;text-indent:-10.1pt;">
<font size="2" face="Times New Roman" style=
"font-size:10.0pt;">Risk-free interest rate</font></p>
</td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style=
"background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>
</td>
<td width="26%" valign="bottom" bgcolor="#CCEEFF" style=
"background:#CCEEFF;padding:0in 0in 0in 0in;width:26.6%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;">
<font size="2" face="Times New Roman" style=
"font-size:10.0pt;">0.63</font></p>
</td>
<td width="4%" valign="bottom" bgcolor="#CCEEFF" style=
"background:#CCEEFF;padding:0in 0in 0in 0in;width:4.1%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">%</font></p>
</td>
</tr>
<tr>
<td width="66%" valign="top" style=
"padding:0in 0in 0in 0in;width:66.78%;">
<p style="margin:0in 0in .0001pt 10.1pt;text-indent:-10.1pt;">
<font size="2" face="Times New Roman" style=
"font-size:10.0pt;">Dividend rate</font></p>
</td>
<td width="2%" valign="bottom" style=
"padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>
</td>
<td width="26%" valign="bottom" style=
"padding:0in 0in 0in 0in;width:26.6%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;">
<font size="2" face="Times New Roman" style="font-size:10.0pt;">—
</font></p>
</td>
<td width="4%" valign="bottom" style=
"padding:0in 0in 0in 0in;width:4.1%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>
</td>
</tr>
</table>
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">The Company’s RSUs vest
annually over four years in equal increments. A summary of all RSU
activity for the three months ended March&nbsp;31, 2018 is
presented below:</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<table border="0" cellspacing="0" cellpadding="0" width="86%"
style="border-collapse:collapse;margin-left:.5in;">
<tr>
<td width="37%" valign="bottom" style=
"padding:0in 0in 0in 0in;width:37.9%;">
<p style="margin:0in 0in .0001pt;"><b><font size="1" face=
"Times New Roman" style=
"font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>
</td>
<td width="1%" valign="bottom" style=
"padding:0in 0in 0in 0in;width:1.38%;">
<p align="center" style=
"margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face=
"Times New Roman" style=
"font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>
</td>
<td width="11%" valign="bottom" style=
"padding:0in 0in 0in 0in;width:11.08%;">
<p align="center" style=
"margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face=
"Times New Roman" style=
"font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>
</td>
<td width="1%" valign="bottom" style=
"padding:0in 0in 0in 0in;width:1.84%;">
<p align="center" style=
"margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face=
"Times New Roman" style=
"font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>
</td>
<td width="15%" colspan="2" valign="bottom" style=
"padding:0in 0in 0in 0in;width:15.02%;">
<p align="center" style=
"margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face=
"Times New Roman" style=
"font-size:8.0pt;font-weight:bold;">Weighted&nbsp;Average</font></b></p>
</td>
<td width="1%" valign="bottom" style=
"padding:0in 0in 0in 0in;width:1.84%;">
<p align="center" style=
"margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face=
"Times New Roman" style=
"font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>
</td>
<td width="15%" valign="bottom" style=
"padding:0in 0in 0in 0in;width:15.02%;">
<p align="center" style=
"margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face=
"Times New Roman" style=
"font-size:8.0pt;font-weight:bold;">Weighted&nbsp;Average</font></b></p>
</td>
<td width="1%" valign="bottom" style=
"padding:0in 0in 0in 0in;width:1.84%;">
<p align="center" style=
"margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face=
"Times New Roman" style=
"font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>
</td>
<td width="12%" colspan="2" valign="bottom" style=
"padding:0in 0in 0in 0in;width:12.92%;">
<p align="center" style=
"margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face=
"Times New Roman" style=
"font-size:8.0pt;font-weight:bold;">Aggregate</font></b></p>
</td>
<td width="1%" valign="bottom" style=
"padding:0in 0in 0in 0in;width:1.14%;">
<p align="center" style=
"margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face=
"Times New Roman" style=
"font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>
</td>
</tr>
<tr>
<td width="37%" valign="bottom" style=
"padding:0in 0in 0in 0in;width:37.9%;">
<p style="margin:0in 0in .0001pt;"><b><font size="1" face=
"Times New Roman" style=
"font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>
</td>
<td width="1%" valign="bottom" style=
"padding:0in 0in 0in 0in;width:1.38%;">
<p align="center" style=
"margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face=
"Times New Roman" style=
"font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>
</td>
<td width="11%" valign="bottom" style=
"padding:0in 0in 0in 0in;width:11.08%;">
<p align="center" style=
"margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face=
"Times New Roman" style=
"font-size:8.0pt;font-weight:bold;">Number&nbsp;of</font></b></p>
</td>
<td width="1%" valign="bottom" style=
"padding:0in 0in 0in 0in;width:1.84%;">
<p align="center" style=
"margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face=
"Times New Roman" style=
"font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>
</td>
<td width="15%" colspan="2" valign="bottom" style=
"padding:0in 0in 0in 0in;width:15.02%;">
<p align="center" style=
"margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face=
"Times New Roman" style=
"font-size:8.0pt;font-weight:bold;">Grant&nbsp;Date</font></b></p>
</td>
<td width="1%" valign="bottom" style=
"padding:0in 0in 0in 0in;width:1.84%;">
<p align="center" style=
"margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face=
"Times New Roman" style=
"font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>
</td>
<td width="15%" valign="bottom" style=
"padding:0in 0in 0in 0in;width:15.02%;">
<p align="center" style=
"margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face=
"Times New Roman" style=
"font-size:8.0pt;font-weight:bold;">Remaining</font></b></p>
</td>
<td width="1%" valign="bottom" style=
"padding:0in 0in 0in 0in;width:1.84%;">
<p align="center" style=
"margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face=
"Times New Roman" style=
"font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>
</td>
<td width="12%" colspan="2" valign="bottom" style=
"padding:0in 0in 0in 0in;width:12.92%;">
<p align="center" style=
"margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face=
"Times New Roman" style=
"font-size:8.0pt;font-weight:bold;">Intrinsic&nbsp;Value</font></b></p>
</td>
<td width="1%" valign="bottom" style=
"padding:0in 0in 0in 0in;width:1.14%;">
<p align="center" style=
"margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face=
"Times New Roman" style=
"font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>
</td>
</tr>
<tr>
<td width="37%" valign="bottom" style=
"padding:0in 0in 0in 0in;width:37.9%;">
<p style="margin:0in 0in .0001pt;"><b><font size="1" face=
"Times New Roman" style=
"font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>
</td>
<td width="1%" valign="bottom" style=
"padding:0in 0in 0in 0in;width:1.38%;">
<p align="center" style=
"margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face=
"Times New Roman" style=
"font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>
</td>
<td width="11%" valign="bottom" style=
"border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:11.08%;">
<p align="center" style=
"margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face=
"Times New Roman" style=
"font-size:8.0pt;font-weight:bold;">Shares</font></b></p>
</td>
<td width="1%" valign="bottom" style=
"padding:0in 0in 0in 0in;width:1.84%;">
<p align="center" style=
"margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face=
"Times New Roman" style=
"font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>
</td>
<td width="15%" colspan="2" valign="bottom" style=
"border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:15.02%;">
<p align="center" style=
"margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face=
"Times New Roman" style=
"font-size:8.0pt;font-weight:bold;">Fair&nbsp;Value</font></b></p>
</td>
<td width="1%" valign="bottom" style=
"padding:0in 0in 0in 0in;width:1.84%;">
<p align="center" style=
"margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face=
"Times New Roman" style=
"font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>
</td>
<td width="15%" valign="bottom" style=
"border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:15.02%;">
<p align="center" style=
"margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face=
"Times New Roman" style=
"font-size:8.0pt;font-weight:bold;">Contractual&nbsp;Term</font></b></p>
</td>
<td width="1%" valign="bottom" style=
"padding:0in 0in 0in 0in;width:1.84%;">
<p align="center" style=
"margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face=
"Times New Roman" style=
"font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>
</td>
<td width="12%" colspan="2" valign="bottom" style=
"border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:12.92%;">
<p align="center" style=
"margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face=
"Times New Roman" style=
"font-size:8.0pt;font-weight:bold;">(in&nbsp;thousands)</font></b></p>
</td>
<td width="1%" valign="bottom" style=
"padding:0in 0in 0in 0in;width:1.14%;">
<p align="center" style=
"margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face=
"Times New Roman" style=
"font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>
</td>
</tr>
<tr>
<td width="37%" valign="top" bgcolor="#CCEEFF" style=
"background:#CCEEFF;padding:0in 0in 0in 0in;width:37.9%;">
<p style="margin:0in 0in .0001pt 10.1pt;text-indent:-10.1pt;">
<font size="2" face="Times New Roman" style=
"font-size:10.0pt;">Awards outstanding at December&nbsp;31,
2017</font></p>
</td>
<td width="1%" valign="bottom" bgcolor="#CCEEFF" style=
"background:#CCEEFF;padding:0in 0in 0in 0in;width:1.38%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>
</td>
<td width="11%" valign="bottom" bgcolor="#CCEEFF" style=
"background:#CCEEFF;padding:0in 0in 0in 0in;width:11.08%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;">
<font size="2" face="Times New Roman" style=
"font-size:10.0pt;">5,089</font></p>
</td>
<td width="1%" valign="bottom" bgcolor="#CCEEFF" style=
"background:#CCEEFF;padding:0in 0in 0in 0in;width:1.84%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>
</td>
<td width="1%" valign="bottom" bgcolor="#CCEEFF" style=
"background:#CCEEFF;padding:0in 0in 0in 0in;width:1.3%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">$</font></p>
</td>
<td width="13%" valign="bottom" bgcolor="#CCEEFF" style=
"background:#CCEEFF;padding:0in 0in 0in 0in;width:13.72%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;">
<font size="2" face="Times New Roman" style=
"font-size:10.0pt;">237.78</font></p>
</td>
<td width="1%" valign="bottom" bgcolor="#CCEEFF" style=
"background:#CCEEFF;padding:0in 0in 0in 0in;width:1.84%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>
</td>
<td width="15%" valign="bottom" bgcolor="#CCEEFF" style=
"background:#CCEEFF;padding:0in 0in 0in 0in;width:15.02%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;">
<font size="2" face="Times New Roman" style=
"font-size:10.0pt;">2.87</font></p>
</td>
<td width="1%" valign="bottom" bgcolor="#CCEEFF" style=
"background:#CCEEFF;padding:0in 0in 0in 0in;width:1.84%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>
</td>
<td width="1%" valign="bottom" bgcolor="#CCEEFF" style=
"background:#CCEEFF;padding:0in 0in 0in 0in;width:1.3%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">$</font></p>
</td>
<td width="11%" valign="bottom" bgcolor="#CCEEFF" style=
"background:#CCEEFF;padding:0in 0in 0in 0in;width:11.64%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;">
<font size="2" face="Times New Roman" style=
"font-size:10.0pt;">37</font></p>
</td>
<td width="1%" valign="bottom" bgcolor="#CCEEFF" style=
"background:#CCEEFF;padding:0in 0in 0in 0in;width:1.14%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>
</td>
</tr>
<tr>
<td width="37%" valign="top" style=
"padding:0in 0in 0in 0in;width:37.9%;">
<p style="margin:0in 0in .0001pt 20.0pt;text-indent:-10.0pt;">
<font size="2" face="Times New Roman" style=
"font-size:10.0pt;">Awarded</font></p>
</td>
<td width="1%" valign="bottom" style=
"padding:0in 0in 0in 0in;width:1.38%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>
</td>
<td width="11%" valign="bottom" style=
"padding:0in 0in 0in 0in;width:11.08%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;">
<font size="2" face="Times New Roman" style="font-size:10.0pt;">—
</font></p>
</td>
<td width="1%" valign="bottom" style=
"padding:0in 0in 0in 0in;width:1.84%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>
</td>
<td width="1%" valign="bottom" style=
"padding:0in 0in 0in 0in;width:1.3%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">$</font></p>
</td>
<td width="13%" valign="bottom" style=
"padding:0in 0in 0in 0in;width:13.72%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;">
<font size="2" face="Times New Roman" style="font-size:10.0pt;">—
</font></p>
</td>
<td width="1%" valign="bottom" style=
"padding:0in 0in 0in 0in;width:1.84%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>
</td>
<td width="15%" valign="bottom" style=
"padding:0in 0in 0in 0in;width:15.02%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;">
<font size="2" face="Times New Roman" style=
"font-size:1.0pt;">&nbsp;</font></p>
</td>
<td width="1%" valign="bottom" style=
"padding:0in 0in 0in 0in;width:1.84%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>
</td>
<td width="12%" colspan="2" valign="bottom" style=
"padding:0in 0in 0in 0in;width:12.92%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;">
<font size="2" face="Times New Roman" style=
"font-size:1.0pt;">&nbsp;</font></p>
</td>
<td width="1%" valign="bottom" style=
"padding:0in 0in 0in 0in;width:1.14%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>
</td>
</tr>
<tr>
<td width="37%" valign="top" bgcolor="#CCEEFF" style=
"background:#CCEEFF;padding:0in 0in 0in 0in;width:37.9%;">
<p style="margin:0in 0in .0001pt 20.0pt;text-indent:-10.0pt;">
<font size="2" face="Times New Roman" style=
"font-size:10.0pt;">Released</font></p>
</td>
<td width="1%" valign="bottom" bgcolor="#CCEEFF" style=
"background:#CCEEFF;padding:0in 0in 0in 0in;width:1.38%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>
</td>
<td width="11%" valign="bottom" bgcolor="#CCEEFF" style=
"background:#CCEEFF;padding:0in 0in 0in 0in;width:11.08%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;">
<font size="2" face="Times New Roman" style=
"font-size:10.0pt;">(1,166</font></p>
</td>
<td width="1%" valign="bottom" bgcolor="#CCEEFF" style=
"background:#CCEEFF;padding:0in 0in 0in 0in;width:1.84%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">)</font></p>
</td>
<td width="1%" valign="bottom" bgcolor="#CCEEFF" style=
"background:#CCEEFF;padding:0in 0in 0in 0in;width:1.3%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">$</font></p>
</td>
<td width="13%" valign="bottom" bgcolor="#CCEEFF" style=
"background:#CCEEFF;padding:0in 0in 0in 0in;width:13.72%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;">
<font size="2" face="Times New Roman" style=
"font-size:10.0pt;">225.52</font></p>
</td>
<td width="1%" valign="bottom" bgcolor="#CCEEFF" style=
"background:#CCEEFF;padding:0in 0in 0in 0in;width:1.84%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>
</td>
<td width="15%" valign="bottom" bgcolor="#CCEEFF" style=
"background:#CCEEFF;padding:0in 0in 0in 0in;width:15.02%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;">
<font size="2" face="Times New Roman" style=
"font-size:1.0pt;">&nbsp;</font></p>
</td>
<td width="1%" valign="bottom" bgcolor="#CCEEFF" style=
"background:#CCEEFF;padding:0in 0in 0in 0in;width:1.84%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>
</td>
<td width="12%" colspan="2" valign="bottom" bgcolor="#CCEEFF"
style="background:#CCEEFF;padding:0in 0in 0in 0in;width:12.92%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;">
<font size="2" face="Times New Roman" style=
"font-size:1.0pt;">&nbsp;</font></p>
</td>
<td width="1%" valign="bottom" bgcolor="#CCEEFF" style=
"background:#CCEEFF;padding:0in 0in 0in 0in;width:1.14%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>
</td>
</tr>
<tr>
<td width="37%" valign="top" style=
"padding:0in 0in 0in 0in;width:37.9%;">
<p style="margin:0in 0in .0001pt 20.0pt;text-indent:-10.0pt;">
<font size="2" face="Times New Roman" style=
"font-size:10.0pt;">Forfeited</font></p>
</td>
<td width="1%" valign="bottom" style=
"padding:0in 0in 0in 0in;width:1.38%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>
</td>
<td width="11%" valign="bottom" style=
"border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:11.08%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;">
<font size="2" face="Times New Roman" style=
"font-size:10.0pt;">(466</font></p>
</td>
<td width="1%" valign="bottom" style=
"padding:0in 0in 0.375pt 0in;width:1.84%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">)</font></p>
</td>
<td width="1%" valign="bottom" style=
"padding:0in 0in 0in 0in;width:1.3%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">$</font></p>
</td>
<td width="13%" valign="bottom" style=
"padding:0in 0in 0in 0in;width:13.72%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;">
<font size="2" face="Times New Roman" style=
"font-size:10.0pt;">204.09</font></p>
</td>
<td width="1%" valign="bottom" style=
"padding:0in 0in 0in 0in;width:1.84%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>
</td>
<td width="15%" valign="bottom" style=
"padding:0in 0in 0in 0in;width:15.02%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;">
<font size="2" face="Times New Roman" style=
"font-size:1.0pt;">&nbsp;</font></p>
</td>
<td width="1%" valign="bottom" style=
"padding:0in 0in 0in 0in;width:1.84%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>
</td>
<td width="12%" colspan="2" valign="bottom" style=
"padding:0in 0in 0in 0in;width:12.92%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;">
<font size="2" face="Times New Roman" style=
"font-size:1.0pt;">&nbsp;</font></p>
</td>
<td width="1%" valign="bottom" style=
"padding:0in 0in 0in 0in;width:1.14%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>
</td>
</tr>
<tr>
<td width="37%" valign="top" bgcolor="#CCEEFF" style=
"background:#CCEEFF;padding:0in 0in 0in 0in;width:37.9%;">
<p style="margin:0in 0in .0001pt 10.1pt;text-indent:-10.1pt;">
<font size="2" face="Times New Roman" style=
"font-size:10.0pt;">Awards outstanding at March&nbsp;31,
2018</font></p>
</td>
<td width="1%" valign="bottom" bgcolor="#CCEEFF" style=
"background:#CCEEFF;padding:0in 0in 0in 0in;width:1.38%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>
</td>
<td width="11%" valign="bottom" bgcolor="#CCEEFF" style=
"background:#CCEEFF;border:none;border-bottom:double windowtext 2.25pt;padding:0in 0in 0in 0in;width:11.08%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;">
<font size="2" face="Times New Roman" style=
"font-size:10.0pt;">3,457</font></p>
</td>
<td width="1%" valign="bottom" bgcolor="#CCEEFF" style=
"background:#CCEEFF;padding:0in 0in 0in 0in;width:1.84%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>
</td>
<td width="1%" valign="bottom" bgcolor="#CCEEFF" style=
"background:#CCEEFF;padding:0in 0in 0in 0in;width:1.3%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">$</font></p>
</td>
<td width="13%" valign="bottom" bgcolor="#CCEEFF" style=
"background:#CCEEFF;padding:0in 0in 0in 0in;width:13.72%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;">
<font size="2" face="Times New Roman" style=
"font-size:10.0pt;">246.45</font></p>
</td>
<td width="1%" valign="bottom" bgcolor="#CCEEFF" style=
"background:#CCEEFF;padding:0in 0in 0in 0in;width:1.84%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>
</td>
<td width="15%" valign="bottom" bgcolor="#CCEEFF" style=
"background:#CCEEFF;padding:0in 0in 0in 0in;width:15.02%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;">
<font size="2" face="Times New Roman" style=
"font-size:10.0pt;">2.61</font></p>
</td>
<td width="1%" valign="bottom" bgcolor="#CCEEFF" style=
"background:#CCEEFF;padding:0in 0in 0in 0in;width:1.84%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>
</td>
<td width="1%" valign="bottom" bgcolor="#CCEEFF" style=
"background:#CCEEFF;padding:0in 0in 0in 0in;width:1.3%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">$</font></p>
</td>
<td width="11%" valign="bottom" bgcolor="#CCEEFF" style=
"background:#CCEEFF;padding:0in 0in 0in 0in;width:11.64%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;">
<font size="2" face="Times New Roman" style=
"font-size:10.0pt;">5</font></p>
</td>
<td width="1%" valign="bottom" bgcolor="#CCEEFF" style=
"background:#CCEEFF;padding:0in 0in 0in 0in;width:1.14%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>
</td>
</tr>
</table>
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">As of March&nbsp;31,
2018, total unamortized stock-based compensation expense related to
unvested RSUs was $1,759,000, with a weighted-average remaining
recognition period of 2.24 years.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><b><font size="2" face=
"Times New Roman" style="font-size:10.0pt;font-weight:bold;">10.
Restructuring Charges and Expenses</font></b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style=
"font-size:10.0pt;margin:0in 0in .0001pt;text-indent:.5in;">
<font size="2" face="Times New Roman" style="font-size:10.0pt;">In
April&nbsp;2017, the Company</font> undertook an organizational
realignment which included a reduction in force, lowering its total
headcount by approximately 33% compared to December&nbsp;31, 2016,
in order to conserve resources. Accordingly, the Company recorded a
restructuring charge of approximately $519,000, relating to
severance related costs at that time. As of December&nbsp;31, 2017,
all of the severance costs related to the April&nbsp;2017
termination of 44 employees had been paid.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style=
"font-size:10.0pt;margin:0in 0in .0001pt;text-indent:.5in;">
<font size="2" face="Times New Roman" style="font-size:10.0pt;">In
September&nbsp;2017, the Company effected a cost reduction
plan,</font> which included a company-wide reduction in force,
lowering its total headcount by 24 employees. The Company recorded
a restructuring charge of approximately $416,000, relating to
severance costs at that time. In October&nbsp;2017, the Company
subleased one of its facilities and ceased to use the facility as
part of the cost reduction plan.&nbsp; The Company recorded a
restructuring charge of approximately $388,000 relating to the cost
to exit the facility.&nbsp; As of December&nbsp;31, 2017, all of
the severance costs related to the termination of 24 employees had
been paid. As of March&nbsp;31, 2018 and December&nbsp;31, 2017,
$160,000 and $98,000, respectively, of the total costs to exit the
facility was included within accrued expenses and other current
liabilities.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style=
"font-size:10.0pt;margin:0in 0in .0001pt;text-align:center;">
21<a name="PB_21_121414_7608" id="PB_21_121414_7608"></a></p>
<div style="margin:0in 0in .0001pt;">
<hr size="3" width="100%" noshade="noshade" align="left" style=
"color:#010101;" /></div>
</div>
<!-- SEQ.=1,FOLIO='21',FILE='C:\JMS\109754\18-8644-1\task8901843\8644-1-fp.htm',USER='109754',CD='May 16 01:09 2018' --><br clear="all"
style="page-break-before:always;" />
<div style="font-family:Times New Roman;">
<p style="margin:0in 0in .0001pt;"><a href="#TableOfContents"
title="Click to go to Table of Contents"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">Table of
Contents</font></a></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style=
"font-size:10.0pt;margin:0in 0in .0001pt 46.1pt;text-indent:-46.1pt;">
<b><font size="2" face="Times New Roman" style=
"font-size:10.0pt;font-weight:bold;">ITEM 2.</font></b><font size=
"1" style=
"font-size:3.0pt;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</font>
<b>MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND
RESULTS OF OPERATIONS</b><a name=
"ITEM2_MANAGEMENTSDISCUSSIONANDAN_113703" id=
"ITEM2_MANAGEMENTSDISCUSSIONANDAN_113703"></a></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:28.0pt;">
<i><font size="2" face="Times New Roman" style=
"font-size:10.0pt;font-style:italic;">You should read the following
discussion and analysis of our financial condition and results of
operations together with the unaudited financial statements and
related notes included elsewhere in this Quarterly Report on
Form&nbsp;10-Q. This discussion and other parts of this Quarterly
Report on Form&nbsp;10-Q contain forward-looking statements that
involve risks and uncertainties, such as statements of our plans,
objectives, expectations and intentions, that are based on the
beliefs of our management, as well as assumptions made by, and
information currently available to, our management. Our actual
results could differ materially from those discussed in these
forward-looking statements. Factors that could cause or contribute
to such differences include, but are not limited to, those
discussed in the section of this Quarterly Report on Form&nbsp;10-Q
entitled “Risk Factors.”</font></i></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt 10.0pt;text-indent:-10.0pt;">
<b><font size="2" face="Times New Roman" style=
"font-size:10.0pt;font-weight:bold;">Overview</font></b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2"
face="Times New Roman" style="font-size:10.0pt;">We are a
commercial-stage medical device company that designs, manufactures
and sells image-guided, catheter-based systems that are used by
physicians to treat patients with peripheral artery disease, or
PAD. Patients with PAD have a build-up of plaque in the arteries
that supply blood to areas away from the heart, particularly the
pelvis and legs. Our mission is to significantly improve the
treatment of vascular disease through the introduction of products
based on our Lumivascular platform, the only intravascular
image-guided system available in this market. We manufacture and
sell a suite of products in the United States and select
international markets. Our current products include our Lightbox
imaging console, the Ocelot family of catheters, which are designed
to allow physicians to penetrate a total blockage in an artery,
known as a chronic total occlusion, or CTO, and Pantheris, our
image-guided atherectomy device which is designed to allow
physicians to precisely remove arterial plaque in PAD patients. We
received 510(k)&nbsp;clearance from the U.S.&nbsp;Food and Drug
Administration, or FDA, for commercialization of Pantheris in
October&nbsp;2015. We received an additional 510(k)&nbsp;clearance
for an enhanced version of Pantheris in March&nbsp;2016 and
commenced sales of Pantheris in the United States and select
European countries promptly thereafter. We also offer the Wildcat
and Kittycat 2 catheters, which are used for crossing CTOs but do
not contain on-board imaging technology.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2"
face="Times New Roman" style="font-size:10.0pt;">During the first
quarter of 2015, we completed enrollment of patients in VISION, a
clinical trial designed to support our August&nbsp;2015
510(k)&nbsp;filing with the FDA for our Pantheris atherectomy
device. VISION was designed to evaluate the safety and efficacy of
Pantheris to perform atherectomy using intravascular imaging and
successfully achieved all primary and secondary safety and efficacy
endpoints. We believe the data from VISION allows us to demonstrate
that avoiding damage to healthy arterial structures, and in
particular disruption of the external elastic lamina, which is the
membrane between the outermost layers of the artery, reduces the
likelihood of restenosis, or re-narrowing, of the diseased artery.
Although the original VISION study protocol was not designed to
follow patients beyond six months, we have worked with 18 of the
VISION sites to re-solicit consent from previous clinical trial
patients in order for them to evaluate patient outcomes through 12
and 24 months following initial treatment. Data collection for the
remaining patients from participating sites was completed in
May&nbsp;2017, and we released the final 12 and 24-month results
for a total of 89 patients in July&nbsp;2017. We commenced
commercialization of Pantheris as part of our Lumivascular platform
in the United States and in select international markets in
March&nbsp;2016, after obtaining the required marketing
authorizations. During the fourth quarter of 2017, we began
enrolling patients in INSIGHT, a clinical trial designed to support
a filing with the FDA to expand the indication for our Pantheris
atherectomy device to include instent restenosis.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2"
face="Times New Roman" style="font-size:10.0pt;">We focus our
direct sales force, marketing efforts and promotional activities on
interventional cardiologists, vascular surgeons and interventional
radiologists. We also work on developing strong relationships with
physicians and hospitals that we have identified as key opinion
leaders. Although our sales and marketing efforts are directed at
these physicians because they are the primary users of our
technology, we consider the hospitals and medical centers where the
procedure is performed to be our customers, as they typically are
responsible for purchasing our products. We are designing future
products to be compatible with our Lumivascular platform, which we
expect to enhance the value proposition for hospitals to invest in
our technology. Pantheris qualifies for existing reimbursement
codes currently utilized by other atherectomy products, further
facilitating adoption of our products.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style=
"font-size:10.0pt;margin:0in 0in .0001pt;text-indent:.5in;">
<font size="2" face="Times New Roman" style=
"font-size:10.0pt;">Prior to the introduction of our Lumivascular
platform our non-imaging catheter products were manufactured by
third parties. All of our products are now manufactured
in-</font>house at our facilities in Redwood City, California using
components and sub-assemblies manufactured both in-house and by
outside vendors. We assemble all of our products at our
manufacturing facility, but certain critical processes such as
coating and sterilization are done by outside vendors. We expect
our current manufacturing facility will be sufficient through at
least 2019.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style=
"font-size:10.0pt;margin:0in 0in .0001pt;text-indent:.5in;">
<font size="2" face="Times New Roman" style="font-size:10.0pt;">In
addition to commercialization of Pantheris in the United States and
select international markets in March&nbsp;2016, we began
commercializing our initial non-Lumivascular platform products in
2009 and introduced our Lumivascular platform products in the
United States in late 2012.</font> We generated revenues of $1.8
million and $3.5 million in the three months ended March&nbsp;31,
2018 and 2017, respectively. During the three months ended
March&nbsp;31, 2018 and 2017, our net loss was $10.7 million and
$15.3&nbsp;million, respectively. We have not been profitable since
inception, and as of March&nbsp;31, 2018, our accumulated deficit
was $311.6&nbsp;million.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style=
"font-size:10.0pt;margin:0in 0in .0001pt;text-align:center;">
22<a name="PB_22_113726_7493" id="PB_22_113726_7493"></a></p>
<div style="margin:0in 0in .0001pt;">
<hr size="3" width="100%" noshade="noshade" align="left" style=
"color:#010101;" /></div>
</div>
<!-- SEQ.=1,FOLIO='22',FILE='C:\JMS\C902525\18-8644-1\task8901807\8644-1-fr.htm',USER='C902525',CD='May 16 00:46 2018' --><br clear="all"
style="page-break-before:always;" />
<div style="font-family:Times New Roman;">
<p style="margin:0in 0in .0001pt;"><a href="#TableOfContents"
title="Click to go to Table of Contents"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">Table of
Contents</font></a></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">Since inception, we
have financed our operations primarily through private placements
of our preferred securities and, to a lesser extent, debt financing
arrangements. In January&nbsp;2015, we completed an initial public
offering, or IPO, of 5.0 million shares. As a result of our IPO,
which closed in February&nbsp;2015, we received net proceeds of
approximately $56.9&nbsp;million, after underwriting discounts and
commissions of approximately $4.5&nbsp;million and other expenses
associated with our IPO of approximately
$3.6&nbsp;million.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style=
"font-size:10.0pt;margin:0in 0in .0001pt;text-indent:38.25pt;">
<font size="2" face="Times New Roman" style="font-size:10.0pt;">In
September&nbsp;2015, we entered into a</font> Term Loan Agreement,
or Loan Agreement, with CRG Partners III L.P. and certain of its
affiliated funds, collectively CRG, under which we were able to
borrow up to $50.0 million on or before March&nbsp;29, 2017,
subject to certain terms and conditions. We borrowed $30.0 million
on September&nbsp;22, 2015 and an additional $10.0 million on
June&nbsp;15, 2016 under the Loan Agreement. Contingent on
achievement of certain revenue milestones, among other conditions,
we would have been eligible to borrow an additional $10.0 million,
on or prior to March&nbsp;29, 2017; however, we did not achieve the
level of revenues required to borrow the final $10.0 million.
Contemporaneously with the execution of the Loan Agreement, we
entered into a Securities Purchase Agreement with CRG, pursuant to
which CRG purchased 8,705 shares of our common stock on
September&nbsp;22, 2015 at a price of $559.64 per share, which
represents the 10-day average of closing prices of our common stock
ending on September&nbsp;21, 2015. Pursuant to the Securities
Purchase Agreement, we filed a registration statement covering the
resale of the shares sold to CRG and must comply with certain
affirmative covenants during the time that such registration
statement remains in effect. We used the proceeds from the CRG
borrowing and securities purchase to retire our outstanding
principal and accrued interest with PDL Biopharma, or PDL, and to
retire the principal and accrued interest underlying our
outstanding promissory notes, or the notes.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style=
"font-size:10.0pt;margin:0in 0in .0001pt;text-indent:.5in;">
<font size="2" face="Times New Roman" style="font-size:10.0pt;">On
February&nbsp;3, 2016, we filed a universal shelf registration
statement to offer up to $150.0 million of our securities and
entered into an “at-the-market” program pursuant to a Sales
Agreement with Cowen and Company, or Cowen, through which we may,
from time to time, issue and sell shares of common stock having an
aggregate offering value of up to $50.0 million.&nbsp;The shelf
registration statement also covers the resale of the shares sold to
CRG.&nbsp;The registration statement was declared effective by the
SEC on March&nbsp;8, 2016. During the year ended December&nbsp;31,
2016, we sold 27,374 shares of common stock through the 
“at-the-market” program at an average price of $194.74 and raised
net proceeds of $5.2 million, after payment of $0.2 million in
commissions and fees to Cowen. During the three months ended
March&nbsp;31, 2018 and 2017, we sold no shares of common stock
through the “at-the-market” program.</font> Due to the SEC’s “baby
shelf rules,” which prohibit companies with a public float of less
than $75 million from issuing securities under a shelf registration
statement in excess of one-third of such company’s public float in
a twelve-month period, at this time we are unable to issue more
shares through our “at-the-market” program. In addition, in
August&nbsp;2016 we completed a follow-on public offering of
246,445 shares of our common stock for net proceeds of
approximately $31.5 million after deducting underwriting discounts
and commissions of approximately $2.4 million and other expenses of
approximately $0.6 million. The 246,445 shares include the exercise
in full by the underwriters of their option to purchase an
additional 32,145 shares of our common stock.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style=
"font-size:10.0pt;margin:0in 0in .0001pt;text-indent:.5in;">
<font size="2" face="Times New Roman" style="font-size:10.0pt;">In
April&nbsp;2017, we undertook an organizational realignment which
included a reduction in force, that lowered our total
headcount</font> by approximately 33% compared to December&nbsp;31,
2016. The organizational realignment was designed to focus our
commercial efforts on driving catheter utilization in our strongest
markets, around our most productive sales professionals. Our field
sales personnel headcount was reduced to 32, down from 60 as of
December&nbsp;31, 2016. This workforce reduction was designed to
reduce operating expenses while continuing to support major product
development and clinical initiatives. The strategic reduction in
the field sales force was designed to maintain robust engagement
with higher volume users of our Lumivascular technology and
position us to increase utilization of our catheters within our
installed base of accounts in 2018 following the launch of our next
generation products. In September&nbsp;2017, we effected a cost
reduction plan, which also included a company-wide reduction in
force, lowering our total headcount by an additional 24 employees.
Our field sales personnel headcount was further reduced to a total
of 20 people.&nbsp; In addition, as part of the cost reduction
plan, in October&nbsp;2017, we subleased a portion of the Company’s
facilities and consolidated our operations primarily into one
building.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style=
"font-size:10.0pt;margin:0in 0in .0001pt;text-indent:.5in;">
<font size="2" face="Times New Roman"><font style=
"font-size:10.0pt;">On November&nbsp;3, 2017, we entered the
Lincoln Park</font> Purchase Agreement</font>, pursuant to which
Lincoln Park is obligated to purchase, at our request, up to $15.0
million of our common stock over a 30-month period, subject to
certain limitations set forth in the Lincoln Park Purchase
Agreement. As a fee for Lincoln Park’s commitment to purchase such
shares, we issued 23,584 shares of common stock to Lincoln Park on
November&nbsp;3, 2017. As obligated under a registration rights
agreement entered into with Lincoln Park in connection with the
Lincoln Park Purchase Agreement, we filed a registration statement
on Form&nbsp;S-1 on November&nbsp;6, 2017 for up to 248,750 of such
shares, which registration statement was declared effective by the
SEC on November&nbsp;17, 2017.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2"
face="Times New Roman" style="font-size:10.0pt;">On
February&nbsp;14, 2018, we entered into Amendment No.&nbsp;2 to the
Term Loan Agreement (the “Amendment No.&nbsp;2 Loan Agreement”)
with CRG.&nbsp; Under its terms, the Amendment No.&nbsp;2 Loan
Agreement, among other things: (1)&nbsp;extended the interest-only
period through June&nbsp;30, 2021; (2)&nbsp;extended the period
during which the Company may elect to pay a portion of interest in
payment-in-kind, or PIK, interest payments through June&nbsp;30,
2021, so long as no default has occurred and is continuing;
(3)&nbsp;permitted the Company to make its entire interest payments
in PIK interest payments for through December&nbsp;31, 2019, so
long as no default has occurred and is continuing;
(4)&nbsp;extended the maturity date to June&nbsp;30, 2023;
(5)&nbsp;reduced the minimum liquidity requirement to $3.5 million
at all times; (6)&nbsp;eliminated the minimum revenue covenant for
2018 and 2019; (7)&nbsp;reduced the minimum revenue covenant to $15
million for 2020, $20 million for 2021 and $25 million for
2022;&nbsp; and (8)&nbsp;provided CRG with board observer
rights.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style=
"font-size:10.0pt;margin:0in 0in .0001pt;text-align:center;">
23<a name="PB_23_113740_7056" id="PB_23_113740_7056"></a></p>
<div style="margin:0in 0in .0001pt;">
<hr size="3" width="100%" noshade="noshade" align="left" style=
"color:#010101;" /></div>
</div>
<!-- SEQ.=1,FOLIO='23',FILE='C:\JMS\C902525\18-8644-1\task8901807\8644-1-fr.htm',USER='C902525',CD='May 16 00:46 2018' --><br clear="all"
style="page-break-before:always;" />
<div style="font-family:Times New Roman;">
<p style="margin:0in 0in .0001pt;"><a href="#TableOfContents"
title="Click to go to Table of Contents"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">Table of
Contents</font></a></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2"
face="Times New Roman" style="font-size:10.0pt;">In addition, on
February&nbsp;14, 2018, we entered into a Series&nbsp;A preferred
stock Purchase Agreement (the “Series&nbsp;A Purchase Agreement”)
with CRG, pursuant to which it agreed to convert $38.0 million of
the outstanding principal amount of its senior secured term loan
(plus $3.8 million in back-end fees and prepayment premium
applicable thereto), totaling $41.8 million, into a newly
authorized Series&nbsp;A preferred stock.&nbsp; The Series&nbsp;A
preferred stock is initially convertible into 20,900,000 shares of
common stock subject to certain limitations contained in the
Series&nbsp;A Purchase Agreement.&nbsp; The holders of
Series&nbsp;A preferred stock are entitled to receive annual
accruing dividends at a rate of 8%, payable in additional shares of
Series&nbsp;A preferred stock or cash, at our option. The shares of
Series&nbsp;A preferred stock have no voting rights and rank senior
to all other classes and series of the Company’s equity in terms of
repayment and certain other rights.&nbsp; The Series&nbsp;A
preferred stock and any of the Company’s common stock issued upon
conversion of the Series&nbsp;A preferred stock is subject to a
lockup agreement through February&nbsp;14, 2019.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2"
face="Times New Roman" style="font-size:10.0pt;">On
February&nbsp;16, 2018, we completed a public offering of 17,979
shares of Series&nbsp;B preferred stock and warrants to purchase
17,979,000 shares of common stock.&nbsp; As a result, we received
net proceeds of approximately $16.0 million after underwriting
discounts, commissions, legal and accounting fees of approximately
$1.9 million.&nbsp; Each share of Series&nbsp;B preferred stock is
accompanied by one warrant that expires on the seventh anniversary
of the date of issuance to purchase up to 500 shares of common
stock (the “Series&nbsp;1 warrants”) and one warrant that expires
on the earlier of (i)&nbsp;the seventh anniversary of the date of
issuance or (ii)&nbsp;the 60th calendar day following the receipt
and announcement of FDA clearance of our Pantheris below-the-knee
device (or the same or similar product with a different name) to
purchase up to 500 shares of common stock; provided, however, if at
any time during such 60-day period the volume weighted average
price for any trading day is less than the then effective exercise
price, the termination date shall be extended to the seven year
anniversary of the initial exercise date (the “Series&nbsp;2
warrants”).</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2"
face="Times New Roman" style="font-size:10.0pt;">We are developing
two next-generation versions of our Pantheris atherectomy device,
Pantheris 3.0 and a lower profile Pantheris (Pantheris 6F), that we
believe represent significant improvements over our existing
product. Pantheris 3.0 includes new features and design
improvements to the handle, shaft, balloon and nose cone that we
believe will improve usability and reliability, while the Pantheris
6F has a smaller diameter and longer length that we believe will
optimize it for use in smaller vessels and below-the-knee
applications. We filed a 510(k)&nbsp;submission for Pantheris 3.0
in December&nbsp;2017 and we plan to file a 510(k)&nbsp;submission
for Pantheris 6F in mid- 2018.&nbsp; We received a CE Mark for
Pantheris 3.0 in December&nbsp;2017.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><b><font size="2" face=
"Times New Roman" style=
"font-size:10.0pt;font-weight:bold;">Critical Accounting Policies
and Estimates</font></b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2"
face="Times New Roman" style="font-size:10.0pt;">Management’s
discussion and analysis of our financial condition and results of
operations is based on our financial statements, which have been
prepared in accordance with U.S. generally accepted accounting
principles. The preparation of these financial statements requires
us to make estimates and assumptions for the reported amounts of
assets, liabilities, revenues, expenses and related disclosures of
contingent assets and liabilities. Our estimates are based on our
historical experience and on various other factors that we believe
are reasonable under the circumstances, the results of which form
the basis for making judgments about the carrying value of assets
and liabilities that are not readily apparent from other sources.
Actual results may differ from these estimates under different
assumptions or conditions and any such differences may be material.
There have been no significant and material changes in our critical
accounting policies during the three months ended March&nbsp;31,
2018, as compared to those disclosed in “Management’s Discussion
and Analysis of Financial Conditions and Results of Operations -
Critical accounting policies and significant judgments and
estimates” in our most recent Annual Report on Form&nbsp;10-K, as
filed with the SEC on March&nbsp;30, 2018.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><b><font size="2" face=
"Times New Roman" style=
"font-size:10.0pt;font-weight:bold;">Components of Our Results of
Operations</font></b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><b><i><font size="2" face=
"Times New Roman" style=
"font-size:10.0pt;font-style:italic;font-weight:bold;">Revenues</font></i></b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style=
"font-size:10.0pt;margin:0in 0in .0001pt;text-indent:.5in;">
<font size="2" face="Times New Roman" style="font-size:10.0pt;">All
of our revenues are currently derived from sales of our Lightbox
console and sales of our various PAD&nbsp;catheters, as well as
related services in the United States and select international
markets. We expect our revenues in</font> the near term to be
adversely affected by the product performance issues we have
experienced with the current version of Pantheris as well as our
strategic decision to reduce the size of our sales force in
April&nbsp;2017 and September&nbsp;2017. However, we expect our
revenues to increase in 2018 as we introduce two next-generation
versions of Pantheris. No single customer accounted for more than
10% of our revenues during the three months ended March&nbsp;31,
2018 and 2017.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style=
"font-size:10.0pt;margin:0in 0in .0001pt;text-indent:.5in;">
<font size="2" face="Times New Roman" style=
"font-size:10.0pt;">Revenues may fluctuate from quarter to quarter
due to a variety of factors</font> including capital equipment
purchasing patterns that are typically increased towards the end of
the calendar year and decreased in the first quarter. In addition,
during the first quarter, our results can be harmed by adverse
weather and by resetting of annual patient healthcare insurance
plan deductibles, both of which may cause patients to delay
elective procedures. In the first quarter, the number of elective
procedures nationwide is historically lower than other quarters
throughout the year, which we believe is primarily attributable to
the summer vacations of physicians and their patients.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style=
"font-size:10.0pt;margin:0in 0in .0001pt;text-align:center;">
24<a name="PB_24_113811_5335" id="PB_24_113811_5335"></a></p>
<div style="margin:0in 0in .0001pt;">
<hr size="3" width="100%" noshade="noshade" align="left" style=
"color:#010101;" /></div>
</div>
<!-- SEQ.=1,FOLIO='24',FILE='C:\JMS\C902525\18-8644-1\task8901807\8644-1-fr.htm',USER='C902525',CD='May 16 00:46 2018' --><br clear="all"
style="page-break-before:always;" />
<div style="font-family:Times New Roman;">
<p style="margin:0in 0in .0001pt;"><a href="#TableOfContents"
title="Click to go to Table of Contents"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">Table of
Contents</font></a></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><b><i><font size="2" face=
"Times New Roman" style=
"font-size:10.0pt;font-style:italic;font-weight:bold;">Cost of
Revenues and Gross Margin</font></i></b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style=
"font-size:10.0pt;margin:0in 0in .0001pt;text-indent:.5in;">
<font size="2" face="Times New Roman" style=
"font-size:10.0pt;">Cost of revenues consists primarily of costs
related to manufacturing overhead, materials and direct
labor.</font> We expense all warranty costs and inventory
provisions as cost of revenues. We periodically write-down
inventory for estimated excess, obsolete and non-sellable
inventories based on assumptions about future demand, past usage,
changes to manufacturing processes and overall market conditions. A
significant portion of our cost of revenues currently consists of
manufacturing overhead costs. These overhead costs include the cost
of quality assurance, material procurement, inventory control,
facilities, equipment and operations supervision and management. We
expect overhead costs as a percentage of revenues to become less
significant as our production volume increases following the
commercial launch of our next-generation Pantheris catheters in
2018. Cost of revenues also includes depreciation expense for
production equipment, depreciation and related maintenance expense
for placed Lightboxes held by customers and certain direct costs
such as those incurred for shipping our products.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2"
face="Times New Roman" style="font-size:10.0pt;">We calculate gross
margin as gross profit divided by revenues. Our gross margin has
been and will continue to be affected by a variety of factors,
primarily production volumes, manufacturing costs, product yields,
headcount, charges for excess and obsolete inventories and
cost-reduction strategies. We expect our gross margin to increase
over the long term as our production volume increases and as we
spread the fixed portion of our manufacturing overhead costs over a
larger number of units produced, thereby reducing our per unit
manufacturing costs. We intend to use our design, engineering and
manufacturing capabilities to further advance and improve the
efficiency of our manufacturing processes, which we believe will
reduce costs and increase our gross margin. In the future, we may
seek to manufacture certain of our products outside the United
States to further reduce costs. Our gross margin will likely
fluctuate from quarter to quarter as we continue to introduce new
products and sales channels, and as we adopt new manufacturing
processes and technologies.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style=
"font-size:10.0pt;margin:0in 0in .0001pt;text-align:center;">
25<a name="PB_25_113821_5796" id="PB_25_113821_5796"></a></p>
<div style="margin:0in 0in .0001pt;">
<hr size="3" width="100%" noshade="noshade" align="left" style=
"color:#010101;" /></div>
</div>
<!-- SEQ.=1,FOLIO='25',FILE='C:\JMS\C902525\18-8644-1\task8901807\8644-1-fr.htm',USER='C902525',CD='May 16 00:46 2018' --><br clear="all"
style="page-break-before:always;" />
<div style="font-family:Times New Roman;">
<p style="margin:0in 0in .0001pt;"><a href="#TableOfContents"
title="Click to go to Table of Contents"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">Table of
Contents</font></a></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><b><i><font size="2" face=
"Times New Roman" style=
"font-size:10.0pt;font-style:italic;font-weight:bold;">Research and
Development Expenses</font></i></b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2"
face="Times New Roman" style="font-size:10.0pt;">Research and
development, or R&amp;D, expenses consist primarily of engineering,
product development, clinical and regulatory affairs, consulting
services, materials, depreciation and other costs associated with
products and technologies in development. These expenses include
employee compensation, including stock-based compensation,
supplies, materials, quality assurance expenses allocated to
R&amp;D programs, consulting, related travel expenses and
facilities expenses. Clinical expenses include clinical trial
design, clinical site reimbursement, data management, travel
expenses and the cost of manufacturing products for clinical
trials. We expect R&amp;D expenses as a percentage of revenues to
vary over time depending on the level and timing of our new product
development efforts, as well as our clinical development, clinical
trial and other related activities.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><b><i><font size="2" face=
"Times New Roman" style=
"font-size:10.0pt;font-style:italic;font-weight:bold;">Selling,
General and Administrative Expenses</font></i></b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2"
face="Times New Roman" style="font-size:10.0pt;">Selling, general
and administrative, or SG&amp;A, expenses consist primarily of
compensation for personnel, including stock-based compensation,
related to selling and marketing functions, physician education
programs, business development, finance, information technology and
human resource functions. Other SG&amp;A expenses include
commissions, training, travel expenses, educational and promotional
activities, marketing initiatives, market research and analysis,
conferences and trade shows, professional services fees, including
legal, audit and tax fees, insurance costs, general corporate
expenses and allocated facilities-related expenses. We expect
SG&amp;A expenses to remain lower in the near term compared to
recent prior years due to our reductions in force in April&nbsp;and
September&nbsp;2017.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><b><i><font size="2" face=
"Times New Roman" style=
"font-size:10.0pt;font-style:italic;font-weight:bold;">Interest
Income (Expense), net</font></i></b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2"
face="Times New Roman" style="font-size:10.0pt;">Interest income
(expense), net consists primarily of interest incurred on our
outstanding indebtedness and non-cash interest related to the
amortization of debt discount and issuance costs associated with
our various debt agreements.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><b><i><font size="2" face=
"Times New Roman" style=
"font-size:10.0pt;font-style:italic;font-weight:bold;">Other Income
(Expense), net</font></i></b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style=
"font-size:10.0pt;margin:0in 0in .0001pt;text-indent:.5in;">
<font size="2" face="Times New Roman" style=
"font-size:10.0pt;">Other income (expense), net primarily consists
of gains and losses resulting from the remeasurement of</font>
foreign exchange transactions.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><b><font size="2" face=
"Times New Roman" style=
"font-size:10.0pt;font-weight:bold;">Results of
Operations:</font></b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<table border="0" cellspacing="0" cellpadding="0" width="73%"
style="border-collapse:collapse;margin-left:1.0in;">
<tr>
<td width="50%" valign="top" style=
"padding:0in 0in 0in 0in;width:50.92%;">
<p style="margin:0in 0in .0001pt 10.1pt;text-indent:-10.1pt;">
<font size="2" face="Times New Roman" style=
"font-size:10.0pt;">Results of Operations:</font></p>
</td>
<td width="3%" valign="bottom" style=
"padding:0in 0in 0in 0in;width:3.4%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>
</td>
<td width="20%" valign="bottom" style=
"padding:0in 0in 0in 0in;width:20.46%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;">
<font size="2" face="Times New Roman" style=
"font-size:1.0pt;">&nbsp;</font></p>
</td>
<td width="3%" valign="bottom" style=
"padding:0in 0in 0in 0in;width:3.4%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>
</td>
<td width="20%" valign="bottom" style=
"padding:0in 0in 0in 0in;width:20.46%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;">
<font size="2" face="Times New Roman" style=
"font-size:1.0pt;">&nbsp;</font></p>
</td>
<td width="1%" valign="bottom" style=
"padding:0in 0in 0in 0in;width:1.36%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>
</td>
</tr>
</table>
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<table border="0" cellspacing="0" cellpadding="0" width="73%"
style="border-collapse:collapse;margin-left:1.0in;">
<tr>
<td width="50%" valign="bottom" style=
"padding:0in 0in 0in 0in;width:50.92%;">
<p style="margin:0in 0in .0001pt;"><b><font size="1" face=
"Times New Roman" style=
"font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>
</td>
<td width="3%" valign="bottom" style=
"padding:0in 0in 0in 0in;width:3.4%;">
<p align="center" style=
"margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face=
"Times New Roman" style=
"font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>
</td>
<td width="44%" colspan="5" valign="bottom" style=
"border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:44.32%;">
<p align="center" style=
"margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face=
"Times New Roman" style=
"font-size:8.0pt;font-weight:bold;">Three&nbsp;Months&nbsp;Ended&nbsp;March&nbsp;31,</font></b></p>
</td>
<td width="1%" valign="bottom" style=
"padding:0in 0in 0in 0in;width:1.36%;">
<p align="center" style=
"margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face=
"Times New Roman" style=
"font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>
</td>
</tr>
<tr>
<td width="50%" valign="bottom" style=
"padding:0in 0in 0in 0in;width:50.92%;">
<p style="margin:0in 0in .0001pt;"><b><font size="1" face=
"Times New Roman" style=
"font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>
</td>
<td width="3%" valign="bottom" style=
"padding:0in 0in 0in 0in;width:3.4%;">
<p align="center" style=
"margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face=
"Times New Roman" style=
"font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>
</td>
<td width="20%" colspan="2" valign="bottom" style=
"border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:20.46%;">
<p align="center" style=
"margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face=
"Times New Roman" style=
"font-size:8.0pt;font-weight:bold;">2018</font></b></p>
</td>
<td width="3%" valign="bottom" style=
"padding:0in 0in 0in 0in;width:3.4%;">
<p align="center" style=
"margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face=
"Times New Roman" style=
"font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>
</td>
<td width="20%" colspan="2" valign="bottom" style=
"border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:20.46%;">
<p align="center" style=
"margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face=
"Times New Roman" style=
"font-size:8.0pt;font-weight:bold;">2017</font></b></p>
</td>
<td width="1%" valign="bottom" style=
"padding:0in 0in 0in 0in;width:1.36%;">
<p align="center" style=
"margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face=
"Times New Roman" style=
"font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>
</td>
</tr>
<tr>
<td width="50%" valign="bottom" style=
"padding:0in 0in 0in 0in;width:50.92%;">
<p style="margin:0in 0in .0001pt;"><b><font size="1" face=
"Times New Roman" style=
"font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>
</td>
<td width="3%" valign="bottom" style=
"padding:0in 0in 0in 0in;width:3.4%;">
<p align="center" style=
"margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face=
"Times New Roman" style=
"font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>
</td>
<td width="44%" colspan="5" valign="bottom" style=
"padding:0in 0in 0in 0in;width:44.32%;">
<p align="center" style=
"margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face=
"Times New Roman" style=
"font-size:8.0pt;font-weight:bold;">(in&nbsp;thousands,&nbsp;except&nbsp;percentages)</font></b></p>
</td>
<td width="1%" valign="bottom" style=
"padding:0in 0in 0in 0in;width:1.36%;">
<p align="center" style=
"margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face=
"Times New Roman" style=
"font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>
</td>
</tr>
<tr>
<td width="50%" valign="top" bgcolor="#CCEEFF" style=
"background:#CCEEFF;padding:0in 0in 0in 0in;width:50.92%;">
<p style="margin:0in 0in .0001pt 10.1pt;text-indent:-10.1pt;">
<font size="2" face="Times New Roman" style=
"font-size:10.0pt;">Revenues</font></p>
</td>
<td width="3%" valign="bottom" bgcolor="#CCEEFF" style=
"background:#CCEEFF;padding:0in 0in 0in 0in;width:3.4%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>
</td>
<td width="1%" valign="bottom" bgcolor="#CCEEFF" style=
"background:#CCEEFF;padding:0in 0in 0in 0in;width:1.54%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">$</font></p>
</td>
<td width="18%" valign="bottom" bgcolor="#CCEEFF" style=
"background:#CCEEFF;padding:0in 0in 0in 0in;width:18.92%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;">
<font size="2" face="Times New Roman" style=
"font-size:10.0pt;">1,809</font></p>
</td>
<td width="3%" valign="bottom" bgcolor="#CCEEFF" style=
"background:#CCEEFF;padding:0in 0in 0in 0in;width:3.4%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>
</td>
<td width="1%" valign="bottom" bgcolor="#CCEEFF" style=
"background:#CCEEFF;padding:0in 0in 0in 0in;width:1.54%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">$</font></p>
</td>
<td width="18%" valign="bottom" bgcolor="#CCEEFF" style=
"background:#CCEEFF;padding:0in 0in 0in 0in;width:18.92%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;">
<font size="2" face="Times New Roman" style=
"font-size:10.0pt;">3,491</font></p>
</td>
<td width="1%" valign="bottom" bgcolor="#CCEEFF" style=
"background:#CCEEFF;padding:0in 0in 0in 0in;width:1.36%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>
</td>
</tr>
<tr>
<td width="50%" valign="top" style=
"padding:0in 0in 0in 0in;width:50.92%;">
<p style="margin:0in 0in .0001pt 10.1pt;text-indent:-10.1pt;">
<font size="2" face="Times New Roman" style=
"font-size:10.0pt;">Cost of revenues</font></p>
</td>
<td width="3%" valign="bottom" style=
"padding:0in 0in 0in 0in;width:3.4%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>
</td>
<td width="20%" colspan="2" valign="bottom" style=
"border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:20.46%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;">
<font size="2" face="Times New Roman" style=
"font-size:10.0pt;">1,415</font></p>
</td>
<td width="3%" valign="bottom" style=
"padding:0in 0in 0in 0in;width:3.4%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>
</td>
<td width="20%" colspan="2" valign="bottom" style=
"border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:20.46%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;">
<font size="2" face="Times New Roman" style=
"font-size:10.0pt;">4,075</font></p>
</td>
<td width="1%" valign="bottom" style=
"padding:0in 0in 0in 0in;width:1.36%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>
</td>
</tr>
<tr>
<td width="50%" valign="top" bgcolor="#CCEEFF" style=
"background:#CCEEFF;padding:0in 0in 0in 0in;width:50.92%;">
<p style="margin:0in 0in .0001pt 20.2pt;text-indent:-10.1pt;">
<font size="2" face="Times New Roman" style=
"font-size:10.0pt;">Gross profit (loss)</font></p>
</td>
<td width="3%" valign="bottom" bgcolor="#CCEEFF" style=
"background:#CCEEFF;padding:0in 0in 0in 0in;width:3.4%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>
</td>
<td width="20%" colspan="2" valign="bottom" bgcolor="#CCEEFF"
style="background:#CCEEFF;padding:0in 0in 0in 0in;width:20.46%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;">
<font size="2" face="Times New Roman" style=
"font-size:10.0pt;">394</font></p>
</td>
<td width="3%" valign="bottom" bgcolor="#CCEEFF" style=
"background:#CCEEFF;padding:0in 0in 0in 0in;width:3.4%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>
</td>
<td width="20%" colspan="2" valign="bottom" bgcolor="#CCEEFF"
style="background:#CCEEFF;padding:0in 0in 0in 0in;width:20.46%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;">
<font size="2" face="Times New Roman" style=
"font-size:10.0pt;">(584</font></p>
</td>
<td width="1%" valign="bottom" bgcolor="#CCEEFF" style=
"background:#CCEEFF;padding:0in 0in 0in 0in;width:1.36%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">)</font></p>
</td>
</tr>
<tr>
<td width="50%" valign="top" style=
"padding:0in 0in 0in 0in;width:50.92%;">
<p style="margin:0in 0in .0001pt 20.2pt;text-indent:-10.1pt;">
<font size="2" face="Times New Roman" style=
"font-size:10.0pt;">Gross margin</font></p>
</td>
<td width="3%" valign="bottom" style=
"padding:0in 0in 0in 0in;width:3.4%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>
</td>
<td width="20%" colspan="2" valign="bottom" style=
"padding:0in 0in 0in 0in;width:20.46%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;">
<font size="2" face="Times New Roman" style=
"font-size:10.0pt;">22</font></p>
</td>
<td width="3%" valign="bottom" style=
"padding:0in 0in 0in 0in;width:3.4%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">%</font></p>
</td>
<td width="20%" colspan="2" valign="bottom" style=
"padding:0in 0in 0in 0in;width:20.46%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;">
<font size="2" face="Times New Roman" style=
"font-size:10.0pt;">-17</font></p>
</td>
<td width="1%" valign="bottom" style=
"padding:0in 0in 0in 0in;width:1.36%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">%</font></p>
</td>
</tr>
<tr>
<td width="50%" valign="top" bgcolor="#CCEEFF" style=
"background:#CCEEFF;padding:0in 0in 0in 0in;width:50.92%;">
<p style="margin:0in 0in .0001pt 10.1pt;text-indent:-10.1pt;">
<font size="2" face="Times New Roman" style=
"font-size:10.0pt;">Operating expenses:</font></p>
</td>
<td width="3%" valign="bottom" bgcolor="#CCEEFF" style=
"background:#CCEEFF;padding:0in 0in 0in 0in;width:3.4%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>
</td>
<td width="20%" colspan="2" valign="bottom" bgcolor="#CCEEFF"
style="background:#CCEEFF;padding:0in 0in 0in 0in;width:20.46%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;">
<font size="2" face="Times New Roman" style=
"font-size:1.0pt;">&nbsp;</font></p>
</td>
<td width="3%" valign="bottom" bgcolor="#CCEEFF" style=
"background:#CCEEFF;padding:0in 0in 0in 0in;width:3.4%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>
</td>
<td width="20%" colspan="2" valign="bottom" bgcolor="#CCEEFF"
style="background:#CCEEFF;padding:0in 0in 0in 0in;width:20.46%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;">
<font size="2" face="Times New Roman" style=
"font-size:1.0pt;">&nbsp;</font></p>
</td>
<td width="1%" valign="bottom" bgcolor="#CCEEFF" style=
"background:#CCEEFF;padding:0in 0in 0in 0in;width:1.36%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>
</td>
</tr>
<tr>
<td width="50%" valign="top" style=
"padding:0in 0in 0in 0in;width:50.92%;">
<p style="margin:0in 0in .0001pt 30.3pt;text-indent:-10.1pt;">
<font size="2" face="Times New Roman" style=
"font-size:10.0pt;">Research and development</font></p>
</td>
<td width="3%" valign="bottom" style=
"padding:0in 0in 0in 0in;width:3.4%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>
</td>
<td width="20%" colspan="2" valign="bottom" style=
"padding:0in 0in 0in 0in;width:20.46%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;">
<font size="2" face="Times New Roman" style=
"font-size:10.0pt;">1,777</font></p>
</td>
<td width="3%" valign="bottom" style=
"padding:0in 0in 0in 0in;width:3.4%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>
</td>
<td width="20%" colspan="2" valign="bottom" style=
"padding:0in 0in 0in 0in;width:20.46%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;">
<font size="2" face="Times New Roman" style=
"font-size:10.0pt;">3,923</font></p>
</td>
<td width="1%" valign="bottom" style=
"padding:0in 0in 0in 0in;width:1.36%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>
</td>
</tr>
<tr>
<td width="50%" valign="top" bgcolor="#CCEEFF" style=
"background:#CCEEFF;padding:0in 0in 0in 0in;width:50.92%;">
<p style="margin:0in 0in .0001pt 30.3pt;text-indent:-10.1pt;">
<font size="2" face="Times New Roman" style=
"font-size:10.0pt;">Selling, general and administrative</font></p>
</td>
<td width="3%" valign="bottom" bgcolor="#CCEEFF" style=
"background:#CCEEFF;padding:0in 0in 0in 0in;width:3.4%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>
</td>
<td width="20%" colspan="2" valign="bottom" bgcolor="#CCEEFF"
style="background:#CCEEFF;border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:20.46%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;">
<font size="2" face="Times New Roman" style=
"font-size:10.0pt;">4,260</font></p>
</td>
<td width="3%" valign="bottom" bgcolor="#CCEEFF" style=
"background:#CCEEFF;padding:0in 0in 0in 0in;width:3.4%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>
</td>
<td width="20%" colspan="2" valign="bottom" bgcolor="#CCEEFF"
style="background:#CCEEFF;border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:20.46%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;">
<font size="2" face="Times New Roman" style=
"font-size:10.0pt;">9,318</font></p>
</td>
<td width="1%" valign="bottom" bgcolor="#CCEEFF" style=
"background:#CCEEFF;padding:0in 0in 0in 0in;width:1.36%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>
</td>
</tr>
<tr>
<td width="50%" valign="top" style=
"padding:0in 0in 0in 0in;width:50.92%;">
<p style="margin:0in 0in .0001pt 40.4pt;text-indent:-10.1pt;">
<font size="2" face="Times New Roman" style=
"font-size:10.0pt;">Total operating expenses</font></p>
</td>
<td width="3%" valign="bottom" style=
"padding:0in 0in 0in 0in;width:3.4%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>
</td>
<td width="20%" colspan="2" valign="bottom" style=
"border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:20.46%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;">
<font size="2" face="Times New Roman" style=
"font-size:10.0pt;">6,037</font></p>
</td>
<td width="3%" valign="bottom" style=
"padding:0in 0in 0in 0in;width:3.4%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>
</td>
<td width="20%" colspan="2" valign="bottom" style=
"border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:20.46%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;">
<font size="2" face="Times New Roman" style=
"font-size:10.0pt;">13,241</font></p>
</td>
<td width="1%" valign="bottom" style=
"padding:0in 0in 0in 0in;width:1.36%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>
</td>
</tr>
<tr>
<td width="50%" valign="top" bgcolor="#CCEEFF" style=
"background:#CCEEFF;padding:0in 0in 0in 0in;width:50.92%;">
<p style="margin:0in 0in .0001pt 10.1pt;text-indent:-10.1pt;">
<font size="2" face="Times New Roman" style=
"font-size:10.0pt;">Loss from operations</font></p>
</td>
<td width="3%" valign="bottom" bgcolor="#CCEEFF" style=
"background:#CCEEFF;padding:0in 0in 0in 0in;width:3.4%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>
</td>
<td width="20%" colspan="2" valign="bottom" bgcolor="#CCEEFF"
style="background:#CCEEFF;padding:0in 0in 0in 0in;width:20.46%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;">
<font size="2" face="Times New Roman" style=
"font-size:10.0pt;">(5,643</font></p>
</td>
<td width="3%" valign="bottom" bgcolor="#CCEEFF" style=
"background:#CCEEFF;padding:0in 0in 0in 0in;width:3.4%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">)</font></p>
</td>
<td width="20%" colspan="2" valign="bottom" bgcolor="#CCEEFF"
style="background:#CCEEFF;padding:0in 0in 0in 0in;width:20.46%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;">
<font size="2" face="Times New Roman" style=
"font-size:10.0pt;">(13,825</font></p>
</td>
<td width="1%" valign="bottom" bgcolor="#CCEEFF" style=
"background:#CCEEFF;padding:0in 0in 0in 0in;width:1.36%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">)</font></p>
</td>
</tr>
<tr>
<td width="50%" valign="top" style=
"padding:0in 0in 0in 0in;width:50.92%;">
<p style="margin:0in 0in .0001pt 10.1pt;text-indent:-10.1pt;">
<font size="2" face="Times New Roman" style=
"font-size:10.0pt;">Interest income (expense), net</font></p>
</td>
<td width="3%" valign="bottom" style=
"padding:0in 0in 0in 0in;width:3.4%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>
</td>
<td width="20%" colspan="2" valign="bottom" style=
"padding:0in 0in 0in 0in;width:20.46%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;">
<font size="2" face="Times New Roman" style=
"font-size:10.0pt;">(4,639</font></p>
</td>
<td width="3%" valign="bottom" style=
"padding:0in 0in 0in 0in;width:3.4%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">)</font></p>
</td>
<td width="20%" colspan="2" valign="bottom" style=
"padding:0in 0in 0in 0in;width:20.46%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;">
<font size="2" face="Times New Roman" style=
"font-size:10.0pt;">(1,518</font></p>
</td>
<td width="1%" valign="bottom" style=
"padding:0in 0in 0in 0in;width:1.36%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">)</font></p>
</td>
</tr>
<tr>
<td width="50%" valign="top" bgcolor="#CCEEFF" style=
"background:#CCEEFF;padding:0in 0in 0in 0in;width:50.92%;">
<p style="margin:0in 0in .0001pt 10.1pt;text-indent:-10.1pt;">
<font size="2" face="Times New Roman" style=
"font-size:10.0pt;">Other income (expense), net</font></p>
</td>
<td width="3%" valign="bottom" bgcolor="#CCEEFF" style=
"background:#CCEEFF;padding:0in 0in 0in 0in;width:3.4%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>
</td>
<td width="20%" colspan="2" valign="bottom" bgcolor="#CCEEFF"
style="background:#CCEEFF;border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:20.46%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;">
<font size="2" face="Times New Roman" style=
"font-size:10.0pt;">1</font></p>
</td>
<td width="3%" valign="bottom" bgcolor="#CCEEFF" style=
"background:#CCEEFF;padding:0in 0in 0in 0in;width:3.4%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>
</td>
<td width="20%" colspan="2" valign="bottom" bgcolor="#CCEEFF"
style="background:#CCEEFF;border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:20.46%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;">
<font size="2" face="Times New Roman" style=
"font-size:10.0pt;">3</font></p>
</td>
<td width="1%" valign="bottom" bgcolor="#CCEEFF" style=
"background:#CCEEFF;padding:0in 0in 0in 0in;width:1.36%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>
</td>
</tr>
<tr>
<td width="50%" valign="top" style=
"padding:0in 0in 0in 0in;width:50.92%;">
<p style="margin:0in 0in .0001pt 10.1pt;text-indent:-10.1pt;">
<font size="2" face="Times New Roman" style="font-size:10.0pt;">Net
loss and comprehensive loss</font></p>
</td>
<td width="3%" valign="bottom" style=
"padding:0in 0in 0in 0in;width:3.4%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>
</td>
<td width="1%" valign="bottom" style=
"border:none;border-bottom:double windowtext 2.25pt;padding:0in 0in 0in 0in;width:1.54%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">$</font></p>
</td>
<td width="18%" valign="bottom" style=
"border:none;border-bottom:double windowtext 2.25pt;padding:0in 0in 0in 0in;width:18.92%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;">
<font size="2" face="Times New Roman" style=
"font-size:10.0pt;">(10,281</font></p>
</td>
<td width="3%" valign="bottom" style=
"padding:0in 0in 2.25pt 0in;width:3.4%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">)</font></p>
</td>
<td width="1%" valign="bottom" style=
"border:none;border-bottom:double windowtext 2.25pt;padding:0in 0in 0in 0in;width:1.54%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">$</font></p>
</td>
<td width="18%" valign="bottom" style=
"border:none;border-bottom:double windowtext 2.25pt;padding:0in 0in 0in 0in;width:18.92%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;">
<font size="2" face="Times New Roman" style=
"font-size:10.0pt;">(15,340</font></p>
</td>
<td width="1%" valign="bottom" style=
"padding:0in 0in 2.25pt 0in;width:1.36%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">)</font></p>
</td>
</tr>
</table>
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2"
face="Times New Roman" style="font-size:10.0pt;">This report
corrects an error in our earnings press release dated on May 14,
2018 with respect to the net loss and net loss per share
attributable to common stockholders for the first quarter ended
March 31, 2018. The earnings press release presented net loss
attributable to common stockholders of $10.7 million and net loss
per share attributable to common stockholders of $5.37 for the
first quarter ended March 31, 2018. The correct amounts presented
in this report reflect net loss attributable to common stockholders
of $15.9 million and basic and diluted net loss per share
attributable to common stockholders of $7.99 for the first quarter
ended March 31, 2018.&nbsp; The changes in these numbers are a
result of a recalculation of the deemed dividend amount allocated
to the holders of preferred stock.&nbsp; The error did not impact
any of the other amounts in the unaudited financial statements
reported in the earnings press release.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><b><i><font size="2" face=
"Times New Roman" style=
"font-size:10.0pt;font-style:italic;font-weight:bold;">Comparison
of Three Months Ended March&nbsp;31, 2018 and
2017</font></i></b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style=
"font-size:10.0pt;margin:0in 0in .0001pt;text-indent:.5in;">
<i><font size="2" face="Times New Roman" style=
"font-size:10.0pt;font-style:italic;">Revenues.</font></i>&nbsp;
Revenues decreased $1.7 million, or 48%, to $1.8 million during the
three months ended March&nbsp;31, 2018, compared to $3.5 million
during the three months ended March&nbsp;31, 2017. For the three
months ended March&nbsp;31, 2018, revenues related to sales of our
disposable catheters decreased by 48% to $1.45 million while
revenues related to our Lightbox imaging consoles decreased by 50%
to $0.3 million. The decreased revenues in the three months ended
March&nbsp;31, 2018 reflect the impact of continued product
performance issues with the current version of Pantheris and the
reduced size of our field sales force, as well as a strategic
decision we made in 2017 to realign the focus of our sales force on
driving the utilization at our current installed base rather than
on building the installed base of Lightbox imaging consoles.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style=
"font-size:10.0pt;margin:0in 0in .0001pt;text-align:center;">
26<a name="PB_26_114045_5704" id="PB_26_114045_5704"></a></p>
<div style="margin:0in 0in .0001pt;">
<hr size="3" width="100%" noshade="noshade" align="left" style=
"color:#010101;" /></div>
</div>
<!-- SEQ.=1,FOLIO='26',FILE='C:\JMS\109754\18-8644-1\task8901961\8644-1-ft.htm',USER='109754',CD='May 16 02:07 2018' --><br clear="all"
style="page-break-before:always;" />
<div style="font-family:Times New Roman;">
<p style="margin:0in 0in .0001pt;"><a href="#TableOfContents"
title="Click to go to Table of Contents"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">Table of
Contents</font></a></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style=
"font-size:10.0pt;margin:0in 0in .0001pt;text-indent:.5in;">
<i><font size="2" face="Times New Roman" style=
"font-size:10.0pt;font-style:italic;">Cost of Revenues and Gross
Margin.</font></i>&nbsp; Cost of revenues decreased $2.7 million,
or 65%, to $1.4 million during the three months ended
March&nbsp;31, 2018, compared to $4.1 million during the three
months ended March&nbsp;31, 2017. This decrease was primarily
attributable to $80,000 in charges for excess and obsolescence in
the three months ended March&nbsp;31, 2018, compared to $1.2
million in the three months ended March&nbsp;31, 2017. Gross margin
for the three months ended March&nbsp;31, 2018 increased to 22%,
compared to (17%) in the three months ended March&nbsp;31, 2017.
The increase in gross margin was primarily due to the decreased
charges for inventory excess and obsolescence and decrease of
warranty expenses during the three months ended March&nbsp;31, 2018
compared to the prior year period.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style=
"font-size:10.0pt;margin:0in 0in .0001pt;text-indent:.5in;">
<i><font size="2" face="Times New Roman" style=
"font-size:10.0pt;font-style:italic;">Research and Development
Expenses.</font></i>&nbsp; R&amp;D expenses decreased $2.1 million,
or 55%, to $1.8 million during the three months ended
March&nbsp;31, 2018, compared to $3.9 million during the three
months ended March&nbsp;31, 2017. This decrease was primarily due
to a $1.4 million decrease in personnel-related expenses, a
decrease of $0.2 million in product development materials and
related costs, a decrease of $0.2 million in outside services, and
a decrease of $0.3 million relating to the allocation of facilities
expense Personnel-related expenses included stock-based
compensation expense of $0.1 million compared to $0.5 million for
the three months ended March&nbsp;31, 2018 and 2017,
respectively.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style=
"font-size:10.0pt;margin:0in 0in .0001pt;text-indent:.5in;">
<i><font size="2" face="Times New Roman" style=
"font-size:10.0pt;font-style:italic;">Selling, General and
Administrative Expenses.</font></i>&nbsp; SG&amp;A expenses
decreased $5.1 million, or 54%, to $4.2 million during the three
months ended March&nbsp;31, 2018, compared to $9.3 million during
the three months ended March&nbsp;31, 2017. This decrease was
primarily due to a $3.9 million decrease in personnel-related
expenses, a decrease of $0.3 million in marketing costs, a decrease
of $0.7 million in outside services and decrease of $0.2 million
relating to the allocation of facilities expense. Personnel-related
expenses decreased due to a decrease in headcount and stock-based
compensation expense as a result of our organizational realignment
in 2017. Personnel-related expenses included stock-based
compensation expense of $0.5 million compared to $0.9 million for
the three months ended March&nbsp;31, 2018 and 2017
respectively.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style=
"font-size:10.0pt;margin:0in 0in .0001pt;text-indent:.5in;">
<i><font size="2" face="Times New Roman" style=
"font-size:10.0pt;font-style:italic;">Interest Income (Expense),
Net.</font></i>&nbsp; Interest income (expense), net increased $3.1
million, or 206%, to an expense of $4.6 million during the three
months ended March&nbsp;31, 2018, compared to an expense of $1.5
million during the three months ended March&nbsp;31, 2017. During
the three months ended March&nbsp;31,2018 the Company incurred $3.8
million in fees relating to the conversion of $38.0 million of
principal under the CRG Loan Agreement.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style=
"font-size:10.0pt;margin:0in 0in .0001pt;text-indent:.5in;">
<i><font size="2" face="Times New Roman" style=
"font-size:10.0pt;font-style:italic;">Other Income (Expense),
Net.</font></i>&nbsp; Other income, net decreased $2,000 to an
income of $1,000, during the three months ended March&nbsp;31,
2018, compared to income of $3,000 during the three months ended
March&nbsp;31, 2017. Other income for the three months ended
March&nbsp;31, 2018 and 2017, was primarily attributable to the
remeasurement of foreign exchange transactions.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><b><font size="2" face=
"Times New Roman" style=
"font-size:10.0pt;font-weight:bold;">Liquidity and Capital
Resources</font></b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style=
"font-size:10.0pt;margin:0in 0in .0001pt;text-indent:.5in;">
<font size="2" face="Times New Roman" style="font-size:10.0pt;">As
of March&nbsp;31, 2018, we had cash and cash equivalents of
$14.4&nbsp;million and an accumulated deficit of
$311.6&nbsp;million,</font> compared to cash and cash equivalents
of $5.4&nbsp;million and an accumulated deficit of
$301.3&nbsp;million as of December&nbsp;31, 2017. We believe that
the net proceeds we received from our Series&nbsp;B Offering on
February&nbsp;16, 2018, &nbsp;net proceeds from the sale of our
common stock to Lincoln Park pursuant to the Lincoln Park Purchase
Agreement entered into on November&nbsp;3, 2017, together with our
cash and cash equivalents at December&nbsp;31, 2017, and expected
revenues from operations, will be sufficient to satisfy our capital
requirements and fund our operations for through at least
October&nbsp;31, 2018. We will need to raise additional funds
through future equity or debt financings within the next seven
months to meet our operational needs and capital requirements for
product development, clinical trials and commercialization. We can
provide no assurance that we will be successful in raising funds
pursuant to additional equity or debt financings or that such funds
will be raised at prices that do not create substantial dilution
for our existing stockholders. Given the recent decline in our
stock price, any financing that we undertake in the foreseeable
future could cause substantial dilution to our existing
stockholders. Additional debt financing, if available, may involve
covenants restricting our operations or our ability to incur
additional debt. Any additional debt financing or additional equity
that we raise may contain terms that are not favorable to us or our
stockholders and require significant debt service payments, which
divert resources from other activities. Additional financing may
not be available at all, or if available, may not be in amounts or
on terms acceptable to us. If we are unable to obtain additional
financing, we may be required to delay the development,
commercialization and marketing of our products and we may be
required to significantly scale back our business and
operations.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style=
"font-size:10.0pt;margin:0in 0in .0001pt;text-indent:.5in;">
<font size="2" face="Times New Roman" style="font-size:10.0pt;">To
date, our primary sources of capital have been private placements
of preferred stock, debt financing agreements, our “at-the-market”
program, our IPO and our follow-on public offerings. As previously
disclosed, on April&nbsp;20, May&nbsp;24, and October&nbsp;24, 2017
we received letters from the Listing Qualifications Department of
The Nasdaq Stock Market, LLC (“Nasdaq”) notifying us that we were
not in compliance with applicable listing rules.</font> On
March&nbsp;1, 2018, Nasdaq informed us that we had regained
compliance with the applicable requirements for listing on the
Nasdaq Capital Market.&nbsp; For more information on this risk, see
Part&nbsp;II,&nbsp;Item 1A “<i>Risk Factors</i>.”</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style=
"font-size:10.0pt;margin:0in 0in .0001pt;text-align:center;">
27<a name="PB_27_114107_3020" id="PB_27_114107_3020"></a></p>
<div style="margin:0in 0in .0001pt;">
<hr size="3" width="100%" noshade="noshade" align="left" style=
"color:#010101;" /></div>
</div>
<!-- SEQ.=1,FOLIO='27',FILE='C:\JMS\109754\18-8644-1\task8901961\8644-1-ft.htm',USER='109754',CD='May 16 02:07 2018' --><br clear="all"
style="page-break-before:always;" />
<div style="font-family:Times New Roman;">
<p style="margin:0in 0in .0001pt;"><a href="#TableOfContents"
title="Click to go to Table of Contents"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">Table of
Contents</font></a></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2"
face="Times New Roman" style="font-size:10.0pt;">In
September&nbsp;2015, we entered into a Loan Agreement with CRG,
under which we could borrow up to $50.0&nbsp;million, of which
$30.0&nbsp;million was immediately available and borrowed by us. Of
the remaining $20.0&nbsp;million, we borrowed $10.0 million on
June&nbsp;15, 2016 and the availability of the remaining $10.0
million was contingent on the achievement of certain net revenue
milestones prior to December&nbsp;31, 2016, which were not
achieved. Under the original terms of the Loan Agreement, the first
sixteen quarterly payments are interest-only payments, and the last
eight quarterly payments will be equal installments in which
interest and principal amounts are paid. Interest is calculated at
a fixed rate of 12.5% per annum. We make quarterly payments of
interest only in arrears commencing on September&nbsp;30, 2015.
During the interest-only period, we may elect to make the 12.5%
interest payment by making a cash payment for 8.5% per annum of
interest and making a payment-in-kind, or PIK, for the remaining
amount, for which the 4.0% per annum of interest would be added to
the outstanding principal amount of the loan. To date, we have
elected the PIK option to the extent available and have made a cash
payment for the remaining amount. Principal is repayable in eight
equal quarterly installments during the final two years of the
term. Under the original terms of the Loan Agreement, all unpaid
principal, and accrued and unpaid interest, is due and payable in
full on September&nbsp;30, 2021. As of March&nbsp;31, 2018, we had
$7.5&nbsp;million outstanding under the Loan Agreement. For more
information, see Part&nbsp;I,&nbsp;Item 2 <i>“Contractual
Obligations.”</i></font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style=
"font-size:10.0pt;margin:0in 0in .0001pt;text-align:center;">
28<a name="PB_28_114121_7748" id="PB_28_114121_7748"></a></p>
<div style="margin:0in 0in .0001pt;">
<hr size="3" width="100%" noshade="noshade" align="left" style=
"color:#010101;" /></div>
</div>
<!-- SEQ.=1,FOLIO='28',FILE='C:\JMS\109754\18-8644-1\task8901961\8644-1-ft.htm',USER='109754',CD='May 16 02:07 2018' --><br clear="all"
style="page-break-before:always;" />
<div style="font-family:Times New Roman;">
<p style="margin:0in 0in .0001pt;"><a href="#TableOfContents"
title="Click to go to Table of Contents"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">Table of
Contents</font></a></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2"
face="Times New Roman" style="font-size:10.0pt;">We may voluntarily
prepay the loan in full, with a prepayment premium beginning at 5%
and declining by 1% annually thereafter, with no premium being
payable if prepayment occurs after the fifth year of the loan. Each
tranche of borrowing requires the payment, on the borrowing date,
of a financing fee equal to 1.5% of the principal amount borrowed.
In addition, a facility fee equal to 7.0% of loan principal
borrowed plus any PIK is payable at the end of the term or when the
loan is repaid in full. The term loan is collateralized by a
security interest in substantially all of our assets.&nbsp; We used
the proceeds from the CRG borrowing and securities purchase to
retire our outstanding debt with PDL and to retire the principal
and accrued interest underlying our outstanding notes, which are
described below.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2"
face="Times New Roman" style="font-size:10.0pt;">The Loan Agreement
requires that we adhere to certain affirmative and negative
covenants, including financial reporting requirements, certain
minimum financial covenants for pre-specified liquidity and revenue
requirements and a prohibition against the incurrence of
indebtedness, or creation of additional liens, other than as
specifically permitted by the terms of the Loan Agreement. In
particular, the covenants of the Loan Agreement, as amended as of
December&nbsp;31, 2017, include a covenant that we maintain a
minimum of $5.0 million of cash and certain cash equivalents.&nbsp;
On December&nbsp;14, 2017, we entered into a waiver and consent
agreement (the “Waiver and Consent”) with CRG.&nbsp; The Waiver and
Consent provided for the waiver of the minimum required revenue
financial covenant for the twelve-month period beginning
January&nbsp;1, 2017, as required under the terms of the Loan
Agreement.&nbsp; Pursuant to the Waiver and Consent, CRG also
consented to our payment of the cash interest payment due on
December&nbsp;31, 2017 in the form of a PIK loan instead.&nbsp; On
January&nbsp;24, 2018, we entered into a waiver agreement (the 
“Waiver”) with CRG.&nbsp; The Waiver provided for the waiver of the
$5,000,0000 minimum liquidity financial covenant and reduced it to
$2,500,000 for the period beginning January&nbsp;1, 2018 through
February&nbsp;28, 2018, as required under the terms of the Loan
Agreement and waived any event of default resulting from
non-compliance with the $5,000,000 minimum liquidity financial
covenant.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style=
"font-size:10.0pt;margin:0in 0in .0001pt;text-indent:.5in;">
<font size="2" face="Times New Roman" style="font-size:10.0pt;">On
February&nbsp;14, 2018, we entered into Amendment No.&nbsp;2 to the
Term Loan Agreement (the “Amendment No.&nbsp;2 Loan Agreement”)
with CRG.&nbsp; Under its terms, the Amendment No.&nbsp;2 Loan
Agreement, among other things: (1)&nbsp;extended the interest-only
period through June&nbsp;30, 2021; (2)&nbsp;extended the period
during which the Company may elect to pay a portion of interest in
PIK interest payments through June&nbsp;30, 2021 so long as no
default has occurred and is continuing; (3)&nbsp;permitted the
Company to make its entire interest payments in PIK interest
payments for through December&nbsp;31, 2019 so long as no default
has occurred and is continuing; (4)&nbsp;extended the maturity date
to June&nbsp;30, 2023; (5)&nbsp;reduced the minimum liquidity
requirement to $3.5 million at all times; (6)&nbsp;eliminated the
minimum revenue covenant for 2018 and 2019; (7)&nbsp;reduced the
minimum revenue covenant to $15 million for 2020, $20</font>
&nbsp;million for 2021 and $25 million for 2022;&nbsp; and
(8)&nbsp;provided CRG with board observer rights.&nbsp; If we fail
to meet the applicable minimum revenue target in any calendar year,
the Loan Agreement provides a cure right if we prepay a portion of
the outstanding principal equal to 2.0 times the revenue shortfall.
In addition, the Loan Agreement prohibits the payment of cash
dividends on our capital stock and also places restrictions on
mergers, sales of assets, investments, incurrence of liens,
incurrence of indebtedness and transactions with affiliates. CRG
may accelerate the payment terms of the Loan Agreement upon the
occurrence of certain events of default set forth therein, which
include our failure to make timely payments of amounts due under
the Loan Agreement, the failure to adhere to the covenants set
forth in the Loan Agreement, our insolvency or upon the occurrence
of a material adverse change. We are currently in compliance with
the covenants under the Loan Agreement, but if we default on any
such covenants we will need, and may not be able to obtain, relief
in the form of waivers or amendments to the applicable debt
agreement.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2"
face="Times New Roman" style="font-size:10.0pt;">In addition, on
February&nbsp;14, 2018, we entered into the Series&nbsp;A Purchase
Agreement with CRG, pursuant to which it agreed to convert $38.0
million of the outstanding principal amount of its senior secured
term loan (plus the back-end fee and prepayment premium applicable
thereto) under the Loan Agreement into a newly authorized
Series&nbsp;A preferred stock.&nbsp; Under the terms of the
Series&nbsp;A Purchase Agreement, the holders of Series&nbsp;A
preferred stock are entitled to receive annual accruing dividends
at a rate of 8%, payable in additional shares of Series&nbsp;A
preferred stock or cash, at our option. The shares of Series&nbsp;A
preferred stock have no voting rights and rank senior to all other
classes and series of the Company’s equity in terms of repayment
and certain other rights.&nbsp; The Series&nbsp;A preferred stock
and any of the Company’s common stock issued upon conversion of the
Series&nbsp;A preferred stock is subject to a lockup agreement
through February&nbsp;14, 2019.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style=
"font-size:10.0pt;margin:0in 0in .0001pt;text-indent:.5in;">
<font size="2" face="Times New Roman" style="font-size:10.0pt;">On
February&nbsp;3, 2016, we filed a universal shelf registration
statement to offer up to $150.0 million of our securities and
entered into an</font> “at-the-market” program pursuant to a Sales
Agreement with Cowen, as sales agent, through which we issued and
sold common stock with an aggregate value of approximately $8.7
million between the registration statement’s effectiveness on
March&nbsp;8, 2016 and September&nbsp;2017. During the year ended
December&nbsp;31, 2016, we sold 27,374 shares of common stock
through the “at-the-market” program at an average price of $194.74
and raised net proceeds of $5.2 million, after payment of $0.2
million in commissions and fees to Cowen. During the three months
ended March&nbsp;31, 2018 and 2017, we sold no shares of common
stock through the “at-the-market” program. Due to the SEC’s “baby
shelf rules,” which prohibit companies with a public float of less
than $75 million from issuing securities under a shelf registration
statement in excess of one-third of such company’s public float in
a twelve-month period, we are unable to issue more shares through
our “at-the-market” program at this time. In addition, in
August&nbsp;2016, we issued and sold 246,445 shares of our common
stock in a follow-on public offering at a public offering price of
$140.00 per share, for net proceeds of approximately $31.5 million
after deducting underwriting discounts and commissions of
approximately $2.4 million and other expenses of approximately $0.6
million. The 246,445 shares include the exercise in full by the
underwriters of their option to purchase an additional 32,145
shares of our common stock.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style=
"font-size:10.0pt;margin:0in 0in .0001pt;text-align:center;">
29<a name="PB_29_114145_7608" id="PB_29_114145_7608"></a></p>
<div style="margin:0in 0in .0001pt;">
<hr size="3" width="100%" noshade="noshade" align="left" style=
"color:#010101;" /></div>
</div>
<!-- SEQ.=1,FOLIO='29',FILE='C:\JMS\109754\18-8644-1\task8901961\8644-1-ft.htm',USER='109754',CD='May 16 02:07 2018' --><br clear="all"
style="page-break-before:always;" />
<div style="font-family:Times New Roman;">
<p style="margin:0in 0in .0001pt;"><a href="#TableOfContents"
title="Click to go to Table of Contents"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">Table of
Contents</font></a></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2"
face="Times New Roman" style="font-size:10.0pt;">On
November&nbsp;3, 2017, we entered into the Lincoln Park Purchase
Agreement pursuant to which Lincoln Park is obligated to purchase,
at our request, up to $15.0 million of our common stock over a
30-month period, subject to certain limitations set forth in the
purchase agreement. As a fee for Lincoln Park’s commitment to
purchase such shares, we issued 943,396 shares of common stock to
Lincoln Park on November&nbsp;3, 2017. As obligated under a
registration rights agreement entered into with Lincoln Park in
connection with the Purchase Agreement, we filed a registration
statement on Form&nbsp;S-1 on November&nbsp;6, 2017 for up to
248,750 of such shares, which registration statement was declared
effective by the SEC on November&nbsp;17, 2017.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2"
face="Times New Roman" style="font-size:10.0pt;">On
February&nbsp;16, 2018, we completed a public offering of 17,979
shares of Series&nbsp;B preferred stock and warrants to purchase
17,979,000 shares of common stock.&nbsp; As a result, we received
net proceeds of approximately $16.0 million after underwriting
discounts, commissions, legal and accounting fees of approximately
$1.9 million.&nbsp; The Series&nbsp;B preferred stock has a
liquidation preference of $0.001 per share, full ratchet price
based anti-dilution protection, has no voting rights and is subject
to certain ownership limitations. The Series&nbsp;B preferred stock
is immediately convertible at the option of the holder, has no
stated maturity, and does not pay regularly stated dividends or
interest.&nbsp; Each share of Series&nbsp;B preferred stock is
accompanied by one Series&nbsp;1 warrant that expires on the
seventh anniversary of the date of issuance to purchase up to 500
shares of common stock&nbsp; and one Series&nbsp;2 warrant that
expires on the earlier of (i)&nbsp;the seventh anniversary of the
date of issuance or (ii)&nbsp;the 60th calendar day following the
receipt and announcement of FDA clearance of our Pantheris
below-the-knee device (or the same or similar product with a
different name) to purchase up to 500 shares of common stock;
provided, however, if at any time during such 60-day period the
volume weighted average price for any trading day is less than the
then effective exercise price, the termination date shall be
extended to the seven year anniversary of the initial exercise
date.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><b><font size="2" face=
"Times New Roman" style="font-size:10.0pt;font-weight:bold;">Cash
Flows</font></b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<table border="0" cellspacing="0" cellpadding="0" width="86%"
style="border-collapse:collapse;margin-left:.5in;">
<tr>
<td width="65%" valign="bottom" style=
"padding:0in 0in 0in 0in;width:65.4%;">
<p style="margin:0in 0in .0001pt;"><b><font size="1" face=
"Times New Roman" style=
"font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>
</td>
<td width="2%" valign="bottom" style=
"padding:0in 0in 0in 0in;width:2.88%;">
<p align="center" style=
"margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face=
"Times New Roman" style=
"font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>
</td>
<td width="30%" colspan="5" valign="bottom" style=
"border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:30.56%;">
<p align="center" style=
"margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face=
"Times New Roman" style=
"font-size:8.0pt;font-weight:bold;">Three&nbsp;Months&nbsp;Ended&nbsp;March&nbsp;31,</font></b></p>
</td>
<td width="1%" valign="bottom" style=
"padding:0in 0in 0in 0in;width:1.16%;">
<p align="center" style=
"margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face=
"Times New Roman" style=
"font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>
</td>
</tr>
<tr>
<td width="65%" valign="bottom" style=
"padding:0in 0in 0in 0in;width:65.4%;">
<p style="margin:0in 0in .0001pt;"><b><font size="1" face=
"Times New Roman" style=
"font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>
</td>
<td width="2%" valign="bottom" style=
"padding:0in 0in 0in 0in;width:2.88%;">
<p align="center" style=
"margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face=
"Times New Roman" style=
"font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>
</td>
<td width="13%" colspan="2" valign="bottom" style=
"border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:13.84%;">
<p align="center" style=
"margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face=
"Times New Roman" style=
"font-size:8.0pt;font-weight:bold;">2018</font></b></p>
</td>
<td width="2%" valign="bottom" style=
"padding:0in 0in 0in 0in;width:2.88%;">
<p align="center" style=
"margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face=
"Times New Roman" style=
"font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>
</td>
<td width="13%" colspan="2" valign="bottom" style=
"border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:13.84%;">
<p align="center" style=
"margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face=
"Times New Roman" style=
"font-size:8.0pt;font-weight:bold;">2017</font></b></p>
</td>
<td width="1%" valign="bottom" style=
"padding:0in 0in 0in 0in;width:1.16%;">
<p align="center" style=
"margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face=
"Times New Roman" style=
"font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>
</td>
</tr>
<tr>
<td width="65%" valign="bottom" style=
"padding:0in 0in 0in 0in;width:65.4%;">
<p style="margin:0in 0in .0001pt;"><b><font size="1" face=
"Times New Roman" style=
"font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>
</td>
<td width="2%" valign="bottom" style=
"padding:0in 0in 0in 0in;width:2.88%;">
<p align="center" style=
"margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face=
"Times New Roman" style=
"font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>
</td>
<td width="30%" colspan="5" valign="bottom" style=
"padding:0in 0in 0in 0in;width:30.56%;">
<p align="center" style=
"margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face=
"Times New Roman" style=
"font-size:8.0pt;font-weight:bold;">(in&nbsp;thousands)</font></b></p>
</td>
<td width="1%" valign="bottom" style=
"padding:0in 0in 0in 0in;width:1.16%;">
<p align="center" style=
"margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face=
"Times New Roman" style=
"font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>
</td>
</tr>
<tr>
<td width="65%" valign="top" bgcolor="#CCEEFF" style=
"background:#CCEEFF;padding:0in 0in 0in 0in;width:65.4%;">
<p style="margin:0in 0in .0001pt 10.1pt;text-indent:-10.1pt;">
<font size="2" face="Times New Roman" style="font-size:10.0pt;">Net
cash (used in) provided by:</font></p>
</td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style=
"background:#CCEEFF;padding:0in 0in 0in 0in;width:2.88%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>
</td>
<td width="13%" colspan="2" valign="bottom" bgcolor="#CCEEFF"
style="background:#CCEEFF;padding:0in 0in 0in 0in;width:13.84%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;">
<font size="2" face="Times New Roman" style=
"font-size:1.0pt;">&nbsp;</font></p>
</td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style=
"background:#CCEEFF;padding:0in 0in 0in 0in;width:2.88%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>
</td>
<td width="13%" colspan="2" valign="bottom" bgcolor="#CCEEFF"
style="background:#CCEEFF;padding:0in 0in 0in 0in;width:13.84%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;">
<font size="2" face="Times New Roman" style=
"font-size:1.0pt;">&nbsp;</font></p>
</td>
<td width="1%" valign="bottom" bgcolor="#CCEEFF" style=
"background:#CCEEFF;padding:0in 0in 0in 0in;width:1.16%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>
</td>
</tr>
<tr>
<td width="65%" valign="top" style=
"padding:0in 0in 0in 0in;width:65.4%;">
<p style="margin:0in 0in .0001pt 20.2pt;text-indent:-10.1pt;">
<font size="2" face="Times New Roman" style=
"font-size:10.0pt;">Operating activities</font></p>
</td>
<td width="2%" valign="bottom" style=
"padding:0in 0in 0in 0in;width:2.88%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>
</td>
<td width="1%" valign="bottom" style=
"padding:0in 0in 0in 0in;width:1.3%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">$</font></p>
</td>
<td width="12%" valign="bottom" style=
"padding:0in 0in 0in 0in;width:12.54%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;">
<font size="2" face="Times New Roman" style=
"font-size:10.0pt;">(6,877</font></p>
</td>
<td width="2%" valign="bottom" style=
"padding:0in 0in 0in 0in;width:2.88%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">)</font></p>
</td>
<td width="1%" valign="bottom" style=
"padding:0in 0in 0in 0in;width:1.3%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">$</font></p>
</td>
<td width="12%" valign="bottom" style=
"padding:0in 0in 0in 0in;width:12.54%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;">
<font size="2" face="Times New Roman" style=
"font-size:10.0pt;">(13,263</font></p>
</td>
<td width="1%" valign="bottom" style=
"padding:0in 0in 0in 0in;width:1.16%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">)</font></p>
</td>
</tr>
<tr>
<td width="65%" valign="top" bgcolor="#CCEEFF" style=
"background:#CCEEFF;padding:0in 0in 0in 0in;width:65.4%;">
<p style="margin:0in 0in .0001pt 20.2pt;text-indent:-10.1pt;">
<font size="2" face="Times New Roman" style=
"font-size:10.0pt;">Investing activities</font></p>
</td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style=
"background:#CCEEFF;padding:0in 0in 0in 0in;width:2.88%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>
</td>
<td width="13%" colspan="2" valign="bottom" bgcolor="#CCEEFF"
style="background:#CCEEFF;padding:0in 0in 0in 0in;width:13.84%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;">
<font size="2" face="Times New Roman" style=
"font-size:10.0pt;">46</font></p>
</td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style=
"background:#CCEEFF;padding:0in 0in 0in 0in;width:2.88%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>
</td>
<td width="13%" colspan="2" valign="bottom" bgcolor="#CCEEFF"
style="background:#CCEEFF;padding:0in 0in 0in 0in;width:13.84%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;">
<font size="2" face="Times New Roman" style=
"font-size:10.0pt;">(29</font></p>
</td>
<td width="1%" valign="bottom" bgcolor="#CCEEFF" style=
"background:#CCEEFF;padding:0in 0in 0in 0in;width:1.16%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">)</font></p>
</td>
</tr>
<tr>
<td width="65%" valign="top" style=
"padding:0in 0in 0in 0in;width:65.4%;">
<p style="margin:0in 0in .0001pt 20.2pt;text-indent:-10.1pt;">
<font size="2" face="Times New Roman" style=
"font-size:10.0pt;">Financing activities</font></p>
</td>
<td width="2%" valign="bottom" style=
"padding:0in 0in 0in 0in;width:2.88%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>
</td>
<td width="13%" colspan="2" valign="bottom" style=
"border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:13.84%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;">
<font size="2" face="Times New Roman" style=
"font-size:10.0pt;">15,860</font></p>
</td>
<td width="2%" valign="bottom" style=
"padding:0in 0in 0in 0in;width:2.88%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>
</td>
<td width="13%" colspan="2" valign="bottom" style=
"border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:13.84%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;">
<font size="2" face="Times New Roman" style=
"font-size:10.0pt;">230</font></p>
</td>
<td width="1%" valign="bottom" style=
"padding:0in 0in 0in 0in;width:1.16%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>
</td>
</tr>
<tr>
<td width="65%" valign="top" bgcolor="#CCEEFF" style=
"background:#CCEEFF;padding:0in 0in 0in 0in;width:65.4%;">
<p style="margin:0in 0in .0001pt 10.1pt;text-indent:-10.1pt;">
<font size="2" face="Times New Roman" style="font-size:10.0pt;">Net
increase (decrease) in cash and cash equivalents</font></p>
</td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style=
"background:#CCEEFF;padding:0in 0in 0in 0in;width:2.88%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>
</td>
<td width="1%" valign="bottom" bgcolor="#CCEEFF" style=
"background:#CCEEFF;border:none;border-bottom:double windowtext 2.25pt;padding:0in 0in 0in 0in;width:1.3%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">$</font></p>
</td>
<td width="12%" valign="bottom" bgcolor="#CCEEFF" style=
"background:#CCEEFF;border:none;border-bottom:double windowtext 2.25pt;padding:0in 0in 0in 0in;width:12.54%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;">
<font size="2" face="Times New Roman" style=
"font-size:10.0pt;">9,029</font></p>
</td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style=
"background:#CCEEFF;padding:0in 0in 0in 0in;width:2.88%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>
</td>
<td width="1%" valign="bottom" bgcolor="#CCEEFF" style=
"background:#CCEEFF;border:none;border-bottom:double windowtext 2.25pt;padding:0in 0in 0in 0in;width:1.3%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">$</font></p>
</td>
<td width="12%" valign="bottom" bgcolor="#CCEEFF" style=
"background:#CCEEFF;border:none;border-bottom:double windowtext 2.25pt;padding:0in 0in 0in 0in;width:12.54%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;">
<font size="2" face="Times New Roman" style=
"font-size:10.0pt;">(13,062</font></p>
</td>
<td width="1%" valign="bottom" bgcolor="#CCEEFF" style=
"background:#CCEEFF;padding:0in 0in 2.25pt 0in;width:1.16%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">)</font></p>
</td>
</tr>
</table>
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><b><i><font size="2" face=
"Times New Roman" style=
"font-size:10.0pt;font-style:italic;font-weight:bold;">Net Cash
Used in Operating Activities</font></i></b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2"
face="Times New Roman" style="font-size:10.0pt;">Net cash used in
operating activities for the three months ended March&nbsp;31, 2018
was $6.9 million, consisting primarily of a net loss of $10.3
million and a decrease in net operating assets of $2.0 million,
offset by non-cash charges of $5.4 million. The decrease in net
operating assets was due to a decrease in other liabilities related
to the payment of litigation settlement expense, assigned interest
to PDL, partially offset by an increase in inventories, prepaid
expenses, accounts payable, due to timing of payments. The non-cash
charges primarily consisted of depreciation, stock-based
compensation, non-cash interest expense and other charges related
to our credit agreement with CRG, and an increased reserve for
excess and obsolescence in inventories.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2"
face="Times New Roman" style="font-size:10.0pt;">Net cash used in
operating activities for the three months ended March&nbsp;31, 2017
was $13.3 million, consisting primarily of a net loss of $15.3
million and an increase in net operating assets of $1.9 million,
offset by non-cash charges of $3.9 million. The increase in net
operating assets was due to an increase in inventories, prepaid
expenses and other current assets, decreases in accounts payable,
due to timing of payments, decreases in other liabilities related
to the repayment of assigned interest to PDL and a decrease in
accrued compensation, partially offset by a decrease in accounts
receivable. The non-cash charges primarily consisted of
depreciation, stock-based compensation, non-cash interest expense
and other charges related to our credit agreement with CRG, and an
increased reserve for excess and obsolescence in
inventories.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><b><i><font size="2" face=
"Times New Roman" style=
"font-size:10.0pt;font-style:italic;font-weight:bold;">Net Cash
Used in Investing Activities</font></i></b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2"
face="Times New Roman" style="font-size:10.0pt;">Net cash used in
investing activities in the three months ended March&nbsp;31, 2018
was $0.3 million consisting of purchases of property and
equipment.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style=
"font-size:10.0pt;margin:0in 0in .0001pt;text-align:center;">
30<a name="PB_30_114228_8146" id="PB_30_114228_8146"></a></p>
<div style="margin:0in 0in .0001pt;">
<hr size="3" width="100%" noshade="noshade" align="left" style=
"color:#010101;" /></div>
</div>
<!-- SEQ.=1,FOLIO='30',FILE='C:\JMS\109754\18-8644-1\task8901961\8644-1-ft.htm',USER='109754',CD='May 16 02:07 2018' --><br clear="all"
style="page-break-before:always;" />
<div style="font-family:Times New Roman;">
<p style="margin:0in 0in .0001pt;"><a href="#TableOfContents"
title="Click to go to Table of Contents"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">Table of
Contents</font></a></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2"
face="Times New Roman" style="font-size:10.0pt;">Net cash used in
investing activities in the three months ended March&nbsp;31, 2017
was $29,000 consisting of purchases of property and
equipment.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><b><i><font size="2" face=
"Times New Roman" style=
"font-size:10.0pt;font-style:italic;font-weight:bold;">Net Cash
Provided by Financing Activities</font></i></b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2"
face="Times New Roman" style="font-size:10.0pt;">Net cash provided
by financing activities in the three months ended March&nbsp;31,
2018 of $15.9 million primarily relates to proceeds from purchases
under our financing activities.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2"
face="Times New Roman" style="font-size:10.0pt;">Net cash provided
by financing activities in the three months ended March&nbsp;31,
2017 of $0.2 million primarily relates to proceeds from purchases
under our employee stock purchase plan.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><b><font size="2" face=
"Times New Roman" style=
"font-size:10.0pt;font-weight:bold;">Off-Balance Sheet
Arrangements</font></b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2"
face="Times New Roman" style="font-size:10.0pt;">We currently have
no off-balance sheet arrangements and we currently do not use any
structured finance, special purpose entities, or variable interest
entities.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><b><font size="2" face=
"Times New Roman" style=
"font-size:10.0pt;font-weight:bold;">Contractual
Obligations</font></b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style=
"font-size:10.0pt;margin:0in 0in .0001pt;text-indent:.5in;">
<font size="2" face="Times New Roman" style="font-size:10.0pt;">Our
principal obligations consist of the operating lease for our
facilities, capital leases related to office equipment,</font> our
remaining royalty obligations with PDL, our Loan Agreement with CRG
and non-cancellable purchase commitments.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2"
face="Times New Roman" style="font-size:10.0pt;">There have been no
other material changes to our contractual obligations from those
described in our Annual Report on Form&nbsp;10-K, as filed with the
SEC on March&nbsp;30, 2018.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style=
"font-size:10.0pt;margin:0in 0in .0001pt 46.1pt;text-indent:-46.1pt;">
<b><font size="2" face="Times New Roman" style=
"font-size:10.0pt;font-weight:bold;">ITEM 3.</font></b><font size=
"1" style=
"font-size:3.0pt;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</font>
<b>QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET
RISK</b><a name="ITEM3_QUANTITATIVEANDQUALITATIVE_114241" id=
"ITEM3_QUANTITATIVEANDQUALITATIVE_114241"></a></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><b><i><font size="2" face=
"Times New Roman" style=
"font-size:10.0pt;font-style:italic;font-weight:bold;">Interest
Rate Risk</font></i></b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2"
face="Times New Roman" style="font-size:10.0pt;">The risk
associated with fluctuating interest rates is primarily limited to
our cash equivalents, which are carried at quoted market prices.
Due to the short-term maturities and low risk profile of our cash
equivalents, an immediate 100 basis point change in interest rates
would not have a material effect on the fair value of our cash
equivalents. We do not currently use or plan to use financial
derivatives in our investment portfolio.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><b><i><font size="2" face=
"Times New Roman" style=
"font-size:10.0pt;font-style:italic;font-weight:bold;">Credit
Risk</font></i></b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2"
face="Times New Roman" style="font-size:10.0pt;">As of
March&nbsp;31, 2018 and December&nbsp;31, 2017, our cash and cash
equivalents were maintained with one financial institution in the
United States, and our current deposits are likely in excess of
insured limits. We have reviewed the financial statements of this
institution and believe it has sufficient assets and liquidity to
conduct its operations in the ordinary course of business with
little or no credit risk to us.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2"
face="Times New Roman" style="font-size:10.0pt;">Our accounts
receivable primarily relates to revenues from the sale of our
Lumivascular platform products to hospitals and medical centers in
the United States. None of our customers represented more than 10%
of our accounts receivable as of March&nbsp;31, 2018 and
December&nbsp;31, 2017.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><b><i><font size="2" face=
"Times New Roman" style=
"font-size:10.0pt;font-style:italic;font-weight:bold;">Foreign
Currency Risk</font></i></b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2"
face="Times New Roman" style="font-size:10.0pt;">Our business is
primarily conducted in U.S. dollars. Any transactions that may be
conducted in foreign currencies are not expected to have a material
effect on our results of operations, financial position or cash
flows. Based on our foreign currency balances of monetary assets
and liabilities, we estimate that a 10% adverse change in Euro
exchange rates versus the U.S. dollar would not have a material
effect on the fair value of our monetary assets.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style=
"font-size:10.0pt;margin:0in 0in .0001pt 46.1pt;text-indent:-46.1pt;">
<b><font size="2" face="Times New Roman" style=
"font-size:10.0pt;font-weight:bold;">ITEM 4.</font></b><font size=
"1" style=
"font-size:3.0pt;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</font>
<b>CONTROLS AND PROCEDURES</b><a name=
"ITEM4_CONTROLSANDPROCEDURES_114248" id=
"ITEM4_CONTROLSANDPROCEDURES_114248"></a></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><b><font size="2" face=
"Times New Roman" style=
"font-size:10.0pt;font-weight:bold;">Evaluation of Disclosure
Controls and Procedures</font></b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style=
"font-size:10.0pt;margin:0in 0in .0001pt;text-indent:.5in;">
<font size="2" face="Times New Roman"><font style=
"font-size:10.0pt;">We maintain disclosure controls and procedures
that are designed to ensure that information required to be
disclosed in our reports under the Securities Exchange Act of 1934,
as amended, or the Exchange Act, and the rules&nbsp;and regulations
thereunder, is</font></font> recorded, processed, summarized and
reported within the time periods specified in the SEC’s
rules&nbsp;and forms and that such</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style=
"font-size:10.0pt;margin:0in 0in .0001pt;text-align:center;">
31<a name="PB_31_114315_7091" id="PB_31_114315_7091"></a></p>
<div style="margin:0in 0in .0001pt;">
<hr size="3" width="100%" noshade="noshade" align="left" style=
"color:#010101;" /></div>
</div>
<!-- SEQ.=1,FOLIO='31',FILE='C:\JMS\109754\18-8644-1\task8901961\8644-1-ft.htm',USER='109754',CD='May 16 02:07 2018' --><br clear="all"
style="page-break-before:always;" />
<div style="font-family:Times New Roman;">
<p style="margin:0in 0in .0001pt;"><a href="#TableOfContents"
title="Click to go to Table of Contents"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">Table of
Contents</font></a></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">information is
accumulated and communicated to our management, including our
principal executive officer and principal financial officer, as
appropriate, to allow for timely decisions regarding required
disclosure. In designing and evaluating the disclosure controls and
procedures, management recognizes that any controls and procedures,
no matter how well designed and operated, can provide only
reasonable assurance of achieving the desired control objectives,
and management is required to apply its judgment in evaluating the
cost-benefit relationship of possible controls and
procedures.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2"
face="Times New Roman" style="font-size:10.0pt;">As required by
Rule&nbsp;13a-15(b)&nbsp;under the Exchange Act, our management,
under the supervision and with the participation of our principal
executive officer and principal financial officer, has evaluated
the effectiveness of the design and operation of our disclosure
controls and procedures (as such term is defined in
Rules&nbsp;13a-15(e)&nbsp;and 15d-15(e)&nbsp;under the Exchange
Act) as of March&nbsp;31, 2018. Based on such evaluation, our
principal executive officer and principal financial officer have
concluded that, as of March&nbsp;31, 2018, our disclosure controls
and procedures were effective.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><b><font size="2" face=
"Times New Roman" style=
"font-size:10.0pt;font-weight:bold;">Changes in Internal Control
over Financial Reporting</font></b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2"
face="Times New Roman" style="font-size:10.0pt;">There were no
changes in our internal controls over financial reporting
identified in management’s evaluation pursuant to
Rules&nbsp;13a-15(d)&nbsp;and 15d-15(d)&nbsp;of the Exchange Act
that occurred during the first quarter of 2018 that materially
affected, or are reasonably likely to materially affect, our
internal control over financial reporting.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style=
"font-size:10.0pt;margin:0in 0in .0001pt;text-align:center;">
32<a name="PB_32_114326_455" id="PB_32_114326_455"></a></p>
<div style="margin:0in 0in .0001pt;">
<hr size="3" width="100%" noshade="noshade" align="left" style=
"color:#010101;" /></div>
</div>
<!-- SEQ.=1,FOLIO='32',FILE='C:\JMS\109754\18-8644-1\task8901961\8644-1-ft.htm',USER='109754',CD='May 16 02:07 2018' --><br clear="all"
style="page-break-before:always;" />
<div style="font-family:Times New Roman;">
<p style="margin:0in 0in .0001pt;"><a href="#TableOfContents"
title="Click to go to Table of Contents"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">Table of
Contents</font></a></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;"><b><font size=
"2" face="Times New Roman" style=
"font-size:10.0pt;font-weight:bold;">PART&nbsp;II.</font></b><font size="1"
style=
"font-size:8.5pt;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</font>
<b>OTHER INFORMATION</b><a name="PARTII_OTHERINFORMATION_114446"
id="PARTII_OTHERINFORMATION_114446"></a></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;"><b><font size=
"2" face="Times New Roman" style=
"font-size:10.0pt;font-weight:bold;">ITEM 1.</font></b><font size=
"1" style=
"font-size:8.5pt;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</font>
<b>LEGAL PROCEEDINGS</b><a name="ITEM1_LEGALPROCEEDINGS_114448" id=
"ITEM1_LEGALPROCEEDINGS_114448"></a></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style=
"font-size:10.0pt;margin:0in 0in .0001pt;text-indent:.5in;">
<font size="2" face="Times New Roman" style=
"font-size:10.0pt;">Except as set forth below, as of the date of
this Quarterly Report on Form&nbsp;10-Q, we are not involved in any
pending legal proceedings that we believe could have a material
adverse effect on our financial condition, results of operations or
cash flows.&nbsp;</font>From time to time we may be involved in
legal proceedings or investigations, which could harm our
reputation, business and financial condition and divert the
attention of our management from the operation of our business.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2"
face="Times New Roman" style="font-size:10.0pt;">Between
May&nbsp;22, 2017 and May&nbsp;25, 2017, three class actions were
filed in the Superior Court of the State of California, County of
San Mateo (“State Court”), against us and certain of our officers
and directors. The underwriters of our IPO in January&nbsp;2015 are
also named as defendants. The actions were captioned Grotewiel v.
Avinger,&nbsp;Inc., et al., No.&nbsp;17-CIV-02240, Gonzalez v.
Avinger,&nbsp;Inc., et al., No.&nbsp;17-CIV-02284, and Olberding v.
Avinger,&nbsp;Inc., et al., No.&nbsp;17-CIV-02307. These lawsuits
allege that the registration statement for our IPO made false and
misleading statements and omissions in violation of the Securities
Act of 1933. Plaintiffs seek to represent a class of purchasers of
our common stock in and/or traceable to our IPO. Plaintiffs seek,
among other things, unspecified compensatory damages, interest,
costs, recission, and attorneys’ fees. On June&nbsp;12, 2017,
defendants removed these actions to the United States District
Court for the Northern District of California (“Federal Court”),
where they were captioned Grotewiel v. Avinger,&nbsp;Inc.,
No.&nbsp;17-cv-03400, Gonzalez v. Avinger,&nbsp;Inc.,
No.&nbsp;17-cv-03401, and Olberding v. Avinger,&nbsp;Inc.,
No.&nbsp;17-cv-03398, and where the actions were related and
assigned to the same judge.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style=
"font-size:10.0pt;margin:0in 0in .0001pt;text-indent:.5in;">
<font size="2" face="Times New Roman" style="font-size:10.0pt;">On
June&nbsp;22, 2017, and June&nbsp;23, 2017, plaintiffs Olberding
and Gonzalez moved to remand their cases to the State Court.
Defendants opposed these motions. On July&nbsp;21, 2017, the
Federal Court granted the motions to remand the Olberding and
Gonzalez actions to the State Court.&nbsp;On August&nbsp;9, 2017,
the State Court consolidated the Olberding and Gonzalez actions
under the caption Gonzalez v. Avinger,&nbsp;Inc., et al.,
No.&nbsp;17-CIV-02284 (“State Action”).&nbsp;On September&nbsp;22,
2017, an amended complaint was filed in the State Action. On
October&nbsp;31, 2017, the parties in the State Action stipulated
to a stay of proceedings until judgment is entered in the</font>
federal Grotewiel action (“Federal Action”).</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2"
face="Times New Roman" style="font-size:10.0pt;">On
October&nbsp;11, 2017, the Federal Court appointed a lead plaintiff
and approved the selection of a lead counsel in the Federal Action.
An amended complaint was filed in the Federal Action on
November&nbsp;21, 2017. In order to allow the parties to pursue
mandatory alternative dispute resolution, the parties have
stipulated and the Federal Court ordered that defendants’ motion to
dismiss the Federal Action will be due on January&nbsp;17, 2018,
with a hearing set for May&nbsp;1, 2018.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2"
face="Times New Roman" style="font-size:10.0pt;">The Company and
its directors believe that the foregoing lawsuits were entirely
without merit however, in the interest of avoiding the cost and
disruption of continuing to defend against these lawsuits, on
February&nbsp;8, 2018 the Company participated in a mediation to
explore whether a settlement could be reached. While a settlement
was not reached then, the parties continued discussions and they
ultimately reached agreement.&nbsp; On March&nbsp;19, 2018, the
Company entered into a binding memorandum of understanding to
settle the securities class actions pending against the Company and
several of its officers and directors. The settlement is for a
total of $5 million and, if approved by the court, will result in a
full release of claims against all defendants. The Company’s total
contribution to the settlement fund is $1.76 million.&nbsp; The
settlement is subject to final documentation, notice to class
members, and approval of the court.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;"><b><font size=
"2" face="Times New Roman" style=
"font-size:10.0pt;font-weight:bold;">ITEM&nbsp;1A.</font></b><font size="1"
style=
"font-size:8.5pt;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</font>
<b>RISK FACTORS</b><a name="ITEM1A_RISKFACTORS_114449" id=
"ITEM1A_RISKFACTORS_114449"></a></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style=
"font-size:10.0pt;margin:0in 0in .0001pt;text-indent:.5in;">
<i><font size="2" face="Times New Roman" style=
"font-size:10.0pt;font-style:italic;">Investing in our common stock
involves a high degree of risk.</font></i> <i>We have identified
the following risks and uncertainties that may have a material
adverse effect on our business, financial condition, results of
operations</i> <i>and future growth prospects</i><i>. Our business
could be harmed by any of these risks. The risks and uncertainties
described below are not the only ones we face.</i> <i>If any of the
risks actually occur, our business, financial condition, results of
operations, cash flows and prospects could be materially and
adversely affected.</i> <i>The trading price of our common stock
could decline due to any of these risks, and you may lose all or
part of your investment. In assessing these risks, you should also
refer to the other information contained in this Quarterly Report
on Form&nbsp;10-Q, including our financial statements and related
notes. Please also see “</i><i>Cautionary Notes</i> <i>Regarding
Forward-Looking Statements.”</i></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style=
"margin:0in 0in .0001pt;text-align:center;"><b><font size="2" face=
"Times New Roman" style="font-size:10.0pt;font-weight:bold;">Risks
Related to Our Business</font></b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><b><i><font size="2" face=
"Times New Roman" style=
"font-size:10.0pt;font-style:italic;font-weight:bold;">Our
quarterly and annual results may fluctuate significantly, may not
fully reflect the underlying performance of our business and may
result in decreases in the price of our common
stock.</font></i></b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2"
face="Times New Roman" style="font-size:10.0pt;">Our quarterly and
annual results of operations, including our revenues, profitability
and cash flow, may vary significantly in the future and
period-to-period comparisons of our operating results may not be
meaningful. Accordingly, the results of any one quarter or period
should not be relied upon as an indication of future performance.
Our quarterly and annual financial results may</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style=
"font-size:10.0pt;margin:0in 0in .0001pt;text-align:center;">
33<a name="PB_33_113435_2212" id="PB_33_113435_2212"></a></p>
<div style="margin:0in 0in .0001pt;">
<hr size="3" width="100%" noshade="noshade" align="left" style=
"color:#010101;" /></div>
</div>
<!-- SEQ.=1,FOLIO='33',FILE='C:\JMS\109761\18-8644-1\task8901132\8644-1-ga.htm',USER='109761',CD='May 15 15:54 2018' --><br clear="all"
style="page-break-before:always;" />
<div style="font-family:Times New Roman;">
<p style="margin:0in 0in .0001pt;"><a href="#TableOfContents"
title="Click to go to Table of Contents"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">Table of
Contents</font></a></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">fluctuate as a result
of a variety of factors, many of which are outside our control and,
as a result, may not fully reflect the underlying performance of
our business. Fluctuation in quarterly and annual results may
decrease the value of our common stock. Factors that may cause
fluctuations in our quarterly and annual results include, without
limitation:</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style=
"font-size:10.0pt;margin:0in 0in .0001pt .75in;text-indent:-.25in;">
<font size="2" face="Symbol" style=
"font-size:10.0pt;">·</font><font size="1" style=
"font-size:8.5pt;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</font> our
ability to obtain and maintain FDA clearance and approval from
foreign regulatory authorities for our products, and the timing of
such clearances and approvals, particularly with respect to current
and future generations of Pantheris;</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style=
"font-size:10.0pt;margin:0in 0in .0001pt .75in;text-indent:-.25in;">
<font size="2" face="Symbol" style=
"font-size:10.0pt;">·</font><font size="1" style=
"font-size:8.5pt;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</font> market
acceptance of our Lumivascular platform and products, including
Pantheris;</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style=
"font-size:10.0pt;margin:0in 0in .0001pt .75in;text-indent:-.25in;">
<font size="2" face="Symbol" style=
"font-size:10.0pt;">·</font><font size="1" style=
"font-size:8.5pt;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</font> the
availability of reimbursement for our Lumivascular platform
products;</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style=
"font-size:10.0pt;margin:0in 0in .0001pt .75in;text-indent:-.25in;">
<font size="2" face="Symbol" style=
"font-size:10.0pt;">·</font><font size="1" style=
"font-size:8.5pt;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</font> our
ability to attract new customers and increase the amount of
business we generate from existing customers;</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style=
"font-size:10.0pt;margin:0in 0in .0001pt .75in;text-indent:-.25in;">
<font size="2" face="Symbol" style=
"font-size:10.0pt;">·</font><font size="1" style=
"font-size:8.5pt;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</font> results of
our clinical trials;</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style=
"font-size:10.0pt;margin:0in 0in .0001pt .75in;text-indent:-.25in;">
<font size="2" face="Symbol" style=
"font-size:10.0pt;">·</font><font size="1" style=
"font-size:8.5pt;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</font> the timing
and success of new product and feature introductions by us or our
competitors or any other change in the competitive dynamics of our
industry, including consolidation among competitors, customers or
strategic partners;</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style=
"font-size:10.0pt;margin:0in 0in .0001pt .75in;text-indent:-.25in;">
<font size="2" face="Symbol" style=
"font-size:10.0pt;">·</font><font size="1" style=
"font-size:8.5pt;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</font> the amount
and timing of costs and expenses related to the maintenance and
expansion of our business and operations;</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style=
"font-size:10.0pt;margin:0in 0in .0001pt .75in;text-indent:-.25in;">
<font size="2" face="Symbol" style=
"font-size:10.0pt;">·</font><font size="1" style=
"font-size:8.5pt;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</font> changes in
our pricing policies or those of our competitors;</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style=
"font-size:10.0pt;margin:0in 0in .0001pt .75in;text-indent:-.25in;">
<font size="2" face="Symbol" style=
"font-size:10.0pt;">·</font><font size="1" style=
"font-size:8.5pt;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</font> general
economic, political, industry and market conditions, including
economic and political uncertainty caused by the recent U.S.
presidential election;</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style=
"font-size:10.0pt;margin:0in 0in .0001pt .75in;text-indent:-.25in;">
<font size="2" face="Symbol" style=
"font-size:10.0pt;">·</font><font size="1" style=
"font-size:8.5pt;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</font> the
regulatory environment;</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style=
"font-size:10.0pt;margin:0in 0in .0001pt .75in;text-indent:-.25in;">
<font size="2" face="Symbol" style=
"font-size:10.0pt;">·</font><font size="1" style=
"font-size:8.5pt;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</font> the
hiring, training and retention of key employees, including our
sales team;</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style=
"font-size:10.0pt;margin:0in 0in .0001pt .75in;text-indent:-.25in;">
<font size="2" face="Symbol" style=
"font-size:10.0pt;">·</font><font size="1" style=
"font-size:8.5pt;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</font> the
ability of our remaining sales and marketing personnel to maintain
and increase our revenues after the April&nbsp;organizational
realignment and September&nbsp;2017 cost reduction plan;</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style=
"font-size:10.0pt;margin:0in 0in .0001pt .75in;text-indent:-.25in;">
<font size="2" face="Symbol" style=
"font-size:10.0pt;">·</font><font size="1" style=
"font-size:8.5pt;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</font> the cost
and potential outcomes of existing and future litigation,
including, without limitation, the purported stockholder class
action described below under “<i>Risks Related to our Common Stock
and Preferred Stock—Our stock price may be volatile, and purchasers
of our common stock could incur substantial losses.</i>”;</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style=
"font-size:10.0pt;margin:0in 0in .0001pt .75in;text-indent:-.25in;">
<font size="2" face="Symbol" style=
"font-size:10.0pt;">·</font><font size="1" style=
"font-size:8.5pt;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</font> our
ability to obtain additional financing; and</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style=
"font-size:10.0pt;margin:0in 0in .0001pt .75in;text-indent:-.25in;">
<font size="2" face="Symbol" style=
"font-size:10.0pt;">·</font><font size="1" style=
"font-size:8.5pt;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</font> advances
and trends in new technologies and industry standards.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><b><i><font size="2" face=
"Times New Roman" style=
"font-size:10.0pt;font-style:italic;font-weight:bold;">We have a
history of net losses and we may not be able to achieve or sustain
profitability.</font></i></b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2"
face="Times New Roman" style="font-size:10.0pt;">We have incurred
significant losses in each period since our inception in 2007. We
incurred net losses of $10.3 million for the three months ended
March&nbsp;31, 2018, $48.7 million in 2017, $56.1 million in 2016
and $47.3 million in 2015. As of March&nbsp;31, 2018, we had an
accumulated deficit of approximately $311.6&nbsp;million. These
losses and our accumulated deficit reflect the substantial
investments we have made to develop our Lumivascular platform and
acquire customers.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2"
face="Times New Roman" style="font-size:10.0pt;">We expect our
losses to continue for the foreseeable future as we continue to
make significant future expenditures to develop and expand our
business. In addition, as a public company, we will continue to
incur significant legal, accounting and other expenses.
Accordingly, we cannot assure you that we will achieve
profitability in the future or that, if we do become profitable, we
will sustain profitability. Our failure to achieve and sustain
profitability would negatively impact the market price of our
common stock.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><b><i><font size="2" face=
"Times New Roman" style=
"font-size:10.0pt;font-style:italic;font-weight:bold;">We may not
be able to secure additional financing on favorable terms, or at
all, to meet our future capital needs and our failure to obtain
additional financing when needed could force us to delay, reduce or
eliminate our product development programs and commercialization
efforts or cause us to become insolvent.</font></i></b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2"
face="Times New Roman" style="font-size:10.0pt;">We believe that
the net proceeds from the recently completed offering of our
Series&nbsp;B preferred stock, par value $0.001 per share, or
Series&nbsp;B preferred stock, together with our cash and cash
equivalents at March&nbsp;31, 2018 and expected revenues
from</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style=
"font-size:10.0pt;margin:0in 0in .0001pt;text-align:center;">
34<a name="PB_34_113605_7056" id="PB_34_113605_7056"></a></p>
<div style="margin:0in 0in .0001pt;">
<hr size="3" width="100%" noshade="noshade" align="left" style=
"color:#010101;" /></div>
</div>
<!-- SEQ.=1,FOLIO='34',FILE='C:\JMS\109761\18-8644-1\task8901132\8644-1-ga.htm',USER='109761',CD='May 15 15:54 2018' --><br clear="all"
style="page-break-before:always;" />
<div style="font-family:Times New Roman;">
<p style="margin:0in 0in .0001pt;"><a href="#TableOfContents"
title="Click to go to Table of Contents"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">Table of
Contents</font></a></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;"><font size="2"
face="Times New Roman" style="font-size:10.0pt;">operations</font>,
will be sufficient to satisfy our capital requirements and fund our
operations for at least the next seven months. Even though we sold
$18.0 &nbsp;million in Series&nbsp;B preferred stock and warrants
under the terms of an underwriting agreement, dated as of
February&nbsp;14, 2018, between us and Ladenburg
Thalmann&nbsp;&amp; Co.&nbsp;Inc. (the “Series&nbsp;B Purchase
Agreement”), we will need to raise additional funds through future
equity or debt financings within the next seven months to meet our
operational needs and capital requirements for product development,
clinical trials and commercialization and may subsequently require
additional fundraising. We can provide no assurance that we will be
successful in raising funds pursuant to additional equity or debt
financings or that such funds will be raised at prices that do not
create substantial dilution for our existing stockholders. Given
the recent decline in our stock price, any financing that we
undertake in the next seven months could cause substantial dilution
to our existing stockholders.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2"
face="Times New Roman" style="font-size:10.0pt;">To date, we have
financed our operations primarily through sales of our products and
net proceeds from the issuance of our preferred stock and debt
financings, our “at-the-market” program, our initial public
offering, or IPO, and our follow-on public offerings. The warrants
issued pursuant to the Series&nbsp;B Purchase Agreement entered
into in connection with the Series&nbsp;B preferred stock follow-on
in February&nbsp;2018 (the “Series&nbsp;B Offering”) prohibit us
from entering into certain transactions involving the issuance of
securities for a price determined by reference to the trading price
of our common stock or otherwise subject to modification following
the date of issuance, in each case for a period of three years from
the closing date of the Series&nbsp;B Offering (and excluding
purchases pursuant to the Series&nbsp;B Purchase Agreement, which
may be made on the 120 day anniversary of the closing date of the
offering). This prohibition may be waived by holders of two-thirds
of the outstanding Series&nbsp;1 and Series&nbsp;2 warrants at any
time. &nbsp;&nbsp;We do not know when or if our operations will
generate sufficient cash to fund our ongoing operations. We cannot
be certain that additional capital will be available as needed on
acceptable terms, or at all. In the future, we may require
additional capital in order to (i)&nbsp;continue to conduct
research and development activities, (ii)&nbsp;conduct post-market
clinical studies, as well as clinical trials to obtain regulatory
clearances and approvals necessary to commercialize our
Lumivascular platform products, (iii)&nbsp;expand our sales and
marketing infrastructure and (iv)&nbsp;acquire complementary
businesses technologies or products; or (v)&nbsp;respond to
business opportunities, challenges, a decline in sales, increased
regulatory obligations or unforeseen circumstances. Our future
capital requirements will depend on many factors,
including:</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style=
"font-size:10.0pt;margin:0in 0in .0001pt .5in;text-indent:-.25in;">
<font size="2" face="Symbol" style=
"font-size:10.0pt;">·</font><font size="1" style=
"font-size:8.5pt;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</font> the degree
of success we experience in commercializing our Lumivascular
platform products, particularly Pantheris, and any next-generation
versions of such products;</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style=
"font-size:10.0pt;margin:0in 0in .0001pt .5in;text-indent:-.25in;">
<font size="2" face="Symbol" style=
"font-size:10.0pt;">·</font><font size="1" style=
"font-size:8.5pt;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</font> the costs,
timing and outcomes of clinical trials and regulatory reviews
associated with our future products;</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style=
"font-size:10.0pt;margin:0in 0in .0001pt .5in;text-indent:-.25in;">
<font size="2" face="Symbol" style=
"font-size:10.0pt;">·</font><font size="1" style=
"font-size:8.5pt;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</font> the costs
and expenses of maintaining or expanding our sales and marketing
infrastructure and our manufacturing operations;</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style=
"font-size:10.0pt;margin:0in 0in .0001pt .5in;text-indent:-.25in;">
<font size="2" face="Symbol" style=
"font-size:10.0pt;">·</font><font size="1" style=
"font-size:8.5pt;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</font> the costs
and timing of developing variations of our Lumivascular platform
products, especially Pantheris and, if necessary, obtaining FDA
clearance of such variations;</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style=
"font-size:10.0pt;margin:0in 0in .0001pt .5in;text-indent:-.25in;">
<font size="2" face="Symbol" style=
"font-size:10.0pt;">·</font><font size="1" style=
"font-size:8.5pt;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</font> the extent
to which our Lumivascular platform is adopted by hospitals for use
by interventional cardiologists, vascular surgeons and
interventional radiologists in the treatment of PAD;</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style=
"font-size:10.0pt;margin:0in 0in .0001pt .5in;text-indent:-.25in;">
<font size="2" face="Symbol" style=
"font-size:10.0pt;">·</font><font size="1" style=
"font-size:8.5pt;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</font> the number
and types of future products we develop and commercialize;</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt .25in;">
<font size="2" face="Symbol" style=
"font-size:10.0pt;">·</font><font size="1" style=
"font-size:8.5pt;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</font> the costs
of defending ourselves against existing and future litigation,
including pending stockholder class action claims;</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style=
"font-size:10.0pt;margin:0in 0in .0001pt .5in;text-indent:-.25in;">
<font size="2" face="Symbol" style=
"font-size:10.0pt;">·</font><font size="1" style=
"font-size:8.5pt;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</font> the costs
of preparing, filing and prosecuting patent applications and
maintaining, enforcing and defending intellectual property-related
claims; and</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style=
"font-size:10.0pt;margin:0in 0in .0001pt .5in;text-indent:-.25in;">
<font size="2" face="Symbol" style=
"font-size:10.0pt;">·</font><font size="1" style=
"font-size:8.5pt;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</font> the extent
and scope of our general and administrative expenses.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style=
"font-size:10.0pt;margin:0in 0in .0001pt;text-indent:.5in;">
<font size="2" face="Times New Roman" style="font-size:10.0pt;">We
may raise additional funds in equity or debt financings or enter
into credit facilities in order to access funds for our capital
needs. Any debt financing obtained by us in the future would cause
us to incur additional debt service expenses and could include
restrictive covenants relating to our capital raising activities
and other financial and operational matters, which may make it more
difficult for us to obtain additional capital and pursue business
opportunities.</font> In addition, due to our current level of
debt, future equity investors may require that we convert all or a
portion of our debt to equity, and our debtholders may not agree to
such terms. &nbsp;If we raise additional funds through further
issuances of equity or convertible debt securities, and/or if we
convert all or a portion of our existing debt to equity, our
existing stockholders could suffer significant dilution in their
percentage ownership of our company, and any new equity securities
we issue could have rights, preferences and privileges senior to
those of holders of our common stock. If we are unable to obtain
adequate financing or financing on terms satisfactory to us when we
require it, we may terminate or delay the development of one or
more of our products, delay clinical trials necessary to market our
products, delay establishment of sales and marketing capabilities
or other activities necessary to commercialize our products, and
significantly scale back our operations, or we may become
insolvent. If this were to occur, our ability to continue to grow
and support our business and to respond to business challenges
could be significantly limited.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style=
"font-size:10.0pt;margin:0in 0in .0001pt;text-align:center;">
35<a name="PB_35_113636_5335" id="PB_35_113636_5335"></a></p>
<div style="margin:0in 0in .0001pt;">
<hr size="3" width="100%" noshade="noshade" align="left" style=
"color:#010101;" /></div>
</div>
<!-- SEQ.=1,FOLIO='35',FILE='C:\JMS\109761\18-8644-1\task8901132\8644-1-ga.htm',USER='109761',CD='May 15 15:54 2018' --><br clear="all"
style="page-break-before:always;" />
<div style="font-family:Times New Roman;">
<p style="margin:0in 0in .0001pt;"><a href="#TableOfContents"
title="Click to go to Table of Contents"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">Table of
Contents</font></a></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;">
<b><i><font size="2" face="Times New Roman" style=
"font-size:10.0pt;font-style:italic;font-weight:bold;">We have a
significant amount of debt, which may adversely affect our ability
to operate our business</font></i></b> <b><i style=
"font-weight:bold;">and our financial position and our ability
to</i></b> <b><i style="font-weight:bold;">secure additional
financing in the future.</i></b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style=
"font-size:10.0pt;margin:0in 0in .0001pt;text-indent:.5in;">
<font size="2" face="Times New Roman" style="font-size:10.0pt;">As
of March&nbsp;31, 2018, we had $7.5 million in principal and
interest outstanding under a Term Loan Agreement, or the Loan
Agreement, with CRG</font> Partners III L.P. and certain of its
affiliated funds (collectively “CRG”).&nbsp; This amount reflects
the completion of the Series&nbsp;B Offering and CRG’s conversion
of $38 million in outstanding principal and interest into
Series&nbsp;A preferred stock (the “CRG Conversion”).&nbsp; Our
significant amount of debt may:</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style=
"font-size:10.0pt;margin:0in 0in .0001pt .5in;text-indent:-.25in;">
<font size="2" face="Symbol" style=
"font-size:10.0pt;">·</font><font size="1" style=
"font-size:8.5pt;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</font> make it
more difficult for us to satisfy our obligations with respect to
the Loan Agreement;</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style=
"font-size:10.0pt;margin:0in 0in .0001pt .5in;text-indent:-.25in;">
<font size="2" face="Symbol" style=
"font-size:10.0pt;">·</font><font size="1" style=
"font-size:8.5pt;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</font> increase
our vulnerability to adverse changes in general economic, industry
and competitive conditions;</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style=
"font-size:10.0pt;margin:0in 0in .0001pt .5in;text-indent:-.25in;">
<font size="2" face="Symbol" style=
"font-size:10.0pt;">·</font><font size="1" style=
"font-size:8.5pt;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</font> require us
to dedicate a substantial portion of our cash flow from operations
to make payments on our debt, thereby reducing the availability of
our cash flow to fund working capital, capital expenditures and
other general corporate purposes;</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style=
"font-size:10.0pt;margin:0in 0in .0001pt .5in;text-indent:-.25in;">
<font size="2" face="Symbol" style=
"font-size:10.0pt;">·</font><font size="1" style=
"font-size:8.5pt;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</font> limit our
flexibility in planning for, or reacting to, changes in our
business and the industry in which we operate;</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style=
"font-size:10.0pt;margin:0in 0in .0001pt .5in;text-indent:-.25in;">
<font size="2" face="Symbol" style=
"font-size:10.0pt;">·</font><font size="1" style=
"font-size:8.5pt;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</font> restrict
us from exploiting business opportunities;</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style=
"font-size:10.0pt;margin:0in 0in .0001pt .5in;text-indent:-.25in;">
<font size="2" face="Symbol" style=
"font-size:10.0pt;">·</font><font size="1" style=
"font-size:8.5pt;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</font> make it
more difficult to satisfy our financial obligations, including
payments on the Loan Agreement</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style=
"font-size:10.0pt;margin:0in 0in .0001pt .5in;text-indent:-.25in;">
<font size="2" face="Symbol" style=
"font-size:10.0pt;">·</font><font size="1" style=
"font-size:8.5pt;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</font> place us
at a competitive disadvantage compared to our competitors that have
less debt obligations; and</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style=
"font-size:10.0pt;margin:0in 0in .0001pt .5in;text-indent:-.25in;">
<font size="2" face="Symbol" style=
"font-size:10.0pt;">·</font><font size="1" style=
"font-size:8.5pt;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</font> limit our
ability to borrow additional funds for working capital, capital
expenditures, acquisitions, debt service requirements, execution of
our business strategy or other general corporate purposes on
satisfactory terms or at all.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.25in;"><font size="2"
face="Times New Roman" style="font-size:10.0pt;">The existence of a
substantial amount of debt may make it difficult for us to run our
business effectively or raise the capital we need to continue our
operations.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><b><font size="2" face=
"Times New Roman" style=
"font-size:10.0pt;font-weight:bold;">Covenants under the Loan
Agreement will restrict our business in many ways.</font></b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt .5in;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">The Loan Agreement
contains various covenants that limit, subject to certain
exceptions, our ability to, among other things:</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style=
"font-size:10.0pt;margin:0in 0in .0001pt .5in;text-indent:-.25in;">
<font size="2" face="Symbol" style=
"font-size:10.0pt;">·</font><font size="1" style=
"font-size:8.5pt;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</font> incur or
assume liens;</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style=
"font-size:10.0pt;margin:0in 0in .0001pt .5in;text-indent:-.25in;">
<font size="2" face="Symbol" style=
"font-size:10.0pt;">·</font><font size="1" style=
"font-size:8.5pt;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</font> incur
additional debt or provide guarantees in respect of obligations of
other persons;</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style=
"font-size:10.0pt;margin:0in 0in .0001pt .5in;text-indent:-.25in;">
<font size="2" face="Symbol" style=
"font-size:10.0pt;">·</font><font size="1" style=
"font-size:8.5pt;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</font> issue
redeemable stock and preferred stock;</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style=
"font-size:10.0pt;margin:0in 0in .0001pt .5in;text-indent:-.25in;">
<font size="2" face="Symbol" style=
"font-size:10.0pt;">·</font><font size="1" style=
"font-size:8.5pt;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</font> pay
dividends or make distributions on capital stock, repurchase,
redeem or make payments on capital stock or repay, repurchase,
redeem, retire, defease, acquire or cancel debt prior to the stated
maturity thereof;</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style=
"font-size:10.0pt;margin:0in 0in .0001pt .5in;text-indent:-.25in;">
<font size="2" face="Symbol" style=
"font-size:10.0pt;">·</font><font size="1" style=
"font-size:8.5pt;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</font> make
loans, investments or acquisitions;</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style=
"font-size:10.0pt;margin:0in 0in .0001pt .5in;text-indent:-.25in;">
<font size="2" face="Symbol" style=
"font-size:10.0pt;">·</font><font size="1" style=
"font-size:8.5pt;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</font> create or
permit restrictions on the ability of our subsidiaries to pay
dividends or make other distributions to us or to guarantee our
debt, limit our or any of our subsidiaries ability to create liens,
or make or pay intercompany loans or advances;</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style=
"font-size:10.0pt;margin:0in 0in .0001pt .5in;text-indent:-.25in;">
<font size="2" face="Symbol" style=
"font-size:10.0pt;">·</font><font size="1" style=
"font-size:8.5pt;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</font> enter into
certain transactions with affiliates;</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style=
"font-size:10.0pt;margin:0in 0in .0001pt .5in;text-indent:-.25in;">
<font size="2" face="Symbol" style=
"font-size:10.0pt;">·</font><font size="1" style=
"font-size:8.5pt;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</font> sell,
transfer, license, lease or dispose of our or our subsidiaries’
assets, including the capital stock of our subsidiaries; and</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style=
"font-size:10.0pt;margin:0in 0in .0001pt .5in;text-indent:-.25in;">
<font size="2" face="Symbol" style=
"font-size:10.0pt;">·</font><font size="1" style=
"font-size:8.5pt;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</font> dissolve,
liquidate, consolidate or merge with or into, or sell substantially
all the assets of us and our subsidiaries, taken as a whole, to,
another person.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style=
"font-size:10.0pt;margin:0in 0in .0001pt;text-align:center;">
36<a name="PB_36_113821_5796" id="PB_36_113821_5796"></a></p>
<div style="margin:0in 0in .0001pt;">
<hr size="3" width="100%" noshade="noshade" align="left" style=
"color:#010101;" /></div>
</div>
<!-- SEQ.=1,FOLIO='36',FILE='C:\JMS\109761\18-8644-1\task8901132\8644-1-ga.htm',USER='109761',CD='May 15 15:54 2018' --><br clear="all"
style="page-break-before:always;" />
<div style="font-family:Times New Roman;">
<p style="margin:0in 0in .0001pt;"><a href="#TableOfContents"
title="Click to go to Table of Contents"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">Table of
Contents</font></a></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style=
"font-size:10.0pt;margin:0in 0in .0001pt;text-indent:.5in;">
<font size="2" face="Times New Roman" style="font-size:10.0pt;">In
particular, the Loan Agreement, as amended, includes a covenant
that we maintain a minimum of $3.5 million of cash and certain cash
equivalents, and we had to achieve minimum revenue of $7.0 million
in 2015 and $18.0 million in 2016, and will have to achieve minimum
revenue of $15.0 million in 2020, $20.0 million in 2021 and $25.0
million in 2022. If we fail to meet the applicable minimum revenue
target in any calendar year, the Loan Agreement provides a cure
right if we prepay a portion of the outstanding principal equal to
2.0 times the revenue shortfall.</font> On December&nbsp;14, 2017,
we entered into a waiver agreement with CRG waiving compliance with
the minimum required revenue financial covenant for calendar year
2017. On January&nbsp;24, 2018, we entered into another waiver
agreement with CRG for the waiver of the $5.0 million minimum
liquidity financial covenant and reduced it to $2.5 million for the
period beginning January&nbsp;1, 2018 through February&nbsp;28,
2018, and waived any event of default resulting from non-compliance
with the $5.0 million minimum liquidity financial covenant. There
can be no assurance as to our future compliance with the covenants
under the Loan Agreement, as amended.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2"
face="Times New Roman" style="font-size:10.0pt;">The covenants
contained in the Loan Agreement could adversely affect our ability
to:</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style=
"font-size:10.0pt;margin:0in 0in .0001pt .5in;text-indent:-.25in;">
<font size="2" face="Symbol" style=
"font-size:10.0pt;">·</font><font size="1" style=
"font-size:8.5pt;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</font> finance
our operations;</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style=
"font-size:10.0pt;margin:0in 0in .0001pt .5in;text-indent:-.25in;">
<font size="2" face="Symbol" style=
"font-size:10.0pt;">·</font><font size="1" style=
"font-size:8.5pt;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</font> make
needed capital expenditures;</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style=
"font-size:10.0pt;margin:0in 0in .0001pt .5in;text-indent:-.25in;">
<font size="2" face="Symbol" style=
"font-size:10.0pt;">·</font><font size="1" style=
"font-size:8.5pt;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</font> make
strategic acquisitions or investments or enter into alliances;</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style=
"font-size:10.0pt;margin:0in 0in .0001pt .5in;text-indent:-.25in;">
<font size="2" face="Symbol" style=
"font-size:10.0pt;">·</font><font size="1" style=
"font-size:8.5pt;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</font> withstand
a future downturn in our business or the economy in general;</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style=
"font-size:10.0pt;margin:0in 0in .0001pt .5in;text-indent:-.25in;">
<font size="2" face="Symbol" style=
"font-size:10.0pt;">·</font><font size="1" style=
"font-size:8.5pt;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</font> refinance
our outstanding indebtedness prior to maturity;</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style=
"font-size:10.0pt;margin:0in 0in .0001pt .5in;text-indent:-.25in;">
<font size="2" face="Symbol" style=
"font-size:10.0pt;">·</font><font size="1" style=
"font-size:8.5pt;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</font> engage in
business activities, including future opportunities, that may be in
our interest; and</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style=
"font-size:10.0pt;margin:0in 0in .0001pt .5in;text-indent:-.25in;">
<font size="2" face="Symbol" style=
"font-size:10.0pt;">·</font><font size="1" style=
"font-size:8.5pt;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</font> plan for
or react to market conditions or otherwise execute our business
strategies.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style=
"font-size:10.0pt;margin:0in 0in .0001pt;text-indent:.5in;">
<font size="2" face="Times New Roman" style="font-size:10.0pt;">We
are also subject to standard event of default provisions under the
Loan Agreement that</font>, if triggered, would allow the debt to
be accelerated, which could significantly deplete our cash
resources, cause us to raise additional capital at unfavorable
terms, require us to sell portions of our business or result in us
becoming insolvent. The existing collateral pledged under the Loan
Agreement may prevent us from being able to secure additional debt
or equity financing on favorable terms, or at all, or to pursue
business opportunities, including potential acquisitions. If we
default under any of these debt covenants and are unable to cure
the default within the relevant cure period, we would need relief
from default or else our creditors could exercise their remedies.
There can be no assurance that our debtholders would accord any
relief from default.&nbsp; In addition, potential sources of equity
financing may decline to invest in our company given the amount of
debt and the rights that debt holders have to get paid before
equity holders. In order to facilitate equity investments, future
equity investors may require that we convert all or a portion of
our debt to equity, and our debtholders may not agree to such
terms. The amount of debt could therefore affect our ability to
finance our company and prevent us from obtaining necessary
operating capital as a result.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><b><i><font size="2" face=
"Times New Roman" style=
"font-size:10.0pt;font-style:italic;font-weight:bold;">We may not
be able to generate sufficient cash to service our credit facility
with CRG. If we fail to comply with the obligations under our
credit facility, the lender may be able to accelerate amounts owed
under the facility and may foreclose upon the assets securing our
obligations.</font></i></b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2"
face="Times New Roman" style="font-size:10.0pt;">Borrowings under
our credit facility are secured by substantially all of our
personal property, including our intellectual property. Our ability
to make scheduled payments or to refinance our debt obligations
depends on numerous factors, including the amount of our cash
reserves and our actual and projected financial and operating
performance. These amounts and our performance are subject to
numerous risks, including the risks in this section, some of which
may be beyond our control. We cannot assure you that we will
maintain a level of cash reserves or cash flows from operating
activities sufficient to permit us to pay the principal, premium,
if any, and interest on our existing or future indebtedness. If our
cash flows and capital resources are insufficient to fund our debt
service obligations, we may be forced to reduce or delay capital
expenditures, sell assets or operations, seek additional capital or
restructure or refinance our indebtedness. We cannot assure you
that we would be able to take any of these actions, or that these
actions would permit us to meet our scheduled debt service
obligations. In addition, in the event of our breach of the Loan
Agreement, we may be required to repay any outstanding amounts
earlier than anticipated. If we fail to comply with our obligations
under the Loan Agreement, the lender would be able to accelerate
the required repayment of amounts due and, if they are not repaid,
could foreclose upon our assets securing our obligations under the
Loan Agreement.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style=
"font-size:10.0pt;margin:0in 0in .0001pt;text-align:center;">
37<a name="PB_37_113916_2897" id="PB_37_113916_2897"></a></p>
<div style="margin:0in 0in .0001pt;">
<hr size="3" width="100%" noshade="noshade" align="left" style=
"color:#010101;" /></div>
</div>
<!-- SEQ.=1,FOLIO='37',FILE='C:\JMS\109761\18-8644-1\task8901132\8644-1-ga.htm',USER='109761',CD='May 15 15:54 2018' --><br clear="all"
style="page-break-before:always;" />
<div style="font-family:Times New Roman;">
<p style="margin:0in 0in .0001pt;"><a href="#TableOfContents"
title="Click to go to Table of Contents"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">Table of
Contents</font></a></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><b><i><font size="2" face=
"Times New Roman" style=
"font-size:10.0pt;font-style:italic;font-weight:bold;">CRG has the
right to acquire a significant percentage of our stock upon
conversion of its Series&nbsp;A preferred stock and has the ability
to exert significant control over matters pursuant to the
protective provisions therein as well as the covenants and other
restrictions in the Loan Agreement.</font></i></b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2"
face="Times New Roman" style="font-size:10.0pt;">Even though
Series&nbsp;A preferred stock is non-voting stock, and has
beneficial ownership restrictions, the Series&nbsp;A Certificate of
Designations has protective provisions that will require CRG to
consent to certain significant Company events. For example, CRG’s
consent would be necessary to create additional shares of
Series&nbsp;A preferred stock, amend our organizational documents,
or approve any merger, sale of assets, or other major corporate
transaction. This consent requirement could delay or prevent any
acquisition of our company on terms that other stockholders may
desire, and may adversely affect the market price of our common
stock.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><b><i><font size="2" face=
"Times New Roman" style=
"font-size:10.0pt;font-style:italic;font-weight:bold;">The
Series&nbsp;A preferred stock has a liquidation preference senior
to our common stock and the Series&nbsp;B preferred
stock.</font></i></b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2"
face="Times New Roman" style="font-size:10.0pt;">Series&nbsp;A
preferred stock has a liquidation preference that gets paid prior
to any payment on our common stock (including shares issuable upon
the exercise of the Series&nbsp;1 or Series&nbsp;2 warrants) and
Series&nbsp;B preferred stock. As a result, if we were to dissolve,
liquidate, merge with another company or sell our assets, the
holders of our Series&nbsp;A preferred stock would have the right
to receive up to approximately $41,800,000 from any such
transaction before any amount is paid to the holders of our
Series&nbsp;B preferred stock or common stock or pursuant to the
redemption rights in the warrants for fundamental transactions. The
payment of the liquidation preferences could result in common
stockholders, Series&nbsp;B preferred stockholders and
warrantholders not receiving any consideration if we were to
liquidate, dissolve or wind up, either voluntarily or
involuntarily.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2"
face="Times New Roman" style="font-size:10.0pt;">The existence of
the liquidation preferences may reduce the value of our common
stock, make it harder for us to sell shares of common stock in
offerings in the future, or prevent or delay a change of control.
Furthermore, any conversion of Series&nbsp;A preferred stock into
common stock will cause substantial dilution to our common stock
holders.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><b><i><font size="2" face=
"Times New Roman" style=
"font-size:10.0pt;font-style:italic;font-weight:bold;">Our limited
commercialization experience and number of approved products makes
it difficult to evaluate our current business, predict our future
prospects, assess the long-term performance of our products, and
forecast our financial performance.</font></i></b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style=
"font-size:10.0pt;margin:0in 0in .0001pt;text-indent:.5in;">
<font size="2" face="Times New Roman" style="font-size:10.0pt;">We
were incorporated in 2007, began commercializing our initial
non-Lumivascular platform products in 2009 and introduced our first
Lumivascular platform products in the United States in late
2012.</font> We received 510(k)&nbsp;clearance from the FDA, for
commercialization of Pantheris in October&nbsp;2015, an additional
510(k)&nbsp;clearance for an enhanced version of Pantheris in
March&nbsp;2016 and commenced sales of Pantheris in the United
States and select international markets promptly thereafter. Our
limited commercialization experience and number of approved
products make it difficult to evaluate our current business and
predict our future prospects. We have encountered and will continue
to encounter risks and difficulties frequently experienced by
companies in rapidly-changing industries. These risks and
uncertainties include the risks inherent in clinical trials, market
acceptance of our products, and increasing and unforeseen expenses
as we continue to attempt to grow our business.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2"
face="Times New Roman" style="font-size:10.0pt;">In addition, we
have in the past, and may in the future, become aware of
performance issues with our products. For example, prior to
becoming commercially available on March&nbsp;1, 2016, Pantheris
had been used in clinical trials mainly in controlled
situations.&nbsp; Since its commercialization and as more
physicians have used Pantheris, we have received additional
feedback on its performance, both positive and negative. We have
addressed certain of these concerns and plan to make additional
product changes and improvements as a result of this feedback.
However, there can be no assurance that the changes and
improvements will fully address the performance issues that have
been raised. Even if these issues are resolved and physician
concerns addressed, future product performance issues may occur and
our reputation could suffer, which could lead to decreased sales of
our products. Our revenue has been and continues to be adversely
impacted by these product performance issues. We also had to incur
additional expenses to make product changes and improvements, and
to replace products in accordance with our warranty policy. This
additional expense, and any future expense that we may incur as a
result of future product performance issues, will negatively impact
our financial performance and results of operations. If we are
unable to improve the performance of our products to meet the
concerns of physicians our revenue may decline further or fail to
increase.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style=
"font-size:10.0pt;margin:0in 0in .0001pt;text-indent:.5in;">
<font size="2" face="Times New Roman" style="font-size:10.0pt;">Our
short commercialization experience and limited number of approved
products also make it difficult for us to forecast our future
financial performance and such forecasts are limited and subject to
a number of uncertainties, including our ability to obtain FDA
clearance for new</font> versions of Pantheris and other
Lumivascular platform products we intend to commercialize in the
United States. If our assumptions regarding the risks and
uncertainties we face, which we use to plan our business, are
incorrect or change due to circumstances in our business or our
markets, or if we do not address these risks successfully, our
operating and financial results could differ materially from our
expectations and our business could suffer.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style=
"font-size:10.0pt;margin:0in 0in .0001pt;text-align:center;">
38<a name="PB_38_113942_3020" id="PB_38_113942_3020"></a></p>
<div style="margin:0in 0in .0001pt;">
<hr size="3" width="100%" noshade="noshade" align="left" style=
"color:#010101;" /></div>
</div>
<!-- SEQ.=1,FOLIO='38',FILE='C:\JMS\109761\18-8644-1\task8901132\8644-1-ga.htm',USER='109761',CD='May 15 15:54 2018' --><br clear="all"
style="page-break-before:always;" />
<div style="font-family:Times New Roman;">
<p style="margin:0in 0in .0001pt;"><a href="#TableOfContents"
title="Click to go to Table of Contents"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">Table of
Contents</font></a></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;">
<b><i><font size="2" face="Times New Roman" style=
"font-size:10.0pt;font-style:italic;font-weight:bold;">Our success
depends in large part on a limited number of products,
particularly</font></i></b> <b><i style=
"font-weight:bold;">Pantheris, all of which</i></b> <b><i style=
"font-weight:bold;">have a limited commercial history. If these
products fail to gain, or lose, market acceptance, our business
will suffer.</i></b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style=
"font-size:10.0pt;margin:0in 0in .0001pt;text-indent:.5in;">
<font size="2" face="Times New Roman" style=
"font-size:10.0pt;">Ocelot, Ocelot PIXL, Ocelot MVRX, Lightbox,
Wildcat, Kittycat&nbsp;2 and Pantheris are our only products
currently cleared for sale, and our current revenues are wholly
dependent on them. Sales of Wildcat and Kittycat&nbsp;2 have
declined and are continuing to decline as we focus on the promotion
of our Lumivascular platform products. In addition, the long-term
viability of our company is largely dependent on the successful
commercialization and continued development of Pantheris and we
expect that sales of Pantheris and our other current and future
Lumivascular platform products in the United States will account
for substantially all of our revenues for the foreseeable
future.</font> Accordingly, our success depends on the continued
and growing acceptance and use of Pantheris and our other
Lumivascular platform products by the medical community. All of our
products have a limited commercial history. For example, we
received 510(k)&nbsp;clearance from the FDA to commercialize
Pantheris in October&nbsp;2015 as well as a separate FDA approval
to market an enhanced version of Pantheris in March&nbsp;2016, and
Pantheris became commercially available in the United States and
select international markets promptly thereafter. As such
acceptance among physicians of these products may not increase or
may decline.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style=
"font-size:10.0pt;margin:0in 0in .0001pt;text-indent:.5in;">
<font size="2" face="Times New Roman" style="font-size:10.0pt;">Our
ability to successfully market Pantheris will also be limited due
to a number of factors including regulatory restrictions in our
labeling. We cannot assure you that demand for Pantheris and our
other Lumivascular platform products will continue to grow and our
products may not significantly penetrate current or new markets.
Market demand for Pantheris and physician adoption of this product
also may be negatively impacted by product performance issues that
we have experienced and the need to replace certain products in
accordance with our warranty policy. Sales of Pantheris and our
other Lumivascular platform products may decline as a result of the
reduced sales and marketing personnel headcount after our
organizational realignment in April&nbsp;2017</font> and the
implementation of our cost reduction plan in September&nbsp;2017.
Utilization of our products has been less than we anticipated
historically. If demand for Pantheris and our other Lumivascular
platform products does not increase and we cannot sell our products
as planned, our financial results will be harmed. In addition,
market acceptance may be hindered if physicians are not presented
with compelling data from long-term studies of the safety and
efficacy of our Lumivascular platform products compared to
alternative procedures, such as angioplasty, stenting, bypass
surgery or other atherectomy procedures. For example, if patients
undergoing treatment with our Lumivascular platform products have
retreatment rates higher than or comparable with the retreatment
rates of alternative procedures, it will be difficult to
demonstrate the value of our Lumivascular platform products. Any
studies we may conduct comparing our Lumivascular platform with
alternative procedures will be expensive, time consuming and may
not yield positive results. Physicians will also need to appreciate
the value of real-time imaging in improving patient outcomes in
order to change current methods for treating PAD patients. In
addition, demand for our Lumivascular platform products may decline
or may not increase as quickly as we expect. Failure of our
Lumivascular platform products to significantly penetrate current
or new markets, or our failure to successfully commercialize
Pantheris, would harm our business, financial condition and results
of operations.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2"
face="Times New Roman" style="font-size:10.0pt;">We are also aware
of certain characteristics and features of our Lumivascular
platform that may prevent widespread market adoption. For example,
in procedures using the current model of Pantheris, some physicians
may prefer to have a technician or second physician assisting with
the operation of the catheter as well as a separate technician to
operate the Lightbox, potentially making it less financially
attractive for physicians and their hospitals and medical
facilities. It may take significant time and expense to modify our
products to allow a single physician to operate the entire system
and we can provide no guarantee that we will be able to make such
modifications, or obtain any additional and necessary regulatory
clearances for such modifications. Although the OCT images created
by our Lightbox may make it possible for physicians to reduce the
degree to which fluoroscopy and contrast dye are used when using
our Lumivascular platform products compared to competing
endovascular products, physicians are still using both fluoroscopy
and contrast dye, particularly with Pantheris. As a result, risks
of complications from radiation and contrast dye are still present
and may limit the commercial success of our products. Finally, it
will require training for technicians and physicians to effectively
operate our Lumivascular platform products, including interpreting
the OCT images created by our Lightbox, which may affect adoption
of our products by physicians. These or other characteristics and
features of our Lumivascular platform may cause our products not to
be widely adopted and harm our business, financial condition and
results of operation.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><b><i><font size="2" face=
"Times New Roman" style=
"font-size:10.0pt;font-style:italic;font-weight:bold;">We rely
heavily on our sales professionals to market and sell our products.
If we are unable to hire, effectively train, manage, improve the
productivity of, and retain our sales professionals, our business
will be harmed, which would impair our future revenue and
profitability.</font></i></b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style=
"font-size:10.0pt;margin:0in 0in .0001pt;text-indent:.5in;">
<font size="2" face="Times New Roman" style="font-size:10.0pt;">Our
success largely depends on our ability to hire, train, manage and
improve the productivity levels of our sales professionals. We have
experienced direct sales employee and sales management turnover in
the past.</font> The loss of any member of our sales team’s senior
management could weaken our sales expertise and harm our business,
and we may not be able to find adequate replacements on a timely
basis, or at all. The changes in senior management that have
occurred over the past several years may continue to create
instability in our sales force leading to attrition in sales
representatives in the future.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style=
"font-size:10.0pt;margin:0in 0in .0001pt;text-align:center;">
39<a name="PB_39_113955_7748" id="PB_39_113955_7748"></a></p>
<div style="margin:0in 0in .0001pt;">
<hr size="3" width="100%" noshade="noshade" align="left" style=
"color:#010101;" /></div>
</div>
<!-- SEQ.=1,FOLIO='39',FILE='C:\JMS\109761\18-8644-1\task8901132\8644-1-ga.htm',USER='109761',CD='May 15 15:54 2018' --><br clear="all"
style="page-break-before:always;" />
<div style="font-family:Times New Roman;">
<p style="margin:0in 0in .0001pt;"><a href="#TableOfContents"
title="Click to go to Table of Contents"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">Table of
Contents</font></a></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2"
face="Times New Roman" style="font-size:10.0pt;">Competition for
sales professionals who are familiar with and trained to sell our
products continues to be strong. We train our sales professionals
to better understand our existing and new product technologies and
how they can be positioned against our competitors’ products. These
initiatives are intended to improve the productivity of our sales
professionals and our revenue and profitability. It takes time for
the sales professionals to become productive following their hiring
and training and there can be no assurance that sales
representatives will reach adequate levels of productivity, or that
we will not experience significant levels of attrition in the
future. Measures we implement to improve the productivity may not
be successful and may instead contribute to instability in our
operations, additional departures from our sales organization, or
further reduce our revenue, profitability, and harm our business
and our stock price may be adversely impacted as a
result.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style=
"font-size:10.0pt;margin:0in 0in .0001pt;text-indent:.5in;">
<font size="2" face="Times New Roman" style="font-size:10.0pt;">In
addition, in April&nbsp;2017, we undertook an organizational
realignment, which included a reduction in force, lowering our
total headcount</font> by approximately 33% compared to
December&nbsp;31, 2016, and reducing our field sales personnel by
nearly 50%. In September&nbsp;2017, we effected a cost reduction
plan, which also included a company-wide reduction in force,
lowering our total headcount by 24 employees. As of March&nbsp;31,
2018, our field sales personnel headcount was reduced to 18,
compared to 19 as of December&nbsp;31, 2017. Other employees may
leave voluntarily as a result of the reduction in force that we
implemented. Given the significant reduction in our sales force,
there can be no assurance that our remaining field sales personnel
will be adequate to successfully commercialize our products.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><b><i><font size="2" face=
"Times New Roman" style=
"font-size:10.0pt;font-style:italic;font-weight:bold;">If our
revenue does not improve, or if our cost of revenue and/or
operating expenses increase by a greater percentage than our
revenue, our gross margins and operating margins may be adversely
impacted, our loss from operations will increase, and our cash used
in operating activities will increase, which could reduce our
assets and have a material adverse effect on our stock
price.</font></i></b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2"
face="Times New Roman" style="font-size:10.0pt;">Our gross margin
was to 22% for the three months ended March&nbsp;31, 2018 compared
to (17%) for the three months ended March&nbsp;31, 2016. Gross
margin for the three months ended March&nbsp;31, 2017 was
positively impacted primarily by an decrease of $1.1 million in
charges for excess and obsolescence predominantly related to our
Pantheris and Lightbox inventories in the three months ended
March&nbsp;31, 2018 compared to the three months ended
March&nbsp;31, 2017.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2"
face="Times New Roman" style="font-size:10.0pt;">Our gross margin
is impacted by the revenue that we generate and the costs incurred
to generate the revenue. To the extent that our revenue does not
grow or declines, it is difficult to improve our gross margins as
our fixed costs must be spread over a lower revenue base. Our
future revenue may be adversely affected by a number of factors
including the competitive market environment in which we operate,
which may result in a decrease in the number of products sold or a
decrease in the average selling prices achieved for our product
sales. If our revenue does not improve, or if our cost of revenue
increases by a greater percentage than our revenue, or if we are
not able to reduce expenses in the event of a decline in revenue,
we may continue to generate losses from operations and use cash,
which could reduce our cash faster than budgeted, cause us to need
to obtain additional financing and have a material adverse effect
on our operations and stock price.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><b><i><font size="2" face=
"Times New Roman" style=
"font-size:10.0pt;font-style:italic;font-weight:bold;">Our ability
to compete is highly dependent on demonstrating the benefits of our
Lumivascular platform to physicians, hospitals and
patients.</font></i></b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2"
face="Times New Roman" style="font-size:10.0pt;">In order to
generate sales, we must be able to clearly demonstrate that our
Lumivascular platform is both a more effective treatment system and
more cost-effective than the alternatives offered by our
competitors. If we are unable to convince physicians that our
Lumivascular platform leads to significantly lower rates of
restenosis, or narrowing of the artery, and leads to fewer adverse
events during treatment than those using competing technologies,
our business will suffer. In order to use Pantheris or our Ocelot
family of catheters, hospitals must make an investment in our
Lightbox. Accordingly, we must convince hospitals and physicians
that our Lumivascular platform results in significantly better
patient outcomes at a competitive overall cost. For example, we may
need to demonstrate that the investment hospitals must make when
purchasing our Lightbox and the incremental costs of having a
technician or a second physician operate Pantheris can be justified
based on the benefits to patients, physicians and hospitals. If we
are unable to develop robust clinical data to support these claims,
we will be unable to convince hospitals and third-party payors of
these benefits and our business will suffer.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2"
face="Times New Roman" style="font-size:10.0pt;">Our value
proposition to physicians and hospitals is largely dependent upon
our contention that the rate of arterial damage when physicians are
using our products is lower than with competing products. If
minimizing arterial damage does not significantly impact patient
outcomes, meaning either (i)&nbsp;that restenosis is often
triggered without disrupting healthy arterial structures, or
(ii)&nbsp;arteries can be damaged during treatment without
triggering restenosis, then we may be unable to demonstrate our
Lumivascular platform’s benefits are any different than competing
technologies. Furthermore, physicians may find our imaging system
difficult to use, and we may not be able to provide physicians with
adequate training to be able to realize the benefits of our
Lumivascular platform. If physicians do not value the benefits of
on-board imaging and the enhanced visualization enabled by our
products during an endovascular intervention as compared to our
competitor’s products, or do not believe that such benefits improve
clinical outcomes, our Lumivascular platform products may not be
widely adopted.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style=
"font-size:10.0pt;margin:0in 0in .0001pt;text-align:center;">
40<a name="PB_40_114015_141" id="PB_40_114015_141"></a></p>
<div style="margin:0in 0in .0001pt;">
<hr size="3" width="100%" noshade="noshade" align="left" style=
"color:#010101;" /></div>
</div>
<!-- SEQ.=1,FOLIO='40',FILE='C:\JMS\109761\18-8644-1\task8901132\8644-1-ga.htm',USER='109761',CD='May 15 15:54 2018' --><br clear="all"
style="page-break-before:always;" />
<div style="font-family:Times New Roman;">
<p style="margin:0in 0in .0001pt;"><a href="#TableOfContents"
title="Click to go to Table of Contents"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">Table of
Contents</font></a></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><b><i><font size="2" face=
"Times New Roman" style=
"font-size:10.0pt;font-style:italic;font-weight:bold;">The use,
misuse or off-label use of the products in our Lumivascular
platform may result in injuries that lead to product liability
suits, which could be costly to our business.</font></i></b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2"
face="Times New Roman" style="font-size:10.0pt;">We require limited
training in the use of our Lumivascular platform products because
we market primarily to physicians who are experienced in the
interventional techniques required to use our device. If demand for
our Lumivascular platform continues to grow, less experienced
physicians will likely use the devices, potentially leading to more
injury and an increased risk of product liability claims. The use
or misuse of our Lumivascular platform products has in the past
resulted, and may in the future result, in complications, including
damage to the treated artery, infection, internal bleeding, and
limb loss, potentially leading to product liability claims. Our
Lumivascular platform products are contraindicated for use in the
carotid, cerebral, coronary, iliac, or renal arteries. Our sales
force does not promote the use of our products for off-label
indications, and our U.S. instructions for use specify that our
Lumivascular platform products are not intended for use in the
carotid, cerebral, coronary, iliac or renal arteries. However, we
cannot prevent a physician from using our Lumivascular platform
products for these off-label applications. The application of our
Lumivascular platform products to coronary arteries, as opposed to
peripheral arteries, is more likely to result in complications that
have serious consequences. For example, if excised plaque were not
captured properly in our device, it could be carried by the
bloodstream to a more narrow location, blocking a coronary artery,
leading to a heart attack, or blocking an artery to the brain,
leading to a stroke. If our Lumivascular platform products are
defectively designed, manufactured or labeled, contain defective
components or are misused, we may become subject to costly
litigation initiated by our customers or their patients. Product
liability claims are especially prevalent in the medical device
industry and could harm our reputation, divert management’s
attention from our core business, be expensive to defend and may
result in sizable damage awards against us. Although we maintain
product liability insurance, the amount or breadth of our coverage
may not be adequate for the claims that are made against
us.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><b><i><font size="2" face=
"Times New Roman" style=
"font-size:10.0pt;font-style:italic;font-weight:bold;">The expense
and potential unavailability of insurance coverage for liabilities
resulting from our products could harm us and our ability to sell
our Lumivascular platform products.</font></i></b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2"
face="Times New Roman" style="font-size:10.0pt;">We may not have
sufficient insurance coverage for future product liability claims.
We may not be able to obtain insurance in amounts or scope
sufficient to provide us with adequate coverage against all
potential liabilities. Any product liability claims brought against
us, with or without merit, could increase our product liability
insurance rates or prevent us from securing continuing coverage,
harm our reputation in the industry, significantly increase our
expenses, and reduce product sales. Product liability claims in
excess of our insurance coverage would be paid out of cash
reserves, harming our financial condition and operating
results.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2"
face="Times New Roman" style="font-size:10.0pt;">Some of our
customers and prospective customers may have difficulty in
procuring or maintaining liability insurance to cover their
operations and use of our Lumivascular platform products. Medical
malpractice carriers are also withdrawing coverage in certain
states or substantially increasing premiums. If this trend
continues or worsens, our customers may discontinue using our
Lumivascular platform products and potential customers may opt
against purchasing our Lumivascular platform products due to the
cost or inability to procure insurance coverage.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><b><i><font size="2" face=
"Times New Roman" style=
"font-size:10.0pt;font-style:italic;font-weight:bold;">Our ability
to compete depends on our ability to innovate
successfully.</font></i></b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2"
face="Times New Roman" style="font-size:10.0pt;">The market for
medical devices in general, and in the PAD market in particular, is
highly competitive, dynamic, and marked by rapid and substantial
technological development and product innovation. There are few
barriers that would prevent new entrants or existing competitors
from developing products that compete directly with ours. Demand
for our Lumivascular platform products could be diminished by
equivalent or superior products and technologies offered by
competitors. If we are unable to innovate successfully, our
Lumivascular platform products could become obsolete and our
revenues would decline as our customers purchase our competitors’
products.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2"
face="Times New Roman" style="font-size:10.0pt;">In order to remain
competitive, we must continue to develop new product offerings and
enhancements to our existing Lumivascular platform products. In
particular, we are currently developing two next-generation
versions of our Pantheris atherectomy device, Pantheris 3.0 and a
lower profile Pantheris. We believe these versions will represent
significant improvements in reliability and usability compared to
our existing products. We anticipate that Pantheris 3.0 and the
lower profile Pantheris will translate into revenue growth and
achieve increased physician acceptance. Because we believe they are
important to our future revenues, we are devoting a significant
portion of our resources to their development. However, we do not
yet know whether these or any other new offerings will be well
received and broadly accepted by physicians, and if so, whether
sales will be sufficient for us to offset costs of development,
implementation, support, operation, sales and marketing.
Additionally, new products may subject us to additional risks of
product performance, customer complaints and litigation. If sales
of our new product offerings, including Pantheris 3.0 and the lower
profile Pantheris, are lower than we expect, fail to gain
anticipated market acceptance or cause us to expend additional
resources to fix unforeseen problems and develop modifications, our
revenues and results of operations may not improve and our business
will be adversely affected.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style=
"font-size:10.0pt;margin:0in 0in .0001pt;text-align:center;">
41<a name="PB_41_114033_7608" id="PB_41_114033_7608"></a></p>
<div style="margin:0in 0in .0001pt;">
<hr size="3" width="100%" noshade="noshade" align="left" style=
"color:#010101;" /></div>
</div>
<!-- SEQ.=1,FOLIO='41',FILE='C:\JMS\109761\18-8644-1\task8901132\8644-1-ga.htm',USER='109761',CD='May 15 15:54 2018' --><br clear="all"
style="page-break-before:always;" />
<div style="font-family:Times New Roman;">
<p style="margin:0in 0in .0001pt;"><a href="#TableOfContents"
title="Click to go to Table of Contents"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">Table of
Contents</font></a></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2"
face="Times New Roman" style="font-size:10.0pt;">Maintaining
adequate research and development personnel and resources to meet
the demands of the market is essential. If we are unable to develop
products, applications or features due to certain constraints, such
as insufficient cash resources, inability to raise sufficient cash
in future equity or debt financings, high employee turnover,
inability to hire sufficient research and development personnel or
a lack of other research and development resources, we may miss
market opportunities. Furthermore, many of our competitors expend a
considerably greater amount of funds on their research and
development programs than we do, and those that do not may be
acquired by larger companies that would allocate greater resources
to our competitors’ research and development programs. Our failure
or inability to devote adequate research and development resources
or compete effectively with the research and development programs
of our competitors could harm our business.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><b><i><font size="2" face=
"Times New Roman" style=
"font-size:10.0pt;font-style:italic;font-weight:bold;">We compete
against companies that have longer operating histories, more
established products and greater resources, which may prevent us
from achieving significant market penetration, increasing our
revenues or becoming profitable.</font></i></b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2"
face="Times New Roman" style="font-size:10.0pt;">Our products
compete with a variety of products and devices for the treatment of
PAD, including other CTO crossing devices, stents, balloons and
atherectomy catheters, as well as products used in vascular
surgery. Large competitors in the CTO crossing, stent and balloon
markets include Abbott Laboratories, Boston Scientific, Cardinal
Health, Cook Medical, CR Bard and Medtronic. Competitors in the
atherectomy market include Boston Scientific, Cardiovascular
Systems, Medtronic and Philips. Some competitors have previously
attempted to combine intravascular imaging with atherectomy and may
have current programs underway to do so. These and other companies
may attempt to incorporate on-board visualization into their
products in the future and may remain competitive with us in
marketing traditional technologies. Other competitors include
pharmaceutical companies that manufacture drugs for the treatment
of symptoms associated with mild to moderate PAD and companies that
provide products used by surgeons in peripheral and coronary bypass
procedures. These competitors and other companies may introduce new
products that compete with our products. Many of our competitors
have significantly greater financial and other resources than we do
and have well-established reputations, as well as broader product
offerings and worldwide distribution channels that are
significantly larger and more effective than ours. Competition with
these companies could result in price-cutting, reduced profit
margins and loss of market share, any of which would harm our
business, financial condition and results of operations.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2"
face="Times New Roman" style="font-size:10.0pt;">Our ability to
compete effectively depends on our ability to distinguish our
company and our Lumivascular platform from our competitors and
their products, and includes such factors as:</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style=
"font-size:10.0pt;margin:0in 0in .0001pt .75in;text-indent:-.25in;">
<font size="2" face="Symbol" style=
"font-size:10.0pt;">·</font><font size="1" style=
"font-size:8.5pt;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</font> procedural
safety and efficacy;</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style=
"font-size:10.0pt;margin:0in 0in .0001pt .75in;text-indent:-.25in;">
<font size="2" face="Symbol" style=
"font-size:10.0pt;">·</font><font size="1" style=
"font-size:8.5pt;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</font> acute and
long-term outcomes;</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style=
"font-size:10.0pt;margin:0in 0in .0001pt .75in;text-indent:-.25in;">
<font size="2" face="Symbol" style=
"font-size:10.0pt;">·</font><font size="1" style=
"font-size:8.5pt;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</font> ease of
use and procedure time;</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style=
"font-size:10.0pt;margin:0in 0in .0001pt .75in;text-indent:-.25in;">
<font size="2" face="Symbol" style=
"font-size:10.0pt;">·</font><font size="1" style=
"font-size:8.5pt;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</font> price;</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style=
"font-size:10.0pt;margin:0in 0in .0001pt .75in;text-indent:-.25in;">
<font size="2" face="Symbol" style=
"font-size:10.0pt;">·</font><font size="1" style=
"font-size:8.5pt;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</font> size and
effectiveness of sales force;</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style=
"font-size:10.0pt;margin:0in 0in .0001pt .75in;text-indent:-.25in;">
<font size="2" face="Symbol" style=
"font-size:10.0pt;">·</font><font size="1" style=
"font-size:8.5pt;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</font> radiation
exposure for physicians, hospital staff and patients; and</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style=
"font-size:10.0pt;margin:0in 0in .0001pt .75in;text-indent:-.25in;">
<font size="2" face="Symbol" style=
"font-size:10.0pt;">·</font><font size="1" style=
"font-size:8.5pt;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</font>
third-party reimbursement.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2"
face="Times New Roman" style="font-size:10.0pt;">In addition,
competitors with greater financial resources than ours could
acquire other companies to gain enhanced name recognition and
market share, as well as new technologies or products that could
effectively compete with our existing products, which may cause our
revenues to decline and would harm our business.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><b><i><font size="2" face=
"Times New Roman" style=
"font-size:10.0pt;font-style:italic;font-weight:bold;">If our
clinical trials are unsuccessful or significantly delayed, or if we
do not complete our clinical trials, our business may be
harmed.</font></i></b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2"
face="Times New Roman" style="font-size:10.0pt;">Clinical
development is a long, expensive, and uncertain process and is
subject to delays and the risk that products may ultimately prove
unsafe or ineffective in treating the indications for which they
are designed. Completion of clinical trials may take several years
or more and failure of the trial can occur at any time. We cannot
provide any assurance that our clinical trials will meet their
primary endpoints or that such trials or their results will be
accepted by the FDA or foreign regulatory authorities. Even if we
achieve positive early or preliminary results in clinical trials,
these results do not necessarily predict final results, and
positive results in early trials may not indicate success in later
trials. Many companies in the medical device industry have suffered
significant setbacks in late-stage clinical trials, even after
receiving promising results in earlier trials or in the preliminary
results from these late-stage clinical trials.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style=
"font-size:10.0pt;margin:0in 0in .0001pt;text-align:center;">
42<a name="PB_42_114435_8146" id="PB_42_114435_8146"></a></p>
<div style="margin:0in 0in .0001pt;">
<hr size="3" width="100%" noshade="noshade" align="left" style=
"color:#010101;" /></div>
</div>
<!-- SEQ.=1,FOLIO='42',FILE='C:\JMS\109761\18-8644-1\task8901132\8644-1-ga.htm',USER='109761',CD='May 15 15:54 2018' --><br clear="all"
style="page-break-before:always;" />
<div style="font-family:Times New Roman;">
<p style="margin:0in 0in .0001pt;"><a href="#TableOfContents"
title="Click to go to Table of Contents"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">Table of
Contents</font></a></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2"
face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2"
face="Times New Roman" style="font-size:10.0pt;">We may experience
numerous unforeseen events during, or because of, the clinical
trial process that could delay or prevent us from receiving
regulatory clearance or approval for new products or modifications
of existing products, including new indications for existing
products, including:</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style=
"font-size:10.0pt;margin:0in 0in .0001pt .75in;text-indent:-.25in;">
<font size="2" face="Symbol" style=
"font-size:10.0pt;">·</font><font size="1" style=
"font-size:3.0pt;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</font>
negative or inconclusive results that may cause us to decide, or
regulators may require us, to conduct additional clinical and/or
preclinical testing which may be expensive and time consuming;</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style=
"font-size:10.0pt;margin:0in 0in .0001pt .75in;text-indent:-.25in;">
<font size="2" face="Symbol" style=
"font-size:10.0pt;">·</font><font size="1" style=
"font-size:3.0pt;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</font>
trial results that do not meet the level of statistical
significance required by the FDA or other regulatory
authorities;</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style=
"font-size:10.0pt;margin:0in 0in .0001pt .75in;text-indent:-.25in;">
<font size="2" face="Symbol" style=
"font-size:10.0pt;">·</font><font size="1" style=
"font-size:3.0pt;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</font>
findings by the FDA or similar foreign regulatory authorities that
the product is not sufficiently safe for investigational use in
humans;</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style=
"font-size:10.0pt;margin:0in 0in .0001pt .75in;text-indent:-.25in;">
<font size="2" face="Symbol" style=
"font-size:10.0pt;">·</font><font size="1" style=
"font-size:3.0pt;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</font>
interpretations of data from preclinical testing and clinical
testing by the FDA or similar foreign regulatory authorities that
may be different from our own;</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style=
"font-size:10.0pt;margin:0in 0in .0001pt .75in;text-indent:-.25in;">
<font size="2" face="Symbol" style=
"font-size:10.0pt;">·</font><font size="1" style=
"font-size:3.0pt;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</font>
delays or failure to obtain approval of our clinical trial
protocols from the FDA or other regulatory authorities;</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style=
"font-size:10.0pt;margin:0in 0in .0001pt .75in;text-indent:-.25in;">
<font size="2" face="Symbol" style=
"font-size:10.0pt;">·</font><font size="1" style=
"font-size:3.0pt;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</font>
delays in obtaining institutional review board approvals or
government approvals to conduct clinical trials at prospective
sites;</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style=
"font-size:10.0pt;margin:0in 0in .0001pt .75in;text-indent:-.25in;">
<font size="2" face="Symbol" style=
"font-size:10.0pt;">·</font><font size="1" style=
"font-size:3.0pt;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</font>
findings by the FDA or similar foreign regulatory authorities that
our or our suppliers’ manufacturing processes or facilities are
unsatisfactory;</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style=
"font-size:10.0pt;margin:0in 0in .0001pt .75in;text-indent:-.25in;">
<font size="2" face="Symbol" style=
"font-size:10.0pt;">·</font><font size="1" style=
"font-size:3.0pt;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</font>
changes in the review policies of the FDA or similar foreign
regulatory authorities or the adoption of new regulations that may
negatively affect or delay our ability to bring a product to market
or receive approvals or clearances to treat new indications;</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style=
"font-size:10.0pt;margin:0in 0in .0001pt .75in;text-indent:-.25in;">
<font size="2" face="Symbol" style=
"font-size:10.0pt;">·</font><font size="1" style=
"font-size:3.0pt;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</font>
trouble in managing multiple clinical sites;</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style=
"font-size:10.0pt;margin:0in 0in .0001pt .75in;text-indent:-.25in;">
<font size="2" face="Symbol" style=
"font-size:10.0pt;">·</font><font size="1" style=
"font-size:3.0pt;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</font>
delays in agreeing on acceptable terms with third-party research
organizations and trial sites that may help us conduct the clinical
trials; and</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style=
"font-size:10.0pt;margin:0in 0in .0001pt .75in;text-indent:-.25in;">
<font size="2" face="Symbol" style=
"font-size:10.0pt;">·</font><font size="1" style=
"font-size:3.0pt;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</font>
the suspension or termination by us, or regulators, of our clinical
trials because the participating patients are being exposed to
unacceptable health risks.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2"
face="Times New Roman" style="font-size:10.0pt;">Failures or
perceived failures in our clinical trials will delay and may
prevent our product development and regulatory approval process,
damage our business prospects and negatively affect our reputation
and competitive position.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><b><i><font size="2" face=
"Times New Roman" style=
"font-size:10.0pt;font-style:italic;font-weight:bold;">From time to
time, we engage outside parties to perform services related to
certain of our clinical studies and trials, and any failure of
those parties to fulfill their obligations could increase costs and
cause delays.</font></i></b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2"
face="Times New Roman" style="font-size:10.0pt;">From time to time,
we engage consultants to help design, monitor, and analyze the
results of certain of our clinical studies and trials. The
consultants we engage interact with clinical investigators to
enroll patients in our clinical trials. We depend on these
consultants and clinical investigators to help facilitate the
clinical studies and trials and monitor and analyze data from these
studies and trials under the investigational plan and protocol for
the study or trial and in compliance with applicable regulations
and standards, commonly referred to as good clinical practices. We
may face delays in our regulatory approval process if these parties
do not perform their obligations in a timely, compliant or
competent manner. If these third parties do not successfully carry
out their duties or meet expected deadlines, or if the quality,
completeness or accuracy of the data they obtain is compromised due
to the failure to adhere to our clinical trial protocols or for
other reasons, our clinical studies or trials may be extended,
delayed or terminated or may otherwise prove to be unsuccessful,
and we may have to conduct additional studies, which would
significantly increase our costs, in order to obtain the regulatory
clearances that we need to commercialize our products.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style=
"font-size:10.0pt;margin:0in 0in .0001pt;text-align:center;">
43<a name="PB_43_113845_5880" id="PB_43_113845_5880"></a></p>
<div style="margin:0in 0in .0001pt;">
<hr size="3" width="100%" noshade="noshade" align="left" style=
"color:#010101;" /></div>
</div>
<!-- SEQ.=1,FOLIO='43',FILE='C:\JMS\109761\18-8644-1\task8901132\8644-1-gc.htm',USER='109761',CD='May 15 15:31 2018' --><br clear="all"
style="page-break-before:always;" />
<div style="font-family:Times New Roman;">
<p style="margin:0in 0in .0001pt;"><a href="#TableOfContents"
title="Click to go to Table of Contents"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">Table of
Contents</font></a></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><b><i><font size="2" face=
"Times New Roman" style=
"font-size:10.0pt;font-style:italic;font-weight:bold;">We have
limited long-term data regarding the safety and efficacy of our
Lumivascular platform products, including Pantheris. Any long-term
data that is generated by clinical trials involving our
Lumivascular platform may not be positive or consistent with our
short-term data, which would harm our ability to obtain clearance
to market and sell our products.</font></i></b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2"
face="Times New Roman" style="font-size:10.0pt;">Our Lumivascular
platform is a novel system, and our success depends on its
acceptance by the medical community as being safe and effective,
and improving clinical outcomes. Important factors upon which the
efficacy of our Lumivascular platform products, including
Pantheris, will be measured are long-term data on the rate of
restenosis following our procedure, and the corresponding duration
of patency, or openness of the artery, and publication of that data
in peer-reviewed journals. Another important factor that physicians
will consider is the rate of reintervention, or retreatment,
following the use of our Lumivascular platform products. The
long-term clinical benefits of procedures that use our Lumivascular
platform products, including Pantheris, are not known.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2"
face="Times New Roman" style="font-size:10.0pt;">The results of
short-term clinical experience of our Lumivascular platform
products, including Pantheris, do not necessarily predict long-term
clinical benefit. Restenosis rates typically increase over time. We
believe that physicians will compare the rates of long-term
restenosis and reintervention for procedures using our Lumivascular
platform products against alternative procedures, such as
angioplasty, stenting, bypass surgery and other atherectomy
procedures. If the long-term rates of restenosis and reintervention
do not meet physicians’ expectations, our Lumivascular platform
products may not become widely adopted and physicians may recommend
alternative treatments for their patients. Another significant
factor that physicians will consider is acute safety data on
complications that occur during the use of our Lumivascular
platform products. If the results obtained from any post-market
studies that we conduct or post-clearance surveillance indicate
that the use of our Lumivascular platform products are not as safe
or effective as other treatment options or as current short-term
data would suggest, adoption of our product may suffer and our
business would be harmed. Even if we believe the data collected
from clinical studies or clinical experience indicate positive
results, each physician’s actual experience with our products will
vary. Physicians who are technically proficient participate in our
clinical trials and are high-volume users of our Lumivascular
platform products. Consequently, the results of our clinical trials
and their experiences using our products may lead to better patient
outcomes than those of physicians that are less proficient, perform
fewer procedures or who use our products infrequently.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><b><i><font size="2" face=
"Times New Roman" style=
"font-size:10.0pt;font-style:italic;font-weight:bold;">Our ability
to market our current products in the United States is limited to
use in peripheral vessels, and if we want to market our products
for other uses, we will need to file for FDA clearances or
approvals and may need to conduct trials to support expanded use,
which would be expensive, time-consuming and may not be
successful.</font></i></b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2"
face="Times New Roman" style="font-size:10.0pt;">Our current
products are cleared in the United States only for crossing
sub-total and chronic total occlusions and for performing
atherectomy in the peripheral vasculature. These clearances
prohibit our ability to market or advertise our products for any
other indication within the peripheral vasculature, which restricts
our ability to sell these products and could affect our growth.
Additionally, our products are contraindicated for use in the
cerebral, carotid, coronary, iliac, and renal arteries. While
off-label uses of medical devices are common and the FDA does not
regulate physicians’ choice of treatments, the FDA does restrict a
manufacturer’s communications regarding such off-label use. We are
not allowed to actively promote or advertise our products for
off-label uses. In addition, we cannot make comparative claims
regarding the use of our products against any alternative
treatments without conducting head-to-head comparative clinical
studies, which would be expensive and time consuming. If our
promotional activities fail to comply with the FDA’s regulations or
guidelines, we may be subject to FDA warnings or enforcement action
by the FDA and other government agencies. In the future, if we want
to market a variation of Ocelot or Pantheris in the United States
for use in other applications for which we do not currently have
clearance, such as the coronary arteries, we will need to make
modifications to these products, conduct further clinical trials
and obtain new clearances or approvals from the FDA. There can be
no assurance that we will successfully develop these modifications,
that future clinical studies will be successful or that the expense
of these activities will be offset by additional
revenues.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><b><i><font size="2" face=
"Times New Roman" style=
"font-size:10.0pt;font-style:italic;font-weight:bold;">The
continuing development of many of our products, including
Pantheris, depends upon maintaining strong working relationships
with physicians.</font></i></b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2"
face="Times New Roman" style="font-size:10.0pt;">The development,
marketing, and sale of our products, including Pantheris, depends
upon our ability to maintain strong working relationships with
physicians. We rely on these professionals to provide us with
considerable knowledge and experience regarding the development,
marketing and sale of our products. Physicians assist us in
clinical trials and as researchers, marketing and product
consultants and public speakers. If we cannot maintain our strong
working relationships with these professionals and continue to
receive their advice and input, the development and marketing of
our products could suffer, which could harm our business, financial
condition and results of operations. The medical device industry’s
relationship with physicians is under increasing scrutiny by the
Office of Inspector General, or OIG, the Department of Justice, or
DOJ, state attorneys general, and other foreign and domestic
government agencies. Our failure to comply with laws,
rules&nbsp;and regulations governing our relationships with
physicians, or an investigation into our compliance by the OIG,
DOJ, state attorneys general and other government agencies, could
significantly harm our business.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style=
"font-size:10.0pt;margin:0in 0in .0001pt;text-align:center;">
44<a name="PB_44_113916_7056" id="PB_44_113916_7056"></a></p>
<div style="margin:0in 0in .0001pt;">
<hr size="3" width="100%" noshade="noshade" align="left" style=
"color:#010101;" /></div>
</div>
<!-- SEQ.=1,FOLIO='44',FILE='C:\JMS\109761\18-8644-1\task8901132\8644-1-gc.htm',USER='109761',CD='May 15 15:31 2018' --><br clear="all"
style="page-break-before:always;" />
<div style="font-family:Times New Roman;">
<p style="margin:0in 0in .0001pt;"><a href="#TableOfContents"
title="Click to go to Table of Contents"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">Table of
Contents</font></a></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><b><i><font size="2" face=
"Times New Roman" style=
"font-size:10.0pt;font-style:italic;font-weight:bold;">We have
limited experience manufacturing our Lumivascular platform products
in commercial quantities, which could harm our
business.</font></i></b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2"
face="Times New Roman" style="font-size:10.0pt;">Because we have
only limited experience in manufacturing our Lumivascular platform
products in commercial quantities, we may encounter production
delays or shortfalls. Such production delays or shortfalls may be
caused by many factors, including the following:</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style=
"font-size:10.0pt;margin:0in 0in .0001pt .75in;text-indent:-.25in;">
<font size="2" face="Symbol" style=
"font-size:10.0pt;">·</font><font size="1" style=
"font-size:3.0pt;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</font>
any expansion in our manufacturing capacity, could require changes
to our production processes;</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style=
"font-size:10.0pt;margin:0in 0in .0001pt .75in;text-indent:-.25in;">
<font size="2" face="Symbol" style=
"font-size:10.0pt;">·</font><font size="1" style=
"font-size:3.0pt;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</font>
key components and sub-assemblies of our Lumivascular platform
products are currently provided by a single supplier or limited
number of suppliers, and we do not maintain large inventory levels
of these components and sub-assemblies; if we experience a shortage
in any of these components or sub-assemblies, we would need to
identify and qualify new supply sources, which could increase our
expenses and result in manufacturing delays;</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style=
"font-size:10.0pt;margin:0in 0in .0001pt .75in;text-indent:-.25in;">
<font size="2" face="Symbol" style=
"font-size:10.0pt;">·</font><font size="1" style=
"font-size:3.0pt;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</font>
we may experience a delay in completing validation and verification
testing for new controlled-environment rooms at our manufacturing
facilities; and</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style=
"font-size:10.0pt;margin:0in 0in .0001pt .75in;text-indent:-.25in;">
<font size="2" face="Symbol" style=
"font-size:10.0pt;">·</font><font size="1" style=
"font-size:3.0pt;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</font>
we have limited experience in complying with the FDA’s QSR, which
applies to the manufacture of our Lumivascular platform
products.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2"
face="Times New Roman" style="font-size:10.0pt;">If we are unable
to keep up with demand for our Lumivascular platform products, our
revenues could be impaired, market acceptance for our Lumivascular
platform products could be harmed and our customers might instead
purchase our competitors’ products. Our inability to successfully
manufacture our Lumivascular platform products would materially
harm our business.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2"
face="Times New Roman" style="font-size:10.0pt;">Our manufacturing
facilities and processes and those of our third-party suppliers are
subject to unannounced FDA and state regulatory inspections for
compliance with QSR. Developing and maintaining a compliant quality
system is time consuming and expensive. Failure to maintain, or not
fully comply with the requirements of, a quality system could
result in regulatory authorities initiating enforcement actions
against us and our third-party suppliers, which could include the
issuance of warning letters, seizures, prohibitions on product
sales, recalls and civil and criminal penalties, any one of which
could significantly impact our manufacturing supply and impair our
financial results.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><b><i><font size="2" face=
"Times New Roman" style=
"font-size:10.0pt;font-style:italic;font-weight:bold;">If our
manufacturing facility becomes damaged or inoperable, or we are
required to vacate the facility, or our electronic systems are
compromised, our ability to manufacture and sell our Lumivascular
platform products and to pursue our research and development
efforts may be jeopardized.</font></i></b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style=
"font-size:10.0pt;margin:0in 0in .0001pt;text-indent:.5in;">
<font size="2" face="Times New Roman" style="font-size:10.0pt;">We
currently manufacture and assemble our Lumivascular platform
products in-house. Our products are comprised of components sourced
from a variety of contract manufacturers, with final assembly
completed at our facility in Redwood City, California. Our facility
and equipment, or those of our suppliers, could be harmed or
rendered inoperable by natural or man-made disasters, including
fire, earthquake, terrorism, flooding and power outages</font>.
Further, our electronic systems may experience service
interruptions, denial-of-service and other cyber-attacks, computer
viruses or other events. Any of these may render it difficult or
impossible for us to manufacture products, pursue our research and
development efforts or otherwise run our business for some period
of time. If our facility is inoperable for even a short period of
time, the inability to manufacture our current products, and the
interruption in research and development of any future products,
may result in harm to our reputation, increased costs, lower
revenues and the loss of customers. Furthermore, it could be costly
and time-consuming to repair or replace our facilities and the
equipment we use to perform our research and development work and
manufacture our products.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><b><i><font size="2" face=
"Times New Roman" style=
"font-size:10.0pt;font-style:italic;font-weight:bold;">We depend on
third-party vendors to manufacture some of our components and
sub-assemblies, which could make us vulnerable to supply shortages
and price fluctuations that could harm our
business.</font></i></b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2"
face="Times New Roman" style="font-size:10.0pt;">We currently
manufacture some of our components and sub-assemblies at our
Redwood City facility and rely on third-party vendors for other
components and sub-assemblies used in our Lumivascular platform.
Our reliance on third-party vendors subjects us to a number of
risks that could impact our ability to manufacture our products and
harm our business, including:</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style=
"font-size:10.0pt;margin:0in 0in .0001pt .75in;text-indent:-.25in;">
<font size="2" face="Symbol" style=
"font-size:10.0pt;">·</font><font size="1" style=
"font-size:3.0pt;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</font>
interruption of supply resulting from modifications to, or
discontinuation of, a supplier’s operations;</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style=
"font-size:10.0pt;margin:0in 0in .0001pt .75in;text-indent:-.25in;">
<font size="2" face="Symbol" style=
"font-size:10.0pt;">·</font><font size="1" style=
"font-size:3.0pt;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</font>
delays in product shipments resulting from uncorrected defects,
reliability issues or a supplier’s failure to consistently produce
quality components;</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style=
"font-size:10.0pt;margin:0in 0in .0001pt;text-align:center;">
45<a name="PB_45_114102_5335" id="PB_45_114102_5335"></a></p>
<div style="margin:0in 0in .0001pt;">
<hr size="3" width="100%" noshade="noshade" align="left" style=
"color:#010101;" /></div>
</div>
<!-- SEQ.=1,FOLIO='45',FILE='C:\JMS\109761\18-8644-1\task8901132\8644-1-gc.htm',USER='109761',CD='May 15 15:31 2018' --><br clear="all"
style="page-break-before:always;" />
<div style="font-family:Times New Roman;">
<p style="margin:0in 0in .0001pt;"><a href="#TableOfContents"
title="Click to go to Table of Contents"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">Table of
Contents</font></a></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style=
"font-size:10.0pt;margin:0in 0in .0001pt .75in;text-indent:-.25in;">
<font size="2" face="Symbol" style=
"font-size:10.0pt;">·</font><font size="1" style=
"font-size:3.0pt;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</font>
price fluctuations due to a lack of long-term supply arrangements
with our suppliers for key components;</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style=
"font-size:10.0pt;margin:0in 0in .0001pt .75in;text-indent:-.25in;">
<font size="2" face="Symbol" style=
"font-size:10.0pt;">·</font><font size="1" style=
"font-size:3.0pt;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</font>
inability to obtain adequate supply in a timely manner or on
commercially reasonable terms;</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style=
"font-size:10.0pt;margin:0in 0in .0001pt .75in;text-indent:-.25in;">
<font size="2" face="Symbol" style=
"font-size:10.0pt;">·</font><font size="1" style=
"font-size:3.0pt;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</font>
difficulty identifying and qualifying alternative suppliers for
components in a timely manner;</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style=
"font-size:10.0pt;margin:0in 0in .0001pt .75in;text-indent:-.25in;">
<font size="2" face="Symbol" style=
"font-size:10.0pt;">·</font><font size="1" style=
"font-size:3.0pt;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</font>
inability of the manufacturer or supplier to comply with QSR as
enforced by the FDA and state regulatory authorities;</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style=
"font-size:10.0pt;margin:0in 0in .0001pt .75in;text-indent:-.25in;">
<font size="2" face="Symbol" style=
"font-size:10.0pt;">·</font><font size="1" style=
"font-size:3.0pt;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</font>
inability to control the quality of products manufactured by third
parties;</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style=
"font-size:10.0pt;margin:0in 0in .0001pt .75in;text-indent:-.25in;">
<font size="2" face="Symbol" style=
"font-size:10.0pt;">·</font><font size="1" style=
"font-size:3.0pt;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</font>
production delays related to the evaluation and testing of products
from alternative suppliers and corresponding regulatory
qualifications; and</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style=
"font-size:10.0pt;margin:0in 0in .0001pt .75in;text-indent:-.25in;">
<font size="2" face="Symbol" style=
"font-size:10.0pt;">·</font><font size="1" style=
"font-size:3.0pt;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</font>
delays in delivery by our suppliers due to changes in demand from
us or their other customers.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2"
face="Times New Roman" style="font-size:10.0pt;">Any significant
delay or interruption in the supply of components or
sub-assemblies, or our inability to obtain substitute components,
sub-assemblies or materials from alternate sources at acceptable
prices in a timely manner, could impair our ability to meet the
demand of our customers and harm our business.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><b><i><font size="2" face=
"Times New Roman" style=
"font-size:10.0pt;font-style:italic;font-weight:bold;">We depend on
single and limited source suppliers for some of our product
components and sub-assemblies, and if any of those suppliers are
unable or unwilling to produce these components and sub-assemblies
or supply them in the quantities that we need, we would experience
manufacturing delays.</font></i></b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style=
"font-size:10.0pt;margin:0in 0in .0001pt;text-indent:.5in;">
<font size="2" face="Times New Roman" style="font-size:10.0pt;">We
rely on single and limited source suppliers for several of our
components and sub-assemblies.</font> For example, we rely on
single vendors for our optical fiber and drive cables that are key
components of our catheters, and we rely on single vendors for our
laser and data acquisition card that are key components of our
Lightbox. These components are critical to our products and there
are relatively few alternative sources of supply. We do not carry a
significant inventory of these components. Identifying and
qualifying additional or replacement suppliers for any of the
components or sub-assemblies used in our products could involve
significant time and cost. Any supply interruption from our vendors
or failure to obtain additional vendors for any of the components
or sub-assemblies incorporated into our products would limit our
ability to manufacture our products and could therefore harm our
business, financial condition and results of operations.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><b><i><font size="2" face=
"Times New Roman" style=
"font-size:10.0pt;font-style:italic;font-weight:bold;">Our future
growth depends on physician adoption of our Lumivascular platform
products, which may require physicians to change their current
practices.</font></i></b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2"
face="Times New Roman" style="font-size:10.0pt;">We educate
physicians on the capabilities of our Lumivascular platform
products and advances in treatment for PAD patients. We target our
sales efforts to interventional cardiologists, vascular surgeons
and interventional radiologists because they are often the
physicians diagnosing and treating both coronary artery disease and
PAD. However, the initial point of contact for many patients may be
general practitioners, podiatrists, nephrologists and
endocrinologists, each of whom commonly treat patients experiencing
complications or symptoms resulting from PAD. If these physicians
are not made aware of our Lumivascular platform products, they may
not refer patients to interventional cardiologists, vascular
surgeons and interventional radiologists for treatment using our
Lumivascular platform procedure, and those patients may instead be
surgically treated or treated with an alternative interventional
procedure. In addition, there is a significant correlation between
PAD and coronary artery disease, and many physicians do not
routinely screen for PAD while screening for coronary artery
disease. If we are not successful in educating physicians about
screening for PAD and about the capabilities of our Lumivascular
platform products, our ability to increase our revenues may be
impaired.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><b><i><font size="2" face=
"Times New Roman" style=
"font-size:10.0pt;font-style:italic;font-weight:bold;">We depend on
our senior management team and the loss of one or more key
employees or an inability to attract and retain highly skilled
employees could harm our business.</font></i></b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style=
"font-size:10.0pt;margin:0in 0in .0001pt;text-indent:.5in;">
<font size="2" face="Times New Roman" style="font-size:10.0pt;">Our
success largely depends upon the continued services of our
executive management team and key employees and the loss of one or
more of our executive officers or key employees could harm us and
directly impact our financial results. Our employees may terminate
their employment with us at any time. Changes in our executive
management team resulting from the hiring or departure of
executives could disrupt our business.</font> For example, in
December&nbsp;2017, Dr.&nbsp;John B. Simpson resigned from our
board of directors and as an employee of our company. This
departure has had and may continue to have a disruptive effect on
our business.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2"
face="Times New Roman" style="font-size:10.0pt;">We must attract
and retain highly qualified personnel. Competition for skilled
personnel is intense, especially for engineers with high levels of
experience in designing and developing medical devices and for
sales professionals. We have, from time to time, experienced, and
we expect to continue to experience, difficulty in hiring and
retaining employees with appropriate qualifications.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style=
"font-size:10.0pt;margin:0in 0in .0001pt;text-align:center;">
46<a name="PB_46_114214_5796" id="PB_46_114214_5796"></a></p>
<div style="margin:0in 0in .0001pt;">
<hr size="3" width="100%" noshade="noshade" align="left" style=
"color:#010101;" /></div>
</div>
<!-- SEQ.=1,FOLIO='46',FILE='C:\JMS\109761\18-8644-1\task8901132\8644-1-gc.htm',USER='109761',CD='May 15 15:31 2018' --><br clear="all"
style="page-break-before:always;" />
<div style="font-family:Times New Roman;">
<p style="margin:0in 0in .0001pt;"><a href="#TableOfContents"
title="Click to go to Table of Contents"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">Table of
Contents</font></a></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">Many of the companies
with which we compete for experienced personnel have greater
resources than we have. If we hire employees from competitors or
other companies, their former employers may attempt to assert that
these employees or we have breached legal obligations, resulting in
a diversion of our time and resources and, potentially, damages. In
addition, job candidates and existing employees, particularly in
the San Francisco Bay Area, often consider the value of the stock
awards they receive in connection with their employment. If the
perceived value of our stock awards declines, it may harm our
ability to recruit and retain highly skilled employees. In
addition, we invest significant time and expense in training our
employees, which increases their value to competitors who may seek
to recruit them. If we fail to attract new personnel or fail to
retain and motivate our current personnel, our business would be
harmed.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><b><i><font size="2" face=
"Times New Roman" style=
"font-size:10.0pt;font-style:italic;font-weight:bold;">We do not
currently intend to devote significant additional resources in the
near-term to market our Lumivascular platform internationally,
which will limit our potential revenues from our Lumivascular
platform products.</font></i></b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2"
face="Times New Roman" style="font-size:10.0pt;">Marketing our
Lumivascular platform outside of the United States would require
substantial additional sales and marketing, regulatory and
personnel expenses. As part of our product development and
regulatory strategy, we plan to expand into select international
markets, but we do not currently intend to devote significant
additional resources to market our Lumivascular platform
internationally in order to focus our resources and efforts on the
U.S. market. Our decision to market our products primarily in the
United States in the near-term will limit our ability to reach all
of our potential markets and will limit our potential sources of
revenue. In addition, our competitors will have an opportunity to
further penetrate and achieve market share outside of the United
States until such time, if ever, that we devote significant
additional resources to market our Lumivascular platform products
or other products internationally.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><b><i><font size="2" face=
"Times New Roman" style=
"font-size:10.0pt;font-style:italic;font-weight:bold;">Our ability
to utilize our net operating loss carryforwards may be
limited.</font></i></b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style=
"font-size:10.0pt;margin:0in 0in .0001pt;text-indent:38.75pt;">
<font size="2" face="Times New Roman" style="font-size:10.0pt;">As
of December&nbsp;31, 2017, we had federal and state net operating
loss carryforwards, or NOLs, due to prior period losses of $258.4
million and $191.9 million, respectively, which if not utilized
will begin to expire in 2027 for federal purposes and 2018 for
state purposes. Generally</font>, subject to certain limitations,
NOLs can be used to offset taxable income for U.S. federal income
tax purposes. However, Section&nbsp;382 of the Internal Revenue
Code of 1986, as amended, may limit the NOLs we may use in any year
for U.S. federal income tax purposes in the event of certain
changes in ownership of our company. A Section&nbsp;382 “ownership
change” generally occurs if one or more stockholders or groups of
stockholders who own at least 5% of our stock increase their
ownership by more than 50 percentage points over their lowest
ownership percentage within a rolling three-year period. Similar
rules&nbsp;may apply under state tax laws. It is possible that
prior transactions with respect to our stock may have caused, and
that future issuances or sales of our stock (including certain
transactions involving our stock that are outside of our control)
could cause, an “ownership change.” The sale of our common stock to
Lincoln Park Capital Fund, LLC (“Lincoln Park”) pursuant to the
Purchase Agreement, dated as of November&nbsp;3, 2017, between us
and Lincoln Park (the “Purchase Agreement”) and the sale of
Series&nbsp;B preferred stock and warrants pursuant to the
Series&nbsp;B Offering may affect our ability to use NOLs. If an 
“ownership change” occurs, Section&nbsp;382 would impose an annual
limit on the amount of pre-ownership change NOLs and other tax
attributes we can use to reduce our taxable income, potentially
increasing and accelerating our liability for income taxes, and
also potentially causing those tax attributes to expire unused. Any
limitation on using NOLs could (depending on the extent of such
limitation and the NOLs previously used) result in our retaining
less cash after payment of U.S. federal income taxes during any
year in which we have taxable income (rather than losses) than we
would be entitled to retain if such NOLs were available as an
offset against such income for U.S. federal income tax reporting
purposes, which could harm our profitability.&nbsp; On
December&nbsp;22, 2017, the Tax Cuts and Jobs Act, or Tax Act, was
enacted into law with many significant changes to the U.S. tax
laws. The Tax Act limits the utilization of NOLs arising in tax
years beginning after December&nbsp;31, 2017 to 80% of taxable
income per year. However, existing NOLs that arose in years prior
to December&nbsp;31, 2017 are not affected by these provisions. Our
ability to utilize NOLs arising in future tax periods may be
limited by the Tax Act.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><b><i><font size="2" face=
"Times New Roman" style=
"font-size:10.0pt;font-style:italic;font-weight:bold;">We may
acquire other companies or technologies or be the target of
strategic transactions, which could divert our management’s
attention, result in additional dilution to our stockholders and
otherwise disrupt our operations and harm our operating
results.</font></i></b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2"
face="Times New Roman" style="font-size:10.0pt;">We may in the
future seek to acquire or invest in businesses, applications or
technologies that we believe could complement or expand our
Lumivascular platform, enhance our technical capabilities or
otherwise offer growth opportunities. The pursuit of potential
acquisitions may divert the attention of management and cause us to
incur various costs and expenses in identifying, investigating and
pursuing suitable acquisitions, whether or not they are
consummated. We may not be able to identify desirable acquisition
targets or be successful in entering into an agreement with any
particular target or obtain the expected benefits of any
acquisition or investment.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2"
face="Times New Roman" style="font-size:10.0pt;">To date, our
technology and product development efforts have been organic, and
we have no experience in acquiring other businesses. In any
acquisition, we may not be able to successfully integrate acquired
personnel, operations and technologies, or effectively manage the
combined business following the acquisition. Acquisitions could
also result in dilutive issuances of equity securities, the use of
our available cash, or the incurrence of debt, which could harm our
operating results. In addition, if an acquired business fails to
meet our expectations, our operating results, business and
financial condition may suffer.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style=
"font-size:10.0pt;margin:0in 0in .0001pt;text-align:center;">
47<a name="PB_47_114319_2897" id="PB_47_114319_2897"></a></p>
<div style="margin:0in 0in .0001pt;">
<hr size="3" width="100%" noshade="noshade" align="left" style=
"color:#010101;" /></div>
</div>
<!-- SEQ.=1,FOLIO='47',FILE='C:\JMS\109761\18-8644-1\task8901132\8644-1-gc.htm',USER='109761',CD='May 15 15:31 2018' --><br clear="all"
style="page-break-before:always;" />
<div style="font-family:Times New Roman;">
<p style="margin:0in 0in .0001pt;"><a href="#TableOfContents"
title="Click to go to Table of Contents"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">Table of
Contents</font></a></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2"
face="Times New Roman" style="font-size:10.0pt;">In addition, we
sometimes receive inquiries relating to potential strategic
transactions, including from third parties who may seek to acquire
us. We will continue to consider and discuss such transactions as
we deem appropriate. Such potential transactions may divert the
attention of management, and cause us to incur various costs and
expenses in investigating and evaluating such transactions, whether
or not they are consummated.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><b><font size="2" face=
"Times New Roman" style="font-size:10.0pt;font-weight:bold;">Risks
Related to Our Intellectual Property</font></b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><b><i><font size="2" face=
"Times New Roman" style=
"font-size:10.0pt;font-style:italic;font-weight:bold;">We may in
the future be a party to intellectual property litigation or
administrative proceedings that could be costly and could interfere
with our ability to sell our Lumivascular platform
products.</font></i></b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2"
face="Times New Roman" style="font-size:10.0pt;">The medical device
industry has been characterized by extensive litigation regarding
patents, trademarks, trade secrets, and other intellectual property
rights, and companies in the industry have used intellectual
property litigation to gain a competitive advantage. It is possible
that U.S. and foreign patents and pending patent applications or
trademarks controlled by third parties may be alleged to cover our
products, or that we may be accused of misappropriating third
parties’ trade secrets. Additionally, our products include hardware
and software components that we purchase from vendors, and may
include design components that are outside of our direct control.
Our competitors, many of which have substantially greater resources
and have made substantial investments in patent portfolios, trade
secrets, trademarks, and competing technologies, may have applied
for or obtained or may in the future apply for or obtain, patents
or trademarks that will prevent, limit or otherwise interfere with
our ability to make, use, sell and/or export our products or to use
product names. They may devote substantial resources towards
obtaining claims that cover the design of our atherectomy products
to prevent the marketing and selling of competitive products. We
may become a party to patent or trademark infringement or trade
secret claims and litigation as a result of these and other
third-party intellectual property rights being asserted against us.
The defense and prosecution of these matters are both costly and
time consuming. Vendors from whom we purchase hardware or software
may not indemnify us in the event that such hardware or software is
accused of infringing a third-party’s patent or trademark or of
misappropriating a third-party’s trade secret.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2"
face="Times New Roman" style="font-size:10.0pt;">Further, if such
patents, trademarks, or trade secrets are successfully asserted
against us, this may harm our business and result in injunctions
preventing us from selling our products, license fees, damages and
the payment of attorney fees and court costs. In addition, if we
are found to willfully infringe third-party patents or trademarks
or to have misappropriated trade secrets, we could be required to
pay treble damages in addition to other penalties. Although patent,
trademark, trade secret, and other intellectual property disputes
in the medical device area have often been settled through
licensing or similar arrangements, costs associated with such
arrangements may be substantial and could include ongoing
royalties. We may be unable to obtain necessary licenses
on&nbsp;&nbsp;&nbsp;&nbsp; satisfactory terms, if at all. If we do
not obtain necessary licenses, we may not be able to redesign our
Lumivascular platform products to avoid infringement.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2"
face="Times New Roman" style="font-size:10.0pt;">Similarly,
interference or derivation proceedings provoked by third parties or
brought by the U.S. Patent and Trademark Office, or USPTO, may be
necessary to determine the priority of inventions or other matters
of inventorship with respect to our patents or patent applications.
We may also become involved in other proceedings, such as
re-examination, inter partes review, or opposition proceedings,
before the USPTO or other jurisdictional body relating to our
intellectual property rights or the intellectual property rights of
others. Adverse determinations in a judicial or administrative
proceeding or failure to obtain necessary licenses could prevent us
from manufacturing and selling our Lumivascular platform products
or using product names, which would have a significant adverse
impact on our business.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2"
face="Times New Roman" style="font-size:10.0pt;">Additionally, we
may need to commence proceedings against others to enforce our
patents or trademarks, to protect our trade secrets or know-how, or
to determine the enforceability, scope and validity of the
proprietary rights of others. These proceedings would result in
substantial expense to us and significant diversion of effort by
our technical and management personnel. We may not prevail in any
lawsuits that we initiate and the damages or other remedies
awarded, if any, may not be commercially meaningful. We may not be
able to stop a competitor from marketing and selling products that
are the same or similar to our products or from using product names
that are the same or similar to our product names, and our business
may be harmed as a result.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><b><i><font size="2" face=
"Times New Roman" style=
"font-size:10.0pt;font-style:italic;font-weight:bold;">We are aware
of patents held by third parties that may be asserted against us in
litigation that could be costly and could limit our ability to sell
our Lumivascular platform products.</font></i></b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2"
face="Times New Roman" style="font-size:10.0pt;">We are aware of
patent families related to catheter positioning, optical coherence
tomography, occlusion cutting and atherectomy owned by third
parties. With regard to atherectomy patents, one of our founders,
Dr.&nbsp;John Simpson, founded FoxHollow Technologies prior to
founding our company. FoxHollow Technologies developed an
atherectomy device that is currently sold by Medtronic, and
Dr.&nbsp;Simpson and our Chief Technology Officer, Himanshu Patel,
are listed as inventors on patents covering that</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style=
"font-size:10.0pt;margin:0in 0in .0001pt;text-align:center;">
48<a name="PB_48_114420_3020" id="PB_48_114420_3020"></a></p>
<div style="margin:0in 0in .0001pt;">
<hr size="3" width="100%" noshade="noshade" align="left" style=
"color:#010101;" /></div>
</div>
<!-- SEQ.=1,FOLIO='48',FILE='C:\JMS\109761\18-8644-1\task8901132\8644-1-gc.htm',USER='109761',CD='May 15 15:31 2018' --><br clear="all"
style="page-break-before:always;" />
<div style="font-family:Times New Roman;">
<p style="margin:0in 0in .0001pt;"><a href="#TableOfContents"
title="Click to go to Table of Contents"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">Table of
Contents</font></a></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">device that are now
held by Medtronic. We are not currently aware of any claims
Medtronic has made or intends to make against us with respect to
Pantheris or any other product or product under development.
Because of a doctrine known as “assignor estoppel,” if any of
Dr.&nbsp;Simpson’s earlier patents are asserted against us by
Medtronic, we may be prevented from asserting an invalidity defense
regarding those patents, and our defense may be compromised.
Medtronic has significantly greater financial resources than we do
to pursue patent litigation and could assert these patent families
against us at any time. Adverse determinations in any such
litigation could prevent us from manufacturing or selling Pantheris
or other products or products under development, which would
significantly harm our business.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><b><i><font size="2" face=
"Times New Roman" style=
"font-size:10.0pt;font-style:italic;font-weight:bold;">Intellectual
property rights may not provide adequate protection, which may
permit third parties to compete against us more
effectively.</font></i></b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2"
face="Times New Roman" style="font-size:10.0pt;">In order to remain
competitive, we must develop and maintain protection of the
proprietary aspects of our technologies. We rely on a combination
of patents, copyrights, trademarks, trade secret laws and
confidentiality and invention assignment agreements to protect our
intellectual property rights. As of March&nbsp;31, 2018, we held 18
issued and allowed U.S. patents and had 24 U.S. utility patent
applications and 6 PCT applications pending. As of March&nbsp;31,
2018, we also had 28 issued and allowed patents outside of the
United States. As of March&nbsp;31, 2018, we had 44 pending patent
applications outside of the United States, including in Australia,
Canada, China, Europe,&nbsp;India and Japan. Our patents and patent
applications include claims covering key aspects of the design,
manufacture and therapeutic use of OCT imaging catheters,
occlusion-crossing catheters, atherectomy devices and our imaging
console. Our patent applications may not result in issued patents
and our patents may not be sufficiently broad to protect our
technology. Any patents issued to us may be challenged by third
parties as being invalid, or third parties may independently
develop similar or competing technology that avoids our patents.
Should such challenges be successful, competitors might be able to
market products and use manufacturing processes that are
substantially similar to ours. We may not be able to prevent the
unauthorized disclosure or use of our technical knowledge or other
trade secrets by consultants, vendors or former or current
employees, despite the existence generally of confidentiality
agreements and other contractual restrictions. Monitoring
unauthorized use and disclosure of our intellectual property is
difficult, and we do not know whether the steps we have taken to
protect our intellectual property will be adequate. In addition,
the laws of many foreign countries will not protect our
intellectual property rights to the same extent as the laws of the
United States. Consequently, we may be unable to prevent our
proprietary technology from being exploited abroad, which could
affect our ability to expand to international markets or require
costly efforts to protect our technology. To the extent our
intellectual property protection is incomplete, we are exposed to a
greater risk of direct competition. In addition, competitors could
purchase our products and attempt to replicate some or all of the
competitive advantages we derive from our development efforts or
design around our protected technology. Our failure to secure,
protect and enforce our intellectual property rights could
substantially harm the value of our Lumivascular platform, brand
and business. We use certain open source software in Lightbox. We
may face claims from companies that incorporate open source
software into their products or from open source licensors,
claiming ownership of, or demanding release of, the source code,
the open source software or derivative works that were developed
using such software, or otherwise seeking to enforce the terms of
the applicable open source license. These claims could result in
litigation and could require us to cease offering Lightbox unless
and until we can re- engineer it to avoid infringement. This
re-engineering process could require significant additional
research and development resources, and we may not be able to
complete it successfully. These risks could be difficult to
eliminate or manage, and, if not addressed, could harm our
business, financial condition and operating results.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><b><font size="2" face=
"Times New Roman" style="font-size:10.0pt;font-weight:bold;">Risks
Related to Government Regulation</font></b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><b><i><font size="2" face=
"Times New Roman" style=
"font-size:10.0pt;font-style:italic;font-weight:bold;">Failure to
comply with laws and regulations could harm our
business.</font></i></b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2"
face="Times New Roman" style="font-size:10.0pt;">Our business is
subject to regulation by various federal, state, local and foreign
governmental agencies, including agencies responsible for
monitoring and enforcing employment and labor laws, workplace
safety, environmental laws, consumer protection laws, anti-bribery
laws, import/export controls, federal securities laws and tax laws
and regulations. In certain jurisdictions, these regulatory
requirements may be more stringent than those in the United States
and in other circumstances these requirements may be more stringent
in the United States. Noncompliance with applicable regulations or
requirements could subject us to investigations, sanctions,
mandatory recalls, enforcement actions, adverse publicity,
disgorgement of profits, fines, damages, civil and criminal
penalties or injunctions and administrative actions. If any
governmental sanctions, fines or penalties are imposed, or if we do
not prevail in any possible civil or criminal litigation, our
business, operating results and financial condition could be
harmed. In addition, responding to any action will likely result in
a significant diversion of management’s attention and resources and
substantial costs. Enforcement actions and sanctions could further
harm our business, operating results and financial
condition.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style=
"font-size:10.0pt;margin:0in 0in .0001pt;text-align:center;">
49<a name="PB_49_114452_7748" id="PB_49_114452_7748"></a></p>
<div style="margin:0in 0in .0001pt;">
<hr size="3" width="100%" noshade="noshade" align="left" style=
"color:#010101;" /></div>
</div>
<!-- SEQ.=1,FOLIO='49',FILE='C:\JMS\109761\18-8644-1\task8901132\8644-1-gc.htm',USER='109761',CD='May 15 15:31 2018' --><br clear="all"
style="page-break-before:always;" />
<div style="font-family:Times New Roman;">
<p style="margin:0in 0in .0001pt;"><a href="#TableOfContents"
title="Click to go to Table of Contents"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">Table of
Contents</font></a></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><b><i><font size="2" face=
"Times New Roman" style=
"font-size:10.0pt;font-style:italic;font-weight:bold;">If we fail
to obtain and maintain necessary regulatory clearances or approvals
for our Lumivascular platform products, or if clearances or
approvals for future products and indications are delayed or not
issued, our commercial operations would be
harmed.</font></i></b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2"
face="Times New Roman" style="font-size:10.0pt;">Our Lumivascular
platform products are medical devices that are subject to extensive
regulation by FDA in the United States and by regulatory agencies
in other countries where we do business. Government regulations
specific to medical devices are wide-ranging and govern, among
other things:</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style=
"font-size:10.0pt;margin:0in 0in .0001pt .75in;text-indent:-.25in;">
<font size="2" face="Symbol" style=
"font-size:10.0pt;">·</font><font size="1" style=
"font-size:3.0pt;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</font>
product design, development and manufacture;</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style=
"font-size:10.0pt;margin:0in 0in .0001pt .75in;text-indent:-.25in;">
<font size="2" face="Symbol" style=
"font-size:10.0pt;">·</font><font size="1" style=
"font-size:3.0pt;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</font>
laboratory, preclinical and clinical testing, labeling, packaging,
storage and distribution;</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style=
"font-size:10.0pt;margin:0in 0in .0001pt .75in;text-indent:-.25in;">
<font size="2" face="Symbol" style=
"font-size:10.0pt;">·</font><font size="1" style=
"font-size:3.0pt;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</font>
pre-marketing clearance or approval;</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style=
"font-size:10.0pt;margin:0in 0in .0001pt .75in;text-indent:-.25in;">
<font size="2" face="Symbol" style=
"font-size:10.0pt;">·</font><font size="1" style=
"font-size:3.0pt;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</font>
record keeping;</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style=
"font-size:10.0pt;margin:0in 0in .0001pt .75in;text-indent:-.25in;">
<font size="2" face="Symbol" style=
"font-size:10.0pt;">·</font><font size="1" style=
"font-size:3.0pt;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</font>
product marketing, promotion and advertising, sales and
distribution; and</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style=
"font-size:10.0pt;margin:0in 0in .0001pt .75in;text-indent:-.25in;">
<font size="2" face="Symbol" style=
"font-size:10.0pt;">·</font><font size="1" style=
"font-size:3.0pt;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</font>
post-marketing surveillance, including reporting of deaths or
serious injuries and recalls and correction and removals.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style=
"font-size:10.0pt;margin:0in 0in .0001pt;text-indent:.5in;">
<font size="2" face="Times New Roman" style=
"font-size:10.0pt;">Before a new medical device, or a new intended
use for, an existing product can be marketed in the United States,
a company must first submit and receive either
510(k)&nbsp;clearance or pre-marketing approval from FDA, unless an
exemption applies. Either process can be expensive, lengthy and
unpredictable. We may not be able to obtain the necessary
clearances or approvals or may be unduly delayed in doing so, which
could harm our business. Furthermore, even if we are granted
regulatory clearances or approvals, they may include significant
limitations on the indicated uses for the product, which may limit
the market for the product. Although we have obtained
510(k)&nbsp;clearance to market</font> Pantheris, our image-guided
atherectomy device, and our Ocelot family of catheters for crossing
sub and total occlusions in the peripheral vasculature, our
clearance can be revoked if safety or efficacy problems develop. We
applied for 510(k)&nbsp;clearance for improvements to our Pantheris
device in December&nbsp;2017, and we intend to file for FDA
clearance of a lower-profile device for below-the-knee peripheral
vascular applications in mid-2018. Delays in obtaining clearance or
approval could increase our costs and harm our revenues and
growth.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2"
face="Times New Roman" style="font-size:10.0pt;">In addition, we
are required to timely file various reports with the FDA, including
reports required by the MDRs that require that we report to the
regulatory authorities if our devices may have caused or
contributed to a death or serious injury or malfunctioned in a way
that would likely cause or contribute to a death or serious injury
if the malfunction were to recur. If these reports are not filed
timely, regulators may impose sanctions and sales of our products
may suffer, and we may be subject to product liability or
regulatory enforcement actions, all of which could harm our
business</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2"
face="Times New Roman" style="font-size:10.0pt;">If we initiate a
correction or removal for one of our devices to reduce a risk to
health posed by the device, we would be required to submit a
publicly available Correction and Removal report to the FDA and in
many cases, similar reports to other regulatory agencies. This
report could be classified by the FDA as a device recall which
could lead to increased scrutiny by the FDA, other international
regulatory agencies and our customers regarding the quality and
safety of our devices. Furthermore, the submission of these reports
has been and could be used by competitors against us in competitive
situations and cause customers to delay purchase decisions or
cancel orders and would harm our reputation.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2"
face="Times New Roman" style="font-size:10.0pt;">The FDA and the
Federal Trade Commission, or FTC, also regulate the advertising and
promotion of our products to ensure that the claims we make are
consistent with our regulatory clearances, that there are adequate
and reasonable scientific data to substantiate the claims and that
our promotional labeling and advertising is neither false nor
misleading in any respect. If the FDA or FTC determines that any of
our advertising or promotional claims are misleading, not
substantiated or not permissible, we may be subject to enforcement
actions, including Warning Letters, adverse publicity, and we may
be required to revise our promotional claims and make other
corrections or restitutions.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2"
face="Times New Roman" style="font-size:10.0pt;">The FDA and state
authorities have broad enforcement powers. Our failure to comply
with applicable regulatory requirements could result in enforcement
action by the FDA or state agencies, which may include any of the
following sanctions:</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style=
"font-size:10.0pt;margin:0in 0in .0001pt .75in;text-indent:-.25in;">
<font size="2" face="Symbol" style=
"font-size:10.0pt;">·</font><font size="1" style=
"font-size:3.0pt;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</font>
adverse publicity, warning letters, fines, injunctions, consent
decrees and civil penalties;</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style=
"font-size:10.0pt;margin:0in 0in .0001pt .75in;text-indent:-.25in;">
<font size="2" face="Symbol" style=
"font-size:10.0pt;">·</font><font size="1" style=
"font-size:3.0pt;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</font>
repair, replacement, refunds, recall or seizure of our
products;</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style=
"font-size:10.0pt;margin:0in 0in .0001pt;text-align:center;">
50<a name="PB_50_114612_141" id="PB_50_114612_141"></a></p>
<div style="margin:0in 0in .0001pt;">
<hr size="3" width="100%" noshade="noshade" align="left" style=
"color:#010101;" /></div>
</div>
<!-- SEQ.=1,FOLIO='50',FILE='C:\JMS\109761\18-8644-1\task8901132\8644-1-gc.htm',USER='109761',CD='May 15 15:31 2018' --><br clear="all"
style="page-break-before:always;" />
<div style="font-family:Times New Roman;">
<p style="margin:0in 0in .0001pt;"><a href="#TableOfContents"
title="Click to go to Table of Contents"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">Table of
Contents</font></a></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style=
"font-size:10.0pt;margin:0in 0in .0001pt .75in;text-indent:-.25in;">
<font size="2" face="Symbol" style=
"font-size:10.0pt;">·</font><font size="1" style=
"font-size:3.0pt;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</font>
operating restrictions, partial suspension or total shutdown of
production;</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style=
"font-size:10.0pt;margin:0in 0in .0001pt .75in;text-indent:-.25in;">
<font size="2" face="Symbol" style=
"font-size:10.0pt;">·</font><font size="1" style=
"font-size:3.0pt;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</font>
refusing our requests for 510(k)&nbsp;clearance or pre-market
approval of new products, new intended uses or modifications to
existing products;</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style=
"font-size:10.0pt;margin:0in 0in .0001pt .75in;text-indent:-.25in;">
<font size="2" face="Symbol" style=
"font-size:10.0pt;">·</font><font size="1" style=
"font-size:3.0pt;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</font>
withdrawing 510(k)&nbsp;clearance or pre-market approvals that have
already been granted; and</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style=
"font-size:10.0pt;margin:0in 0in .0001pt .75in;text-indent:-.25in;">
<font size="2" face="Symbol" style=
"font-size:10.0pt;">·</font><font size="1" style=
"font-size:3.0pt;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</font>
criminal prosecution.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2"
face="Times New Roman" style="font-size:10.0pt;">If any of these
events were to occur, our business and financial condition would be
harmed.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><b><i><font size="2" face=
"Times New Roman" style=
"font-size:10.0pt;font-style:italic;font-weight:bold;">Material
modifications to our Lumivascular platform products may require new
510(k)&nbsp;clearances or pre-market approvals or may require us to
recall or cease marketing our Lumivascular platform products until
clearances or approvals are obtained.</font></i></b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2"
face="Times New Roman" style="font-size:10.0pt;">Material
modifications to the intended use or technological characteristics
of our Lumivascular platform products will require new
510(k)&nbsp;clearances or pre-market approvals or require us to
recall or cease marketing the modified devices until these
clearances or approvals are obtained. Based on published FDA
guidelines, the FDA requires device manufacturers to initially make
and document a determination of whether or not a modification
requires a new approval, supplement or clearance; however, the FDA
can review a manufacturer’s decision. Any modification to an
FDA-cleared device that would significantly affect its safety or
efficacy or that would constitute a major change in its intended
use would require a new 510(k)&nbsp;clearance or possibly a
pre-market approval. We may not be able to obtain additional
510(k)&nbsp;clearances or pre-market approvals for new products or
for modifications to, or additional indications for, our
Lumivascular platform products in a timely fashion, or at all.
Delays in obtaining required future clearances would harm our
ability to introduce new or enhanced products in a timely manner,
which in turn would harm our future growth. We have made
modifications to our Lumivascular platform products in the past and
will make additional modifications in the future that we believe do
not or will not require additional clearances or approvals. If the
FDA disagrees and requires new clearances or approvals for the
modifications, we may be required to recall and to stop selling or
marketing our Lumivascular platform products as modified, which
could harm our operating results and require us to redesign our
Lumivascular platform products. In these circumstances, we may be
subject to significant enforcement actions. We plan to make further
modifications to the design of Pantheris to enhance cutting
efficiency and access smaller vessels. Future versions of Pantheris
incorporating these enhancements may require additional regulatory
clearances or approvals.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><b><i><font size="2" face=
"Times New Roman" style=
"font-size:10.0pt;font-style:italic;font-weight:bold;">If we or our
suppliers fail to comply with the FDA’s QSR, our manufacturing
operations could be delayed or shut down and Lumivascular platform
sales could suffer.</font></i></b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2"
face="Times New Roman" style="font-size:10.0pt;">Our manufacturing
processes and those of our third-party suppliers are required to
comply with the FDA’s QSR, which covers the procedures and
documentation of the design, testing, production, control, quality
assurance, labeling, packaging, storage and shipping of our
Lumivascular platform products. We are also subject to similar
state requirements and licenses. In addition, we must engage in
extensive recordkeeping and reporting and must make available our
manufacturing facilities and records for periodic unannounced
inspections by governmental agencies, including the FDA, state
authorities and comparable agencies in other countries. If we fail
a QSR inspection, our operations could be disrupted and our
manufacturing interrupted. Failure to take adequate corrective
action in response to an adverse QSR inspection could result in,
among other things, a shut-down of our manufacturing operations,
significant fines, suspension of marketing clearances and
approvals, seizures or recalls of our device, operating
restrictions and criminal prosecutions, any of which would cause
our business to suffer. Furthermore, our key component suppliers
may not currently be or may not continue to be in compliance with
applicable regulatory requirements, which may result in
manufacturing delays for our products and cause our revenues to
decline.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style=
"font-size:10.0pt;margin:0in 0in .0001pt;text-indent:.5in;">
<font size="2" face="Times New Roman" style="font-size:10.0pt;">We
have registered with the FDA as a medical device manufacturer and
have obtained a manufacturing license from the CDHS. The FDA has
broad post-market and regulatory enforcement powers. We are subject
to unannounced inspections by the FDA and the Food and Drug Branch
of CDHS to determine our compliance with the QSR and other
regulations, and these inspections may include the manufacturing
facilities of our suppliers. Our current facility has been
inspected by the FDA in 2009, 2011 and 2013, and two, three and
zero observations, respectively, were noted during those
inspections. BSI, our European Notified Body, inspected our
facility in 2014 and 2015 and found zero non-conformances. BSI
conducted four external audits in 2016 and zero non-conformances
were found in all except for one audit, for which four minor
non-conformances were found.</font> The BSI audit performed in
January&nbsp;2017 resulted in zero non-conformances. We can provide
no assurance that we will continue to remain in substantial
compliance with the QSR. If the FDA, CDHS or BSI inspect our
facility and discover compliance problems, we may have to shut down
our facility and cease manufacturing until we can take the
appropriate remedial steps to correct the audit findings. Taking
corrective action may be expensive, time consuming and a
distraction for management and if we experience a shutdown or delay
at our manufacturing facility we may be unable to produce our
Lumivascular platform products, which would harm our business.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style=
"font-size:10.0pt;margin:0in 0in .0001pt;text-align:center;">
51<a name="PB_51_114704_7608" id="PB_51_114704_7608"></a></p>
<div style="margin:0in 0in .0001pt;">
<hr size="3" width="100%" noshade="noshade" align="left" style=
"color:#010101;" /></div>
</div>
<!-- SEQ.=1,FOLIO='51',FILE='C:\JMS\109761\18-8644-1\task8901132\8644-1-gc.htm',USER='109761',CD='May 15 15:31 2018' --><br clear="all"
style="page-break-before:always;" />
<div style="font-family:Times New Roman;">
<p style="margin:0in 0in .0001pt;"><a href="#TableOfContents"
title="Click to go to Table of Contents"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">Table of
Contents</font></a></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><b><i><font size="2" face=
"Times New Roman" style=
"font-size:10.0pt;font-style:italic;font-weight:bold;">Our
Lumivascular platform products may in the future be subject to
product recalls that could harm our reputation.</font></i></b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2"
face="Times New Roman" style="font-size:10.0pt;">FDA and similar
governmental authorities in other countries have the authority to
require the recall of commercialized products in the event of
material regulatory deficiencies or defects in design or
manufacture. A government mandated or voluntary recall by us could
occur as a result of component failures, manufacturing errors or
design or labeling defects. Recalls of our Lumivascular platform
products would divert managerial attention, be expensive, harm our
reputation with customers and harm our financial condition and
results of operations. A recall announcement would negatively
affect our stock price.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><b><i><font size="2" face=
"Times New Roman" style=
"font-size:10.0pt;font-style:italic;font-weight:bold;">Changes in
coverage and reimbursement for procedures using our Lumivascular
platform products could affect the adoption of our Lumivascular
platform and our future revenues.</font></i></b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2"
face="Times New Roman" style="font-size:10.0pt;">Currently, our
Lumivascular platform procedure is typically reimbursed by
third-party payors, including Medicare and private healthcare
insurance companies, under existing reimbursement codes. These
payors may change their coverage and reimbursement policies, as
well as payment amounts, in a way that would prevent or limit
reimbursement for our products, which would significantly harm our
business. Also, healthcare reform legislation or regulation may be
proposed or enacted in the future, which may adversely affect such
policies and amounts. We cannot predict whether and to what extent
existing coverage and reimbursement will continue to be available.
If physicians, hospitals and other providers are unable to obtain
adequate coverage and reimbursement for procedures performed using
our Lumivascular platform products, they are significantly less
likely to use our Lumivascular platform products and our business
would be harmed.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><b><i><font size="2" face=
"Times New Roman" style=
"font-size:10.0pt;font-style:italic;font-weight:bold;">Healthcare
reform measures could hinder or prevent our planned products’
commercial success.</font></i></b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style=
"font-size:10.0pt;margin:0in 0in .0001pt;text-indent:.5in;">
<font size="2" face="Times New Roman" style="font-size:10.0pt;">In
the United States, there have been, and we expect there will
continue to be, a number of legislative and regulatory changes to
the healthcare system in ways that could harm our future revenues
and profitability and the future revenues and profitability of our
potential customers. Federal and state lawmakers regularly propose
and, at times, enact legislation that would result in significant
changes to the healthcare system, some of which are intended to
contain or reduce the costs of medical products and services. For
example, one of the most significant healthcare reform measures in
decades, the Patient Protection and Affordable Care Act, as amended
by the Health Care and Education Affordability Reconciliation Act,
or Affordable Care Act, was enacted in 2010. The Affordable Care
Act contains a number of provisions, including those governing
enrollment in federal healthcare programs, reimbursement changes
and fraud and abuse measures, all of which will impact existing
government healthcare programs and will result in the development
of new programs. The Affordable Care Act, among other things,
imposed an excise tax of 2.3% on the sale of most medical devices,
including ours, and any failure to pay this amount could result in
the imposition of an injunction on the sale of our products, fines
and penalties. Although this tax has been suspended</font> through
2019, it is expected to apply to sales of our products in 2020 and
thereafter. The current presidential administration and Congress
may continue to attempt broad sweeping changes to the current
health care laws. We face uncertainties that might result from
modifications or repeal of any of the provisions of the Affordable
Care Act, including as a result of current and future executive
orders and legislative actions. The impact of those changes on us
and potential effect on the medical device industry as a whole is
currently unknown. Any changes to the Affordable Care Act are
likely to have an impact on our results of operations, and may have
a material adverse effect on our results of operations. We cannot
predict what other health care programs and regulations will
ultimately be implemented at the federal or state level or the
effect of any future legislation or regulation in the United States
may have on our business.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2"
face="Times New Roman" style="font-size:10.0pt;">The continuing
efforts of the government, insurance companies, managed care
organizations and other payors of healthcare services to contain or
reduce costs of health care may harm:</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style=
"font-size:10.0pt;margin:0in 0in .0001pt .75in;text-indent:-.25in;">
<font size="2" face="Symbol" style=
"font-size:10.0pt;">·</font><font size="1" style=
"font-size:3.0pt;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</font>
our ability to set a price that we believe is fair for our
products;</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style=
"font-size:10.0pt;margin:0in 0in .0001pt .75in;text-indent:-.25in;">
<font size="2" face="Symbol" style=
"font-size:10.0pt;">·</font><font size="1" style=
"font-size:3.0pt;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</font>
our ability to generate revenues and achieve or maintain
profitability; and</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style=
"font-size:10.0pt;margin:0in 0in .0001pt .75in;text-indent:-.25in;">
<font size="2" face="Symbol" style=
"font-size:10.0pt;">·</font><font size="1" style=
"font-size:3.0pt;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</font>
the availability of capital.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style=
"font-size:10.0pt;margin:0in 0in .0001pt;text-align:center;">
52<a name="PB_52_114819_8146" id="PB_52_114819_8146"></a></p>
<div style="margin:0in 0in .0001pt;">
<hr size="3" width="100%" noshade="noshade" align="left" style=
"color:#010101;" /></div>
</div>
<!-- SEQ.=1,FOLIO='52',FILE='C:\JMS\109761\18-8644-1\task8901132\8644-1-gc.htm',USER='109761',CD='May 15 15:31 2018' --><br clear="all"
style="page-break-before:always;" />
<div style="font-family:Times New Roman;">
<p style="margin:0in 0in .0001pt;"><a href="#TableOfContents"
title="Click to go to Table of Contents"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">Table of
Contents</font></a></p>
<p style="margin:0in 0in .0001pt;"><b><i><font size="2" face=
"Times New Roman" style=
"font-size:10.0pt;font-style:italic;font-weight:bold;">&nbsp;</font></i></b></p>
<p style="margin:0in 0in .0001pt;"><b><i><font size="2" face=
"Times New Roman" style=
"font-size:10.0pt;font-style:italic;font-weight:bold;">If we fail
to comply with healthcare regulations, we could face substantial
penalties and our business, operations and financial condition
could be adversely affected.</font></i></b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2"
face="Times New Roman" style="font-size:10.0pt;">Even though we do
not and will not control referrals of healthcare services or bill
directly to Medicare, Medicaid or other third-party payors, certain
federal and state healthcare laws and regulations pertaining to
fraud and abuse and patients’ rights are and will be applicable to
our business. We could be subject to healthcare fraud and abuse and
patient privacy regulation by both the federal government and the
states in which we conduct our business. The regulations that will
affect how we operate include:</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style=
"font-size:10.0pt;margin:0in 0in .0001pt .75in;text-indent:-.25in;">
<font size="2" face="Symbol" style=
"font-size:10.0pt;">·</font><font size="1" style=
"font-size:3.0pt;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</font>
the federal healthcare program Anti-Kickback Statute, which
prohibits, among other things, any person from knowingly and
willfully offering, soliciting, receiving or providing
remuneration, directly or indirectly, in exchange for or to induce
either the referral of an individual for, or the purchase, order or
recommendation of, any good or service for which payment may be
made under federal healthcare programs, such as the Medicare and
Medicaid programs;</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style=
"font-size:10.0pt;margin:0in 0in .0001pt .75in;text-indent:-.25in;">
<font size="2" face="Symbol" style=
"font-size:10.0pt;">·</font><font size="1" style=
"font-size:3.0pt;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</font>
the federal False Claims Act, which prohibits, among other things,
individuals or entities from knowingly presenting, or causing to be
presented, false claims, or knowingly using false statements, to
obtain payment from the federal government;</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style=
"font-size:10.0pt;margin:0in 0in .0001pt .75in;text-indent:-.25in;">
<font size="2" face="Symbol" style=
"font-size:10.0pt;">·</font><font size="1" style=
"font-size:3.0pt;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</font>
federal criminal laws that prohibit executing a scheme to defraud
any healthcare benefit program or making false statements relating
to healthcare matters;</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style=
"font-size:10.0pt;margin:0in 0in .0001pt .75in;text-indent:-.25in;">
<font size="2" face="Symbol" style=
"font-size:10.0pt;">·</font><font size="1" style=
"font-size:3.0pt;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</font>
the Sunshine Act, created under the Affordable Care Act, and its
implementing regulations, which require manufacturers of drugs,
medical devices, biologicals and medical supplies for which payment
is available under Medicare, Medicaid, or the Children’s Health
Insurance Program to report annually to the HHS information related
to payments or other transfers of value made to physicians and
teaching hospitals, as well as ownership and investment interests
held by physicians and their immediate family members;</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style=
"font-size:10.0pt;margin:0in 0in .0001pt .75in;text-indent:-.25in;">
<font size="2" face="Symbol" style=
"font-size:10.0pt;">·</font><font size="1" style=
"font-size:3.0pt;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</font>
HIPAA, as amended by the HITECH Act, which protects the security
and privacy of protected health information; and</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style=
"font-size:10.0pt;margin:0in 0in .0001pt .75in;text-indent:-.25in;">
<font size="2" face="Symbol" style=
"font-size:10.0pt;">·</font><font size="1" style=
"font-size:3.0pt;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</font>
state law equivalents of each of the above federal laws, such as
anti-kickback and false claims laws which may apply to items or
services reimbursed by any third-party payor, including commercial
insurers.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2"
face="Times New Roman" style="font-size:10.0pt;">The Affordable
Care Act, among other things, amends the intent requirement of the
Federal Anti-Kickback Statute and criminal healthcare fraud
statutes. A person or entity no longer needs to have actual
knowledge of this statute or specific intent to violate it. In
addition, the Affordable Care Act provides that the government may
assert that a claim including items or services resulting from a
violation of the Federal Anti-Kickback Statute constitutes a false
or fraudulent claim for purposes of the False Claims
Act.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2"
face="Times New Roman" style="font-size:10.0pt;">Efforts to ensure
that our business arrangements will comply with applicable
healthcare laws may involve substantial costs. It is possible that
governmental and enforcement authorities will conclude that our
business practices do not comply with current or future statutes,
regulations or case law interpreting applicable fraud and abuse or
other healthcare laws and regulations. If any such&nbsp; actions
are instituted against us, and we are not successful in defending
ourselves or asserting our rights, those actions could have a
significant impact on our business, including the imposition of
civil, criminal and administrative penalties, damages,
disgorgement, monetary fines, possible exclusion from participation
in Medicare, Medicaid and other federal healthcare programs,
contractual damages, reputational harm, diminished profits and
future earnings, and curtailment of our operations, any of which
could harm our ability to operate our business and our results of
operations. In addition, the clearance or approval and
commercialization of any of our products outside the United States
will also likely subject us to foreign equivalents of the
healthcare laws mentioned above, among other foreign
laws.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><b><i><font size="2" face=
"Times New Roman" style=
"font-size:10.0pt;font-style:italic;font-weight:bold;">Compliance
with environmental laws and regulations could be expensive. Failure
to comply with environmental laws and regulations could subject us
to significant liability.</font></i></b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style=
"font-size:10.0pt;margin:0in 0in .0001pt;text-indent:.5in;">
<font size="2" face="Times New Roman" style="font-size:10.0pt;">Our
research and development and manufacturing operations involve the
use of hazardous substances and are subject to a variety of
federal, state, local and foreign environmental laws and
regulations relating to the storage, use, discharge, disposal,
remediation of, and human exposure to, hazardous substances and the
sale, labeling, collection, recycling, treatment and disposal of
products containing hazardous substances. In addition, our research
and development and manufacturing operations produce biological
waste materials, such as human and animal tissue, and waste
solvents, such as isopropyl alcohol. These operations are permitted
by regulatory authorities, and the resultant waste materials are
disposed of in material compliance with environmental laws</font>
and regulations. Liability under environmental laws and regulations
can be joint and several and without regard to fault or negligence.
Compliance with environmental laws and regulations may be expensive
and non-compliance could result in substantial liabilities,</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style=
"font-size:10.0pt;margin:0in 0in .0001pt;text-align:center;">
53<a name="PB_53_115048_402" id="PB_53_115048_402"></a></p>
<div style="margin:0in 0in .0001pt;">
<hr size="3" width="100%" noshade="noshade" align="left" style=
"color:#010101;" /></div>
</div>
<!-- SEQ.=1,FOLIO='53',FILE='C:\JMS\109761\18-8644-1\task8901132\8644-1-ge.htm',USER='109761',CD='May 15 15:52 2018' --><br clear="all"
style="page-break-before:always;" />
<div style="font-family:Times New Roman;">
<p style="margin:0in 0in .0001pt;"><a href="#TableOfContents"
title="Click to go to Table of Contents"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">Table of
Contents</font></a></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">fines and penalties,
personal injury and third party property damage claims and
substantial investigation and remediation costs. Environmental laws
and regulations could become more stringent over time, imposing
greater compliance costs and increasing risks and penalties
associated with violations. We cannot assure you that violations of
these laws and regulations will not occur in the future or have not
occurred in the past as a result of human error, accidents,
equipment failure or other causes. The expense associated with
environmental regulation and remediation could harm our financial
condition and operating results.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><b><i><font size="2" face=
"Times New Roman" style=
"font-size:10.0pt;font-style:italic;font-weight:bold;">Regulations
related to “conflict minerals” may force us to incur additional
expenses, may result in damage to our business reputation and may
adversely impact our ability to conduct our
business.</font></i></b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style=
"font-size:10.0pt;margin:0in 0in .0001pt;text-indent:.5in;">
<font size="2" face="Times New Roman" style=
"font-size:10.0pt;">Pursuant to the Dodd-Frank Wall Street Reform
and Consumer Protection Act, the SEC promulgated final
rules&nbsp;regarding disclosure of the use of certain minerals,
known as conflict minerals, that are mined from the Democratic
Republic of the Congo and adjoining countries, as well as
procedures regarding a manufacturer’s efforts to prevent the
sourcing of such minerals and metals produced from those minerals.
These disclosure requirements require ongoing due diligence efforts
and disclosure obligations.</font> We have incurred and expect to
incur additional costs to comply with these disclosure
requirements, including costs related to determining the source of
any of the relevant minerals and metals used in our products.
Additional costs could include the cost of remediation and other
changes to products, processes, or sources of supply as a
consequence of such verification activities. In addition, our
implementation of these rules&nbsp;could adversely affect the
sourcing, supply, and pricing of materials used in our products. We
may face reputational harm if we determine that certain of our
components contain minerals not determined to be conflict free or
if we are unable to alter our processes or sources of supply to
avoid using such materials. Reputational harm could adversely
affect our business, financial condition or results of
operations.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt 10.0pt;text-indent:-10.0pt;">
<b><font size="2" face="Times New Roman" style=
"font-size:10.0pt;font-weight:bold;">Risks Related to Our Common
Stock and Preferred Stock</font></b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><b><i><font size="2" face=
"Times New Roman" style=
"font-size:10.0pt;font-style:italic;font-weight:bold;">Our stock
price may be volatile, and purchasers of our common stock could
incur substantial losses.</font></i></b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2"
face="Times New Roman" style="font-size:10.0pt;">Our stock price
has fluctuated significantly since our IPO and is likely to
continue to fluctuate substantially. As a result of this price
fluctuation, investors may experience losses on their investments
in our stock. In addition, the development stage of our operations
may make it difficult for investors to evaluate the success of our
business to date and to assess our future viability. The market
price for our common stock may be influenced by many factors,
including:</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style=
"font-size:10.0pt;margin:0in 0in .0001pt .5in;text-indent:-.25in;">
<font size="2" face="Symbol" style=
"font-size:10.0pt;">·</font><font size="1" style=
"font-size:3.0pt;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</font>
sales of stock by our existing stockholders, including our
affiliates;</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style=
"font-size:10.0pt;margin:0in 0in .0001pt .5in;text-indent:-.25in;">
<font size="2" face="Symbol" style=
"font-size:10.0pt;">·</font><font size="1" style=
"font-size:3.0pt;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</font>
market acceptance of our Lumivascular platform and products,
including Pantheris;</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style=
"font-size:10.0pt;margin:0in 0in .0001pt .5in;text-indent:-.25in;">
<font size="2" face="Symbol" style=
"font-size:10.0pt;">·</font><font size="1" style=
"font-size:3.0pt;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</font>
the results of our clinical trials;</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style=
"font-size:10.0pt;margin:0in 0in .0001pt .5in;text-indent:-.25in;">
<font size="2" face="Symbol" style=
"font-size:10.0pt;">·</font><font size="1" style=
"font-size:3.0pt;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</font>
changes in analysts’ estimates, investors’ perceptions,
recommendations by securities analysts or our failure to achieve
analysts’ and our own estimates;</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style=
"font-size:10.0pt;margin:0in 0in .0001pt .5in;text-indent:-.25in;">
<font size="2" face="Symbol" style=
"font-size:10.0pt;">·</font><font size="1" style=
"font-size:3.0pt;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</font>
the financial projections we may provide to the public, any changes
in these projections or our failure to meet these projections;</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style=
"font-size:10.0pt;margin:0in 0in .0001pt .5in;text-indent:-.25in;">
<font size="2" face="Symbol" style=
"font-size:10.0pt;">·</font><font size="1" style=
"font-size:3.0pt;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</font>
actual or anticipated fluctuations in our financial condition and
operating results;</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style=
"font-size:10.0pt;margin:0in 0in .0001pt .5in;text-indent:-.25in;">
<font size="2" face="Symbol" style=
"font-size:10.0pt;">·</font><font size="1" style=
"font-size:3.0pt;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</font>
quarterly variations in our or our competitors’ results of
operations;</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style=
"font-size:10.0pt;margin:0in 0in .0001pt .5in;text-indent:-.25in;">
<font size="2" face="Symbol" style=
"font-size:10.0pt;">·</font><font size="1" style=
"font-size:3.0pt;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</font>
general market conditions and other factors unrelated to our
operating performance or the operating performance of our
competitors;</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style=
"font-size:10.0pt;margin:0in 0in .0001pt .5in;text-indent:-.25in;">
<font size="2" face="Symbol" style=
"font-size:10.0pt;">·</font><font size="1" style=
"font-size:3.0pt;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</font>
changes in operating performance and stock market valuations of
other technology companies generally, or those in the medical
device industry in particular;</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style=
"font-size:10.0pt;margin:0in 0in .0001pt .5in;text-indent:-.25in;">
<font size="2" face="Symbol" style=
"font-size:10.0pt;">·</font><font size="1" style=
"font-size:3.0pt;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</font>
the loss of key personnel, including changes in our board of
directors and management;</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style=
"font-size:10.0pt;margin:0in 0in .0001pt .5in;text-indent:-.25in;">
<font size="2" face="Symbol" style=
"font-size:10.0pt;">·</font><font size="1" style=
"font-size:3.0pt;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</font>
legislation or regulation of our business;</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style=
"font-size:10.0pt;margin:0in 0in .0001pt .5in;text-indent:-.25in;">
<font size="2" face="Symbol" style=
"font-size:10.0pt;">·</font><font size="1" style=
"font-size:3.0pt;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</font>
lawsuits threatened or filed against us;</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style=
"font-size:10.0pt;margin:0in 0in .0001pt;text-align:center;">
54<a name="PB_54_115201_7091" id="PB_54_115201_7091"></a></p>
<div style="margin:0in 0in .0001pt;">
<hr size="3" width="100%" noshade="noshade" align="left" style=
"color:#010101;" /></div>
</div>
<!-- SEQ.=1,FOLIO='54',FILE='C:\JMS\109761\18-8644-1\task8901132\8644-1-ge.htm',USER='109761',CD='May 15 15:52 2018' --><br clear="all"
style="page-break-before:always;" />
<div style="font-family:Times New Roman;">
<p style="margin:0in 0in .0001pt;"><a href="#TableOfContents"
title="Click to go to Table of Contents"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">Table of
Contents</font></a></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style=
"font-size:10.0pt;margin:0in 0in .0001pt .5in;text-indent:-.25in;">
<font size="2" face="Symbol" style=
"font-size:10.0pt;">·</font><font size="1" style=
"font-size:3.0pt;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</font>
the announcement of new products or product enhancements by us or
our competitors;</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style=
"font-size:10.0pt;margin:0in 0in .0001pt .5in;text-indent:-.25in;">
<font size="2" face="Symbol" style=
"font-size:10.0pt;">·</font><font size="1" style=
"font-size:3.0pt;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</font>
announcements related to patents issued to us or our competitors
and to litigation; and</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style=
"font-size:10.0pt;margin:0in 0in .0001pt .5in;text-indent:-.25in;">
<font size="2" face="Symbol" style=
"font-size:10.0pt;">·</font><font size="1" style=
"font-size:3.0pt;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</font>
developments in our industry.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2"
face="Times New Roman" style="font-size:10.0pt;">From time to time,
our affiliates may sell stock for reasons due to their personal
financial circumstances. These sales may be interpreted by other
stockholders as an indication of our performance and result in
subsequent sales of our stock that have the effect of creating
downward pressure on the market price of our common stock. In
addition, the stock prices of many companies in the medical device
industry have experienced wide fluctuations that have often been
unrelated to the operating performance of those
companies.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2"
face="Times New Roman" style="font-size:10.0pt;">Our stock price
has decreased significantly over the course of the past
year.&nbsp;&nbsp; As a result of the decrease in our stock price,
the options held by our employees are less valuable which make it
more likely that certain of our employees may leave our company.
The loss of key employees could have an adverse effect on our
business.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><b><i><font size="2" face=
"Times New Roman" style=
"font-size:10.0pt;font-style:italic;font-weight:bold;">We may fail
to meet our publicly announced guidance or other expectations about
our business and future operating results, which would cause our
stock price to decline.</font></i></b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2"
face="Times New Roman" style="font-size:10.0pt;">We have provided
in the past and may provide guidance in the future about our
business and future operating results. In developing this guidance,
our management must make certain assumptions and judgments about
our future performance, including projected revenues and the timing
of regulatory approvals. Furthermore, analysts and investors may
develop and publish their own projections of our business, which
may form a consensus about our future performance. Our business
results may vary significantly from such guidance or that consensus
due to a number of factors, many of which are outside of our
control, and which could adversely affect our operations and
operating results. Furthermore, if we make downward revisions of
our previously announced guidance, or if our publicly announced
guidance of future operating results fails to meet expectations of
securities analysts, investors or other interested parties, the
price of our common stock would decline.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><b><i><font size="2" face=
"Times New Roman" style=
"font-size:10.0pt;font-style:italic;font-weight:bold;">If
securities or industry analysts do not publish research or reports
about our business, or publish negative reports about our business,
our share price and trading volume could
decline.</font></i></b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style=
"font-size:10.0pt;margin:0in 0in .0001pt;text-indent:.5in;">
<font size="2" face="Times New Roman" style="font-size:10.0pt;">The
trading market for our common stock will depend in part on the
research and reports that securities or industry analysts publish
about us or our business, our market and our competitors. We do not
have any control over these analysts. The analysts who previously
published research reports on our stock following our IPO have
discontinued coverage. Although one new analyst initiated coverage
of our business in March&nbsp;2018, if additional</font> analysts
do not begin regularly publishing reports on us, we could lose
visibility in the financial markets, which could cause our share
price or trading volume to decline. If our operating results fail
to meet the forecast of analysts, our stock price will likely
decline.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><b><i><font size="2" face=
"Times New Roman" style=
"font-size:10.0pt;font-style:italic;font-weight:bold;">Sales of a
substantial number of shares of our common stock in the public
market, including by our existing stockholders, could cause our
stock price to fall.</font></i></b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2"
face="Times New Roman" style="font-size:10.0pt;">Sales of a
substantial number of shares of our common stock in the public
market, or the perception that these sales might occur, could
depress the market price of our common stock and could impair our
ability to raise capital through the sale of additional equity
securities. We are unable to predict the effect that these sales
and others may have on the prevailing market price of our common
stock.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2"
face="Times New Roman" style="font-size:10.0pt;">We will need to
raise additional funds through future equity or debt financings
within the next nine months to meet our operational needs and
capital requirements for product development, clinical trials and
commercialization. We can provide no assurance that we will be
successful in raising funds pursuant to additional equity or debt
financings or that such funds will be raised at prices that do not
create substantial dilution for our existing stockholders. Given
the recent decline in our stock price, any financing that we
undertake in the next nine months could cause substantial dilution
to our existing stockholders.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style=
"font-size:10.0pt;margin:0in 0in .0001pt;text-align:center;">
55<a name="PB_55_115353_455" id="PB_55_115353_455"></a></p>
<div style="margin:0in 0in .0001pt;">
<hr size="3" width="100%" noshade="noshade" align="left" style=
"color:#010101;" /></div>
</div>
<!-- SEQ.=1,FOLIO='55',FILE='C:\JMS\109761\18-8644-1\task8901132\8644-1-ge.htm',USER='109761',CD='May 15 15:52 2018' --><br clear="all"
style="page-break-before:always;" />
<div style="font-family:Times New Roman;">
<p style="margin:0in 0in .0001pt;"><a href="#TableOfContents"
title="Click to go to Table of Contents"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">Table of
Contents</font></a></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style=
"font-size:10.0pt;margin:0in 0in .0001pt;text-indent:.5in;">
<font size="2" face="Times New Roman" style="font-size:10.0pt;">On
February&nbsp;3, 2016, we filed a universal shelf registration
statement</font> (the “Shelf Registration Statement”) to offer up
to $150.0 million of our securities and entered into an 
“at-the-market” program pursuant to a Sales Agreement with Cowen
and Company (“Cowen”), through which we issued and sold
approximately 200,000 shares of common stock having an aggregate
offering value of approximately $8.7 million between the Shelf
Registration Statement’s effectiveness on March&nbsp;8, 2016 and
September&nbsp;2017. In addition, in August&nbsp;2016, we issued
and sold 200,000 shares of our common stock in our follow-on public
offering at a public offering price of $140.00 per share, for net
proceeds of approximately $31.5 million after deducting
underwriting discounts and commissions of approximately $2.4
million and other expenses of approximately $0.6 million. We have
established, and may in the future establish, “at-the-market”
programs pursuant to which we may offer and sell shares of our
common stock pursuant to the Shelf Registration Statement. During
the year ended December&nbsp;31, 2016, we sold 27,374 shares of
common stock under our “at-the-market” program with Cowen at an
average price of $194.74 and raised net proceeds of $5.2 million,
after payment of $0.2 million in commissions and fees to Cowen.
During the three months ended March&nbsp;31, 2018, we sold no
shares of common stock through the “at-the-market” program. Due to
the SEC’s “baby shelf rules,” which prohibit companies with a
public float of less than $75 million from issuing securities under
a shelf registration statement in excess of one-third of such
company’s public float in a twelve-month period, we are unable to
issue more shares in our “at-the-market” program at this
time.&nbsp; Accordingly, it has been necessary to register the
shares sold pursuant to the Purchase Agreement, the CRG Conversion
and Series&nbsp;B Purchase Agreement on Form&nbsp;S-1. This has
increased our transaction expenses and the number of shares
required to be sold to finance our operations.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style=
"font-size:10.0pt;margin:0in 0in .0001pt;text-align:center;">
56<a name="PB_56_115420_4141" id="PB_56_115420_4141"></a></p>
<div style="margin:0in 0in .0001pt;">
<hr size="3" width="100%" noshade="noshade" align="left" style=
"color:#010101;" /></div>
</div>
<!-- SEQ.=1,FOLIO='56',FILE='C:\JMS\109761\18-8644-1\task8901132\8644-1-ge.htm',USER='109761',CD='May 15 15:52 2018' --><br clear="all"
style="page-break-before:always;" />
<div style="font-family:Times New Roman;">
<p style="margin:0in 0in .0001pt;"><a href="#TableOfContents"
title="Click to go to Table of Contents"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">Table of
Contents</font></a></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2"
face="Times New Roman" style="font-size:10.0pt;">In addition,
pursuant to our Securities Purchase Agreement with CRG, the Shelf
Registration Statement also registered for resale 8,705 shares of
common stock held by CRG, which may be sold freely in the public
market. On November&nbsp;3, 2017, we also entered into the Lincoln
Park Purchase Agreement with Lincoln Park, pursuant to which
Lincoln Park is obligated to purchase, at our request, up to $15.0
million of our common stock over a 30-month period, subject to
certain limitations set forth in the Purchase Agreement. The
warrants issued in connection with the Series&nbsp;B preferred
stock prohibits us from entering into certain transactions
involving the issuance of securities for a price determined by
reference to the trading price of our common stock or otherwise
subject to modification following the date of issuance, in each
case for a period of three years from the closing date of the
Series&nbsp;B Offering, other than purchases pursuant to the
Series&nbsp;B Purchase Agreement, which may be made on the 120 day
anniversary of the closing date of the Series&nbsp;B Offering. This
prohibition may be waived by holders of two-thirds of the
outstanding Series&nbsp;1 and Series&nbsp;2 warrants at any time.
&nbsp;If these additional shares are sold, or if it is perceived
that they will be sold, in the public market, the trading price of
our common stock could decline. Sales of newly issued securities
under any registration statement will result in dilution of our
stockholders and could cause our stock price to fall.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style=
"font-size:10.0pt;margin:0in 0in .0001pt;text-indent:.5in;">
<font size="2" face="Times New Roman" style="font-size:10.0pt;">Our
directors and employees may sell our stock through 10b5-1 trading
plans or in the market during open windows under our insider
trading policy without such plans in place.&nbsp; Sales of our
common stock by our directors and employees could be perceived
negatively by investors or cause downward pressure on our common
stock and cause a reduction in the price of our common stock as a
result.</font> We have also registered shares of our common stock
that we may issue under our employee equity incentive plans. These
shares will be able to be sold freely in the public market upon
issuance.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><b><i><font size="2" face=
"Times New Roman" style=
"font-size:10.0pt;font-style:italic;font-weight:bold;">Our 2017
financial statements contained disclosure that there is substantial
doubt about our ability to continue as a going concern, and we will
need additional financing to execute our business plan, to fund our
operations and to continue as a going concern.</font></i></b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2"
face="Times New Roman" style="font-size:10.0pt;">Since inception,
we have experienced recurring operating losses and negative cash
flows and we expect to continue to generate operating losses and
consume significant cash resources for the foreseeable future.
There is substantial doubt regarding our ability to continue as a
going concern. Our independent registered public accounting firm
has expressed in its auditors’ report on our 2017 financial
statements, included in our Annual Report on Form&nbsp;10-K, as
filed with the SEC on March&nbsp;30, 2018, a “going concern”
opinion, meaning that we have recurring losses from operations and
negative cash flows from operations that raise substantial doubt
regarding our ability to continue as a going concern. We have
prepared our financial statements on a going concern basis, which
contemplates the realization of assets and the satisfaction of
liabilities and commitments in the normal course of business. Our
2017 financial statements do not include any adjustment to reflect
the possible future effects on the recoverability and
classification of assets or the amounts and classification of
liabilities that may result from the outcome of this
uncertainty.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><b><i><font size="2" face=
"Times New Roman" style=
"font-size:10.0pt;font-style:italic;font-weight:bold;">The
requirements of being a public company may strain our resources,
divert management’s attention and affect our ability to attract and
retain executive management and qualified board
members.</font></i></b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2"
face="Times New Roman" style="font-size:10.0pt;">As a public
company, we are subject to the reporting requirements of the
Securities Exchange Act of 1934, as amended, or the Exchange Act,
the Sarbanes-Oxley Act, the Dodd-Frank Act, the listing
requirements of Nasdaq and other applicable securities laws,
rules&nbsp;and regulations. Compliance with these laws,
rules&nbsp;and regulations have increased our legal and financial
compliance costs and will make some activities more difficult,
time-consuming or costly and increase demand on our systems and
resources, particularly after we are no longer an “emerging growth
company.” The Exchange Act requires, among other things, that we
file annual, quarterly and current reports with respect to our
business and operating results. The Sarbanes-Oxley Act requires,
among other things, that we maintain effective disclosure controls
and procedures and internal control over financial reporting. In
order to maintain and, if required, improve our disclosure controls
and procedures and internal control over financial reporting to
meet this standard, significant resources and management oversight
may be required. Our management and other personnel now need to
devote a substantial amount of time to these compliance
initiatives. As a result, management’s attention may be diverted
from other business concerns and our costs and expenses will
increase, which could harm our business and operating results. We
may need to hire more employees in the future or engage outside
consultants to comply with these requirements, which will increase
our costs and expenses.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2"
face="Times New Roman" style="font-size:10.0pt;">In addition,
changing laws, regulations and standards relating to corporate
governance and public disclosure are creating uncertainty for
public companies, increasing legal and financial compliance costs
and making some activities more time consuming. These laws,
regulations and standards are subject to varying interpretations,
in many cases due to their lack of specificity and, as a result,
their application in practice may evolve over time as new guidance
is provided by regulatory and governing bodies. This could result
in continuing uncertainty regarding compliance matters and higher
costs necessitated by ongoing revisions to disclosure and
governance practices. We intend to invest resources to comply with
evolving laws, regulations and standards, and this investment may
result in increased general and administrative expenses and a
diversion of management’s time and attention from
revenue-generating activities to compliance activities. If our
efforts to comply with new laws, regulations and standards differ
from the activities intended by regulatory or governing bodies due
to ambiguities related to their application and practice,
regulatory authorities may initiate legal proceedings against us
and our business may be harmed.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style=
"font-size:10.0pt;margin:0in 0in .0001pt;text-align:center;">
57<a name="PB_57_115508_8627" id="PB_57_115508_8627"></a></p>
<div style="margin:0in 0in .0001pt;">
<hr size="3" width="100%" noshade="noshade" align="left" style=
"color:#010101;" /></div>
</div>
<!-- SEQ.=1,FOLIO='57',FILE='C:\JMS\109761\18-8644-1\task8901132\8644-1-ge.htm',USER='109761',CD='May 15 15:52 2018' --><br clear="all"
style="page-break-before:always;" />
<div style="font-family:Times New Roman;">
<p style="margin:0in 0in .0001pt;"><a href="#TableOfContents"
title="Click to go to Table of Contents"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">Table of
Contents</font></a></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2"
face="Times New Roman" style="font-size:10.0pt;">We will incur
additional compensation costs in the event that we decide to pay
our executive officers cash compensation closer to that of
executive officers of other public medical device companies, which
would increase our general and administrative expense and could
harm our profitability. Any future equity awards will also increase
our compensation expense. We also expect that being a public
company and compliance with applicable rules&nbsp;and regulations
will make it more expensive for us to obtain director and officer
liability insurance, and we may be required to accept reduced
coverage or incur substantially higher costs to obtain coverage.
These factors could also make it more difficult for us to attract
and retain qualified executive officers and members of our board of
directors, particularly to serve on our audit committee and
compensation committee.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2"
face="Times New Roman" style="font-size:10.0pt;">As a result of
disclosure of information in this Quarterly Report on
Form&nbsp;10-Q and in filings required of a public company, our
business and financial condition will become more visible, which
could be advantageous to our competitors and clients and could
result in threatened or actual litigation, including by competitors
and other third parties. If such claims are successful, our
business and operating results could be harmed, and even if the
claims are resolved in our favor, these claims, and the time and
resources necessary to resolve them, could divert the resources of
our management and harm our business and operating
results.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><b><i><font size="2" face=
"Times New Roman" style=
"font-size:10.0pt;font-style:italic;font-weight:bold;">We are an
emerging growth company and we cannot be certain if the reduced
disclosure requirements applicable to emerging growth companies
will make our common stock less attractive to
investors.</font></i></b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2"
face="Times New Roman" style="font-size:10.0pt;">We are an emerging
growth company. For as long as we continue to be an emerging growth
company, we may take advantage of certain exemptions from reporting
requirements that are applicable to other public companies
including, but not limited to, not being required to comply with
the auditor attestation requirements of Section&nbsp;404 of the
Sarbanes-Oxley Act, reduced disclosure obligations regarding
executive compensation in our periodic reports and proxy
statements, and exemptions from the requirements of holding a
nonbinding advisory vote on executive compensation and stockholder
approval of any golden parachute payments not previously approved.
We cannot predict if investors will find our common stock less
attractive because we will rely on these exemptions. If some
investors find our common stock less attractive as a result, there
may be a less active trading market for our common stock and our
stock price may be more volatile or decline.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2"
face="Times New Roman" style="font-size:10.0pt;">We will remain an
emerging growth company until the earlier of (1)&nbsp;the last day
of the fiscal year (a)&nbsp;following the fifth anniversary of our
IPO, (b)&nbsp;in which we have total annual gross revenue of at
least $1.0&nbsp;billion, or (c)&nbsp;in which we are deemed to be a
large accelerated filer, which means the market value of our common
stock that is held by non-affiliates exceeds $700&nbsp;million as
of the prior June&nbsp;30th, and (2)&nbsp;the date on which we have
issued more than $1.0&nbsp;billion in non-convertible debt
securities during the prior three-year period. We cannot predict if
investors will find our common stock less attractive because we may
rely on these exemptions. If some investors find our common stock
less attractive as a result, there may be a less active trading
market for our common stock and our stock price may suffer or be
more volatile.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><b><i><font size="2" face=
"Times New Roman" style=
"font-size:10.0pt;font-style:italic;font-weight:bold;">Nasdaq may
delist our securities from its exchange, which could harm our
business and limit our stockholders’ liquidity.</font></i></b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2"
face="Times New Roman" style="font-size:10.0pt;">Our common stock
is currently listed on the Nasdaq Capital Market, which has
qualitative and quantitative listing criteria.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style=
"font-size:10.0pt;margin:0in 0in .0001pt;text-indent:.5in;">
<font size="2" face="Times New Roman" style="font-size:10.0pt;">On
March&nbsp;1, 2018, we regained compliance with all applicable
Nasdaq listing criteria; however, there can be no assurance that we
will continue to be compliant with such listing criteria.</font> In
the event of a delisting, we can provide no assurance that any
action taken by us to restore compliance with listing requirements
would allow our common stock to become listed again, stabilize the
market price or improve the liquidity of our common stock, prevent
our common stock from dropping below the Nasdaq minimum market
value of listed securities and minimum closing bid price
requirements or prevent future non-compliance with Nasdaq’s listing
requirements.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><b><i><font size="2" face=
"Times New Roman" style=
"font-size:10.0pt;font-style:italic;font-weight:bold;">Anti-takeover
provisions in our amended and restated certificate of incorporation
and bylaws and Delaware law could discourage a
takeover.</font></i></b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2"
face="Times New Roman" style="font-size:10.0pt;">Our amended and
restated certificate of incorporation and bylaws contain provisions
that might enable our management to resist a takeover. These
provisions include:</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style=
"font-size:10.0pt;margin:0in 0in .0001pt .75in;text-indent:-.25in;">
<font size="2" face="Symbol" style=
"font-size:10.0pt;">·</font><font size="1" style=
"font-size:3.0pt;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</font>
a classified board of directors;</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style=
"font-size:10.0pt;margin:0in 0in .0001pt .75in;text-indent:-.25in;">
<font size="2" face="Symbol" style=
"font-size:10.0pt;">·</font><font size="1" style=
"font-size:3.0pt;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</font>
advance notice requirements applicable to stockholders for matters
to be brought before a meeting of stockholders and requirements as
to the form and content of a stockholder’s notice;</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style=
"font-size:10.0pt;margin:0in 0in .0001pt;text-align:center;">
58<a name="PB_58_115554_7906" id="PB_58_115554_7906"></a></p>
<div style="margin:0in 0in .0001pt;">
<hr size="3" width="100%" noshade="noshade" align="left" style=
"color:#010101;" /></div>
</div>
<!-- SEQ.=1,FOLIO='58',FILE='C:\JMS\109761\18-8644-1\task8901132\8644-1-ge.htm',USER='109761',CD='May 15 15:52 2018' --><br clear="all"
style="page-break-before:always;" />
<div style="font-family:Times New Roman;">
<p style="margin:0in 0in .0001pt;"><a href="#TableOfContents"
title="Click to go to Table of Contents"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">Table of
Contents</font></a></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style=
"font-size:10.0pt;margin:0in 0in .0001pt .75in;text-indent:-.25in;">
<font size="2" face="Symbol" style=
"font-size:10.0pt;">·</font><font size="1" style=
"font-size:3.0pt;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</font>
a supermajority stockholder vote requirement for amending certain
provisions of our amended and restated certificate of incorporation
and bylaws;</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style=
"font-size:10.0pt;margin:0in 0in .0001pt .75in;text-indent:-.25in;">
<font size="2" face="Symbol" style=
"font-size:10.0pt;">·</font><font size="1" style=
"font-size:3.0pt;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</font>
the right to issue preferred stock without stockholder approval,
which could be used to dilute the stock ownership of a potential
hostile acquirer;</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style=
"font-size:10.0pt;margin:0in 0in .0001pt .75in;text-indent:-.25in;">
<font size="2" face="Symbol" style=
"font-size:10.0pt;">·</font><font size="1" style=
"font-size:3.0pt;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</font>
allowing stockholders to remove directors only for cause;</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style=
"font-size:10.0pt;margin:0in 0in .0001pt .75in;text-indent:-.25in;">
<font size="2" face="Symbol" style=
"font-size:10.0pt;">·</font><font size="1" style=
"font-size:3.0pt;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</font>
a requirement that the authorized number of directors may be
changed only by resolution of the board of directors;</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style=
"font-size:10.0pt;margin:0in 0in .0001pt .75in;text-indent:-.25in;">
<font size="2" face="Symbol" style=
"font-size:10.0pt;">·</font><font size="1" style=
"font-size:3.0pt;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</font>
allowing all vacancies, including newly created directorships, to
be filled by the affirmative vote of a majority of directors then
in office, even if less than a quorum, except as otherwise required
by law;</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style=
"font-size:10.0pt;margin:0in 0in .0001pt .75in;text-indent:-.25in;">
<font size="2" face="Symbol" style=
"font-size:10.0pt;">·</font><font size="1" style=
"font-size:3.0pt;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</font>
a requirement that our stockholders may only take action at annual
or special meetings of our stockholders and not by written
consent;</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style=
"font-size:10.0pt;margin:0in 0in .0001pt .75in;text-indent:-.25in;">
<font size="2" face="Symbol" style=
"font-size:10.0pt;">·</font><font size="1" style=
"font-size:3.0pt;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</font>
limiting the forum for certain litigation against us to Delaware;
and</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style=
"font-size:10.0pt;margin:0in 0in .0001pt .75in;text-indent:-.25in;">
<font size="2" face="Symbol" style=
"font-size:10.0pt;">·</font><font size="1" style=
"font-size:3.0pt;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</font>
limiting the persons that can call special meetings of our
stockholders to our board of directors, the chairperson of our
board of directors, the chief executive officer or the president
(in the absence of a chief executive officer).</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2"
face="Times New Roman" style="font-size:10.0pt;">These provisions
might discourage, delay or prevent a change in control of our
company or a change in our management. The existence of these
provisions could adversely affect the voting power of holders of
common stock and limit the price that investors might be willing to
pay in the future for shares of our common stock. In addition,
because we are incorporated in Delaware, we are governed by the
provisions of Section&nbsp;203 of the Delaware General Corporation
Law, which generally prohibits a Delaware corporation from engaging
in any of a broad range of business combinations with any 
“interested” stockholder for a period of three years following the
date on which the stockholder became an “interested”
stockholder.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><b><i><font size="2" face=
"Times New Roman" style=
"font-size:10.0pt;font-style:italic;font-weight:bold;">Our amended
and restated certificate of incorporation provides that the Court
of Chancery of the State of Delaware will be the sole and exclusive
forum for substantially all disputes between us and our
stockholders, which could limit our stockholders’ ability to obtain
a favorable judicial forum for disputes with us or our directors,
officers or employees.</font></i></b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2"
face="Times New Roman" style="font-size:10.0pt;">Our amended and
restated certificate of incorporation provides that, unless we
consent to the selection of an alternative forum, the Court of
Chancery of the State of Delaware is the sole and exclusive forum
for (i)&nbsp;any derivative action or proceeding brought on our
behalf, (ii)&nbsp;any action asserting a claim of breach of
fiduciary duty owed by any of our directors, officers or other
employees to us or to our stockholders, (iii)&nbsp;any action
asserting a claim arising pursuant to the Delaware General
Corporation Law or our certificate of incorporation or bylaws
(iv)&nbsp;any action to interpret apply, enforce or determine the
validity of our certificate of incorporation or bylaws or
(v)&nbsp;any action asserting a claim governed by the internal
affairs doctrine. The choice of forum provision may limit a
stockholder’s ability to bring a claim in a judicial forum that it
finds favorable for disputes with us or our directors, officers or
other employees, which may discourage such lawsuits against us and
our directors, officers and other employees. Alternatively, if a
court were to find the choice of forum provision contained in our
amended and restated certificate of incorporation to be
inapplicable or unenforceable in an action, we may incur additional
costs associated with resolving such action in other jurisdictions,
which could harm our business, operating results and financial
condition.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><b><i><font size="2" face=
"Times New Roman" style=
"font-size:10.0pt;font-style:italic;font-weight:bold;">We have not
paid dividends in the past and do not expect to pay dividends in
the future, and any return on investment may be limited to the
value of our stock.</font></i></b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style=
"font-size:10.0pt;margin:0in 0in .0001pt;text-indent:.5in;">
<font size="2" face="Times New Roman" style="font-size:10.0pt;">We
have never paid cash dividends and do not anticipate paying cash
dividends in the foreseeable future</font>, except the cumulative
dividend payable on our Series&nbsp;A preferred stock. The payment
of all other dividends will depend on our earnings, capital
requirements, financial condition, prospects and other factors our
board of directors may deem relevant. In addition, our Loan
Agreement with CRG prohibits us from, among other things, paying
any dividends or making any other distribution or payment on
account of our common stock. The terms of our Series&nbsp;A
preferred stock and our Series&nbsp;B preferred stock provide that
we may not pay dividends on our common stock without concurrently
declaring dividends on each.&nbsp; If we do not pay dividends, our
stock may be less valuable because a return on your investment will
only occur if you sell our common stock after our stock price
appreciates.&nbsp; For more information on restrictions governing
our ability to pay dividends, see the section titled “<i>Dividend
Policy</i>” in our Annual Report on Form&nbsp;10-K, as filed with
the SEC on March&nbsp;30, 2018.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style=
"font-size:10.0pt;margin:0in 0in .0001pt;text-align:center;">
59<a name="PB_59_115654_3736" id="PB_59_115654_3736"></a></p>
<div style="margin:0in 0in .0001pt;">
<hr size="3" width="100%" noshade="noshade" align="left" style=
"color:#010101;" /></div>
</div>
<!-- SEQ.=1,FOLIO='59',FILE='C:\JMS\109761\18-8644-1\task8901132\8644-1-ge.htm',USER='109761',CD='May 15 15:52 2018' --><br clear="all"
style="page-break-before:always;" />
<div style="font-family:Times New Roman;">
<p style="margin:0in 0in .0001pt;"><a href="#TableOfContents"
title="Click to go to Table of Contents"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">Table of
Contents</font></a></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;"><b><font size=
"2" face="Times New Roman" style=
"font-size:10.0pt;font-weight:bold;">ITEM 2.</font></b><font size=
"1" style=
"font-size:3.0pt;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</font>
<b>UNREGISTERED SALES OF EQUITY SECURITIES AND USE OF
PROCEEDS</b><a name="ITEM2_UNREGISTEREDSALESOFEQUITYS_121058" id=
"ITEM2_UNREGISTEREDSALESOFEQUITYS_121058"></a></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2"
face="Times New Roman" style="font-size:10.0pt;">As previously
disclosed in the Company’s Current Report on Form 8-K filed
February 14, 2018, the Company sold shares of Series A preferred
stock to CRG pursuant to the CRG Conversion.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;"><b><font size=
"2" face="Times New Roman" style=
"font-size:10.0pt;font-weight:bold;">ITEM 3.</font></b><font size=
"1" style=
"font-size:3.0pt;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</font>
<b>DEFAULTS UPON SENIOR SECURITIES</b><a name=
"ITEM3_DEFAULTSUPONSENIORSECURITI_121104" id=
"ITEM3_DEFAULTSUPONSENIORSECURITI_121104"></a></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:25.0pt;"><font size=
"2" face="Times New Roman" style=
"font-size:10.0pt;">None.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;"><b><font size=
"2" face="Times New Roman" style=
"font-size:10.0pt;font-weight:bold;">ITEM 4.</font></b><font size=
"1" style=
"font-size:3.0pt;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</font>
<b>MINE SAFETY DISCLOSURES</b><a name=
"ITEM4_MINESAFETYDISCLOSURES_121108" id=
"ITEM4_MINESAFETYDISCLOSURES_121108"></a></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:25.0pt;"><font size=
"2" face="Times New Roman" style="font-size:10.0pt;">Not
applicable.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;"><b><font size=
"2" face="Times New Roman" style=
"font-size:10.0pt;font-weight:bold;">ITEM 5.</font></b><font size=
"1" style=
"font-size:3.0pt;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</font>
<b>OTHER INFORMATION</b><a name="ITEM5_OTHERINFORMATION_121112" id=
"ITEM5_OTHERINFORMATION_121112"></a></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.35in;"><font size="2"
face="Times New Roman" style="font-size:10.0pt;">None.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style=
"font-size:10.0pt;margin:0in 0in .0001pt;text-align:center;">
60<a name="PB_60_115720_9621" id="PB_60_115720_9621"></a></p>
<div style="margin:0in 0in .0001pt;">
<hr size="3" width="100%" noshade="noshade" align="left" style=
"color:#010101;" /></div>
</div>
<!-- SEQ.=1,FOLIO='60',FILE='C:\JMS\109761\18-8644-1\task8901132\8644-1-ge.htm',USER='109761',CD='May 15 15:52 2018' --><br clear="all"
style="page-break-before:always;" />
<div style="font-family:Times New Roman;">
<p style="margin:0in 0in .0001pt;"><a href="#TableOfContents"
title="Click to go to Table of Contents"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">Table of
Contents</font></a></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;"><b><font size=
"2" face="Times New Roman" style=
"font-size:10.0pt;font-weight:bold;">ITEM 6.</font></b><font size=
"1" style=
"font-size:3.0pt;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</font>
<b>EXHIBITS</b><a name="ITEM6_EXHIBITS_121119" id=
"ITEM6_EXHIBITS_121119"></a></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2"
face="Times New Roman" style="font-size:10.0pt;">The following
exhibits are being filed herewith:</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<table border="0" cellspacing="0" cellpadding="0" width="100%"
style="border-collapse:collapse;">
<tr>
<td width="9%" valign="bottom" style=
"border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:9.16%;">
<p style="margin:0in 0in .0001pt;"><b><font size="1" face=
"Times New Roman" style=
"font-size:8.0pt;font-weight:bold;">Exhibit<br />
Number</font></b></p>
</td>
<td width="2%" valign="bottom" style=
"padding:0in 0in 0in 0in;width:2.68%;">
<p align="center" style=
"margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face=
"Times New Roman" style=
"font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>
</td>
<td width="88%" valign="bottom" style=
"border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:88.16%;">
<p align="center" style=
"margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face=
"Times New Roman" style=
"font-size:8.0pt;font-weight:bold;">Exhibit&nbsp;Title</font></b></p>
</td>
</tr>
<tr>
<td width="9%" valign="top" style=
"padding:0in 0in 0in 0in;width:9.16%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
</td>
<td width="2%" valign="bottom" style=
"padding:0in 0in 0in 0in;width:2.68%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
</td>
<td width="88%" valign="top" style=
"padding:0in 0in 0in 0in;width:88.16%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
</td>
</tr>
<tr>
<td width="9%" valign="top" style=
"padding:0in 0in 0in 0in;width:9.16%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">10.1</font><font size=
"1" style=
"font-size:6.5pt;position:relative;top:-3.0pt;">(1)</font></p>
</td>
<td width="2%" valign="bottom" style=
"padding:0in 0in 0in 0in;width:2.68%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>
</td>
<td width="88%" valign="top" style=
"padding:0in 0in 0in 0in;width:88.16%;">
<p style="margin:0in 0in .0001pt;"><a href=
"http://www.sec.gov/Archives/edgar/data/1506928/000110465918005137/a18-5059_1ex10d1.htm">
<font size="2" face="Times New Roman" style=
"font-size:10.0pt;">Waiver and Consent, dated as of
January&nbsp;24, 2018, by and among the Company, CRG Partners III
L.P., CRG Partners III — Parallel Fund “A” L.P., CRG Partners III —
Parallel Fund “B” (Cayman) L.P. and CRG Partners III (Cayman)
L.P.</font></a></p>
</td>
</tr>
<tr>
<td width="9%" valign="top" style=
"padding:0in 0in 0in 0in;width:9.16%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
</td>
<td width="2%" valign="bottom" style=
"padding:0in 0in 0in 0in;width:2.68%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
</td>
<td width="88%" valign="top" style=
"padding:0in 0in 0in 0in;width:88.16%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
</td>
</tr>
<tr>
<td width="9%" valign="top" style=
"padding:0in 0in 0in 0in;width:9.16%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">10.2</font><font size=
"1" style=
"font-size:6.5pt;position:relative;top:-3.0pt;">(2)</font></p>
</td>
<td width="2%" valign="bottom" style=
"padding:0in 0in 0in 0in;width:2.68%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>
</td>
<td width="88%" valign="top" style=
"padding:0in 0in 0in 0in;width:88.16%;">
<p style="margin:0in 0in .0001pt;"><a href=
"http://www.sec.gov/Archives/edgar/data/1506928/000110465918009906/a18-2705_13ex10d1.htm">
<font size="2" face="Times New Roman" style=
"font-size:10.0pt;">Amendment No.&nbsp;2 to Term Loan Agreement,
dated as of February&nbsp;14, 2018, among the Company, CRG Partners
III L.P., CRG Partners III - Parallel Fund “A” L.P., CRG Partners
III — Parallel Fund “B” (Cayman) L.P., CRG Partners III (Cayman)
Lev AIV I L.P., and CRG Partners III (Cayman) Unlev AIV I
L.P.</font></a></p>
</td>
</tr>
<tr>
<td width="9%" valign="top" style=
"padding:0in 0in 0in 0in;width:9.16%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
</td>
<td width="2%" valign="bottom" style=
"padding:0in 0in 0in 0in;width:2.68%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
</td>
<td width="88%" valign="top" style=
"padding:0in 0in 0in 0in;width:88.16%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
</td>
</tr>
<tr>
<td width="9%" valign="top" style=
"padding:0in 0in 0in 0in;width:9.16%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">10.3</font><font size=
"1" style=
"font-size:6.5pt;position:relative;top:-3.0pt;">(3)</font></p>
</td>
<td width="2%" valign="bottom" style=
"padding:0in 0in 0in 0in;width:2.68%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>
</td>
<td width="88%" valign="top" style=
"padding:0in 0in 0in 0in;width:88.16%;">
<p style="margin:0in 0in .0001pt;"><a href=
"http://www.sec.gov/Archives/edgar/data/1506928/000110465918009906/a18-2705_13ex10d2.htm">
<font size="2" face="Times New Roman" style=
"font-size:10.0pt;">Series&nbsp;A Preferred Stock Purchase
Agreement. Dated as of February&nbsp;14, 2018, among the Company,
CRG Partners III L.P., CRG Partners III - Parallel Fund “A” L.P.,
CRG Partners III — Parallel Fund “B” (Cayman) L.P., CRG Partners
III (Cayman) Lev AIV I L.P., and CRG Partners III (Cayman) Unlev
AIV I L.P.</font></a></p>
</td>
</tr>
<tr>
<td width="9%" valign="top" style=
"padding:0in 0in 0in 0in;width:9.16%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
</td>
<td width="2%" valign="bottom" style=
"padding:0in 0in 0in 0in;width:2.68%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
</td>
<td width="88%" valign="top" style=
"padding:0in 0in 0in 0in;width:88.16%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
</td>
</tr>
<tr>
<td width="9%" valign="top" style=
"padding:0in 0in 0in 0in;width:9.16%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">10.4</font><font size=
"1" style=
"font-size:6.5pt;position:relative;top:-3.0pt;">(4)</font></p>
</td>
<td width="2%" valign="bottom" style=
"padding:0in 0in 0in 0in;width:2.68%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>
</td>
<td width="88%" valign="top" style=
"padding:0in 0in 0in 0in;width:88.16%;">
<p style="margin:0in 0in .0001pt;"><a href=
"http://www.sec.gov/Archives/edgar/data/1506928/000110465918011716/a18-2705_14ex10d1.htm">
<font size="2" face="Times New Roman" style=
"font-size:10.0pt;">Registration Rights Agreement, dated as of
February&nbsp;16, 2018, among the Company, CRG Partners III L.P.,
CRG Partners III - Parallel Fund “A” L.P., CRG Partners III —
Parallel Fund “B” (Cayman) L.P. CRG Partners III (Cayman) Lev AIV I
L.P., and CRG Partners III (Cayman) Unlev AIV I L.P.</font></a></p>
</td>
</tr>
<tr>
<td width="9%" valign="top" style=
"padding:0in 0in 0in 0in;width:9.16%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
</td>
<td width="2%" valign="bottom" style=
"padding:0in 0in 0in 0in;width:2.68%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
</td>
<td width="88%" valign="top" style=
"padding:0in 0in 0in 0in;width:88.16%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
</td>
</tr>
<tr>
<td width="9%" valign="top" style=
"padding:0in 0in 0in 0in;width:9.16%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">31.1</font></p>
</td>
<td width="2%" valign="bottom" style=
"padding:0in 0in 0in 0in;width:2.68%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>
</td>
<td width="88%" valign="top" style=
"padding:0in 0in 0in 0in;width:88.16%;">
<p style="margin:0in 0in .0001pt;"><a href=
"a18-8644_1ex31d1.htm#Exhibit31_1_114144" title=
"Click to goto "><font size="2" face="Times New Roman" style=
"font-size:10.0pt;">Certification of the Principal Executive
Officer pursuant to Securities Exchange Act
Rules&nbsp;13a-14(a)&nbsp;and 15d-14(a), as adopted pursuant to
Section&nbsp;302 of the Sarbanes-Oxley Act of 2002.</font></a></p>
</td>
</tr>
<tr>
<td width="9%" valign="top" style=
"padding:0in 0in 0in 0in;width:9.16%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
</td>
<td width="2%" valign="bottom" style=
"padding:0in 0in 0in 0in;width:2.68%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
</td>
<td width="88%" valign="top" style=
"padding:0in 0in 0in 0in;width:88.16%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
</td>
</tr>
<tr>
<td width="9%" valign="top" style=
"padding:0in 0in 0in 0in;width:9.16%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">31.2</font></p>
</td>
<td width="2%" valign="bottom" style=
"padding:0in 0in 0in 0in;width:2.68%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>
</td>
<td width="88%" valign="top" style=
"padding:0in 0in 0in 0in;width:88.16%;">
<p style="margin:0in 0in .0001pt;"><a href=
"a18-8644_1ex31d2.htm#Exhibit31_2_114324" title=
"Click to goto "><font size="2" face="Times New Roman" style=
"font-size:10.0pt;">Certification of the Principal Financial
Officer pursuant to Securities Exchange Act
Rules&nbsp;13a-14(a)&nbsp;and 15d-14(a), as adopted pursuant to
Section&nbsp;302 of the Sarbanes-Oxley Act of 2002.</font></a></p>
</td>
</tr>
<tr>
<td width="9%" valign="top" style=
"padding:0in 0in 0in 0in;width:9.16%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
</td>
<td width="2%" valign="bottom" style=
"padding:0in 0in 0in 0in;width:2.68%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
</td>
<td width="88%" valign="top" style=
"padding:0in 0in 0in 0in;width:88.16%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
</td>
</tr>
<tr>
<td width="9%" valign="top" style=
"padding:0in 0in 0in 0in;width:9.16%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">32.1*</font></p>
</td>
<td width="2%" valign="bottom" style=
"padding:0in 0in 0in 0in;width:2.68%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>
</td>
<td width="88%" valign="top" style=
"padding:0in 0in 0in 0in;width:88.16%;">
<p style="margin:0in 0in .0001pt;"><a href=
"a18-8644_1ex32d1.htm#Exhibit32_1_114452" title=
"Click to goto "><font size="2" face="Times New Roman" style=
"font-size:10.0pt;">Certifications of the Chief Executive Officer
and Chief Financial Officer pursuant to 18 U.S.C.
Section&nbsp;1350, as adopted pursuant to Section&nbsp;906 of the
Sarbanes-Oxley Act of 2002.</font></a></p>
</td>
</tr>
<tr>
<td width="9%" valign="top" style=
"padding:0in 0in 0in 0in;width:9.16%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
</td>
<td width="2%" valign="bottom" style=
"padding:0in 0in 0in 0in;width:2.68%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
</td>
<td width="88%" valign="top" style=
"padding:0in 0in 0in 0in;width:88.16%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
</td>
</tr>
<tr>
<td width="9%" valign="top" style=
"padding:0in 0in 0in 0in;width:9.16%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">101.INS</font></p>
</td>
<td width="2%" valign="bottom" style=
"padding:0in 0in 0in 0in;width:2.68%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>
</td>
<td width="88%" valign="top" style=
"padding:0in 0in 0in 0in;width:88.16%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">XBRL Instance
Document</font></p>
</td>
</tr>
<tr>
<td width="9%" valign="top" style=
"padding:0in 0in 0in 0in;width:9.16%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
</td>
<td width="2%" valign="bottom" style=
"padding:0in 0in 0in 0in;width:2.68%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
</td>
<td width="88%" valign="top" style=
"padding:0in 0in 0in 0in;width:88.16%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
</td>
</tr>
<tr>
<td width="9%" valign="top" style=
"padding:0in 0in 0in 0in;width:9.16%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">101.SCH</font></p>
</td>
<td width="2%" valign="bottom" style=
"padding:0in 0in 0in 0in;width:2.68%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>
</td>
<td width="88%" valign="top" style=
"padding:0in 0in 0in 0in;width:88.16%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">XBRL Taxonomy Extension
Schema Document</font></p>
</td>
</tr>
<tr>
<td width="9%" valign="top" style=
"padding:0in 0in 0in 0in;width:9.16%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
</td>
<td width="2%" valign="bottom" style=
"padding:0in 0in 0in 0in;width:2.68%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
</td>
<td width="88%" valign="top" style=
"padding:0in 0in 0in 0in;width:88.16%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
</td>
</tr>
<tr>
<td width="9%" valign="top" style=
"padding:0in 0in 0in 0in;width:9.16%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">101.CAL</font></p>
</td>
<td width="2%" valign="bottom" style=
"padding:0in 0in 0in 0in;width:2.68%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>
</td>
<td width="88%" valign="top" style=
"padding:0in 0in 0in 0in;width:88.16%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">XBRL Taxonomy Extension
Calculation Linkbase Document</font></p>
</td>
</tr>
<tr>
<td width="9%" valign="top" style=
"padding:0in 0in 0in 0in;width:9.16%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
</td>
<td width="2%" valign="bottom" style=
"padding:0in 0in 0in 0in;width:2.68%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
</td>
<td width="88%" valign="top" style=
"padding:0in 0in 0in 0in;width:88.16%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
</td>
</tr>
<tr>
<td width="9%" valign="top" style=
"padding:0in 0in 0in 0in;width:9.16%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">101.DEF</font></p>
</td>
<td width="2%" valign="bottom" style=
"padding:0in 0in 0in 0in;width:2.68%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>
</td>
<td width="88%" valign="top" style=
"padding:0in 0in 0in 0in;width:88.16%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">XBRL Taxonomy Extension
Definition Linkbase Document</font></p>
</td>
</tr>
<tr>
<td width="9%" valign="top" style=
"padding:0in 0in 0in 0in;width:9.16%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
</td>
<td width="2%" valign="bottom" style=
"padding:0in 0in 0in 0in;width:2.68%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
</td>
<td width="88%" valign="top" style=
"padding:0in 0in 0in 0in;width:88.16%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
</td>
</tr>
<tr>
<td width="9%" valign="top" style=
"padding:0in 0in 0in 0in;width:9.16%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">101.LAB</font></p>
</td>
<td width="2%" valign="bottom" style=
"padding:0in 0in 0in 0in;width:2.68%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>
</td>
<td width="88%" valign="top" style=
"padding:0in 0in 0in 0in;width:88.16%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">XBRL Taxonomy Extension
Label Linkbase Document</font></p>
</td>
</tr>
<tr>
<td width="9%" valign="top" style=
"padding:0in 0in 0in 0in;width:9.16%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
</td>
<td width="2%" valign="bottom" style=
"padding:0in 0in 0in 0in;width:2.68%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
</td>
<td width="88%" valign="top" style=
"padding:0in 0in 0in 0in;width:88.16%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
</td>
</tr>
<tr>
<td width="9%" valign="top" style=
"padding:0in 0in 0in 0in;width:9.16%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">101.PRE</font></p>
</td>
<td width="2%" valign="bottom" style=
"padding:0in 0in 0in 0in;width:2.68%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>
</td>
<td width="88%" valign="top" style=
"padding:0in 0in 0in 0in;width:88.16%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">XBRL Taxonomy Extension
Presentation Linkbase Document</font></p>
</td>
</tr>
</table>
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<div style="margin:0in 0in .0001pt;">
<hr size="1" width="25%" noshade="noshade" align="left" style=
"color:black;" /></div>
<p style=
"font-size:10.0pt;margin:0in 0in .0001pt .5in;text-indent:-.5in;">
<font size="1" face="Times New Roman" style=
"font-size:6.5pt;position:relative;top:-3.0pt;">(1)</font><font size="1"
style=
"font-size:3.0pt;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</font>
Incorporated by reference to Exhibit&nbsp;10.1 to Registrant’s
Current Report on Form&nbsp;8-K filed with the SEC on January 30,
2018.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style=
"font-size:10.0pt;margin:0in 0in .0001pt .5in;text-indent:-.5in;">
<font size="1" face="Times New Roman" style=
"font-size:6.5pt;position:relative;top:-3.0pt;">(2)</font><font size="1"
style=
"font-size:3.0pt;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</font>
Incorporated by reference to Exhibit 10.1 to Registrant’s Current
Report on Form 8-K filed with the SEC on February 15, 2018.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style=
"font-size:10.0pt;margin:0in 0in .0001pt .5in;text-indent:-.5in;">
<font size="1" face="Times New Roman" style=
"font-size:6.5pt;position:relative;top:-3.0pt;">(3)</font><font size="1"
style=
"font-size:3.0pt;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</font>
Incorporated by reference to Exhibit 10.2 to Registrant’s Current
Report on Form 8-K filed with the SEC on February 15, 2018.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style=
"font-size:10.0pt;margin:0in 0in .0001pt .5in;text-indent:-.5in;">
<font size="1" face="Times New Roman" style=
"font-size:6.5pt;position:relative;top:-3.0pt;">(4)</font><font size="1"
style=
"font-size:3.0pt;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</font>
Incorporated by reference to Exhibit 10.1 to Registrant’s Current
Report on Form 8-K filed with the SEC on February 23, 2018.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style=
"font-size:10.0pt;margin:0in 0in .0001pt .5in;text-indent:-.5in;">
<font size="2" face="Times New Roman" style=
"font-size:10.0pt;">*</font><font size="1" style=
"font-size:3.0pt;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</font>
The certifications filed as Exhibits 32.1 are not deemed “filed”
for purposes of Section&nbsp;18 of the Securities Exchange Act of
1934 and are not to be incorporated by reference into any filing of
the Company under the Securities Exchange Act of 1933 or the
Securities Exchange Act of 1934, whether made before or after the
date hereof irrespective of any general incorporation by reference
language contained in any such filing, except to the extent that
the registrant specifically incorporates it by reference.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style=
"font-size:10.0pt;margin:0in 0in .0001pt;text-align:center;">
61<a name="PB_61_120351_8715" id="PB_61_120351_8715"></a></p>
<div style="margin:0in 0in .0001pt;">
<hr size="3" width="100%" noshade="noshade" align="left" style=
"color:#010101;" /></div>
</div>
<!-- SEQ.=1,FOLIO='61',FILE='C:\JMS\109761\18-8644-1\task8901132\8644-1-ge.htm',USER='109761',CD='May 15 15:52 2018' --><br clear="all"
style="page-break-before:always;" />
<div style="font-family:Times New Roman;">
<p style="margin:0in 0in .0001pt;"><a href="#TableOfContents"
title="Click to go to Table of Contents"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">Table of
Contents</font></a></p>
<p style="margin:0in 0in .0001pt;"><b><font size="2" face=
"Times New Roman" style=
"font-size:10.0pt;font-weight:bold;">&nbsp;</font></b></p>
<p align="center" style=
"margin:0in 0in .0001pt;text-align:center;"><b><font size="2" face=
"Times New Roman" style=
"font-size:10.0pt;font-weight:bold;">SIGNATURES</font></b><a name=
"SIGNATURES_114037" id="SIGNATURES_114037"></a></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:24.0pt;"><font size=
"2" face="Times New Roman" style="font-size:10.0pt;">Pursuant to
the requirements of the Securities Exchange Act of 1934, the
registrant has duly caused this report to be signed on its behalf
by the undersigned thereunto duly authorized.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<table border="0" cellspacing="0" cellpadding="0" width="100%"
style="border-collapse:collapse;">
<tr>
<td width="50%" valign="top" style=
"padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><b><font size="2" face=
"Times New Roman" style=
"font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>
</td>
<td width="50%" valign="top" style=
"padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><b><font size="2" face=
"Times New Roman" style=
"font-size:10.0pt;font-weight:bold;">Avinger,&nbsp;Inc.</font></b></p>
</td>
</tr>
<tr>
<td width="50%" valign="top" style=
"padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>
</td>
<td width="50%" valign="top" style=
"padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">(Registrant)</font></p>
</td>
</tr>
<tr>
<td width="50%" valign="top" style=
"padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
</td>
<td width="50%" valign="top" style=
"padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
</td>
</tr>
<tr>
<td width="50%" valign="top" style=
"padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
</td>
<td width="50%" valign="top" style=
"padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
</td>
</tr>
<tr>
<td width="50%" valign="top" style=
"padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">Date: May 15,
2018</font></p>
</td>
<td width="50%" valign="top" style=
"border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:50.0%;">
<p align="center" style=
"margin:0in 0in .0001pt;text-align:center;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">/s/ JEFFERY M.
SOINSKI</font></p>
</td>
</tr>
<tr>
<td width="50%" valign="top" style=
"padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>
</td>
<td width="50%" valign="top" style=
"padding:0in 0in 0in 0in;width:50.0%;">
<p align="center" style=
"margin:0in 0in .0001pt;text-align:center;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">Jeffrey M.
Soinski</font></p>
</td>
</tr>
<tr>
<td width="50%" valign="top" style=
"padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><i><font size="2" face=
"Times New Roman" style=
"font-size:1.0pt;font-style:italic;">&nbsp;</font></i></p>
</td>
<td width="50%" valign="top" style=
"padding:0in 0in 0in 0in;width:50.0%;">
<p align="center" style=
"margin:0in 0in .0001pt;text-align:center;"><i><font size="2" face=
"Times New Roman" style="font-size:10.0pt;font-style:italic;">Chief
Executive Officer</font></i></p>
</td>
</tr>
<tr>
<td width="50%" valign="top" style=
"padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><i><font size="2" face=
"Times New Roman" style=
"font-size:1.0pt;font-style:italic;">&nbsp;</font></i></p>
</td>
<td width="50%" valign="top" style=
"padding:0in 0in 0in 0in;width:50.0%;">
<p align="center" style=
"margin:0in 0in .0001pt;text-align:center;"><i><font size="2" face=
"Times New Roman" style=
"font-size:10.0pt;font-style:italic;">(Principal Executive
Officer)</font></i></p>
</td>
</tr>
<tr>
<td width="50%" valign="top" style=
"padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><i><font size="2" face=
"Times New Roman" style=
"font-size:10.0pt;font-style:italic;">&nbsp;</font></i></p>
</td>
<td width="50%" valign="top" style=
"padding:0in 0in 0in 0in;width:50.0%;">
<p align="center" style=
"margin:0in 0in .0001pt;text-align:center;"><i><font size="2" face=
"Times New Roman" style=
"font-size:10.0pt;font-style:italic;">&nbsp;</font></i></p>
</td>
</tr>
<tr>
<td width="50%" valign="top" style=
"padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">Date: May 15,
2018</font></p>
</td>
<td width="50%" valign="top" style=
"border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:50.0%;">
<p align="center" style=
"margin:0in 0in .0001pt;text-align:center;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">/s/&nbsp;MATTHEW B.
FERGUSON</font></p>
</td>
</tr>
<tr>
<td width="50%" valign="top" style=
"padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>
</td>
<td width="50%" valign="top" style=
"padding:0in 0in 0in 0in;width:50.0%;">
<p align="center" style=
"margin:0in 0in .0001pt;text-align:center;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">Matthew B.
Ferguson</font></p>
</td>
</tr>
<tr>
<td width="50%" valign="top" style=
"padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><i><font size="2" face=
"Times New Roman" style=
"font-size:1.0pt;font-style:italic;">&nbsp;</font></i></p>
</td>
<td width="50%" valign="top" style=
"padding:0in 0in 0in 0in;width:50.0%;">
<p align="center" style=
"margin:0in 0in .0001pt;text-align:center;"><i><font size="2" face=
"Times New Roman" style="font-size:10.0pt;font-style:italic;">Chief
Financial Officer</font></i></p>
</td>
</tr>
<tr>
<td width="50%" valign="top" style=
"padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><i><font size="2" face=
"Times New Roman" style=
"font-size:1.0pt;font-style:italic;">&nbsp;</font></i></p>
</td>
<td width="50%" valign="top" style=
"padding:0in 0in 0in 0in;width:50.0%;">
<p align="center" style=
"margin:0in 0in .0001pt;text-align:center;"><i><font size="2" face=
"Times New Roman" style=
"font-size:10.0pt;font-style:italic;">(Principal Financial and
Accounting Officer)</font></i></p>
</td>
</tr>
</table>
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style=
"font-size:10.0pt;margin:0in 0in .0001pt;text-align:center;">
62<a name="PB_62_113847_6677" id="PB_62_113847_6677"></a></p>
<div style="margin:0in 0in .0001pt;">
<hr size="3" width="100%" noshade="noshade" align="left" style=
"color:#010101;" /></div>
<p align="center" style=
"margin:0in 0in .0001pt;text-align:center;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
</div>
<!-- SEQ.=1,FOLIO='62',FILE='C:\JMS\C902519\18-8644-1\task8900823\8644-1-jc.htm',USER='C902519',CD='May 15 11:55 2018' -->
</body>
</html>

